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The first section of this book deals with various primary glomerular diseases. It 
discusses the pathogenic aspects of Alport’s syndrome. The second section focuses on 
tubular diseases. Dent’s disease, which is an important tubular disorder, has also been 
highlighted. The third section gives some insight into the kidney's role in various 
systemic diseases, as illustrated in the chapters on diabetic kidney disease. The other 
important systemic disease that has significant renal involvement is systemic lupus 
erythematosus. The latest developments in the field of SLE which have been 
incorporated will be of use to the readers in their clinical practice. 
The role of uric acid in health and disease is an area of active research. Kidney diseases 
may be the cause or effect of disturbed uric acid metabolism, which is very well 
illustrated in the chapter on uric acid and the kidney. The book also provides insight into 
the effect of pregnancy on the kidney. The kidney is an innocent bystander in various 
hemolytic anemias and the renal involvement in sickle cell disease highlights this point. 
It is widely recognized that obesity contributes to morbidity and mortality from 
diabetes, heart disease, stroke, and some forms of cancer, yet the important role that it 
plays in the progression of kidney disease is rarely mentioned. The chapter on obesity 
and kidney disease aims to raise awareness about the importance of obesity in chronic 
kidney disease. 
This book will contribute to the readers' development of a lifelong interest in 
nephrology. The aim of this book is to give ample opportunities to the learners as well 
as masters of the subject. 
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1. Introduction  
Most Alport cases, 85%, are caused by mutations in the X-linked gene, COL4A5 that encodes 
the α5 chain of type IV collagen, the most abundant structural protein in the glomerular 
basement membrane (GBM). The remaining 15% of cases are caused by autosomal recessive 
mutations in the genes that encode the α3 and α4 chains of the type IV collagen, 
COL4A3/COL4A4 1,2. Thin basement membrane nephropathy (TBMN) is reportedly also a 
genetically heterogeneous condition, caused by heterozygous COL4A3/COL4A4 mutations 
in about 40-50% of the cases. No other responsible genes have been identified as yet. 
Collagen type IV, as all collagens, is a trimer formed by combinations of three of the six 
alpha chains, α1-α6. Genes COL4A1 and COL4A2 map to chromosome 13q34, COL4A3 and 
COL4A4 map to chromosome 2q36–q37 and COL4A5 and COL4A6 map to Xq22-23. All six 
genes are encoded in nearly 50 exons and close to 1600 aminoacids, and consist of an N-
terminal 7S domain, a C-terminal non-collagenous (NC1) domain and a large collagenous 
domain in between, containing the characteristic Gly-X-Y repeat, common to all collagens. 
All six alpha chains contain 22-26 natural interruptions of the Gly-X-Y repeats, spread 
throughout their central collagenous domain. These are presumably regions of specific 
function and/or ligand binding sequences, of significance to its structural role in the 
basement membrane. Although there are many possible combinations among the six alpha 
chains, only three are biologically compatible and found in basement membranes. These are 
composed of α1α1α2, α3α4α5 and α5α5α6. Type IV collagen participates in forming 
networks interacting with additional important components of the basement membranes, 
such as laminin and nidogen 3,4. As a component of the glomerular filtration barrier, along 
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with the endothelial cells and the podocytes, basement membranes play a crucial role as a 
selective filter, based on molecular size and charge. A damage of the basement membrane or 
inherited defects such as mutations in type IV collagen lead to the abnormal passage of red 
blood cells in the urine. Mutations in five of the six COL4A chains have been linked to 
specific phenotypes (Table 1). 
 
Chain Gene Chromosome Disease association References 
α1(IV) COL4A1 13q34 
Porencephaly; Brain small vessel disease with 
hemorrhage;  autosomal dominant hereditary 
angiopathy with nephropathy, aneurysms, and 
muscle cramps (HANAC syndrome) 
20-22 
α2(IV) COL4A2 13q34 None  
α3(IV) COL4A3 2q36–q37 
Autosomal Recessive Alport Syndrome;  
Autosomal Dominant Alport Syndrome; Benign 
Familial Hematuria and Thin Basement 
Membrane Nephropathy; Thin Basement 
Membrane Nephropathy associated with Focal 
Segmental Glomerulosclerosis 
1, 9, 23, 24 
α4(IV) COL4A4 2q36–q37 
Autosomal Recessive Alport Syndrome;  
Autosomal Dominant Alport Syndrome; Benign 
Familial Hematuria and Thin Basement 
Membrane Nephropathy; Thin Basement 
Membrane Nephropathy associated with Focal 
Segmental Glomerulosclerosis 
1, 9, 25, 26 
α5(IV) COL4A5 Xq22-23 X-liked Alport Syndrome 27 
α6(IV) COL4A6 Xq22-23 
X-liked Alport Syndrome with Diffuse 
Leiomyomatosis 
(Contiguous Gene Syndrome) 
28 
Table 1. Type IV collagen chains, genes, chromosomal locations and related diseases. 
2. Familial microscopic hematuria 
In view of the Case we are presenting in the next section, it is worth discussing the issue of 
microscopic hematuria as the presenting symptom of patients with TBMN due to 
heterozygous mutations in the collagen IV genes. According to some older publications, 
these patients occasionally progress to proteinuria and chronic kidney disease (CKD) while 
a small percentage reach end-stage kidney disease (ESKD) on long follow-up 5-8. In a paper 
we published in 2007, we presented our initial experience in investigating 116 patients of 13 
Cypriot families, where 20 renal biopsies had the dual diagnosis of focal segmental 
glomerulosclerosis (FSGS) and TBMN. These families segregated microscopic hematuria, 
mild proteinuria and CKD of variable severity, including several patients with ESKD. 
Initially, we searched with no success, for mutations in genes responsible for primary 
autosomal dominant FSGS, such as ACTN4 (α-actinin 4) and CD2AP that were known and 
cloned at the time 9. After some lengthy molecular investigations and new ideas, we ended 
up discovering that all patients who had FSGS on biopsy as well as many others in the same 
families, had heterozygous mutations in the COL4A3 or COL4A4 genes, which when 
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inherited in homozygosity or compound heterozygosity cause the classic autosomal form of 
Alport syndrome. In fact in one of our families, two patients developed classical Alport 
syndrome, as compound heterozygotes, after they inherited two mutations, one from each 
parent (G1334E/G871C) 9. 
In heterozygous patients, this dual diagnosis of TBMN and FSGS in the presence of CKD could 
not be easily explained. However this work established that under certain circumstances that 
are not so uncommon, several such patients do not remain with only familial benign 
microscopic hematuria that offers excellent renal prognosis but rather after the age of 40-50, 
some of them progress to CKD and ESKD. Long follow-up is the norm in our setting in 
Cyprus, where owing to the small population and the limited number of nephrology centers 
(six in total, including one pediatric nephrology clinic), the patients are attended by a small 
number of experts over several decades. Our current data of 180 patients reveal that nearly 
50% of patients at all ages develop additional proteinuria with some degree of CKD, while 
21% progress to ESKD (25% of all patients >50-yo) perhaps owing to the confounding role of 
modifier gene(s). These data cast doubt on the correctness of the belief that the diagnosis of 
TBMN, in patients who are heterozygous carriers of mutations in the COL4A3/COL4A4 genes, 
is synonymous to "benign familial hematuria" with excellent renal prognosis. 
3. Case presentation 
In early 2008, a young Greek couple from Athens was referred to our laboratory with a clinical 
situation summarized as follows: The proband, individual III-2 in Figure 1A, was married and 
interested in having children. She and her husband asked for appropriate investigations 
aiming, if possible, to have an antenatal test, in order to avoid having children who might 
develop ESKD like her father. On her father’s side there was no previous easily diagnosed 
history for a familial renal disease. Her father II-1, had presented in a London hospital in 1991, 
at age 46 years, with persistent microscopic hematuria, proteinuria 3.3g/day, hypertension on 
treatment with Enalapril, and with chronic renal failure, as evidenced by elevated serum 
creatinine and urea levels. The attending nephrologist estimated his creatinine clearance at 40-
50 ml/min. A renal biopsy showed early glomerulo-sclerosis and uniform thinning of the 
GBM on EM that also included focal splitting. In the report, the diagnosis of possible 
hereditary Alport nephritis was discussed but it was not certain. He reached ESKD, four years 
later, at 50 and was transplanted at 52-yo, still with no deafness. The proband and her older 
sister had microscopic hematuria since childhood. In addition to microscopic hematuria, the 
proband’s sister, III-1, had proteinuria. The proband’s mother was healthy. The paternal uncle, 
subject II-3, had proteinuria of 2g/day, reduced GFR and elevated plasma creatinine at 2.8 
mg/dl, with normal hearing which remained normal until the age of 54 when the last 
information is available. He also underwent a renal biopsy at age 45 years, which was 
compatible with focal and segmental glomerulosclerosis but no EM results were available. The 
proband’s paternal grand-mother, subject I-2, was diagnosed with mild renal failure at age 76-
yo, when she was evaluated and was refused to serve as a living kidney donor to her son. Her 
findings could not be properly evaluated and were attributed at the time to a familial 
condition or age related. The proband had been a competitive swimmer during adolescence 
and had studied physical education, something that initially prompted her nephrologist in 
Greece to attribute her microscopic hematuria to her extreme physical activities. Because of the 
above uncertain family history, the proband sought professional counselling and inquired 
about the prospects of molecular genetics helping her reach a correct diagnosis. At the same 
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time she and her husband were interested in undergoing a prenatal diagnosis in order to 
minimize the likelihood of bearing an affected child. 
 
 
Fig. 1. A: Pedigree with relevant clinical information of the subjects under study. Note that 
the overall clinical scenario does not support a clear-cut X-linked or autosomal inheritance 
pattern. 
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4. Differential diagnosis 
Even though the X-linked Alport syndrome was a reasonable suspicion, the attending 
nephrologist in Greece was not in a position to support this diagnosis unequivocally. The 
biopsy histological picture and the EM findings of diffuse thinning of the GBM in particular, 
the absence of deafness as well as the very late age of onset of ESKD of the proband’s father 
were not supportive of the classic adolescence onset X-linked Alport, as known in the early 
1990’s. This uncertainty was strengthened by the similar and even milder clinical course of 
his brother. The diagnosis was rather on the borderline between X-linked Alport syndrome 
and the heterozygous autosomal recessive Alport syndrome that actually presents with 
TBMN and microscopic hematuria, and then on long follow-up may develop FSGS with 
progression to CKD and ESKD. This second scenario for TBMN as the primary diagnosis 
was supported by our recent publication at the time, where we showed that in a large cohort 
of patients with COL4A3/COL4A4 heterozygous mutations, a great percentage of patients 
can progress to CKD and/or ESKD with the need for hemodialysis or kidney 
transplantation, mostly around or after 50 years of age 9. Actually, our current data show 
that 21% of such patients at all ages progress to ESKD, most of them after the age of 50. 
The proband was interested in a prenatal diagnosis by molecular means, if possible. 
Therefore, considering that the molecular analysis of the implicated genes is costly and 
cumbersome some prerequisites had to be satisfied: 
a. Confirmation of the familial nature of the disease,  
b. a definite clinical diagnosis,  
c. the gene at fault had to be identified unequivocally,  
d. the germline mutation or the affected haplotype had to be identified, and  
e. a definite and unequivocal molecular test had to be developed. 
In view of the uncertainty of the clinical diagnosis, a genetic counseling session took place 
between the nephrologist, the gynecologist and the parents in Greece, and the geneticist in 
Cyprus, which resulted in the decision to investigate further the family with molecular 
tools, with the purpose of satisfying the above necessary criteria before proceeding to 
pregnancy and a molecular prenatal test. At the time, the only credible symptom that 
segregated in the family in a dominant fashion was the microscopic hematuria, with three 
patients in two generations. 
5. Molecular investigations 
In order to solve the diagnostic dilemma we were faced with and be able to perform a 
prenatal molecular diagnosis according to the couple’s desire, we used the molecular 
approach. To this end, we first performed classic DNA linkage analysis for the Xq22-23-
linked COL4A5 locus and the chromosome 2q36-37-linked COL4A3/COL4A4 locus.  
As shown in Figure 1B, 1C, we used four polymorphic microsatellite markers flanking  
the COL4A3/COL4A4 locus and four markers flanking the X-linked locus of COL4A5. Under 
the assumption that the two affected brothers, subject II-1 and subject II-3, had inherited  
the same disease, we saw that they had inherited from their parents two different 
haplotypes around the COL4A3/COL4A4 locus. The probability for this to happen is 25%  
but this serendipitous event assisted us in excluding this locus as being at fault. Please note 
that under either an autosomal dominant or autosomal recessive mode of inheritance, if  
the two brothers had inherited the same disease from their parents we expected them to 
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have at least one haplotype or two haplotypes, respectively, in common. In Figure 1C  
the analyses with the X-chromosome-linked markers show that both affected brothers, 
inherited the same haplotype from their mother which, as expected was passed on to the 
subject’s two daughters. Even though this data was not strong enough based on the 
uncertain clinical diagnosis, we interpreted it as exclusion of the 2q locus and probable 
linkage to the X-linked locus. 
 
 
Fig. 1. B: Pedigree with DNA linkage analysis results at locus 2q36-37 (COL4A3/COL4A4). 
Note that the two brothers, II-1 and II-3, have inherited different haplotypes from their 
parents, hence proving no linkage to this locus. 
The Power of Molecular Genetics in Establishing the  




Fig. 1. C: Pedigree with DNA linkage analysis data for locus Xq22-23 (COL4A5). Note that 
these results are compatible with X-linked inheritance. 
We then engaged into re-sequencing the COL4A5 gene in patient II-1 by amplifying and 
sequencing all exons, including the splicing junctions and around 100 bp of flanking intronic 
regions. This sequencing revealed several polymorphic sites as well as a collagen mutation at 
position 624 that resulted in substitution of glycine by aspartic acid, G624D 10. This mutation 
had been previously reported by three other groups and it was known to be associated with a 
milder Alport Syndrome phenotype, something that supported the mild presentation in our 
family 11-13. Further molecular analysis for this mutation by polymerase chain reaction and 
restriction enzyme digestion showed that the two brothers II-1 and II-3 share this identical 
mutation which they have both inherited from their mother, individual I-2 in the pedigree 
(Figure 2). As expected, both daughters of subject II-1 inherited this mutation as they both 
inherited the X chromosome from their father. We now had a definite molecular test we could 
use for a prenatal diagnosis. We then communicated this information to the doctors and the 
couple and they went on with a pregnancy and a chorionic villous sampling at around ten 
weeks of gestation. Molecular testing was performed which showed that the foetus was a 
mutation-free male. The mother delivered a boy that on testing had no microscopic hematuria. 
No molecular analysis has been performed on the child yet. Approximately two years later the 
couple went on for a second pregnancy and a prenatal diagnosis showed again a healthy male. 
The pregnancy is still in progress. 
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Fig. 2. DNA amplification by polymerase chain reaction, followed by restriction digest with 
enzyme EcoRV and electrophoresis on 3% agarose gel. The mutation G624D introduces a 
recognition site for EcoRV. Samples in lanes 1, 3 are from normal subjects, lane 2 is from a 
heterozygous female and lane 4 is from a hemizygous male. The region amplified 
encompasses exon 25 where the mutation G624D is located. It is a substitution of aminoacid 
glycine by aspartate because of a G>A transition at the second position of codon 624. 
6. Ethical issues 
The issue of prenatal diagnosis is always a difficult one and should be accompanied by 
proper professional genetic counselling. The classic Alport Syndrome is supposed to be one 
of the most severe glomerular diseases usually leading to ESKD before 30 years of age. It is 
true however, that in addition to this so called juvenile onset disease, there is the adult type 
where patients develop CKD and reach ESKD at older ages 14,15. Based on current literature, 
this is certainly published and known by many experts; apparently though it has not 
become common knowledge to the average practising clinician. In addition to the family 
presented here we have identified five other families of Hellenic origin who share this same 
mutation, G624D, with a total of 13 male patients (unpublished results). Although the 
spectrum of clinical presentation is quite variable, the overall impression is that this 
mutation is a very mild one that leads to ESKD after the age of 40 years, even close to or 
after 50 years, in most cases. At the same time the EM studies do not show the classical 
thickening and lamellation of the usual X-linked Alport but extensive thinning of the GBM. 
Our findings agree with data presented in previous publications that identified this 
mutation in families from other populations 10-13. However, the uncertainty and anxiety that 
accompany at-risk members belonging to families with conditions like this cannot always be 
dealt adequately clinically. This anxiety in the family and the uncertainty as to whether they 
were dealing with an X-linked or autosomal disease and the possibility of bringing to life an 
affected child, had led them to terminate an earlier pregnancy where the foetus was a male 
one. We only became aware of this event after the successful birth of their healthy first child. 
The aborted embryo might have been an affected or a healthy male under the scenario of  
X-linked inheritance; alternatively the embryo might have been a healthy male carrying no 
mutation or a heterozygous male, under the scenario of autosomal inheritance.  
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7. Discussion-concluding remarks 
One cannot escape the conclusion that molecular genetics is an extremely powerful tool to 
use in present day clinical medicine. In another two families we had in Cyprus that 
segregated COL4A5 mutation P628L, none of the clinicians that cared for the patients had 
initially thought of X-linked Alport Syndrome. The variable expression, the very late onset 
of ESKD and the milder atypical symptoms of male and female patients, even in the 
presence of older patients with ESKD, did not prompt us to suspect at the beginning  
X-linked Alport syndrome. A renal biopsy in one patient established the presence of TBMN, 
thereby suggesting different explanations. Interestingly, the pedigree structure could not 
give a clear-cut information for X-linked or autosomal inheritance, considering that some 
females had symptoms of the disease 10. The symptoms in six female carriers included 
microscopic hematuria while two of them exhibited additional non-nephrotic proteinuria. 
Also, a renal biopsy of a 19-year-old female showed TBMN with FSGS. At this setting, 
perhaps a skin biopsy and immunostaining for collagen IV might be enlightening if the 
staining came out negative for the alpha 5 chain. No such biopsy was attempted. 
Molecular testing for the COL4A5 was attempted based on the inheritance of microscopic 
hematuria and exclusion of linkage to the chromosome 2 locus. It was only the molecular 
approach that established the diagnosis and enabled proper counselling and treatment to 
the concerned members. 
Another issue that complicates matters is the genetic heterogeneity observed in a number of 
diseases, including inherited kidney conditions. Molecular defects in more than one gene 
complicate things as it doubles or triples the effort and the cost for a definite diagnosis. 
Newer tools and more robust methods for gene re-sequencing are clearly making things 
easier. Next generation sequencing and exome sequencing aimed at analyzing specifically 
the coding exonic sequences, can accelerate COL4A3/COL4A4 screening in 1-2 weeks instead 
of the 8-12 months needed with the conventional methods in small laboratories 16. However, 
still not every routine clinical diagnostic or University research laboratory is equipped with 
or has easy access to this newer generation of technology and machinery. 
In conclusion, as regards the Alport Syndrome and mutations in one of the COL4 genes, one 
should be aware of a) the rare, milder cases of X-linked COL4A5, Alport syndrome that 
presents with TBMN and delayed ESKD in the 50’s and b) the late development of CKD and 
ESKD in patients with heterozygous COL4A3/COL4A4 mutations and TBMN, also referred 
to by some as autosomal dominant Alport. The spectrum of these collagen IV nephropathies 
extends from vary mild cases with isolated microscopic hematuria for life on one end, and 
patients reaching ESKD during adolescence on the other end. Professionals involved in 
offering treatment and genetic counselling should be aware of these wide scenarios and they 
should offer the best possible advice making use of all available tools of our generation, 
including molecular approaches. Finally, it should be realized that the aetiology of familial 
microscopic hematuria is even more heterogeneous genetically. Recently, another inherited 
glomerulopathy, CFHR5 nephropathy, was described by Gale et al (2010) 17 and Athanasiou 
et al (2011) 18 that is mainly characterized by isolated C3 deposits in the mesangium and the 
sub-endothelial GBM area of the glomerulous. This nephropathy presents usually in 
childhood with persistent microscopic hematuria and 25% of such patients also show 
episodes of macroscopic hematuria that usually follow upper respiratory tract infections. 
Mostly affected are the male patients who can also progress to CKD and ESKD at ages over 
30-40. Therefore, a useful algorithm is presented as a guideline for molecular testing of 
patients belonging to families segregating glomerular microscopic hematuria. A kidney or a 
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skin biopsy may be performed before or after the molecular analysis depending on the 
clinical status or disease progression of the patient, for histological evaluation 19 (Figure 3). 
 
 
Fig. 3. Algorithm for molecular testing of patients belonging to families segregating 
microscopic hematuria of glomerular origin. A histological evaluation via a skin or renal 
biopsy accompanied by immunostaining before or after molecular investigations are 
performed, may assist in the diagnosis or provide useful clues for the direction of molecular 
analysis. When a causative germinal mutation is identified, it becomes feasible to offer genetic 
counseling as well as a reliable molecular diagnosis and prenatal testing with much easier and 
mush less costly approaches (From ref. 19, with permission from Springer Publisher).  
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Dent’s disease (MIM #300009) is a rare X-linked disorder characterized by various degrees of 
proximal tubular (PT) dysfunction, nephrocalcinosis and nephrolithiasis. The exact 
prevalence is unknown. The disease was first reported by Dent and Friedman, who 
described two males with vitamin D resistant rickets, hypercalciuria and low molecular 
weight proteinuria (LMWP) (Dent & Friedman, 1964). Based on these data and another 13 
patients with a similar phenotype, Wrong et al. coined the term “Dent’s disease” for the 
combination of X-linked low molecular weight proteinuria, hypercalciuria, 
nephrocalcinosis, metabolic bone disease and progressive renal failure (Wrong et al., 1994). 
With the advent of molecular genetics it has become clear that the phenotypically similar 
disorders X-linked recessive nephrolithiasis with renal failure (MIM #310468) and X-linked 
recessive hypophosphatemic rickets (MIM #300554) are also due to mutations in the CLCN5  
gene (Lloyd et al., 1996). Familial idiopathic LMW proteinuria with hypercalciuria in 
Japanese patients (MIM #308990) – also referred to as Dent’s Japan disease (Igarashi et al., 
1995) - is a fourth clinical entity resulting from CLCN5 mutations (Nakazato et al., 1997). 
Therefore, Scheinman proposed to summarize CLCN5-associated renal disease under the 
term “X-linked hypercalciuric nephrolithiasis” (Scheinman, 1998). The same clinical 
phenotype has been observed with some mutations in the oculo-cerebrorenal syndrome of 
Lowe (OCRL) gene and is referred to as Dent-2 disease (MIM #300555) (Hoopes et al., 2005; 
Utsch et al., 2006).  
2. Clinical manifestations 
The clinical presentation of Dent’s disease is frequently subtle with the majority of patients 
being asymptomatic during childhood. Therefore, many patients are identified through 
urine screening for hematuria and proteinuria as it is done systematically in Japanese school 
children (Lloyd et al., 1997).  
A summary and the frequency of the major clinical and biochemical characteristics of Dent’s 
disease are presented in table 1. Hereby it should be noted that the manifestations of Dent’s 
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disease are highly variable even within the same family and there is no genotype-phenotype 








LMWP 100% (212/212) 
100% 
(28/28) 
Hypercalciuria 90% (180/200) 
86% 
(24/28) 
Nephrocalcinosis 75% (137/182) 
39% 
(11/28) 
Aminoaciduria 41% (31/75) 
52% 
(11/21) 
Renal tubular acidosis 3% (2/68) 
4% 
(1/27) 
Phosphate wasting 22% (35/156) 
24% 
(6/25) 
Potassium wasting 15% (10/67) 
6% 
(1/18) 
Glycosuria 17% (18/108) 
11% 
(3/28) 
Renal failure 30% (60/203) 
32% 
(8/25) 
Table 1. Spectrum of renal dysfunction in Dent’s disease due to CLCN5 (Dent 1) and OCRL  
(Dent 2) mutations (adapted from Bökenkamp et al., 2009).  
Although nephrocalcinosis and hypercalciuria are characteristic findings in Dent’s disease, it 
is the presence of LMWP, which distinguishes patients with CLCN5 mutations from other 
hypercalciuric stone-formers (Scheinman et al., 2000). Protein excretion in Dent’s disease is 
around 0.5 to 1 g per day, with LMWP accounting for 50 to 70% of the total protein 
(Scheinman et al., 1998).  LMWP can be detected by means of SDS-PAGE urine 
electrophoresis, or by measurement of marker proteins such as alpha-1 microglobulin, beta-
2-microglobulin, cystatin C, lysozyme or retinol-binding protein in the urine. As albumin 
absorption by endocytosis in the proximal tubule is also impaired, albuminuria is present as 
well and can be detected by urine dipstick analysis. Recently, two papers reported 
asymptomatic nephrotic-range proteinuria of up to 50 mg/m2/h in 6 patients with CLCN5 
mutations (Frishberg et al., 2009; Copelovitch et al., 2007). Of note, serum albumin was 
normal in all these patients and urine protein consisted largely of low molecular proteins, 
which underscores the need to measure low molecular proteins in patients with 
unexplained proteinuria. 
The majority of patients have nephrocalcinosis, while nephrolithiasis is observed in some 
40% of patients (Claverie-Martin et al., 2011). The kidney stones are composed of calcium 
phosphate, calcium oxalate or a combination of both (Wrong et al., 1994; Scheinman, 1998). 
Nephrolithiasis and nephrocalcinosis are also observed in the absence of hypercalciuria 
(Ludwig et al., 2006), which may be explained by a defect in the clearance of microcrystals in 





2003, 2004).  Urinary excretion of citrate and oxalate is normal in the majority of cases 
(Wrong et al., 1994; Scheinman et al., 1998), while urinary acidification may become 
impaired with progressive nephrocalcinosis (Ludwig et al., 2006).   
Mild to moderate hypercalciuria of 4 to 6 mg/kg per day is characteristic for Dent’s disease, 
with higher calcium excretion being found in childhood (Scheinman, 1998). In about 10% of 
patients with CLCN5 mutations, hypercalciuria is missing, in particular in patients with renal 
failure because calcium excretion diminishes with decreasing GFR (Ludwig et al., 2006). Half 
of the patients are reported to have fasting hypercalciuria and almost all have an exaggerated 
calciuric response after an oral calcium load (Reinhart et al., 1995). Serum parathyroid 
hormone levels are usually low, while levels of 1,25-dihydroxyvitamin D are frequently high 
(Scheinman, 1998). This reflects the complex balance between the loss of 25-hydroxyvitamin D 
along with vitamin D binding protein and the stimulation of 1,25-dihydroxyvitamin D 
synthesis by increased luminal parathyroid hormone delivery (Günther et al., 2003).   
Kidney function is normal during childhood in most patients with a slowly progressive 
decline during adulthood leading to end-stage renal failure in 30 to 80% of affected patients 
in the 3rd to 5th decade (Wrong et al., 1994; Bökenkamp et al., 2009).  Histological studies 
may be normal or show tubular atrophy and interstitial fibrosis, foci of calcinosis and non-
specific glomerular changes as hyalinosis, sclerosis and periglomerular fibrosis (Wrong et 
al., 1994). Recently, two papers reported focal segmental glomerulosclerosis with 
asymptomatic nephrotic range proteinuria associated with CLCN5 mutations (Frishberg et 
al., 2009; Copelovitch et al., 2007). As pointed out by Wrong et al., the progressive decline in 
renal function is more severe than would be expected as a result of nephrocalcinosis alone 
(Wrong et al., 1994), but is characteristic for various forms of the renal Fanconi syndrome 
(Norden et al., 2001). Norden et al. demonstrated increased concentrations of potentially 
bioactive hormones and chemokines such as parathyroid hormone, insulin, insulin-like 
growth factor 3, growth hormone and monocyte chemoattractant protein 1 in the urine of 
patients with Dent’s disease, autosomal dominant Fanconi syndrome and Lowe syndrome 
which may be involved in the pathogenesis of the progressive tubulointerstitial damage 
(Norden et al., 2001).  
The proximal-tubular defect in Dent’s disease may lead to hypophosphatemia. However, 
there is no clear correlation between the degree of hypophosphatemia and the presence of 
rickets, which can be observed in about 1/3 of Dent’s patients (Scheinman, 1998). Renal 
potassium wasting – although relatively infrequent - may be exacerbated by the use of 
thiazide diuretics as reported by Blanchard et al. (Blanchard et al., 2008).  Another finding in 
patients with Dent’s disease as well as in other conditions with proximal tubular 
dysfunction is the decreased uptake of 99mcTc-DMSA (dimercaptosuccinic acid) in renal 
parenchyma with rapid excretion of the tracer into the urine (Lee et al., 2009).  
Depending on the degree of lionization, female carriers display a milder phenotype. LMWP is 
seen in 60 to 90%, while hypercalciuria was observed in around 30% (Reinhart et al., 1995). 
Although abnormal, the amount of LMWP is 10 to 100 times lower than in males (Scheinman, 
1998). Nephrolithiasis and nephrocalcinosis are infrequently seen, and there is only 1 case of 
end stage renal disease in a female carrier reported so far (Devuyst & Thakker, 2010).  
The diagnosis of Dent’s disease is based on the presence of low molecular weight proteinuria, 
hypercalciuria, nephrocalcinosis/nephrolithiasis and various degrees of generalized 
proximal dysfunction and decreased GFR in otherwise phenotypically healthy males.  
Differential diagnosis should include other inherited and acquired causes of proximal tubular 
dysfunction such as cystinosis, Lowe syndrome, mitochondrial nephropathy or ifosfamide 
nephropathy.  
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3. Underlying genetic causes 
3.1 CLCN5 gene (Dent 1, MIM #300008) 
The CLCN5 gene, affected in patients with Dent 1 disease, was initially identified in a family 
with a microdeletion on the X-chromosome (Fisher et al., 1995). The inheritance is X-linked 
with ~10% of the mutations being de novo (Devuyst & Thakker, 2010). CLCN5 encodes an 
electrogenic Cl-/H+ antiporter (ClC-5) (Picollo & Pusch, 2005; Scheel et al., 2005) with a 
transport stoichiometry of 2 Cl- / 1 H+ (Zifarelli & Pusch 2009). ClC-5 contains two 
phosphorylation and one N-glycosylation sites and comprises 18 helices (A - R), which show 
an internally repeated pattern (helices B - I and J - Q, respectively) forming two roughly 
repeated halves that span the membrane in opposite (antiparallel) orientations (Dutzler et 
al., 2002) (Fig.1). The selective flow of chloride ions across cell membranes is catalyzed by a 
ClC-5 homodimer, with each channel subunit forming its own chloride pore (Dutzler et al., 
2002; Jentsch, 2002). 
 
 
Fig. 1. Topology diagram of the ClC-5 protein adopted from Dutzler et al. (2002, 2003) and 
Wu et al. (2003). Boxed areas depict helices A-R with the extracellular region shown above, 
and the cytoplasmic region shown below. Amino acids (helices D, F, N, and R) involved in 
chloride selectivity filter formation are indicated by black triangles; helices H, I, P, and Q are 
involved in formation of the dimer interface. Further regions of functional significance are 
boxed in light gray: SSS, sorting signal sequence (Schwappach et al., 1998); CBS1 and CBS2, 
cystathionine-β-synthase sequences forming the so-called Bateman domain (Bateman, 1997) 
that binds ATP (Scott et al., 2004); PY, proline/tyrosine-like internalization signal motif 
(Schwake et al., 2001). The additional 70 aminoterminal residues in the enlarged ClC-5 
isoform (Ludwig et al., 2003) are shown with overall numbering starting with the 
methionine of the short variant (from Ludwig et al., 2005 printed with kind permission of 





The CLCN5 gene spans ~170 kb on chromosome Xp11.23/p11.22 and comprises 17 exons 
with transcription initiating from at least four different start sites. Transcripts including the 
untranslated exon 1a (Hayama et al., 2000) or 1b (Fisher et al., 1995) are spliced to exon 2 
containing the start-ATG, whereas a third mRNA comprises a larger exon 1b and retains 
intron 1 (Forino et al., 2004). Two further transcripts (harbouring additional exons I-IV), 
arise due to alternative splicing of exon II, and are also spliced to exon 2 (Ludwig et al., 
2003). Both transcripts carry the start-ATG in exon III, thereby coding for a longer isoform of 
the ClC-5 protein with additional 70 amino acids at the intracellular amino terminus. Since 
these two mRNAs maintain the reading frame, the start-codon of the shorter form (746 
amino acids) here resides at position 71. So far, the longer variant has only been detected at 
mRNA but not at protein level (Ludwig et al., 2003). 
More than 140 distinct CLCN5 mutations, distributed along the entire gene, have been 
reported in patients with Dent 1 disease and no major mutational hot spots have been 
observed (Wu et al., 2009). There is also no evidence for a genotype-phenotype correlation. 
Various mutations were found to be associated with quite different clinical phenotypes 
ranging from ‘classic’ Dent 1 disease to very slight urinary abnormalities, not only in 
unrelated patients, but even within the same family (Ludwig et al., 2006).  
Dysfunction of mutant ClC-5 channels may be caused by various mechanisms and a lot of 
the mutations observed are predicted to result in a truncated or absent protein. Complete 
loss of antiporter function might be caused by impaired homodimerization, altered current 
kinetics, altered ion selectivity, or defective intracellular trafficking. Heterologous 
expression of various CLCN5 mutants, in either Xenopus laevis oocytes or HEK293 cells, 
determined a loss of Cl- conductance in the majority of mutations tested (Lloyd et al., 1996; 
Ludwig et al., 2005). Further consequences of CLCN5 mutations were (i) improper N-
glycosylation with endoplasmic reticulum retention and degradation of ClC-5 (ii) defective 
endosomal acidification, (iii) altered endosomal distribution of ClC-5 but not defective 
endosomal acidification (IV) delayed processing with reduced stability and lower cell 
surface expression, or impaired internalization (Ludwig et al., 2005; Smith et al., 2009; Grand 
et al., 2011). The majority of missense mutations cluster at the dimer interface and have been 
shown to disrupt the assembly of the homodimers (Wu et al., 2003; Smith et al., 2009).  
ClC-5-deficient mice recapitulate the human phenotype of Dent’s disease with LMWP, 
generalized aminoaciduria, glycosuria, hypercalciuria and renal calcium deposits. Proximal 
tubular endocytosis is severely impaired in ClC-5-deficient mice, proving a role for ClC-5 in 
endosomal uptake of low molecular weight proteins (Wang et al., 2000).  
3.2 OCRL gene (Dent 2, MIM #300555) 
Recent investigations have revealed defects in the OCRL gene in about 15% of patients with 
a Dent’s phenotype (Hoopes et al., 2005; Böckenhauer et al., 2011). This gene, located at 
Xq26.1 comprises 24 exons occupying 52 kb, and alternative splicing of exon 18a enlarges 
the resultant 893 amino acids-long protein by eight (in frame) additional amino acids 
(Nussbaum et al., 1997). OCRL encodes a phospatidylinositol 4,5-bisphosphate 5-
phosphatase and mutations herein were initially found to cause Lowe syndrome (MIM 
#309000), a pleiotropic disease, characterized by the triad of congenital cataracts, mental 
retardation and incomplete renal Fanconi syndrome (Böckenhauer et al., 2008). In the OMIM 
database, Dent’s disease associated with OCRL mutations is now termed Dent 2 disease 
(MIM #300555) to distinguish these patients from the more severe Lowe phenotype. Except 
a lower prevalence of nephrocalcinosis, the renal phenotype is comparable to Dent 1 cases 
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harbouring a CLCN5 mutation (Table 1). Dent 2 may present with (mild) extra-renal Lowe 
symptoms (peripheral cataracts, stunted growth, mild retardation, elevation of serum 
CK/LDH), implying that Dent 2 disease actually represents a mild form of Lowe syndrome 
(Bökenkamp et al., 2009; Böckenhauer et al., 2011). 
By now, 44 Dent 2 patients having OCRL mutations have been reported (Böckenhauer et al., 
2011; Hichri et al., 2011). Whereas frame shift mutations or splice defects leading to a 
premature stop codon in Dent 2 patients all cluster in exons 1-7, they exclusively affect 
exons 8-23 in Lowe syndrome. Dent 2 was also observed with several missense mutations in 
exons 9-19, exons typically implicated in Lowe syndrome. Initially, none of the mutations 
observed in Dent 2 cases had been found in association with classic Lowe syndrome and 
there was no explanation why the phenotypic consequences of premature termination 
mutations, expected to cause classic Lowe syndrome, led to the milder form of Dent 2. Most 
recently, however, Hichri et al. (2011) reported two different OCRL mutations (p.Ile274Thr, 
p.Arg318Cys) each causing both phenotypes even in the same family. Moreover, a patient 
showing the complete phenotypic Lowe spectrum but absence of any ocular involvement 
harboured an exon 8 termination mutation (p.Gln199X) (Ludwig et al., 2011), thereby 
presenting the most severe clinical intermediate between Dent disease and Lowe syndrome. 
Given these observations, there exists a phenotypic continuum between patients with Dent 2 
disease and Lowe syndrome, not only between patients harbouring different OCRL 
mutations but also between family members affected by the same OCRL defect. 
Nonetheless, the reason(s) why different OCRL mutations manifest with the respective 
phenotype remain(s) to be elucidated. This may be related to the expression profile of 
inositol polyphosphate 5-phosphatase (INPP5B), which has been shown to compensate for 
Ocrl deficiency in a mouse model (Jänne et al., 1998). Mice deficient in Ocrl or Inpp5b show 
little or no phenotype, whereas deficiency of both genes leads to death before implantation. 
Interestingly, mouse Inpp5b and human INPP5B differ in expression and splice-site choice 
(Bothwell et al., 2010). Most recently a mouse model for Lowe syndrome and Dent 2 disease 
tubulopathy was established by expressing human INPP5B in the Ocrl-/- mice (Bothwell et 
al., 2011). These mice showed reduced postnatal growth, LMWP, and aminoaciduria and 
suggest that human INPP5B genotype may influence the clinical manifestation of Dent 
2/Lowe syndrome.  
It has also been speculated that the use of alternative initiation codons (methionine at 
position 158, 187, and 206) in exons 7 and 8 will allow the synthesis of truncated OCRL 
proteins. Indeed, Hichri et al. (2011) have detected two smaller proteins (around 80 kDa) 
instead of the 104 kDa full-length protein in a Dent 2 case lacking the normal initiator ATG 
in exon 1. Hence, some residual activity of these smaller products might contribute to the 
phenotypic differences observed.  
3.3 Dent’s disease and other candidate genes 
Molecular analyses provided evidence for genetic heterogeneity in Dent’s disease as in 
around 25% of patients with typical features of Dent’s disease no CLCN5 or OCRL mutations 
could be detected (Böckenhauer et al., 2011). These patients may carry a CLCN5/OCRL 
mutation undetectable by the common PCR analysis (e.g. in the promoter or an intron, 
thereby leading to a decrease in expression or a cryptic splice product). On the other hand, a 
defect in another gene phenocopying Dent’s disease might be responsible. Four candidate 





CLCN4, the gene encoding ClC-4 has been analyzed (Ludwig and Utsch, 2004; Hoopes et al. 
2005; Wu et al., 2009), since it is located on Xp22.3 and mutations herein would consequently 
show an X-linked mode of inheritance. ClC-4 (i) is also a member of the ClC-family of 
chloride channels, giving rise to strongly outwardly rectifying anion currents closely 
resembling those of ClC-5 (Friedrich et al., 1999), (ii) alike ClC-5, contributes to endosomal 
acidification and trafficking by epithelial cells of the renal proximal tubule (Mohammad-
Panah et al., 2003), and (iii) could be co-immunoprecipitated with ClC-5, indicating that 
both channels may interact in vivo (Mohammad-Panah et al., 2003). In a total of 30 unrelated 
cases no defect was observed. 
Hoopes et al. (2005) investigated the SLC9A6 gene in a panel of 13 patients that met the strict 
criteria for Dent's disease. SLC9A6, located at Xq26.3, encodes the Na+/H+ exchanger 6 
(NHE6; Numata et al., 1998). This sodium-proton exchanger localizes to early recycling 
endosomes and may contribute to the maintenance of the unique acidic pH values of Golgi 
and post-Golgi compartments (Nakamura et al., 2005). The X-linked TMEM27 gene has also 
been suggested a good candidate since it codes for collectrin, a transmembrane glycoprotein 
expressed on the apical membrane of proximal tubuli that was shown to be essential for 
renal amino acid transport (Danilczyk et al., 2006). However, mutation analysis was 
negative in 26 Dent-like patients as well (Tosetto et al., 2009) as was the case in 10 patients 
analyzed for defects in CFL1 (Wu et al., 2009). This autosomal gene locates on chromosome 
11q13.1 and encodes cofilin, a protein shown to interact with ClC-5 in regulating albumin 
uptake in the proximal tubule (Hryciw et al., 2003). 
Given these negative results, a further causative gene still awaits identification. Moreover, 
effects of (a) modifier locus(i) may influence the phenotype in Dent’s patients. This would 
explain the heterogeneity in the clinical features observed among non-related patients 
sharing the same mutation or even between family members affected by the same defect 
(Ludwig et al., 2006). 
4. Pathophysiology of Dent’s disease 
4.1 Localisation of ClC-5 in the kidney 
In the kidney ClC-5 is found predominantly expressed in the proximal tubule and in α-
intercalated cells of the distal nephron. A small fraction may be present at the cell surface of 
the medullary thick ascending limb of Henle’s loop. In the proximal tubule ClC-5 is mainly 
located in the intracellular subapical endosomes, where it is co-expressed with the proton 
pump (V-type H+ ATPase).  
4.2 Role of ClC-5 in endosomal acidification 
Along the endocytic pathway a successively decreasing pH from 6.3 to 4.7 is detected in 
early endosomes, late endosomes and lysosomes with a change in the ionic composition 
along the endocytic pathway (Casey et al., 2010; Scott et al., 2010). The acidification is mainly 
due to vacuolar H+ ATPase, mediating ATP-dependent transport of protons. The movement 
of H+ across the endosomal membrane results in a net charge translocation, which has to be 
neutralized by a passive influx of counter ions such as chloride or by efflux of another 
cation. Na+ entry increases the membrane potential and limits acidification.  
TRPML3 belongs to the mucolipin family of the TRP ion channels and is present in the early 
endosomes (Puertollano et al., 2009). Shortly after internalisation of the endosomes there is 
rapid release of Ca2+ from early endosomes through TRPML3 that is necessary for allowing 
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acidification of this compartment. Once late endosomes or lysosomes become highly acidic, 
the low pH inhibits TRPML3 channel activity, stopping Ca2+ exit and preventing further 
acidification (Martina et al., 2009; Lelouvier et al., 2010) (Fig.2). 
In a study in isolated endosomes performed by Saito et al. (2007) the presence of two poor 
channels (TPC), releasing Ca2+ from the endosome, was demonstrated. Ca2+ release was 
inhibited by the endosome luminal Cl- with a K50 of 82 mM. Reduction of Cl- activated Ca2+ 
release, which in turn stimulates H+ transport to the lumen (Fig.2).  
There is ample evidence that ClC-5 has an essential role in the acidification of the 
endosomes (Plans et al., 2009; Wellhouser et al., 2010; Smith & Lippiat, 2010).  Two research 
groups demonstrated that ClC-5 functions as a voltage–dependent electrogenic 
chloride/proton exchanger (Picollo et al., 2005; Scheel et al., 2005). In their studies the 
currents required 20-40 mV voltages, which are not observed in vivo. When transposed to 
endosomal membranes, it means a movement of a positive charge (H+) into and of negative 
charge (Cl-) out of the endosome.  Sonawane et al. (2009) showed that within 60 s Cl- 
concentration in the lumen is decreased from 120 to 20-30 mmol. Zifarelli and Pusch (2009) 
determined the absolute proton fluxes using Xenopus oocytes from the extracellular proton 
gradient using a pH sensitive dye. A transport stochiometry of 2Cl-/1H+ was demonstrated. 
Smith and Lippiat (2010) demonstrated using a targeted pH sensitive fluorescent protein in 
opossum proximal tubular cells that endosomal acidification was only partially sensitive to 
the inhibitor of V-ATPase bafilomycin–A1. In the presence of bafilomycin-A1, the 
acidification was almost fully ablated by the knockdown of endogenous ClC-5 by siRNA. 
Contrasting previous assumption, these authors suggested that ClC-5 exchanges two Cl- 
ions from the endosomal lumen for a proton from the cytoplasm. This leads to endosomal 
acidification directly by ClC-5 in parallel with V-ATPase (Fig.2).  
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Fig. 2. Major classes of transporters in the early endosome; protons can enter endosome via 
V-ATPase, ClC-5 and NHE6. Ca 2+ exit via TRPM3 and via TPC counteracting net charge 
translocation facilitating endosomal acidification.  Na+ entry increases endosomal 





4.3 Role of decreased endosomal acidification in the disturbed proximal tubule 
transport 
A remarkable study was performed by Novarino et al. (2010). They generated mice with a 
mutation that converted ClC-5 exchanger into a pure Cl- conductor. In these conditions 
ATP-dependent acidification of renal endosomes was normal however, proximal tubular 
endocytosis was impaired. Because the mutation was introduced into the 
intramembraneous part of the protein, this study made it unlikely that a disturbed 
interaction between ClC-5 and other partners is involved in the pathogenesis of Dent’s 
disease (Reed et al., 2010). The impaired reabsorption in the proximal tubule is still 
presumably due to the failure to recycle specific transporters, released by the low 
endosomal pH, to the apical membrane. A definite pathogenetic concept, however, is still 
lacking.  
4.4 Consequences of ClC-5 dysfunction for the α-intercalated cells 
As the acidifying capacity after ammonium chloride loading is normal in the initial phase of 
Dent’s disease, normal H+ ATPase has to be present at the apical surface of the  
α-intercalated cells. Carr et al. (2006) demonstrated in a collecting duct cell line, in which 
ClC-5 was disrupted, a marked increase in annexin A2, a crystal-binding molecule at the 
plasma membrane. This leads to an accumulation of crystal binding molecules at this site 
and might underlie nephrocalcinosis in patients with Dent’s disease. Interestingly, 
aquaporin 6 co-localizes with H+ ATPase in α-intercalated cells and functions as an anion 
channel, facilitating Cl- transport (Yasui et al., 1999). The physiological role of aquaporin 6 
and its relation to ClC-5 in α-intercalated cells remains to be established.  
4.5 Role of OCRL in endosomal trafficking 
Detailed description of the cellular phenotype caused by OCRL mutations is beyond the 
scope of this chapter. OCRL protein belongs to a type II polyphosphate 5-phosphatases and 
is ubiquitously expressed in the Trans-Golgi Network (TGN), endosomes and plasma 
membrane. OCRL interacts with a broad range of small Rab GTPases, a family of proteins, 
which together with phosphatidylinositols regulate cellular vesicle trafficking (Vicinanza et 
al., 2008). Other OCRL interactors include clathrin and adaptor proteins AP1 and AP2. Some 
mutations detected in patients with Lowe syndrome disturb interaction between OCRL-
protein and several Rab GTPases (Hou et al., 2011), however, functional consequences of the 
other mutations found in Lowe syndrome or in Dent 2 disease are unknown and a 
mechanistic explanation of differences between the two phenotypes remains to be clarified.  
5. Treatment of Dent’s disease 
At this moment there is no curative treatment of Dent’s disease. Supportive therapy is 
focused on preventing renal stone formation and slowing down the deterioration of renal 
function. Increased fluid intake and administration of hydrochlorothiazide (HCT) decrease 
urinary calcium concentrations (Raja et al., 2002), however, hypovolemia and hypokalemia 
can complicate thiazide treatment (Blanchard et al., 2008). High citrate diet has a positive 
effect on renal stone formation in the ClC-5 knockout mice (Chebotaru et al., 2005), but its 
efficiency has not been proven in humans. Inhibition of the renin-angiotensin-aldosterone 
system (RAAS) might be of potential benefit by reducing proteinuria, but its effect in Dent’s 
disease patients has not been studied. Treatment of rickets with vitamin D and phosphate 
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supplementation should be performed with caution as it can enhance hypercalciuria and 
nephrocalcinosis.  
Smith et al. (2009) reported that some ClC-5 missense mutants are retained in the 
endoplasmatic reticulum. The authors suggested that the export of mutant channels might 
be improved by exposure to chaperones improving forward trafficking by allosteric means. 
Therefore, the identification of allosteric modulators, specific for ClC-5, may provide a 
therapy for Dent 1 disease at least caused by this type of mutation. 
6. Conclusions 
Dent’s disease is a rare X-linked disorder characterized by various degrees of proximal 
tubular dysfunction, nephrocalcinosis and nephrolithiasis. The disease leads to progressive 
loss of kidney function and causes end stage renal failure (ESRD) mostly in the 3rd to 4th 
decades of life. Dent’s disease mostly affects males, however, female carries can develop 
mild proximal tubular dysfunction and more rarely nephrolithiasis. Approximately 60% of 
all Dent’s patients (i.e. Dent 1 patients) have inactivating mutations in the CLCN5 gene 
encoding the electrogenic Cl-/H+ exchanger ClC-5, which is extensively expressed on the 
early endosomes in renal PT and is involved in the receptor-mediated endocytosis.  
About 15% of Dent’s patients have mutations in the OCRL gene and are classified as having 
Dent 2 disease. OCRL gene, encoding phosphatidyl-inositol phosphate 5-phosphatase, is 
known to cause Lowe syndrome, a severe form of X-linked mental retardation associated 
with proximal tubular dysfunction and congenital cataract.  
Studying the pathogenesis of Dent’s has elucidated the crucial role of the ClC-5 protein in 
endosomal acidification required for the progression along the endocytotic machinery. 
Recent studies demonstrated that ClC-5 functions as a 2Cl-/H+ exchanger, which is directly 
involved in the acidification of early endosomes.  
Treatment of patients with Dent’s disease is supportive and focused on preventing renal 
stone formation and slowing down the deterioration of their renal function. Increased fluid 
intake and cautious administration of HCT can decrease urinary calcium concentrations. 
Inhibition of RAAS might be of potential benefit by reducing proteinuria.  
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Obstructive Sleep Apnea Syndrome  
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1. Introduction 
It is widely accepted that manifestation of target organs damage in patients with metabolic 
syndrome (MS) often has simultaneous and rapid pattern. Non-alcoholic fatty liver disease 
(NAFLD) has been described as one of metabolic syndrome-induced target organ damage. 
NAFLD clinical manifestations vary from ultrasonographically detected liver steatosis to 
non-alcoholic steatohepatitis (NASH) (Sowers, 2008). Detailed analysis of NAFLD 
relationship with other organs impairment in MS patients is particularly important for 
diagnostic procedures adjustment and optimization of treatment. 
Different experimental and clinical research data demonstrate strict relation between 
NAFLD and chronic kidney disease (CKD). In a population study including more than 8,000 
healthy men, recruited in South Korea, NAFLD with elevated serum gamma-
glutamyltransferase (GGT) concentration was associated with an increased CKD risk among 
nondiabetic, nonhypertensive men, irrespective of metabolic syndrome. The association was 
evident even after adjustment for age, glomerular filtration rate (GFR), triglycerides, and 
high-density lipoprotein cholesterol (Chang et al., 2008). Another study data suggested that 
NAFLD is associated with an increased prevalence of CKD in type 2 diabetic individuals 
independent from numerous baseline confounding factors (Targher et al., 2008). 
Presence of association between NAFLD and CKD revealed similar risk factors and rate of 
their coexistence in MS patients and could be explained by similar development 
mechanisms. Multiple mediators known as adipokines expressed are secreted by adipocytes 
and play an important role in the induction of endothelial dysfunction, tissue hypertrophy 
and fibrosis even at an early stage of target organ damage (Antuna-Puente et al., 2008). Pair 
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of adipokines – leptin and adiponectin are physiological antagonists. Combination of leptin 
hyperproduction and peripheral tissues resistance to it in patients with abdominal type of 
obesity is paired with protector insufficiency – adiponectin. It leads to progression of 
dysmetabolism, particularly insulin resistance development and organ remodeling 
intensification (Anubhuti & Arora, 2008; Han et al., 2009). Obstructive sleep apnea 
syndrome (OSAS) could be integral pathogenetic chain in CKD and NAFLD (Tokuda et al., 
2008). Investigation of correlation between plasma leptin and adiponectin concentrations, 
OSAS and CKD development in NAFLD patients gives opportunity to get closer to 
mechanisms of target organs damage in MS with subsequent optimization of prophylactic 
strategy. 
2. Materials and methods 
Research involved 86 patients (64 males and 22 females) with MS diagnosed according to 
standard criteria (Alberti et al., 2006) and NAFLD (ultrasonic proven liver steatosis in 
combination with elevated transaminases, GGT and/or alkaline phosphatase level increase 
without signs of viral hepatitis or other diseases with hepatic manifestation). 
All the patients had abdominal obesity (waist circumference (WC) >94 cm in males and >80 
cm in females (Alberti et al., 2006)). Mean age was 44.0±11.0. 
Along with general investigation all patients were tested for common risk factors presence 
and severity (Mancia et al., 2009). Blood pressure was measured using a standard mercury 
sphygmomanometer under standard conditions as mentioned in cardiovascular survey 
methods. Each person was examined for height, weight and WC without shoes with 
minimal clothing as per cardiovascular survey methods. Body mass index (BMI) was 
calculated by formula of weight in kg/height m2. All patients underwent biochemical tests: 
concentrations of HDL cholesterol, LDL cholesterol, VLDL cholesterol, total cholesterol and 
triglycerides (Biosystems S.A. kit, Spain) were measured on automatic analyzer Beckman 
Synchron Clinical System CX5delta; also atherogenic index was calculated using equation: 
atherogenic index = (total cholesterol – HDL cholesterol) / HDL cholesterol. 
Presence and grade of insulin resistance and disturbances of carbohydrates metabolism 
related to it were estimated by fasting serum glucose level (Biosystems S.A. kit, Spain), C-
peptide (DРС kit, USA), fasting insulin serum concentration (DРС kit, USA) and HOMA-
index calculation (fasting glucose (mmol/L) x insulin (IU/mL) / 22.5). 
Plasma concentration of adipokines – leptin and adiponectin were measured by immune-
enzyme analysis (“Human Adiponectin ELISA” (BioVendor GmbH, Germany), “Leptin 
(Sandwich) Elisa” (DRG, USA)). 
Signs of target organs damage were registered according to standard recommendations 
(Alberti et al., 2006): left ventricular hypertrophy was diagnosed echocardiographically 
using Sokolow-Lyon criteria and left ventricular mass index (Acuson Sequoia 512 (Siemens 
Acuson, USA)); atherosclerotic involvement of carotid artery was diagnosed by ultrasonic 
investigation of carotid artery intima-media thickness (CIMT) and/or by detection of 
atherosclerotic plaque in its wall (ESAOTE (Technos MPX, Italy)); albuminuria was 
estimated using nephelometric assay (Immage Immunochemistry Systems, Beckman 
Coulter, USA), GFR was estimated using MDRD formula. 
For statistical processing data were analysed by STATISTICA 8.0 (StatSoft, Russia). Various 
numbers are given as mean value and standard deviation (for normal distribution); median 
value and interquartile range (for asymmetric distribution). Categorical variables have been 
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compared by parametric and nonparametric methods. The Pvalue < 0.05 was considered as 
significant. 
3. Results 
Patients were divided into two groups depending on stage of NAFLD: 48 subjects with 
clinically unsuspected liver steatosis detected only by ultrasonic investigation and 38 
subjects with signs of NASH. Transaminases and G-GT serum levels were comparatively 
higher in patients with NASH (Table 1), whereas De Ritis ratio was comparatively higher in 
patients with liver steatosis. 
 
 NASH(n=38) Liver steatosis (n=48) 
AST, IU/mL 54±31* 24±8 
ALT, UI/mL 99±73* 32±17 
De Ritis ratio 0.6±0.2* 0.8±0.2 
G-GT, IU/mL 97±65* 47±30 
Table 1. Serum AST, ALT, G-GT levels and De Ritis ratio in patients with MS and NAFLD 
(n=86). * P<0.001 
Comparison of CKD and NASH prevalence rate according to number of damaged target 
organs revealed that both CKD and NASH prevalence was significantly higher in group of 
patients with >3 target organ damage (Table 2) and lower in other groups (patients with 1 or 
2 target organ damage). The patients with 2 and >3 target organ damage showed significant 
increase in albuminuria level. There was no significant difference in plasma concentrations 
of adiponectin and leptin in all the groups, but ratio leptinemia/adiponectinemia increased 
significantly in concordance with number of damaged target organ and reached maximum 
in patients with >3 target organ damage. 
 
 
 1 target organ 
damage (n=18) 
2 target organ 
damage (n=39) 
>3 target organ 
damage (n=18) 
CKD rate, % 17% 
P<0.05 vs 2 и >3 
44% 67% 
NASH rate, % 39% 
P<0.05 vs >3 
44% 78% 
P<0.05 vs 2 
Albumiuria, mg/24h 6.0 (4.3 – 9.0) 
P<0.05 vs 2 and >3 
12.6 (8.0 – 38.0) 30.2 (17.3 – 48.0) 
Leptin, ng/mL 23.6+23.4 31.6+27.3 31.2+26.0 
Adiponectin, μg/mL 31.3+17.5 22.9+20.2 11.8+5.5 
Leptin/Adiponectin 1.0+0.8 
P<0.05 vs 2 and >3 
1.7+1.4 3.1+1.6 
P<0.05 vs 2 
Table 2. CKD and NASH prevalence, albuminuria and adipokines plasma concentration in 
patients with MS and NAFLD (n=86). 
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Among all patients with MS and NASH 37.2% (32 patients) were diagnosed CKD, 26 of 
them had microalbuminuria, 6 subjects had urinary albumin excretion over 300 mg/24h. 
Five patients had CKD III stage (GFR <60 mL/min/1.73m2), all of them also had signs of 
NASH. Patients with MS, NAFLD and CKD showed marked insulin resistance: fasting 
insulinemia level, HOMA index and plasma C-peptide concentration in this type of patients 
were higher than in patients with NAFLD without CKD (Table 3). Moreover in patients with 
MS, NAFLD and CKD registered significantly higher plasma leptin level.  
 
 Patients with CKD (n=32) 
Patients without CKD 
(n=54) 
Insulin, μU/mL 16.8±9.2 11.5±5.6** 
HOMA index 4.2±2.2 2.9±1.5** 
C-peptide, pmol/L 1326±411 999±341*** 
Leptin, ng/mL 38.2±28.8 21.6±19.8* 
Adiponectin, μg/mL 23.7±19.5 18.1±14.8 
Leptin/Adiponectin 2.15±1.58 1.71±1.52 
Table 3. Comparison of insulin resistance and plasma adipokines levels in patients with MS 
and NAFLD in case of CKD presence or absence. *-P=0.003; **-P=0.002; ***-P<0.001. 
Correlation analysis showed direct correlation of leptin concentration and BMI, systolic 
blood pressure, adiponectin level and albumiuria (Table 4). Adiponectin level correlated 
directly with leptin level, serum HDL cholesterol concentration and De Ritis ratio. Inverse 
correlation was registered between atherogenic index, CIMT and serum level of adiponectin. 
 
Parameter Leptin Adiponectin 
BMI r = 0.27* r = 0.29  
WC r = 0.21  r = 0.33  
Systolic blood pressure r = 0.24* r = 0.10  
Atherogenic index r = -0.14  r = –0.43* 
HDL cholesterol r = 0.18  r = 0.43* 
CIMT r = -0.04  r = -0.38* 
HOMA index r = 0.32* r = -0.18  
C-peptide r = 0.29* r = -0.02  
Insulin r = 0.35* r = -0.10  
De Ritis ratio r = 0.13  r = 0.36* 
Leptin - r = 0.39* 
Adiponectin r = 0.39* - 
Albuminuria r = 0.28* r = 0.19  
Table 4. Correlation of plasma adipokines concentration with MS criteria and target organs 
damage in patients with MS and NAFLD (n=86). * - significant correlations 
OSAS was diagnosed in 20 (24%) patients (Table 5). These patients had significantly higher 
blood pressure, BMI, WC, fasting insulin serum concentration and C-peptide. Obese 
patients with OSAS demonstrated significantly marked target organs damage signs (higher 
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level of albuminuria and lower GFR) in comparison with obese patients without OSAS. Also 
obese patients with CKD developed OSAS more frequent than obese patients without CKD 







Male/female 17/3 47/19 
Mean age, years old 45±10 43±11 
Mean blood pressure, mm/Hg 106±9 100±9 
BMI, kg/m2 39.8±7.9** 31.5±4.3 
WC, cm 125±17** 108±11 
HOMA-index 4.1±1.9* 3.1±1.9 
C-peptide, pmol/L 1337±422* 1092±384 
Leptin, ng/mL 36.7±29.9 25.3±23.0 
Adiponectin, μg/mL 20.4±10.8 21.2±19.1 
Insulin, μU/mL 16.9±7.8* 12.7±7.3 
Albuminuria, mg/24h 21.0 (12.0;38.4)* 10.3 (6.3;19.4) 
GFR, mL/min/1.73m2 81±17* 95±24 
Table 5. Clinical and laboratory characteristics of patients with MS and NAFLD (n=86) in 
case of OSAS presence or absence. *-P<0.05; **-P<0.001 
4. Discussion 
According to our data an increase of target organs damage in patients with MS and NAFLD 
leads to an increase of CKD and NASH development rate and albuminuria level. 
Relationship of NAFLD and albuminuria was also shown in other clinical invetigations. 
Hwang S.T. et al. examined 1361 patients with type 2 diabetes mellitus and prediabetes 
(Hwang et al., 2010). 
The patients with NAFLD had higher prevalence rates of microalbuminuria (6.3% vs 19%; 
P=0.001 in prediabetes, 4.5% vs 32.6%; P<0.001 in diabetes) and also had a greater albumin-
to-creatinine ratio (14.6 +/- 52.0 μg/mg Cr vs 27.7 +/- 63.9 μg/mg Cr; P=0.051 in 
prediabetes, 11.4 +/- 21.4 μg/mg Cr vs 44.7 +/- 76.4 μg/mg Cr; P<0.001 in diabetes) than 
those without NAFLD. NAFLD was associated with 3.66 (P=0.013) times higher rate of 
microalbuminuria in prediabetes patients and 5.47 (P=0.048) times higher in diabetes 
patients. Our patients with MS and NAFLD showed highest albuminuria level in the group 
with highest NASH prevalence rate. Leptin/adiponectin ratio raised significantly in 
observed by our team patients with MS and NAFLD when albuminuria level and NASH 
prevalence rate increased. It probably indicates that increased expression of tissue-
destructive adipokine – leptin is not combined with adequate plasma concentration increase 
of protective adipokine – adiponectin. It was shown that the increase of leptin/adiponectin 
ratio is associated with increase of visceral fat mass, MS prevalence (Kumagai et al., 2005) 
and severity of insulin resistance (Oda et al., 2008). 
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Hwang S.T. et al. examined 1361 patients with type 2 diabetes mellitus and prediabetes 
(Hwang et al., 2010). 
The patients with NAFLD had higher prevalence rates of microalbuminuria (6.3% vs 19%; 
P=0.001 in prediabetes, 4.5% vs 32.6%; P<0.001 in diabetes) and also had a greater albumin-
to-creatinine ratio (14.6 +/- 52.0 μg/mg Cr vs 27.7 +/- 63.9 μg/mg Cr; P=0.051 in 
prediabetes, 11.4 +/- 21.4 μg/mg Cr vs 44.7 +/- 76.4 μg/mg Cr; P<0.001 in diabetes) than 
those without NAFLD. NAFLD was associated with 3.66 (P=0.013) times higher rate of 
microalbuminuria in prediabetes patients and 5.47 (P=0.048) times higher in diabetes 
patients. Our patients with MS and NAFLD showed highest albuminuria level in the group 
with highest NASH prevalence rate. Leptin/adiponectin ratio raised significantly in 
observed by our team patients with MS and NAFLD when albuminuria level and NASH 
prevalence rate increased. It probably indicates that increased expression of tissue-
destructive adipokine – leptin is not combined with adequate plasma concentration increase 
of protective adipokine – adiponectin. It was shown that the increase of leptin/adiponectin 
ratio is associated with increase of visceral fat mass, MS prevalence (Kumagai et al., 2005) 
and severity of insulin resistance (Oda et al., 2008). 
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Both insufficient adiponectin effect and leptin hyperproduction predetermine the increase of 
insulin resistance. It reaches maximum level in the group of patients with NAFLD and CKD 
demonstrating highest values of fasting insulin serum concentration, C-peptide and HOMA-
index. Evidently insulin resistance in such patients is caused mainly by leptin excess 
(Anubhuti & Arora, 2008), which maximal plasma concentration registered in patients with 
NAFLD and CKD. Leptin contribution to insulin resistance of peripheral tissues 
intensification is more evident as NAFLD progresses and CKD develops, adiponectin 
plasma concentration and its tissue protective effect gradually decrease (this is also 
evidenced by our observation of significant leptin/adiponectin ratio increase). It should be 
noted that leptin mainly shows properties similar to insulin excess and hereby comes into 
synergic effect with it, in particular by inducing expression of profibrogenic chemokines in 
target tissues (e.g.  transforming growth factor beta (TGF-β)) leading to tissue fibrosis 
development. Currently, the role of leptin in kidney tissue firosis development is clear (Wolf 
& Ziyadeh, 2006), pathogenetic role of obesity as CKD risk factor in general population 
determined in several epidemiological investigations (Foster et al., 2008; Kramer et al., 2005) 
could be explained by consequences of hyperleptinemia (similar as adiponectin  
insufficiency). It was also shown that leptin directly increases fibrogenesis in liver tissue in 
patients with NAFLD. Ikejima K. et al. demonstrated leptin key role in stimulation of TGF-β 
mRNA expression in Kupffer cells and sinusoidal endothelial cells in rodents with 
genetically determined leptin and leptin receptor deficiency (Ikejima et al., 2005). Moreover, 
leptin augmented platelet derived growth factor-dependent proliferation of hepatic stellate 
cells by enhancing downstream intracellular signaling pathways. Hereby NAFLD and CKD 
progression in patients with MS is determined mainly by profibrogenic effect of leptin and 
excess of insulin. 
Along with indicated above, leptin and insulin induced endothelial dysfunction could stand 
as another common mechanism of NAFLD and CKD development. Increasing albuminuria– 
is a local kidney marker of endothelial dysfunction. It was proved, that hyperleptinemia 
directly related to microalbuminuria in patients with abdominal obesity (Ikee et al., 2008). 
Close associations of NAFLD with global impairment of endothelial function were 
estimated. Thus, examination of 250 obese children showed that presence of NAFLD entails 
more severe functional and anatomic changes in the arterial wall. Flow-mediated 
vasodilatation of brachial artery (one of the signs of endothelial dysfunction) was 
remarkably reduced and CIMT was increased in obese subjects with confirmed MS and 
NAFLD (Pacifico et al., 2010). Hypertensive patients with NAFLD have a reduced 
endothelium-dependent vasodilation and highest insulin resistance in comparison with 
hypertensive patients without NAFLD. In keeping with this, it is possible to hypothesize 
that liver steatosis may be considered a marker of vascular damage in essential hypertension 
(Sciacqua et al., 2010). Integrally, NAFLD presence in patients with MS is always combined 
with the most pronounced endothelial dysfunction, which mainly predetermines intensity 
of other target organs remodeling, including kidney. The role of hepatic endothelial cells 
impaired function, related to hyperleptinemia, insulin resistance and insufficient effects of 
adiponectin, in progression of NAFLD could not be completely excluded. Development of 
specific laboratory investigation methods is necessary to evaluate their contribution. 
Relationships between NAFLD and CKD revealed in this research in patients with MS could 
be explained by an imbalanced action of antagonistic adipokines – leptin and adiponectin – 
and combined with it the intensification of insulin resistance. Taking into consideration our 
correlation analysis data leptin plasma concentration directly correlates with body mass; in 
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parallel with it – insulin resistance and albuminuria. In addition hyperleptinemia is 
associated with an increased blood pressure. Hypertensive effect of leptin was confirmed in 
general population. During one of the phases of prospective population investigation - 
Copenhagen City Heart Study - new-onset hypertension was examined in 620 women and 
300 men who were normotensive in the previous examination, which was performed in 
1991-1994 (Asferg et al., 2010). Leptin plasma concentration was significantly associated 
with new-onset hypertension (odds ratio of 1.28 (1.08-1.53; P < 0.005) for 1 s.d. higher level 
of log-transformed leptin), whereas adiponectin was not significantly associated with new-
onset hypertension. Adiponectin plasma concentration directly correlated with 
concentration of HDL cholesterol, and correlated inversely with CIMT and atherogenic 
index. Our data matches generally accepted conception of adiponectin antiatherogenic 
properties and its ability to withstand intensification of metabolic disorders, particularly 
insulin resistance in patients with MS (Han et al., 2009). 
Direct correlation between adiponectinemia and De Ritis ratio demonstrated in our study 
shows inhibitory action of adiponectin on NAFLD progression rate. In case of NASH onset 
in such patients adiponectin plasma concentration and level of its expression by liver tissue 
significantly decrease (Jiang et al., 2009; Ma et al., 2009). Thereby leptin/adiponectin 
imbalance may be regarded as one of the most important mechanisms of organ damage 
including CKD and NAFLD in patients with MS. 
OSAS had a special place among other independent risk factors of CKD severity and 
progression in patients with MS and NAFLD examined by our team. Patients with OSAS 
showed maximum levels of insulin resistance markers and exactly those subjects 
demonstrated the highest albuminuria level and a lower level of estimated GFR in 
comparison with groups of patients with MS without OSAS. Recently OSAS has been 
considered as one of “most malignant” variant of MS, during which both target organ 
damage rate and severity of metabolic impairments could reach maximal intensity. Highest 
expression levels of adipokines with tissue-destructive effect, in particular – leptin were 
registered in patients with OSAS. Presence of direct significant correlation between leptin 
plasma concentration and apnea/hypopnea index was evaluated in patients with OSAS 
(Tokuda et al., 2008). Stepwise multiple regression analysis showed that BMI (r=0.807, 
p<0.0001), the percentage of time with less than 90% hemoglobin saturation level in total 
sleep time (%T<90)(r=0.399, p<0.001) and apnea/hypopnea index (r=0.552, p<0.001) were 
determinant factors for serum leptin levels. Thus, hyperleptinemia raised as OSAS severity 
and BMI increased. Among the patients who had successful surgical correction of OSAS 
(uvulopalatopharyngoplasty; or uvulopalatopharyngoplasty and tonsillectomy; or 
uvulopalatopharyngoplasty, tonsillectomy and radiofrequency ablation of the base of the 
tongue) leptin and other adipokines with similar effect (interleukin-6. tumor necrosis factor-
alfa) plasma concentration dramatically decreased, whereas adiponectin plasma 
concentration significantly increased after surgery (Adeseun & Rosas, 2010). 
Typical for OSAS adipokines hyperproduction leads to the enhancement of target organ 
damage development. It was confirmed in multiple clinical and epidemiological 
investigations. In this way OSAS is considered as one of CKD risk factors (Eun et al., 2010). 
Patients with OSAS demonstrate significantly lower estimated GFR in comparison with 
patients without OSAS (84.57 and 94.67 mL/min/1.73m2 respectively, P=0.037) 
(Fleischmann et al., 2010). Patients with estimated GFR <60 mL/min/1.73m2 show 6 times 
higher frequency of central apnea episodes in comparison with group of patients with 
estimated GFR  >60 mL/min/1.73m2. Presence of OSAS as concomitant condition in our 
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patients without OSAS (84.57 and 94.67 mL/min/1.73m2 respectively, P=0.037) 
(Fleischmann et al., 2010). Patients with estimated GFR <60 mL/min/1.73m2 show 6 times 
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patients with NAFLD was associated with significant decrease of estimated GFR which was 
calculated using MDRD formula. Thereby this category of patients should be subjected to 
medical examination at first visit  for detection of early stages of CKD (assessment of 
albuminuria level, estimated GFR, including new markers for GFR estimation, particularly 
cystatin C). 
5. Conclusion 
The results of our study indicate that in patients with MS a relationship exists between 
NAFLD and CKD: NASH development is closely related to increase in albuminuria levels. 
Association of NAFLD and CKD in patients with MS may be explained by mutual 
mechanisms of onset and progression, among which should be mentioned hyperleptinemia, 
lack of adiponectin effects and related to it increase of insulin resistance. From this point of 
view all the patients with MS and NAFLD must be checked for CKD signs (albuminuria, 
serum creatinine, estimated GFR). Dynamical changes of these markers could play the role 
of efficacy indicators of integral therapeutic approaches, e.g. medications for treatment of 
obesity (orlistat), oral hypoglycemic agents (metformin), antihyperlipidemic agents (statins, 
fenofibrate) and also several antihypertensive drugs (angiotensin receptor blockers). 
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1. Introduction 
It is a fact we are all too well aware of. The world, as we know it, continues to grow fat. The 
popular press has done an excellent job of educating the lay person about the link between 
obesity and heart disease, hypertension, etc. However, despite scientific evidence to the 
contrary, the effect of obesity on the kidneys’ function is less well-known. Kidney disease 
from obesity can progress to End Stage Renal Disease (ESRD), which mandates the use of 
dialysis to keep the patient alive. It is hence a huge risk factor for morbidity and mortality. 
Last, but not the least, it puts a tremendous economic and social strain on the healthcare 
resources of nations around the world.   
2. The alarming statistics 
The World Health Organization (WHO) considers obesity an international epidemic, stating 
in 1997 that “obesity’s impact is so diverse and extreme that it should now be regarded as 
one of the greatest neglected public health problems of our time with an impact on health 
which may well prove to be as great as that of smoking.” A quick look at the WHO’s 
statistics paints a scary picture of what we are up against. It is hard to imagine that in 2008 
almost one-quarter of humanity, or 1.5 billion people, were reported to be overweight (a 
body mass index greater than or equal to 25). Of these, over 200 million men and 300 million 
women were obese (body mass index greater than or equal to 30). Obesity, in combination 
with diabetes, is the largest epidemic the world has ever faced. It is also the fifth leading 
cause of deaths worldwide, killing 2.8 million people every year.  The prevalence of obesity 
currently ranges from less than 5% in rural China, Japan and some African countries, to 
levels as high as 75% of the adult population in urban Samoa. 68% of U.S. adults are either 
overweight or obese. With this enormous health burden worldwide, the deleterious effects 
of obesity on kidney function are being increasingly recognized.  
2.1 Obesity and kidney disease: The weight of the evidence 
There now is a well established risk between obesity and the development of kidney 
disease. The Framingham Offspring data reported obesity as a major risk factor for the 
development of kidney disease. This was a large study that followed 1223 men and 1362 
women (who were initially free of preexisting kidney disease) for a mean period of 18.5 
years. At the end of this follow up period, 244 participants (9.4 percent) had developed 
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kidney disease (defined as estimated glomerular filtration rate (GFR) of less than 64 and 59 
mL/min per 1.73 m2 for men and women, respectively). The researchers also reported a 
23% increase in the odds of development of kidney disease for each standard deviation 
increase in the Body Mass Index (BMI). This risk was present even after adjustment for age, 
sex, smoking, diabetes, and baseline glomerular filtration rate (GFR). Another study by Hsu 
et al showed that there is a greater relative risk of development of end-stage renal disease 
(ESRD) necessitating dialysis, with each gradient increase in BMI. Higher BMI was a risk 
factor for ESRD in multivariable models that adjusted for age, sex, race, education level, 
smoking status, history of myocardial infarction, serum cholesterol level, urinalysis 
proteinuria, urinalysis hematuria, and serum creatinine level. Compared with persons who 
had normal weight (BMI, 18.5 to 24.9 kg/m2), the adjusted relative risk for ESRD was 1.87 
(95% CI, 1.64 to 2.14) for those who were overweight (BMI, 25.0 to 29.9 kg/m2), 3.57 (CI, 3.05 
to 4.18) for those with class I obesity (BMI, 30.0 to 34.9 kg/m2), 6.12 (CI, 4.97 to 7.54) for 
those with class II obesity (BMI, 35.0 to 39.9 kg/m2), and 7.07 (CI, 5.37 to 9.31) for those with 
extreme obesity (BMI > or = 40 kg/m2). Higher baseline BMI remained an independent 
predictor for ESRD after additional adjustments for baseline blood pressure level and 
presence or absence of diabetes mellitus. 
Similarly, a recent large cohort study of 177570 individuals found obesity to be one of the 
most potent risk factors for the development of ESRD.  
3. How obesity causes kidney disease 
Obesity is associated with multiple other conditions that are known to cause compromised 
renal function, including hypertension, diabetes, hyperuricemia, and the metabolic 
syndrome that can independently have a detrimental effect on renal function. However, as 
we can gauge from the evidence quoted in the above section, obesity has been found to 
cause kidney disease and ESRD even after adjustment for these factors. Hence, the 
pathogenesis of obesity related kidney disease can be sub-classified in to direct and indirect 
effects. 
3.1 Direct effects of obesity on kidney function  
Data from the Framingham Offspring study, the Hypertension Detection and Follow-Up 
Program, and the Multiphasic Health Testing Services Program suggest that obesity may be 
independently associated with the risk of developing chronic kidney disease. Obesity seems to 
cause a change in the renal hemodynamics that promotes progressive kidney disease. These 
changes begin early in the course of obesity, even before overt renal manifestations of obesity 
are clinically apparent. This was shown in a landmark study from a center conducting kidney 
biopsies on obese patients who presented for weight loss/bariatric surgery in Spain. The 
investigators studied the glomerular architecture in renal biopsies of 95 patients undergoing 
bariatric surgery for extreme obesity but whose renal function was clinically normal. These 
subjects had no known prior history of any kidney disease. These patients were then 
compared with a control group of 40 patients undergoing nephrectomy or donating a kidney, 
and having protocol biopsies. This second control group had patients who had normal weight 
and renal function, and were non-diabetic and non-hypertensive. Logistic regression models 
were then applied to determine associations between the clinical and biochemical variables 
and glomerular lesions. Focal and segmental glomerulosclerosis (FSGS) was present in only 
five extremely obese patients but absent in controls. Increased mesangial matrix, podocyte 
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hypertrophy, mesangial cell proliferation, and glomerulomegaly were more frequent in the 
obese cohort than in the control group. Body mass index was found to be a significant 
independent risk factor associated with glomerular lesions in all 135 patients and in the 95 
extremely obese patients. This was hence an elegant demonstration of the fact that even in 
patients with no overt clinical renal symptoms, there were a variety of glomerular 
abnormalities that correlated with body mass, even after adjustment for other factors like high 
blood pressure, diabetes, metabolic syndrome, and sleep apnea. 
3.1.1 The role of adipokines 
One of the keys to unravel obesity’s effect on the kidneys is understanding the concept of 
body-fat as an independent endocrine organ, rather than simply a passive storage depot for 
triglycerides. The overarching factor in this is the dysregulated production of bioactive 
substances called “adipokines” by adipose cells that cause systemic effects, and directly 
influence insulin sensitivity and vascular injury.  
Adipokines, and other neuro-humoral factors, have already been well studied in the 
pathogenesis of obesity. Serum levels of adipokines like leptin correlate with the total body 
fat content. Hence, the levels tend to be higher in the obese. In normal-weight subjects, food 
intake is reduced by systemic leptin administration, but the response to leptin decreases as 
the subjects become obese. This leads to a vicious circle of hyperphagia and obesity. Another 
interesting hormone that plays a role in the pathogenesis of obesity is ghrelin, a peptide 
produced by the stomach and duodenum. This peptide stimulates growth hormone 
secretion, and increases food intake in rodents and humans. Serum concentrations are 
suppressed by food ingestion in normal-weight subjects. However, this suppression is 
impaired in the obese, leading to increased food intake.  
Not surprisingly, dysregulated adipokine production also leads to hemodynamic and 
structural changes in the kidney, and has been shown to play an important 
pathophysiologic role in obesity related kidney disease. These adipokines include cytokines 
like leptin, adiponectin, interleukin-6, tumor necrosis factor-alpha, resistin, and 
angiotensinogen.   Whereas some of these adipokines act in an autocrine or paracrine 
manner, others act as signaling molecules in remote tissues like liver, skeletal muscle, and 
endothelium.  These cytokines then induce a pro-inflammatory state causing glomerular 
capillary hypertension, and fibrosis in the renal parenchyma. Of these adipokines, one of the 
best understood roles is that of angiotensinogen. Angiotensinogen is an α-2-globulin that is 
produced constitutively, mainly by the liver. However, plasma levels of angiotensin are also 
positively correlated with body fat mass, indicating increased production of this molecule 
from adipocytes. In fact, all other components of the renin-angiotensin system (RAS), 
including renin, angiotensin converting enzyme, angiotensin II, and AT-1 and AT-2 
receptors, are expressed as well as secreted from adipocytes. Increased angiotensinogen 
kick-starts the RAS, and in turn increases the downstream effects of this system, namely, 
fluid retention and increased vascular tone.  Elevated levels of angiotensinogen and 
angiotensin II then lead to efferent arteriolar constriction in the glomerulus. This increases 
the intraglomerular pressure, leading to a rise in the GFR. From an evolutionary standpoint, 
acutely this adaptation served to preserve GFR and prevent low blood pressure in the face 
of volume depletion. However, over the long term, this effect becomes maladaptive. Raised 
intraglomerular pressure causes injury to the glomerulus and subsequent hyperfiltration. 
Eventually, the kidneys start to spill protein in to the urine and begin to undergo permanent 
irreversible fibrosis.  
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The relation between RAS and body fat is actually a two-way street. In 1998, Karlsson et al 
demonstrated that angiotensin-II stimulated preadipocyte differentiation, and hence 
stimulates adipogenesis. Thus, the RAS itself may also be involved in regulation of body 
weight and development of obesity. RAS has also been postulated to play an important 
role in the development of the cardiomyopathy commonly occurring in obesity. The 
discovery of these mechanisms has had immense clinical implications. Drugs that block 
the RAS now form the mainstay of treatment to decrease glomerular hyperfiltration and 
proteinuria, and have found clinical applications in the prevention and treatment of 
endothelial dysfunction, obesity-related glomerulopathy, diabetic nephropathy, 
cardiomyopathy etc. Clinical trials of strategies to block the RAS after coronary 
angioplasty have demonstrated significant decreases in inflammatory markers of systemic 
inflammation, including IL-6, CRP, and TNF-alpha in response to inhibition of the renin-
angiotensin axis.     
3.1.2 Other hemodynamic and structural effects  
The first large renal-biopsy based clinico-pathologic study on obesity-related kidney disease 
studied the incidence and structural changes seen in obesity-related glomerulopathy (ORG). 
This study reviewed 6818 kidney biopsies and reported the presence of structural changes 
like hyperplasia of the juxta-glomerular apparatus, consistent presence of glomerulomegaly 
and foot process fusion in patients who were diagnosed to have ORG. Another histologic 
feature noted in some ORG patients was the presence of focal changes in the form of mild 
focal mesangial sclerosis or mild focal thickening of glomerular/tubular basement 
membranes. These changes were not very dissimilar to changes that are more often 
associated with the presence of diabetic nephropathy. 
Obese patients have also been shown to have elevations in both renal plasma flow  
and GFR. A study investigated differential solute clearances to characterize glomerular 
function in 12 nondiabetic subjects with severe obesity (body mass index >38). Glomerular 
filtration rate (GFR) and renal plasma flow (RPF) was found to exceed the control  
value by 51 and 31%, respectively. Consequently, the filtration fraction was increased  
as well. The augmented RPF suggests a state of renal vasodilatation involving mainly  
the afferent arteriole. The analysis suggests that the high GFR in very obese subjects  
may be the result of an increase in transcapillary hydraulic pressure difference. An 
abnormal transmission of increased arterial pressure to the glomerular capillaries through 
a dilated afferent arteriole could account for the augmentation in this transcapillary 
pressure. 
3.2 Indirect effects 
Certain co-morbid conditions that come as a “package deal” in patients afflicted with 
obesity serve as indirect agents of destruction of renal function. The strong association 
between obesity and the dreaded metabolic syndrome, hypertension, diabetes, 
hyperuricemia, dyslipidemia, and sleep apnea indirectly has deleterious effects on kidney 
function.  
3.2.1 Effect of hypertension on kidney function 
Long standing hypertension causes changes in the kidneys’ glomeruli, vasculature, and the 
tubulointerstitium. These changes are broadly referred to as hypertensive nephrosclerosis.  
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Intimal thickening and luminal narrowing of the renal arteries and glomerular arterioles is 
seen. This is thought to be a consequence of a hypertrophic response to chronic 
hypertension causing medial hypertrophy, followed by deposition of plasma protein 
constituents such as inactive C3b in to the damaged vessel wall. Abnormal metabolism of 
nitric oxide is thought to play a major role in this process. This can eventually lead to an 
ischemic state within the kidney. 
The glomeruli may undergo focal global/segmental sclerosis as a consequence of the 
ensuing ischemic injury. This ischemia also causes alterations in antigen expression on the 
surface of the tubular cells, inciting an inflammatory response that leads to chronic 
interstitial nephritis. These alterations cause a decrease in GFR.  
3.2.2 Effect of diabetes on kidney function 
Glomerular hyperfiltration and hypertension is a well studied phenomenon that develops 
early in the course of diabetes. However, elevated glucose levels are known to stimulate 
mesangial cell matrix production. Non-enzymatic glycation of tissue proteins also may 
contribute to the development of diabetic nephropathy. In this process, excess glucose 
combines with free amino acids on circulating or tissue proteins eventually leading to the 
formation of advanced glycation end products (AGEs). These AGEs then crosslink with 
collagen and cause vascular complications. Glomerular permeability is also thought to 
increase via activation of protein kinase C that happens in diabetes.  
Other molecules that have been postulated to have a role in the development  
of nephropathy in diabetes include prorenin (which activates protein kinases, and  
hence mitosis), and other cytokines that cause inflammation and fibrosis. These cytokines 
include vascular endothelial growth factor (VEGF), transforming growth factor-beta  
(TGF-beta) etc. 
3.2.3 Hyperuricemia and kidney function 
Elevated levels of uric acid, or hyperuricemia, that can progress to gout is more prevalent in 
the obese population. It has been proposed that hyperuricemia may contribute to worsening 
of renal function by decreasing renal perfusion. This happens because of arteriolosclerosis  
of the afferent arterioles. It is believed that uric acid stimulates afferent arteriolar  
vascular smooth muscle cell proliferation. Long standing hyperuricemia and gout can 
potentially cause chronic urate nephropathy, and uric acid stones to form in the kidneys or 
the urinary tract.  
3.2.4 Hyperlipidemia and renal function 
It has been shown in animal models that hyperlipidemia can cause mesangial cell 
proliferation by activating LDL receptors present on mesangial cells. This also leads to 
increased production of inflammatory growth factors and reactive oxygen species.  
3.2.5 Metabolic syndrome 
Metabolic syndrome is the dreaded constellation of clinical signs that include increased 
waist circumference, insulin resistance, hypertension, and dyslipidemia. These 
comorbidities act in concert to cause kidney dysfunction through the pathways outlined 
above.  
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The relation between RAS and body fat is actually a two-way street. In 1998, Karlsson et al 
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4. Obesity and kidney disease: The clinico-pathologic manifestations 
Before clinical kidney disease is apparent in obesity, patients might already have very 
limited renal disease in a few glomeruli, as discussed in section 3.1. Subclinical disease, with 
sclerotic lesions in a few glomeruli (with no overt proteinuria) was demonstrated in a series 
of 95 patients who had renal biopsies while undergoing bariatric surgery for extreme 
obesity. FSGS was observed in approximately 5 percent of extremely obese patients but not 
in any of the non-obese patients. Mesangial and podocyte hypertrophy also occurred more 
frequently in obese patients.  
Early markers of glomerular disease like microalbuminuria and albuminuria have been 
reported in as much as 41% and 4% of the extremely obese patients, respectively. Focal 
segmental glomerulosclerosis (FSGS) and obesity-related glomerulopathy (ORG), 
characterized by glomerular enlargement and mesangial expansion have been described in 
patients with severe obesity, and clinically manifest initially with proteinuria, and in severe 
states can progress to renal failure. Obesity-related glomerulopathy may be reversible with 
weight loss.  
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The term "obesity-related glomerulopathy" is sometime used interchangeably with FSGS 
associated with obesity. However, multiple studies have shown that these might be different 
processes pathologically. It is entirely possible that these entities represent a spectrum of 
kidney disease. In 1985, Wesson et al were one of the first ones to report nephrotic range 
heavy proteinuria in patients who had no glomerulosclerosis and no epithelial cell injury or 
foot process fusion on renal biopsy. Later studies reported some of such patients to only 
have mesangial expansion and glomerular capillary loop enlargement leading to 
glomerulomegaly. Classically, ORG is considered to be distinct from idiopathic FSGS, with a 
lower incidence of nephrotic syndrome and a more indolent course. Glomerulomegaly is 
typically more consistent in ORG, as is milder foot process fusion. 
Obese patients with FSGS tend to have elevated glomerular filtration rates and increased 
glomerular size. Serum levels of an adipokine, adiponectin may be seen in the obese. FSGS 
in obese subjects presents with proteinuria that may reach the nephrotic range. Both weight 
loss and ACE inhibitors have been shown to reduce this protein excretion by up to 85 
percent. However, just like the other causes of secondary FSGS, nephrotic syndrome is 
atypical and the presence of edema is uncommon.. Praga et al studied 15 patients with 
obesity associated FSGS with significant proteinuria (mean of 3.1 g/day), and found that 
edema and hypoalbuminemia were not observed in any individual.   
It has been suggested that the difference between obesity-related glomerulonephropathy or 
secondary-FSGS from obesity, and idiopathic FSGS is that only some nephrons leak protein 
in the former, as opposed to global nephron involvement in idiopathic FSGS. This leakage of 
protein then leads to abnormal renal handling of sodium, which subsequently causes 
retention of salt and water. Hence ORG and obesity-related secondary FSGS is not 
associated with edema while the edema in idiopathic FSGS is severe.  
Kambham et al reported in their landmark study that the mean age of patients at the time of 
biopsy diagnosis of ORG was 42.9 years (range 8–71 years). The youngest patients in the 
study group included an 8-year-old girl [height 4.0 ft (121.9 cm), weight 190 lbs (86.4 kg)].  
The patients' weights ranged from 81.8 kg to 186.4 kg. The mean BMI was 41.7 kg/m2 (range 
of 30.9 to 62.7); 38 patients had BMI> 40 kg/m2 and 33 had BMI <40 kg/m2. Their was a 
slight male preponderance with a male-to-female ratio of 44:27 (1.6). The majority of patients 
were Caucasian (75%), followed by African American (21%) and Hispanic (4%). None of 
these patients had renal biopsy findings of diabetic nephropathy. Forty-four patients had a 
prior history of hypertension and eight patients carried a diagnosis of obstructive sleep 
apnea syndrome prior to renal biopsy. 
There are other ways in which obesity can affect renal function. Obesity and weight gain 
during adulthood have been known to increase the risk of kidney stones. In women, obesity 
is an important risk factor for urinary incontinence.   
4.1 Clinical course 
As stated above, weight loss, and drugs like ACE inhibitors can stem the progression of 
kidney disease in obesity and actually reverse the changes (unless most of the glomeruli are 
already fibrosed). Weight loss may result in remission of proteinuria. This was 
demonstrated in a study of 63 patients with biopsy-demonstrated ORG. Patients who 
started the study had a mean protein excretion of 1.48 g/day.  These patients were then 
followed for two years. Protein excretion was reduced from 1.7 to 1 g/24 hours among 29 
patients who successfully lowered their BMI but increased among 9 patients whose BMI 
went up. 
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In patients in whom this does not happen, the disease can progress relentlessly with a 
progressive decrease in GFR. Uremic symptoms can ensue below a GFR of 15 ml/min, and 
eventually, symptoms like failure to thrive, dysgeusia, nausea, vomiting, itching, insomnia, 
hyperkalemia, fluid overload, or acidosis can mandate the initiation of dialysis.  
5. Managing the disease 
Obesity associated kidney disease is a ticking time bomb, and the affected patient stands a 
huge risk of progression to End Stage Renal Disease (ESRD) that mandates dialysis, a 
treatment that is hugely cumbersome and expensive. It is hence imperative that the disease 
be diagnosed and managed aggressively from the outset. It goes without saying that weight 
loss is of utmost importance and can itself cause remission of the disease to a certain extent. 
However, treatment of associated risk factors like hypertension, diabetes or insulin 
resistance, sleep apnea, dyslipidemia is also necessary.  
Medications that block the renin-angiotensin axis in the kidney like the angiotensin 
converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) have been 
shown to have a beneficial effect on reducing glomerular hypertension and proteinuria, 
and preventing disease progression. Praga at al demonstrated this in 17 obese patients 
with proteinuria>1 g/day. Their age was 34-70 years; 11 were females and 6 males. Renal 
biopsy was done in five of these patients. This showed focal glomerulosclerosis in 2 cases, 
minimal changes in 2 and mesangial proliferation in 1. Nine patients (group 1) were then 
put on hypocaloric diets and followed for one year. There was a significant correlation 
between body weight loss and decrease in proteinuria. A second group of eight patients 
were started on captopril, an ACE inhibitor (without any dietary changes). BMI in this 
group remained stable but proteinuria showed a dramatic decrease, similar to that in 
group 1. Given the findings of this study, it makes clinical sense to prescribe both body 
weight loss and ACE inhibitor treatment to patients suspected to have obesity related 
kidney disease. 
6. Conclusion  
The World Health Organization considers obesity an international epidemic, stating in 1997 
that “obesity’s impact is so diverse and extreme that it should now be regarded as one of the 
greatest neglected public health problems of our time with an impact on health which may 
well prove to be as great as that of smoking.” Despite scientific evidence to the contrary, the 
effect of obesity on the function of the kidneys is less well-known. There now is a well 
established risk between obesity and the development of kidney disease. The Framingham 
Offspring reported obesity as a major risk factor for the development of kidney disease 
Kidney disease from obesity can progress to End Stage Renal Disease (ESRD), which 
mandates the use of dialysis to keep the patient alive. It is hence a huge risk factor for 
morbidity and mortality. 
Obesity is associated with multiple other conditions that are known to cause compromised 
renal function, including hypertension, diabetes, hyperuricemia, and the metabolic 
syndrome that can independently have a detrimental effect on renal function. However, 
obesity has been found to cause kidney disease and ESRD even after adjustment for these 
factors. The pathogenesis of obesity related kidney disease can be sub-classified in to direct 
and indirect effects. 
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Obesity seems to cause a change in the renal hemodynamics that promotes progressive 
kidney disease. These changes begin early in the course of obesity, even before overt renal 
manifestations of obesity are clinically apparent. One of the keys to unravel obesity’s 
effect on the kidneys is to understand the concept of body fat as an independent 
endocrine organ rather than simply a passive storage depot for triglycerides. A central 
factor in this is the dysregulated production by adipose cells of bioactive substances, 
called “adipokines” that cause systemic effects and directly influence insulin sensitivity 
and vascular injury. This results in hemodynamic and structural changes in the kidney. 
These adipokines include cytokines like leptin, adiponectin, interleukin-6, tumor necrosis 
factor-alpha, resistin, and angiotensinogen. These cytokines then induce a pro-
inflammatory state causing glomerular capillary hypertension and fibrosis in the renal 
parenchyma. Of these adipokines, one of the best understood roles is that of 
angiotensinogen. Increased angiotensinogen kick-starts the RAS and in turn increases the 
downstream effects of this system, namely, fluid retention and increased vascular tone. 
 Elevated levels of angiotensinogen and angiotensin II then lead to efferent arteriolar 
constriction in the glomerulus. This increases the intraglomerular pressure, leading to a 
rise in the GFR. 
Obese patients have been shown to have elevations in both renal plasma flow (RPF) and 
GFR. The augmented RPF suggests a state of renal vasodilatation involving mainly the 
afferent arteriole. The analysis suggests that the high GFR in very obese subjects may be the 
result of an increase in transcapillary hydraulic pressure difference. An abnormal 
transmission of increased arterial pressure to the glomerular capillaries through a dilated 
afferent arteriole could account for the augmentation in this transcapillary pressure. 
Certain pathognomonic changes are seen in the kidney as a result of long standing obesity. 
These changes encompass what is referred to as Obesity Related Glomerulopathy (ORG). 
These include structural changes like hyperplasia of the juxta-glomerular apparatus, 
consistent presence of glomerulomegaly, and foot process fusion. Another histologic feature 
noted in some ORG patients is the presence of focal changes in the form of mild focal 
mesangial sclerosis or mild focal thickening of glomerular/tubular basement membranes. 
These changes are not very dissimilar to changes that are more often associated with the 
presence of diabetic nephropathy.  
The strong association between obesity and other entities like the dreaded metabolic 
syndrome, hypertension, diabetes, hyperuricemia, dyslipidemia, and sleep apnea also 
causes indirect effects on renal structure and function. Long standing hypertension causes 
changes in the kidneys’ glomeruli, vasculature, and the tubulointerstitium. These changes 
are broadly referred to as hypertensive nephrosclerosis.  Intimal thickening and luminal 
narrowing of the renal arteries and glomerular arterioles is seen. The glomeruli may 
undergo focal global/segmental sclerosis as a consequence of the ensuing ischemic injury. 
Glomerular hyperfiltration and hypertension is a well studied phenomenon that develops 
early in the course of diabetes. Elevated glucose levels are known to stimulate mesangial cell 
matrix production. Non-enzymatic glycation of tissue proteins also may contribute to the 
development of diabetic nephropathy. It has been proposed that hyperuricemia may 
contribute to worsening of renal function by decreasing renal perfusion. This happens 
because of arteriolosclerosis of the afferent arterioles. It is believed that uric acid stimulates 
afferent arteriolar vascular smooth muscle cell proliferation. It has been shown in animal 
models that hyperlipidemia can cause mesangial cell proliferation by activating LDL 
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receptors present on mesangial cells. This leads to increased production of inflammatory 
growth factors and reactive oxygen species.  
Before overt clinical kidney disease becomes clinically apparent in obesity, patients may 
start to develop limited renal disease in a few glomeruli. Early markers of glomerular 
disease like microalbuminuria and albuminuria have been reported in as much as 41% and 
4% of the extremely obese patients, respectively. Focal segmental glomerulosclerosis (FSGS) 
and obesity-related glomerulopathy (ORG), as explained above, have been described in 
patients with severe obesity, and manifest initially with proteinuria. These can, in severe 
states, progress to renal failure. However, as is the case with other causes of secondary 
FSGS, nephrotic syndrome is atypical and the presence of edema is uncommon. It has been 
suggested that the difference between obesity-related glomerulonephropathy or secondary-
FSGS from obesity, and idiopathic FSGS is that only some nephrons leak protein in the 
former, as opposed to global nephron involvement in idiopathic FSGS.  
Weight loss, and drugs like ACE inhibitors (eg captopril, lisinopril) or angiotensin receptor 
blockers (like losartan, irbesartan) can stem the progression of kidney disease in obesity, and 
are sometimes able to actually reverse the changes induced by obesity related kidney 
disease. However, this is less likely to happen if most of the glomeruli are already fibrosed. 
In such cases, the disease can progress relentlessly with a progressive decrease in GFR. 
Uremic symptoms can ensue below a GFR of 15 ml/min, and eventually, symptoms like 
failure to thrive, dysgeusia, nausea, vomiting, itching, insomnia, hyperkalemia, fluid 
overload, or acidosis can mandate the initiation of dialysis. It thus makes clinical sense to 
prescribe both weight loss and ACE inhibitor/angiotensin receptor blocker treatment to 
patients suspected of having obesity related kidney disease.  
7. Methods 
We searched PubMed for English, German, French, and Spanish language references 
published as of June 2011, using combinations of the following terms: “obesity”, “kidney 
disease”, “glomerulopathy”, “FSGS”, “gastric bypass”, “diabetes mellitus”, “dyslipidemia”, 
“hypertension”, “metabolic syndrome”, “metabolic effects”, “renal effects”, “nutrition”, 
“epidemiology”. The bibliographies of the articles thus obtained, as well as those of relevant 
review articles were also reviewed for inclusion of publications. 
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Since the discovery of hyperuricemia as the cause of gout in the early 1800s, hypertension, 
cardiovascular disease and kidney disease have also been related to increased serum uric 
acid (UA) levels in subsequent years (Nakagawa et al., 2006); patients with gout had a much 
higher prevalence of hypertension (25-50%), mild-to-moderate kidney disease (20-60%) 
(Kutzing & Firestein, 2008) and cardiovascular disease (90%) compared to the general 
population. However, conflicting results regarding the role of UA as the causative factor in 
diseases other than gouty arthritis resulted in a shift of interest away from UA. In recent 
years, uric acid regained the lost popularity due to new findings in a number of disease 
states including hypertension, renal disease, metabolic syndrome and many more (Feig et 
al., 2008).  
Hyperuricemia arises from excess dietary purine or ethanol intake, decreased renal 
excretion of UA, or from tumor lyses in lymphoma, leukaemia, or solid tumours (Kutzing & 
Firestein, 2008). Finally, several drugs alter UA handling by the kidney, for example drug 
therapy with candesartan (Li et al., 2008) or both loop- and thiazide diuretics, all of which 
increase the net urate reabsorption (Suliman et al., 2006). In the majority of individuals, 
hyperuricemia will be asymptomatic, but as UA tends to precipitate in tissues and in other 
body fluids, persistent hyperuricemia may eventually lead to the accumulation of urate 
crystals in many places, resulting in either acute painful conditions, like gout/tophaceous 
gout/gouty arthritis, urolithiasis, or, in severe cases, like tumor lysis syndrome, in acute UA 
nephropathy (Riegersperger et al., 2011). 
In recent years, increased fructose intake, particularly via sweetened beverages, started to 
attract more attention from the medical community. During the last two centuries, at least in 
the western world, dietary fructose intake dramatically increased, with corresponding 
increases in serum UA levels (Feig et al., 2008). The increase in fructose intake and 
hyperuricemia is now being associated to the development of metabolic syndrome. 
Hyperuricemia is associated with an increased risk for developing CKD (Obermayr et al., 
2008) and a risk factor for renal dysfunction in patients with rheumatoid arthritis 
(Daoussis et al., 2009). Retrospective data suggest an influence of hyperuricemia on graft 
loss after kidney transplantation (Haririan et al., 2010). A screening among 18,020 
individuals with chronic kidney diseases (CKD) found a 20.6% prevalence of 
hyperuricemia. A cross-sectional study in individuals aged over 40 years found 10.5% 
prevalence of CKD, and among these, 26% were hyperuricemic (Shan et al., 2010). A 
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multi-center study of 2,145 consecutive patients with essential hypertension found a 
prevalence of hyperuricemia of 35% in males and 43% in females, and this was associated 
with elevated serum creatinine levels (Lin et al., 2010). A screening among 5,722 
individuals found a 5.4% incidence of chronic kidney disease, and serum UA (sUA) 
correlated with serum creatinine levels (Chen et al., 2009). A cross-sectional study in 9,375 
participants of a health-screening program found 14.5% hyperuricemic individuals (Kuo 
et al., 2010). A screening study found a higher incidence of end-stage renal disease among 
hyperuricemic women (Iseki et al., 2004), and a post-hoc analysis in 294 patients initiating 
renal replacement therapy found that half of these were hyperuricemic with a  
twofold increase in mortality when UA levels were ≥9.0 mg/dL (≥535 µmol/l) (Suliman et 
al., 2006). 
2. Uric acid metabolism 
UA is the end-product of purine nucleotide metabolism in humans. In contrast to many 
lower vertebrates, human lack UA oxidase (uricase), an enzyme which further catalyses UA 
to allantoin, more soluble end product (Sautin & Johnson, 2008). Humans have higher 
serum UA levels when compared to other mammals due to the lack of uricase (Johnson et 
al., 2003). UA is primarily excreted via the urine. The balance between dietary intake, 
endogenous metabolism of purines and the urinary excretion rate of UA determines plasma 
UA levels (Kutzing & Firestein, 2008). 
Almost all serum UA is present in the ionized form, monosodium urate, and only about 5% of 
urate is protein bound at physiological pH. The definition of hyperuricemia is currently 
arbitrary and varies from >6 mg/dL (360µmol/l) in women and >7 mg/dL (416µmol/l) in 
men, to ≥6.5 mg/dL (387µmol/l), or to >8.3 mg/dL (494 µmol/l), regardless of gender. UA 
levels physiologically and gradually rise during the human lifetime; in female individuals, UA 
levels additionally rise after menopause (Hak et al., 2008). 
Renal handling. Kidneys eliminate two-thirds, and the gastrointestinal tract eliminates  
one-third of the UA load. Urate is filtered completely at the renal glomerulus. However,  
the normal fractional excretion of UA is only 8% to 12%. Therefore, postglomerular 
reabsorption and secretion are the ultimate factors regulating the amount of UA excretion 
(Gutman et al., 1968; Steele et al., 1973). The proximal tubule is the site of UA reabsorption 
and secretion. Almost complete reabsorption of urate occurs at the S1 segment of the 
proximal tubule. However, in the S2 segment of the proximal tubule urate is secreted at a 
range greater than reabsorption via transporters URAT1, OAT1, -2, and -3, -4, and -10, the 
multi-drug resistance proteins ABCC4 and ABCG2, and the glucose transporters GLUT 9a 
and b, and others. Finally, post-secretory resorption occurs at a more distal site of the 
proximal tubule. Approximately 10% of the filtered urate appears in the urine (Shekarriz et 
al., 2002). 
UA Chemistry. UA is a weak acid with 2 dissociation constants. Two factors contribute to 
UA solubility: UA concentration and solution pH. However, the solubility of UA in urine is 
primarily determined by urinary pH. The first pKa of UA is at a pH of 5.5, resulting in the 
loss of 1 proton from UA and the formation of anionic urate (Finlayson, 1974). The second 
pKa is 10.3, which has no physiological significance in humans. The supersaturation of urine 
with UA occurs when urinary pH is less than 5.5. In contrast, at a pH of more than 6.5 the 
majority of UA is in the form of anionic urate. The solubility of urate salts is affected by the 
relative concentrations of cations present in the urine. Increased urinary sodium 
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concentrations promote formation of the monosodium urate complex, which is more soluble 
than undissociated UA. Urine is frequently supersaturated with sodium urate but stones of 
this type are infrequent. However, supersaturation with sodium urate may contribute to 
calcium oxalate stone formation via heterogeneous nucleation.  
UA pool. UA may be derived by endogenous or exogenous routes. The endogenous 
production of UA from purine synthesis, and tissue catabolism under normal circumstances, 
is relatively constant at 300 to 400mg per day. However, the exogenous pool varies 
significantly with diet. A diet rich in animal protein contributes significantly to the purine 
pool and subsequent UA formation by a series of enzymatic reaction involving xanthine 
oxidase as the final step. 
Excretion. Renal excretion is the primary mode of UA clearance, accounting for two-thirds 
of its elimination. Intestine, skin, hair and nails account for the remaining one-third of UA 
excretion. In the intestine bacteria catabolise UA into carbon dioxide and ammonia, which 




Fig. 1. Schematic representation of the metabolism of Uric Acid 
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3. Mechanisms of uric acid-induced hypertension 
It is well established that when UA is deposited in tissues in the crystalline form, it initiates 
a proinflammatory state, as seen in gouty arthritis (Sanchez-Lozada et al., 2006). However, 
the precise pathogenetic role of soluble UA in the serum is somewhat less clear. Moreover, 
markedly elevated serum UA is clearly associated with gouty arthritis and nephrolithiasis, 
whereas the importance of subtle elevation in UA levels still remains to be established.  
For many years, UA was regarded as a metabolically inert substance. However, several lines 
of evidence have demonstrated that soluble UA is a strong antioxidant (Ames et al., 1981). 
Despite these well-recognized antioxidant effects, UA also behaves as a pro-oxidant and 
proinflammatory factor. A few points should be emphasized to better understand this 
apparent paradox. First, UA acts differently inside the cells or in the extracellular milieu, 
where it is present in soluble form. While being a potent antioxidant in extracellular fluid, 
UA exerts pro-oxidative effects once inside the cell (Sautin et al., 2007; Corry et al., 2008; 
Convento et al., 2011). 
Second, one isoform of xanthine oxidoreductase – xanthine dehydrogenase – undergoes 
extensive phenotypic conversion to xanthine oxidase under local ischemic conditions. 
Unlike xanthine dehydrogenase, xanthine oxidase uses molecular oxygen instead  
of Nicotinamide Adenine Dinucleotide (NAD) as an electron acceptor (Glantzounis et  
al., 2005).  
In addition to interference with free radical production, UA has some direct effects on 
endothelial and smooth muscle cells of the vascular wall, which ultimately lead to 
endothelial dysfunction (Mazzali et al., 2002). In endothelial cells, UA blocks nitric oxide 
(NO) release, inhibits endothelial proliferation and stimulates C-reactive protein production 
(Khosla et al., 2005). Several experimental studies also showed that UA can activate smooth 
muscle cells via activation of  specific MAP kinases, nuclear transcription factors, 
stimulation of ciclooxigenase-2 (Cox-2), and various inflammatory mediators such as the 
tissue renin-angiotensin system (Corry et al., 2008; Watanabe et al., 2002; Kang et al., 2002). 
Recent evidence also suggests that hyperuricemia increased cellular proliferation, 
angiotensin II (AII) and endothelin-1 (ET-1) in human mesangial cells (Albertoni et al., 2010), 
which could contribute to reduce GFR. 
In a landmark study by Mazzali et al., 2001 pharmacologically induced mild-to-moderate 
hyperuricemia via oxonic acid administration in rats resulted in the development of 
hypertension. Conversely, when UA elevation was treated with allopurinol or with a 
uricosuric agent, development of hypertension could be prevented. Other experimental 
studies show that at a concentration of 10 mg/dL UA significantly decreases the production 
of ET-1 in mesangial cells after 24h of treatment.  This effect was blocked by Losartan (LOS), 
an AII receptor type 1 antagonist (Albertoni et al, 2010). 
It is also possible that genetic polymorphisms of transporters or enzymes involved in UA 
metabolism affect blood pressure, especially in younger subjects. For example, hypertension 
has been associated with polymorphisms of xanthine oxidoreductase (Chaves et al., 2007). 
4. Uric acid and acute renal failure 
Uric acid, as the end-product of purine metabolism in humans, presents a clinical impact 
since its has a relative insolubility, particularly in the acidic environment of the distal 
nephron. As a result, states of enhanced purine catabolism increases the urate load on the 
kidney, leading to intrarenal precipitation. Major causes of increases on purine metabolism 
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are malignancies with rapid cell turnover, such as leukemia and lymphomas, and the added 
acceleration of cell lyses that occurs with chemotherapy and radiation. Serum urate levels 
rise rapidly, and acute renal failure occurs as a consequence of tubular deposition and 
obstruction  of urate and uric acid. The keys to the diagnosis of acute uric acid nephropathy 
are the appropriate clinical settings as cell lyses increases, oliguria, marked hyperuricemia, 
and hyperuricosuria. A urinary uric acid-to-creatinine ratio greater than 1 helps to 
distinguish acute uric acid nephropathy from other catabolic forms of acute renal failure in 
which serum urate is elevated. Preventive treatment involves pharmacologic xanthine 
oxidase inhibition with allopurinol and alkaline diuresis. Occasionally, acute renal failure 
occurs despite allopurinol due to tubular precipitation of the metabolites precursors, such as 
xanthine, which accumulate with xanthine oxidase inhibition. Dialysis therapy may be 
required both to correct azotemia and to reduce the body burden of urate. Hemodialysis is 
preferred since it can achieve greater clearance than other dialysis modes. (Conger, 1990). 
5. Uric acid and kidney disease 
Association of UA with chronic kidney disease dates back to 1890s. Any functional declive 
which reduces glomerular filtration rates (GFR) and tubular reabsorption secondarily leads 
to UA elevation, but also the decrease in glomerular filtration rate can increase serum UA 
(Feig, 2009). To determine which comes first was the principal endeavor of UA researchers 
in the last two decades.  
Experimental studies performed by Mazzali et al., 2002, demonstrated that hyperuricemic 
rats developed hypertension, afferent arteriolopathy, glomerular hypertrophy, and 
increased glomerular pressure, tubulointerstitial damage and macrophage infiltration 
(Mazzali et al., 2002; Sanchez-Lozada et al., 2005; Nakagawa et al., 2003). 
Several works analyzed the effects of UA in kidney cells and hyperuricemic animal models. 
Firstly, hyperuricemia induces endothelial dysfunction and inflammation (Yu et al., 2010, 
Khosla et al., 2005). UA has the ability to increase monocyte chemoattractant protein (MCP-
1) in cultured vascular smooth muscle cells (Kanellis et al., 2003) and human proximal 
tubular epithelial cells (Cirillo et al., 2006). UA can induce the contraction (Albertoni, et al., 
2010) and reactive oxygen species produced in mesangial cells (Convento et al., 2011). 
6. Uric acid, metabolic syndrome and diabetes 
The relationship between hyperuricemia, hypertension, and the metabolic syndrome has long 
been debated. Are the conditions different manifestations of a common underlying metabolic 
disorder? Is hyperuricemia in part responsible for hypertension? Recent evidences from 
animal studies and epidemiology suggest that hyperuricemia has a primary role in both 
hypertension and the metabolic syndrome. Rats that were made hyperuricemic rapidly 
developed hypertension through activation of the renin-angiotensin system, induction of 
endothelial dysfunction, and vascular smooth muscle proliferation. Lowering UA in these 
animals prevented this effect (Johnson et al., 2005). In a longitudinal study in children, there 
was a strong correlation between hyperuricemia and the subsequent development of 
hypertension (Feig et al., 2006). Recent epidemiological data suggest also that hyperuricemia is 
an independent risk factor for developing hypertension. In a group of subjects who did not 
have the metabolic syndrome, normotensive men with baseline hyperuricemia had 80% more 
risk of develop hypertension compared with those who did not have hyperuricemia (Krishnan 
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3. Mechanisms of uric acid-induced hypertension 
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et al., 2007). Finally, the degree of hyperuricemia is strongly correlated with the prevalence of 
the metabolic syndrome (Yoo et al., 2005; Choi et al., 2007; Facchini et al., 1992). 
Metabolic syndrome has many components which may independently mediate or lead to 
kidney damage, including increased inflammation (Calabro & Yeh, 2008), insulin resistance 
and endothelial dysfunction (Kim et al., 2006). Additionally, diets high in fructose constitute 
one of the major predisposing factors for the metabolic syndrome epidemia (Cirillo et al., 
2006). Fructose is unique among sugars by its ability to rapidly deplete ATP, with resultant 
purine nucleotide degradation and eventual UA generation. 
Experimental studies in rodents have suggested that UA may contribute to the development 
of the metabolic syndrome, hypertension, and kidney disease (Feig et al., 2008) and recently 
clinical studies focusing on UA and the development and progression of diabetic kidney 
disease have been published (Hovind et al., 2011). In the early report of the Modification of 
Diet in Renal Disease Study (Hunsicker et al., 1997), UA was not found to be an independent 
predictor for renal disease. Others large epidemiologic studies have revealed conflicting 
results in this respect. While the majority (Iseki et al., 2001; Domrongkitchaiporn et al., 2005; 
See et al., 2010; Chang et al., 2010; Obermayr et al., 2008) of these studies suggest an 
independent predictive role for UA in renal disease, others (Tomita et al., 2000; Sturm et al., 
2008; Madero et al., 2009) argue against it.  
Historically, the elevated level of UA observed in the metabolic syndrome has been attributed 
to hyperinsulinemia, since insulin reduces renal excretion of UA (Quinõnes et al., 1995).  
Hyperuricemia, however, often precedes the development of hyperinsulinemia (Nakagawa 
et al., 2005; Carnethon et al., 2003), obesity (Masuo et al., 2003), and diabetes (Nakanishi et 
al., 2003; Dehghan et al., 2008; Chien et al., 2008). Hyperuricemia may also be present in the 
metabolic syndrome in people who are not overweight or obese.  
The strongest evidence of a role for UA in the development of the metabolic syndrome has 
been from studies models showing that decreasing UA levels can prevent or reverse features 
of the metabolic syndrome (Nakagawa et al., 2006; Sanchez-Lozada et al., 2008; Reungjui et 
al., 2007). Two mechanisms have been suggested to explain how hyperuricemia might 
induce the metabolic syndrome. The first mechanisms is related to the fact that glucose 
uptake in skeletal muscle depend in part on increases in blood flow mediated by the insulin-
stimulated release of NO from endothelial cells. Features of the metabolic syndrome 
develop in mice lacking endothelial nitric oxide synthase (iNOs) (Cook et al., 2003). The 
observations that hyperuricemia can induce endothelial dysfunction in rats (Khosla et al., 
2005) and that treatment with allopurinol can improve endothelial function in patients with 
hyperuricemia (Mercuro et al., 2004) would support this mechanism. The second 
mechanism concerns the inflammatory and oxidative changes UA induces in adipocytes 
(Sautin et al., 2007), a process that is key in causing the metabolic syndrome in obese mice 
(Furukawa et al., 2004).  
The prevalence of diabetes, and for that matter the associated complications, has increased 
dramatically. Presently, diabetes is the leading cause of end-stage renal disease in the 
western world (United States Renal Data System, 2008). Although the progression of renal 
disease can be halted partially, diabetic nephropathy is still regarded as an irreversible and 
progressive disease (Parving et al., 2008). 
Therefore, it has become increasingly essential to determine the pathophysiological 
mechanisms underlying the development and progression of diabetic nephropathy. 
Evidence is available of a complicated interaction between different contributors to the 
disease process. It is possible that genetic susceptibility, metabolic abnormalities, 
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hemodynamic changes, upregulated growth factors, and cytokines may all play a part in the 
development of diabetic glomerulopathy; however, the complex pathogenesis of 
development of diabetic nephropathy has not been fully clarified (Hovind et al., 2011). 
Recently clinical studies focusing on UA, albuminuria and diabetic kidney disease have 
been published (Bonakdaran et al., 2011; Kim et al., 2010; Kuo et al., 2010). The new evidence 
suggests that UA could be a risk factor for the development of diabetic nephropathy; 
however, the significance of serum UA as pathogenic factor in the development of diabetic 
nephropathy is not yet fully clarified (Hovind et al., 2011). 
7. Uric acid stones 
A high concentration of urate and low pH are the determinants of UA stone formation. 
The prevalence of UA stones in the United States is estimated to be 5% to 10% (Gutman et 
al., 1968). Interestingly, these data originate from studies performed more than 30 years 
ago. Therefore, the current incidence of UA stones in the United States may be different. 
In a more recent study from Veterans Administration hospital stone analyses revealed 
that 12% of stones contained some UA component and 9.7% comprised pure UA (Mandel 
et al., 1989). Incidence also may vary with age. The incidence of UA stones was 11% in a 
geriatric population (Gentle et al., 1997). The frequency of UA stones also varies in 
different geographical locations within the United States. In southern states the incidence 
has been reported at 4% compared with 17% in Chicago (Riese et al., 1992). Other 
industrialized countries have wide variations in UA stone rates, with Germany reporting 
17% to 25%, Sweden 4% and Israel up to 40% (Hesse et al., 1975; Scholz et al.,  
1979; Grenabo et al., 1985; Atsmon et al., 1963). Urate stones have frequently been 
reported in Iran and Pakistan. However, the majority of these stones are ammonium acid 
urate (Minon et al., 1983). These apparent geographical variations indicate that genetic, 
dietary and environmental factors may have an important role in the formation of  
UA stones. 
Composition and different types of UA stones. UA stones can be classified based on 
crystalline composition as anhydrous uric acid, uric acid dehydrate, sodium acid urate 
monohydrate or ammonium acid urate (Halabe et al., 1994). The anhydrous form is 
thermodynamically the most stable crystal. The dehydrate form is unstable and undergoes 
dehydration to the anhydrous form. Uric acid dehydrate has been identified in 20% of UA 
calculi and may represent the entire component. Ammonium acid urate precipitation 
requires high urate and ammonium concentrations and occurs at a higher pH. Recently, a 
classification of UA stones based on their crystalline growth pattern has been suggested 
(Grases et al., 2000). 
Mechanism of stone formation. UA stone formation requires supersaturation of urinary 
UA. Three factors contribute to the formation of these calculi: acidic urine, hyperuricemia 
and decreased urinary volume. One or more of these conditions may coexist in a specific 
patient and contribute to stone disease severity (Shekarriz et al., 2002). 
Hyperuricosuria. Hyperuricosuria is defined as a mean 24-hour urinary UA excretion of 
more than 600 mg/24 hr in 2 of 3 collected samples (Pak et al., 1980). Hyperuricosuria may 
be associated with hyperuricemia, such as in primary gout, or may manifest as an isolated 
abnormality due to various factors such as diet or medications. The degree of hyperuricemia 
correlates with the incidence of UA stone formation. In patients with gout the incidence of 
UA stones was 23% in those with urinary UA levels less than 600 mg/24hr compared with 
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50% in those with UA levels greater than 1,000 mg/24 hr (Yu et al., 1967). In other study 
11% of patients with UA excretion less than 300 mg/24 hr had UA stones (Hall et al., 1967; 
Katz et al., 1970). In patients with gout the rate of stone formation is higher when uricosuric 
drugs are administered.  
Urinary pH. All conditions contributing to acidic urine promote uric acid stone formation. 
Urinary pH is abnormally low in a significant number of patients with gout and in 
idiopathic UA stone formers (Gutman et al., 1968; Yu et al., 1967; Zechner et al., 1982; Ito et 
al., 1995). Urinary alkalization is the cornerstone of medical management of UA stones. The 
concept of UA stone dissolution is not new. Shekarriz et al., 2002 observed impressive 
dissolution of large burden UA renal stones with oral alkalization. UA stone dissolution by 
oral alkalization is generally effective, with a reported success rate of 80% (Shekarriz et al., 
2002). Continued alkalization will help prevent future stones, but in the treatment of gout, 
alkalinization  of urine (over pH 6.5) to maintain the solubility may precipitate calcium 
phosphate crystals (Meyer et al., 1990). 
8. Gout 
Gout is a disease of ancient origin and its association with UA stones has long been 
recognized. In 1683 London physician Thomas Sydenham, who suffered from renal stones, 
described the clinical features of gout. Michelangelo’s special interest in anatomy and 
kidney function has been ascribed to his own urinary stone disease (Eknoyan et al., 2000).  
Studies of the composition of urinary calculi were limited before the advent of modern 
chemistry. Gout is an inflammatory process initiated by tissue deposition of monosodium 
urate (MSU) crystals. A typical attack is an acute monoarthritis accompanied by classical 
signs of inflammation. However, inflammation can occur in any tissue in which MSU is 
deposited, as typified by tophaceous gout and by urate nephropathy due to renal medullary 
deposition of MSU crystals (So, 2008).  
Multiple risk factors may interact and lead to development of gout: 
Genetics – Monogenic disorders that result in overproduction of UA via enzyme defects in 
purine metabolism are extremely rare. Nevertheless, common primary gout in men often 
shows strong familiar predisposition, although the genetic basis remains unknown. Twin 
studies have show high heritability for both UA renal clearance (60%) and UA: creatinine 
ratio (87%) and several susceptibility loci for this have been reported (Roddy et al., 2007). 
Gender and age – Men have higher urate levels than women and an increased prevalence of 
gout at all ages, though less pronounced in older age. Estrogens have a uricosuric effect, 
making gout very rare in younger women. However, after the menopause, urate levels rise 
and gout becomes increasingly prevalent. Ageing is an important risk factor in both  
men and women, possibly due to multiple factors including: an increase in sUA levels 
(mainly due to reduced renal function); increased use of diuretics and others drugs that 
raise sUA; age-related changes in connective tissues, which may encourage crystal 
formation (Roddy et al., 2007). 
Diet – Historically, gout has long been linked with a rich lifestyle involving excesses of meat 
and alcohol, but it is only recently that population studies have been undertaken to 
determine the risk associated with individual dietary components. Data from the large 
Health Professionals Follow-up Study (HPFS) have show that the relative risk of gout is 
higher in people who eat a high red meat diet: the relative risk of a first attack of gout 
associated with an additional daily portion of meat was 1.21 (95% CI 1.04, 1.41). Higher 
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consumption of seafood was associated with a lesser, but still significant, increase in risk. 
Diets high in purine-rich vegetables did not increase the risk, while diets high in low-fat 
dairy products were associated with reduced risk (relative risk with additional daily 0.79; 
95% CI 0.71, 0.87) (Choi et al., 2004). 
Alcohol – Some alcoholic drinks are rich in purines, notably beer which contains guanosine. 
Alcohol is though to increase the risk of gout because the metabolism of ethanol to acetyl 
CoA leads to adenine nucleotide degradation, resulting in increased formation of adenosine 
monophosphate, a precursor of UA. Alcohol also raises the lactic acid level in blood, which 
inhibits UA excretion. In the HPFS, overall the higher the daily alcohol intake, the higher the 
risk of gout (Choi et al., 2004). However, differences in risk were observed with different 
alcoholic drinks. Beer had the greatest effect, probably because of its high purine content, 
then alcohol, whereas wine had no increased risk (Choi et al., 2004). 
Drugs – Many drugs which either increase sUA levels (e.g. diuretics and pyrazinamide) or 
reduces sUA levels (e.g.uricosurics such as benzbromarone, sulphinpyrazone and vitamin 
C) effect these changes via interaction with urate transporters such as URAT1 (Anzai et al., 
2005) and GLUT9 (Caulfield et al., 2008). 
RENAL DISEASE AND GOUT – Gout frequently associates with kidney disease, each 
being a risk factor for the other. Primary kidney disease can lead to hyperuricemia and it has 
been suggested that the increasing prevalence of end-stage renal disease may be one cause 
of recent increases in gout (Roddy et al., 2007). Kidney damage secondary to gout is 
associated with urate crystals and microtophi in the interstitium and/or UA crystals within 
tubules. Evidence from animal studies suggests that hyperuricemia may accelerate chronic 
kidney disease, and several studies have demonstrated a significant and independent 
association between sUA levels and the progression of chronic kidney disease (Kang et al., 
2002; Kang et al., 2005). A history of gout is an independent risk factor for urolithiasis in 
men (Kramer et al., 2003). The increased risk is not just for UA stones, but also for more 
common calcium phosphate stones. High urinary levels of UA increase the risk of stone 
formation and in gout patients, the higher the excretion of UA, the greater the risk of stone 
formation (Yu et al., 1967). However, the most important risk factor for UA stone formation 
is persistently acidic urine, favoring the precipitation of urate (Shekarriz et al., 2002). In 
patients with UA stones, a high urinary UA: creatinine ratio indicates overproduction of 
UA, which should prompt a search for an abnormality of purine metabolism. 
9. Advances in therapy of hyperuricemia and gout 
The treatment of hyperuricemia and gout remains a challenge even though we appear to 
have a number of effective drugs. Many clinicians recognize that our existing treatment 
choices are often limited in the routine clinical setting. Allopurinol, the most commonly 
used drug to treat hyperuricemia, can provoke severe allergic-type reactions and needs to be 
used with caution in renal failure. Fortunately, the incidence of these rare reactions is low, 
but skin rashes are frequently reported (Hung et al., 2005). Benzbromarone, a very effective 
uricosuric drug, was recently withdrawn from general distribution because of a number of 
cases of hepatic failure associated with its use. Other hypouricemic drugs are therefore 
needed. Recently, a new xanthine-oxidase inhibitor, febuxostat, underwent clinical trials and 
was show to be as effective as allopurinol in reducing hyperuricemia (Becker et al., 2005). 
Febuxostat, unlike allopurinol, is not a purine analog and does not cross-react with 
allopurinol. In clinical trials, when administered at a daily dose of either 80 or 120 mg, it was 
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50% in those with UA levels greater than 1,000 mg/24 hr (Yu et al., 1967). In other study 
11% of patients with UA excretion less than 300 mg/24 hr had UA stones (Hall et al., 1967; 
Katz et al., 1970). In patients with gout the rate of stone formation is higher when uricosuric 
drugs are administered.  
Urinary pH. All conditions contributing to acidic urine promote uric acid stone formation. 
Urinary pH is abnormally low in a significant number of patients with gout and in 
idiopathic UA stone formers (Gutman et al., 1968; Yu et al., 1967; Zechner et al., 1982; Ito et 
al., 1995). Urinary alkalization is the cornerstone of medical management of UA stones. The 
concept of UA stone dissolution is not new. Shekarriz et al., 2002 observed impressive 
dissolution of large burden UA renal stones with oral alkalization. UA stone dissolution by 
oral alkalization is generally effective, with a reported success rate of 80% (Shekarriz et al., 
2002). Continued alkalization will help prevent future stones, but in the treatment of gout, 
alkalinization  of urine (over pH 6.5) to maintain the solubility may precipitate calcium 
phosphate crystals (Meyer et al., 1990). 
8. Gout 
Gout is a disease of ancient origin and its association with UA stones has long been 
recognized. In 1683 London physician Thomas Sydenham, who suffered from renal stones, 
described the clinical features of gout. Michelangelo’s special interest in anatomy and 
kidney function has been ascribed to his own urinary stone disease (Eknoyan et al., 2000).  
Studies of the composition of urinary calculi were limited before the advent of modern 
chemistry. Gout is an inflammatory process initiated by tissue deposition of monosodium 
urate (MSU) crystals. A typical attack is an acute monoarthritis accompanied by classical 
signs of inflammation. However, inflammation can occur in any tissue in which MSU is 
deposited, as typified by tophaceous gout and by urate nephropathy due to renal medullary 
deposition of MSU crystals (So, 2008).  
Multiple risk factors may interact and lead to development of gout: 
Genetics – Monogenic disorders that result in overproduction of UA via enzyme defects in 
purine metabolism are extremely rare. Nevertheless, common primary gout in men often 
shows strong familiar predisposition, although the genetic basis remains unknown. Twin 
studies have show high heritability for both UA renal clearance (60%) and UA: creatinine 
ratio (87%) and several susceptibility loci for this have been reported (Roddy et al., 2007). 
Gender and age – Men have higher urate levels than women and an increased prevalence of 
gout at all ages, though less pronounced in older age. Estrogens have a uricosuric effect, 
making gout very rare in younger women. However, after the menopause, urate levels rise 
and gout becomes increasingly prevalent. Ageing is an important risk factor in both  
men and women, possibly due to multiple factors including: an increase in sUA levels 
(mainly due to reduced renal function); increased use of diuretics and others drugs that 
raise sUA; age-related changes in connective tissues, which may encourage crystal 
formation (Roddy et al., 2007). 
Diet – Historically, gout has long been linked with a rich lifestyle involving excesses of meat 
and alcohol, but it is only recently that population studies have been undertaken to 
determine the risk associated with individual dietary components. Data from the large 
Health Professionals Follow-up Study (HPFS) have show that the relative risk of gout is 
higher in people who eat a high red meat diet: the relative risk of a first attack of gout 
associated with an additional daily portion of meat was 1.21 (95% CI 1.04, 1.41). Higher 
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allopurinol. In clinical trials, when administered at a daily dose of either 80 or 120 mg, it was 
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more effective than a 300 mg daily dose of allopurinol in achieving the target value of 
uricemia (less than 6 mg/dL or less than 360 µmol/L), a target that has been recommended 
in treatment guidelines for gout and hyperuricemia (Zhang et al., 2006). 
10. Conclusion 
It is becoming clear that the role of UA is no longer confined solely to gout and 
nephrolithiasis. Increasing evidence now points to a significant relation of UA to 
hypertension and renal disease. Moreover, recent studies have started to unveil the causal 
nature of this relationship in both hypertension and renal disease. Despite considerable 
progress, given the numerous confounders, more compelling evidence is needed before 
ultimately labelling UA as a causative factor in hypertension and renal disease. Persistently 
acidic urine resulting in supersaturation of UA is the only metabolic abnormality found in 
many patients with UA stones. Although the mechanism responsible for acidic urine in 
many patients remains unclear, urinary alkalization is the cornerstone of medical 
management and should be the primary mode of treatment in the absence of absolute 
indications for surgical intervention. Furthermore, prophylaxis with urinary alkalization 
using oral alkali prevents stone recurrence and associated morbidity. Hyperuricemia is the 
central risk factor for gout and is a key component of the metabolic syndrome, is also an 
independent risk factor for cardiovascular disease, although at present there is no evidence 
to support urate-lowering therapy for asymptomatic hyperuricemia. More studies in this 
exciting and provocative area of research are being conducted and published (Kanbay et al., 
2007; 2010; Turgut et al., 2009). 
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1. Introduction 
Pregnancy in women with different renal diseases has important consequences for the 
developing fetus and maternal health. Kidneys and the urinary tract have to adapt to the 
pregnancy status and therefore suffer significant anatomical, hemodynamic and 
endocrine changes. Failure to adapt can aggravate the preexisting maternal disease and 
can also create suboptimal environment for fetal development and increase the risk of 
obstetric complications. Knowledge and correct interpretation of the renal functional tests 
is necessary for the modern obstetrician, avoiding an incorrect diagnosis for renal disease 
where only specific renal changes during pregnancy are present, but meanwhile a correct 
evaluation of the renal function and changes can detect a pathology that can aggravate 
both the mother’s and the baby’s condition. Improvement and better understanding of the 
renal pathophysiology in pregnancy made possible that pregnant woman look forward 
for a good outcome, including here also the women with renal transplant. Nowadays is 
underlined the concept of multidisciplinary teamwork, a very important concept of 
modern medicine. The obstetrician should consider nephrologists as key players in the 
team and in our opinion should refer to them the pregnant women for a routine check-up 
of the renal status in the 2nd or beginning of 3rd trimester by ultrasound, beside the usual 
blood and urine analysis. The nephrologists and urologists should be involved in the 
management of severe medical conditions, such as preeclampsia, acute and chronic renal 
failure and never the less in the complex management of dialysis or renal transplant 
patients. In pregnancy it can be encountered several renal diseases, some of them 
preexisting the pregnancy and other developed or being direct influenced by pregnancy. 
This chapter will discuss briefly the basic evaluation of renal status in order to present 
and better understand the acute and chronic renal disorders in pregnancy. The chapter 
will focus on the most common preexisting diseases in pregnancy such as: chronic 
glomerulonephritis, secondary glomerular nephropathies, interstitial nephropathies 
(chronic pyelonephritis, renal tuberculosis), diabetes nephropathy, unique surgical 
kidney, chronic renal failure. From the renal diseases directly influenced by pregnancy it 
will be discussed: asymptomatic bacteriuria, symptomatic urinary infection, urolithiasis 
and acute renal failure in pregnancy.  
It will be presented also the management of dialysis in pregnancy and pregnant women 
with renal transplant. 
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2. Evaluation of the renal function in pregnancy 
Evaluation of the renal function is very important in pregnant women. Serum uric acid, blood 
urea nitrogen (BUN), and serum creatinine levels are important indices of renal function in 
pregnancy. Urinalysis is a useful tool for screening, further testing being necessary if changes 
in renal status are detected. Another useful method is the 24 hour urine sample, used 
especially for total protein analysis. Most investigators consider the value of up to 260 
mg/day of total urinary protein normal in pregnancy. Usually higher values indicate a 
decline of renal function due to preeclampsia. It should be noted that when serial 24-hour 
urine samples are performed in order to evaluate the change of renal status, it is crucial that 
the collection be standardized [Airoldi, 2007]. The total amount of creatinine excreted in 24 
hour is considered to be the best method to compare two urine samples, as the cleared 
creatinine in a day should remain constant through pregnancy. The significance of dipstick 
or microscopic hematuria in pregnancy is uncertain, but some studies suggested it is 
associated with a greater risk for preeclampsia [Brown, 2005]. A study of McNair and 
collaborators compared urinalysis with uroculture for screening of asymptomatic 
bacteriuria [McNair, 2000]. They found that urinalysis has a sensitivity of 80.6% and 
specificity of 71.5% in their population. Given the 19.4% of false negative rate and the 
morbidity of the undiagnosed bacteriuria it is recommended that urine culture should be 
used as the primary method for screening in pregnant women. Although baseline creatinine 
clearance is decreased in patients with chronic renal insufficiency, it should still be elevated 
in pregnancy. Pregnancy may lead to permanent worsening of renal function in more than 
40% women with serum creatinine (SCr) of 250 μmol/l or greater or creatinine clearance < 
50 ml/minute and therefore it should serve as a contraindication to pregnancy. However, at 
that level of impaired renal function fertility is reduced and pregnancy is rare. The treatment 
of microalbuminuria with ACE-inhibitors should be interrupted in women that want to 
become pregnant. A moderate decrease of creatinine clearance is often observed during late 
gestation in women with renal disease. Typically this decrease is more severe in women 
with diffuse glomerular disease and it usually reverses after delivery. The long-term effect 
of pregnancy on renal disease remains controversial. Pregnant women with renal disease 
that have normal or near normal renal function at conception and a SCr < 120 μmol/L carry 
only a slightly increased risk of a long-term damage to their kidneys from pregnancy 
compared with never pregnant women with mild renal disease. In a larger multicenter 
study, 40% of women with moderate renal impairment (SCr 124-168 μmol/L; 1.49-1.90 
mg/dL) had pregnancy related deterioration in renal function that persisted after delivery 
in almost 50% of cases [Williams, 2004]. One of the series from this study showed that only 
2% of the pregnancies in women with initial SCr below 2.00 mg/dL rapidly decline to ESRF 
[Jungers, 1995; Jones, 1996; Epstein, 1996; Sibai, 2002]. Two-thirds of women with SCr > 2.0 
mg/dL have a gestational deterioration in renal function that nearly always persists in the 
post-partum period. The recovery of the renal function after the delivery is rare. One third 
of women will develop ESRF during or following pregnancy. If renal function significantly 
worsens during pregnancy, studies showed that the termination of pregnancy will not 
improve the maternal outcome, therefore abortion cannot be routinely recommended for 
pregnant women with SCr over 1.5 mg/dL. Ideally before conception counseling should be 
provided for women with renal chronic disease. Severe hypertension is considered to be the 
greatest threat to pregnant woman with chronic renal disease, as uncontrolled hypertension 
can lead to intracerebral hemorrhage, or worse renal status. Diastolic blood pressure > 110 
 
Renal Disease and Pregnancy 
 
77 
mmHg or greater will develop in ~ 20% of the patient with hypertension, a bigger chance of 
eclampsia being present in these cases. Proteinuria usually increases in chronic renal disease 
during pregnancy often reaching nephrotic ranges. A study remarked a correlation between 
low serum albumin and low birth weight [Studd, 1969].  
Estimated glomerular filtration rate is another useful marker of renal function that depends on 
the value of serum creatinine and variables like patient age and gender. In the United 
Kingdom, estimated glomerular filtration rate is usually calculated using the four-variable 
Modification of Diet in Renal Disease (MDRD) formula although importantly this is  
not validated for use in pregnancy and it is inaccurate at values greater than 60 ml/min 
[Hall, 2010]. 
3. Pregnancy and underlying chronic renal disease 
Historically, pregnancy has been commonly regarded as very high risk in women with 
chronic renal disease. Attempts have been made to clarify these risks in the settings of 
chronic renal insufficiency, dialysis, and transplanted kidneys. Chronic renal disease can be 
silent until advanced stages. As obstetricians routinely examine the patient’s urine for 
presence of protein, glucose and ketones, they may be the first to detect chronic renal 
disease. The effect of pregnancy-related changes in women with preexisting renal disease 
depends on the type of renal impairment and complications such as hypertension, 
proteinuria and infection. Advice to women with renal impairment regarding pregnancy 
must take into account all these parameters in an effort to answer the two most important 
questions:  
- What effect will the pregnancy have on the mother’s kidney disease? 
- What effect will the mother’s kidney disease have on the pregnancy? 
The features that are detrimental to long-term maternal renal function and pregnancy 
outcome are:  
- The impaired renal function (preconception SCr > 177 μmol/L (2.00 mg/dL) or 
glomerular filtration rate (GRF) < 25 mL/min) will lead in 2/3 of mothers to have an 
accelerated decline in renal function and one third to develop End-Stage Renal Failure 
(ESRF) in association with pregnancy. There is also considerable risk for preterm labor, 
intrauterine growth restriction (IUGR) and preeclampsia 
- Hypertension increases risk of preeclampsia, IUGR, preterm labor and can accelerate 
the decline of maternal renal function 
- Proteinuria in nephritic levels is associated with maternal thromboembolism, IUGR, 
preterm labor and poorer long-term maternal renal prognosis  
- Reduced plasma volume with IUGR 
- Hyperglycemia leads to large-for-gestational-age babies, but when associated with 
microvascular disease there is increased risk of IUGR 
Although fertility is diminished in chronic kidney disease (CKD), even women on dialysis 
may in rare instances become pregnant. Most women will experience an increase of blood 
pressure and proteinuria and decrease of GRF, which can be irreversible. Affected women 
are at increased risk of fetal loss, intrauterine growth retardation, and early labor, 
especially if they experience an acute onset of kidney disease, nephritic syndrome, or 
hypertension. Additionally, high maternal blood urea nitrogen levels can act as an 
osmotic diuretic in the fetal kidney and can cause early labor and fetal loss. Progression of 
the underlying maternal disease depends less on the specific disease than on its severity. 
 
Diseases of Renal Parenchyma 
 
76
2. Evaluation of the renal function in pregnancy 
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post-partum period. The recovery of the renal function after the delivery is rare. One third 
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worsens during pregnancy, studies showed that the termination of pregnancy will not 
improve the maternal outcome, therefore abortion cannot be routinely recommended for 
pregnant women with SCr over 1.5 mg/dL. Ideally before conception counseling should be 
provided for women with renal chronic disease. Severe hypertension is considered to be the 
greatest threat to pregnant woman with chronic renal disease, as uncontrolled hypertension 
can lead to intracerebral hemorrhage, or worse renal status. Diastolic blood pressure > 110 
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hypertension. Additionally, high maternal blood urea nitrogen levels can act as an 
osmotic diuretic in the fetal kidney and can cause early labor and fetal loss. Progression of 
the underlying maternal disease depends less on the specific disease than on its severity. 
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One third of women with moderate kidney disease (GFR < 70 mL/min or serum 
creatinine > 1.4 mg/dL) are at risk for more rapid declines of renal function than are 
patients with less severe CKD. Dilated afferent arterioles associated with hypertension in 
pregnancy can further increase the already elevated intraglomerular pressures.  If kidney 
function deteriorates quickly in early pregnancy, especially with no apparent diagnosis, 
renal biopsy should be considered and can be performed safely. According to Katz, 85% 
of women with chronic renal disease will have a surviving infant if renal function is well 
preserved, earlier reports being more pessimistic [Katz, 1980]. Many studies underlined 
that if there isn’t a good control of the blood pressure there is a high likelihood of 
pregnancy loss. Developing of the antepartum fetal surveillance and advances in neonatal 
care have improved the perinatal outcome. Hou and collaborators reported a 13.8% of 
fetal loss rate, including miscarriage, stillbirths and neonatal deaths, this percent being 
close to the general population’s one [Hou, 1999]. Holley and collaborators appreciated 
that early pregnancies losses are more common in patients with preexisting renal disease 
[Holley, 1996]. Higher rates of preterm delivery and IUGR were observed in women with 
normal or near normal renal function and mild to moderate renal impairment. Preexisting 
severe renal impairment (SCr > 220 umol/L) is associated with more preterm deliveries 
and lower birth weights than a lower SCr. A higher rate of cesarean section is seen in 
these women and older studies, before 1995, the perinatal outcome was good. Most 
authors agreed that it is difficult to assess the independent contribution to poor fetal 
outcome of maternal hypertension, proteinuria and renal impairment. The balance of 
evidence suggested that each parameter is individually and cumulative detrimental to 
fetal outcome. A blood pressure higher than 140/90 mmHg in the context of chronic renal 
disease leads to a fetal mortality of ~23%, 6 times higher than in normal population. 
Treatment of maternal hypertension in pregnancy is also challenging because only few 
classes of antihypertensive drugs are permitted in pregnancy: methyldopa, labetolol, 
nifedipine, or alpha antagonists.  A study showed that increased proteinuria in pregnancy 
is associated with decreased infant weight. The risk of thromboembolism is also higher in 
pregnant women with nephrotic syndrome. The authors still have controversy on 
administration of prophylactic low-dose aspirin during pregnancy in attempt to prevent 
glomerular capillary thrombi, preserve maternal renal function and reduce the risk of 
preeclampsia [Katz, 1980; Barcello, 1986; Coomarasamy, 2003].  
4. Specific renal diseases in pregnancy 
Glomerular diseases such as membrane-proliferative glomerulonephritis, focal 
glomerulosclerosis, and reflux nephropathy were associated with poorer renal outcomes. In 
addition, pregnant women with autosomal dominant polycystic kidney disease that are 
hypertensive have a high risk for fetal and maternal complications, but women who are 
normotensive with mild kidney disease usually have uncomplicated pregnancies. In women 
with systemic lupus erythematosus, the best outcomes occur in stables inactive lupus for 6 
months or longer before conception. Usually renal flares in pregnancy associated with 
proteinuria, hypertension, and decreased GFR, makes the distinction from preeclampsia 
very difficult. However, low complement levels may be helpful in distinguishing between 
women with preeclampsia and those with active lupus nephritis. All these women should 
be screened for anti-SSA (Ro) antibodies, due to the risk of congenital heart block. Treatment 
is difficult because usually used drugs in lupus therapy like cyclophosphamide and 
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mycophenolate mofetil are potentially teratogenic in early pregnancy. Pregnant women 
with diabetic nephropathy may also develop proteinuria and hypertension. 
4.1 Preeclampsia 
Preeclampsia rarely causes acute renal failure severe enough to require dialysis. Acute renal 
failure (ARF) has become a rare complication of pregnancy in developed countries [Prakash, 
2006]. Studies show that temporary dialysis was needed in hemorrhage due to placental 
abruption or HELLP syndrome. Women with preexisting renal disease as presented before 
are more vulnerable to preeclampsia, a higher risk population being that with chronic 
hypertension. A meta-analysis of trials investigating the effectiveness of low-dose aspirin 
administration (50-150 mg/day) in pregnant women with moderate to severe renal disease 
revealed significant reduction in the risk of preeclampsia and perinatal death [Drakely, 
2002]. Delivery of the baby and placenta is the cure of severe preeclampsia. This will halt the 
general progression of preeclampsia, but postpartum maternal renal function usually 
deteriorates before improving [Rosenne-Montella, 2008]. Dialysis is limited to few cases, 
HELLP syndrome or placental abruption and SCr doubled in 24-48 hours, being such cases. 
Fluid balance is essential in the management of ARF in pregnancy, as well as the control of 
hypertension. 
4.2 Primary glomerulonephritis 
Acute primary glomerular disease rarely coincides with pregnancy. Barnes, from all 
available records observed a fetal salvage of only 43 600 and a maternal mortality of 20-25% 
during pregnancy but made it clear that such statistics would be improved with modern 
treatment [Barnes, 1970]. Self-limited glomerular disease preceding pregnancy has, 
however, no adverse effects [Tillman, 1951; Felding, 1968]. Chronic glomerular diseases, 
mainly on account of their diverse pathogenesis, have a less clear-cut relationship to 
pregnancy. Some are more progressive than others, their courses often punctuated by 
remissions and relapses. An established proteinuria before pregnancy may worse during it, 
considering increased GRF. Augmented by salt and water retention, it may produce a full 
nephrotic syndrome. However, assuming the edema is adequately controlled by diuretics 
and that neither hypertension nor renal failures supervene, the outlook for both mother and 
fetus is good. Several studies sustained this idea. In 1963, Johnston and collaborators studied 
29 pregnancies in 10 patients with nephrosis (uncomplicated in five cases and complicated 
in five cases). In 1969, Studd and Blainey recorded only two infant deaths in 31 nephrotic 
pregnant women. In uncomplicated group were registered 11 live births from 12 
pregnancies and in complicated group were 2 miscarriages, six abortion and only nine 
successful deliveries. In a 10-year follow up of 23 nephrotic patients involving 35 
pregnancies were recorded 33 normal deliveries although infant weights were reduced 
relative to their maturities [Blainey, 1971]. Only two mothers with severe proliferative 
glomerulonephritis showed serious deterioration of renal function requiring dialysis or 
transplantation. In another study of 41 pregnancies in 25 patients whose renal diseases had 
been defined by renal biopsy were obtained favourable results [Strauch, 1974]. 
4.3 Lupus nephritis in pregnancy 
Glomerulopathies form an important aspect of several systemic diseases of which systemic 
lupus erythematosus (SLE) is one of the more important. About 50% of women with this 
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mycophenolate mofetil are potentially teratogenic in early pregnancy. Pregnant women 
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hypertension. A meta-analysis of trials investigating the effectiveness of low-dose aspirin 
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disease experience renal involvement in a wide variety of forms which may range from a 
focal proliferative glomerulonephritis to a more indolent and diffuse thickening of 
glomerular basement membranes. This variety of glomerular involvement, together with 
changing treatment over the years, accounted for some of the controversy which surrounds 
its relationship to pregnancy. 20 years ago, women with systemic lupus erythematosus 
(SLE) were advised against pregnancy due to fear of irreversible consequences for the 
mother. Today the advent of combined teams of obstetricians and ‘lupus doctors’ offering 
coordinated care for both, the mother and the baby improved significantly these terms 
[Ruiz-Irastorza, 2009]. The fertility rate in women with SLE is relatively normal compared to 
the general population; however, fetuses born to mothers with SLE may face major 
complications [Mok, 2001]. Multiple adverse pregnancies such as fetal loss, preterm birth, 
and pre-eclampsia are associated with SLE. The risk is caused by the ability of maternal 
autoantibodies to cross the placenta and initiate pathogenesis of the fetus. One of the most 
severe SLE-associated conditions is the formation of congenital heart block and can develop 
as a result of the passage of maternal autoantibodies.  A lot of researchers studied the 
interrelationship of pregnancy and SLE and concluded that a great number of complications 
are possible in pregnant women with SLE. The presence of proteinuria, thrombocytopenia 
and arterial hypertension in the first semester in pregnant mother with SLE are major risks 
factors for pregnancy loss. The women with such risk factors have a probability of 
pregnancy loss of 30-40% [Clowse, 2006]. A study performed in United States from 2000-
2003, compared maternal and pregnancy complications for all pregnancy-related admissions 
for women with and without systemic lupus erythematosus. Of more than 16.7 million 
admissions for childbirth over the 4 years, 13,555 were to women with systemic lupus 
erythematosus. The study related a maternal mortality of 20-fold higher among women with 
systemic lupus erythematous [Clowse, 2008]. Different signs and symptoms of pregnancy 
may easily be confused with signs of active lupus. Symptoms such as fatigue, melasma, 
palmar erythema and facial hair in the postpartum dyspnea, arthralgia, and headache are 
frequent in a normal pregnancy. Arthralgias are common among pregnant women due to 
increased weight as well as the effect of relaxin on the joints [Clowse, 2007]. A complete set 
of auto-antibodies should be done in every pregnant women with SLE, especially anti-
phospholipid antibodies (aPL), both anti-cardiolipin antibodies (aCL) and lupus 
anticoagulant (LA) and anti-Ro and anti-La antibodies, given their close link with specific 
pregnancy complications (thrombosis, embryo/fetal loss, pre-eclampsia and congenital 
heart block) [Ruiz-Irastorza, 2009]. During pregnancy, C3 and C4 may be elevated, though a 
flare may occur despite apparently normal levels. However, a decrease of C3 or C4 levels by 
more than 25% may be considered an indicator of disease activity [Buyon 1999]. 
Lymphopenia, but not leucopenia, should be considered an indicator of SLE activity in 
pregnancy, because a neutrophil leucocytosis can occur in the third trimester [Motha, 2009]. 
Elevated uric acid levels indicates toxemia, while the presences of hematuria and/or cellular 
casts, extrarenale activity, elevated anti-DNA antibody levels, and decreased complement 
levels indicate lupus nephritis [Mackillop, 2007]. The treatment in pregnant with SLE is 
based on hydroxychloroquine, low-dose steroids, azathioprine and in patients with anti-
phospholipid antibodies, low-dose aspirin ± low molecular weight heparin. It is 
recommended a close surveillance, with monitoring of blood pressure, proteinuria and 
placental blood flow by Doppler studies [Ruiz-Irastorza, 2009]. Maintenance of the 
autoantibody levels in the mother's blood is essential and a key method in sustaining the 
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health of the fetus by preventing the likelihood of maternal-fetal exchange of SLE-associated 
autoantibodies. Another major contributor to adverse SLE pregnancy outcomes is 
antiphospholipid syndrome (APS), defined as the presence of an antiphospholipid antibody 
(APL) in association with clinic features of venous/arterial thrombosis or specific pregnancy 
complications [Smith, 2009]. Optimal management is not over with the birth of a healthy 
baby. Postnatal maternal monitoring by a nephrologist is indicated for optimization of 
hypertension and lupus nephritis treatment, without concerns for medication-related fetal 
adverse effects. A close surveillance in the first 4 weeks after delivery is warranted, 
especially in women with recent activity or previous severe disease. However, no specific 
prophylactic therapy (such as increasing the dose of steroids) is recommended [Ruiz-
Irastorza, 2009]. 
4.4 Urinary tract infections and pyelonephritis in pregnancy 
Urinary tract infections (UTIs) are one of the most common medical complications of 
pregnancy [Berard, 2011]. It is estimated that one in three women of childbearing age will 
have a UTI [Duarte, 2008].  The incidence of asymptomatic bacteriuria is 2% to 10%, which is 
the same during pregnancy as it is in sexually active nonpregnant women [Hooton, 2000]. 
However, the structural and immune changes the urothelium of the renal tract in pregnancy 
make it more likely that a lower UTI will ascend to cause acute pyelonephritis. Studies 
mention that between 12.5% and 30% of patients with untreated asymptomatic bacteriuria 
will develop acute pyelonephritis, causing significant morbidity to both mother and fetus 
[Little, 1966; Nowicki, 2000]. The most common uropathogens are: Escherichia Coli (70-
80%), Klebsiella, Proteus, Enterobacter and Staphylococcus saphrophyticus. Asymptomatic 
bacteriuria beside its risk to progress to acute pyelonephritis as mentioned has a high 
recurrence risk, and is also associated with increased risk for preterm delivery and low birth 
weight [Tincello, 1998]. Although controversial modern literature doesn’t advice for 
asymptomatic bacteriuria screening unless the population has a prevalence of more than 5% 
(usually the prevalence is ~2.5%), or in particular cases with history of frequent urinary 
infection, or other subsequent risk factors for urinary infection. Treatment of asymptomatic 
bacteriuria should take into account that the most frequent agent causing it is Escherichia 
Coli. Patients can therefore be safely treated with nitrofurantoin, ampicilin, cephalosporins 
and short-acting sulfa drugs. Therapy should be for 3-7 days and the patient should repeat 
the urine culture 1 to 2 weeks after finishing the treatment. Aprox 15% will experience 
reinfection and/or will not respond to the initial therapy [Romero, 1989; Davison, 1989].  
Although pyelonephritis affects only 1–2% of pregnant women, it is accompanied by 
significant maternal morbidity and fetal morbidity and mortality [Gilstrap, 2001]. In 20–30% 
of pregnant women with pyelonephritis can result premature labor and the babies at high 
risk of neonatal death [Steer, 2005]. It is the most common non-obstetric cause for 
hospitalization during pregnancy. It is caused by the same uropathogens that cause 
asymptomatic bacteriuria. Studies reflect that the screen for asymptomatic bacteriuria in 
high risk population (history of asymptomatic bacteriuria, previous recurrent UTIs, 
preexisting renal disease- especially scared kidneys due to reflux nephropathy, structural 
and neurophatic abnormalities of the renal tract, renal calculi, preexisting diabetes mellitus-
but not gestational diabetes, sickle cell disease, low socioeconomic group and less than 12 
years higher education)decreases the risk for acute pyelonephritis to less than 1% [Plattner, 
1994]. Most women will present pyelonephritis in the second or third trimester of pregnancy 
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health of the fetus by preventing the likelihood of maternal-fetal exchange of SLE-associated 
autoantibodies. Another major contributor to adverse SLE pregnancy outcomes is 
antiphospholipid syndrome (APS), defined as the presence of an antiphospholipid antibody 
(APL) in association with clinic features of venous/arterial thrombosis or specific pregnancy 
complications [Smith, 2009]. Optimal management is not over with the birth of a healthy 
baby. Postnatal maternal monitoring by a nephrologist is indicated for optimization of 
hypertension and lupus nephritis treatment, without concerns for medication-related fetal 
adverse effects. A close surveillance in the first 4 weeks after delivery is warranted, 
especially in women with recent activity or previous severe disease. However, no specific 
prophylactic therapy (such as increasing the dose of steroids) is recommended [Ruiz-
Irastorza, 2009]. 
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Urinary tract infections (UTIs) are one of the most common medical complications of 
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have a UTI [Duarte, 2008].  The incidence of asymptomatic bacteriuria is 2% to 10%, which is 
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Although pyelonephritis affects only 1–2% of pregnant women, it is accompanied by 
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hospitalization during pregnancy. It is caused by the same uropathogens that cause 
asymptomatic bacteriuria. Studies reflect that the screen for asymptomatic bacteriuria in 
high risk population (history of asymptomatic bacteriuria, previous recurrent UTIs, 
preexisting renal disease- especially scared kidneys due to reflux nephropathy, structural 
and neurophatic abnormalities of the renal tract, renal calculi, preexisting diabetes mellitus-
but not gestational diabetes, sickle cell disease, low socioeconomic group and less than 12 
years higher education)decreases the risk for acute pyelonephritis to less than 1% [Plattner, 
1994]. Most women will present pyelonephritis in the second or third trimester of pregnancy 
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and will accuse in over 80% of cases: backache, fever, rigors, and costovertebral angle 
tenderness, and about half have lower urinary tract symptoms, nausea and vomiting. 
Bacteremia is present in 15% to 20% and only very few will develop septic shock or more 
severe complications. High risk cases will present: highest fever (> 39.4 degrees C), 
tachycardia (>110 bpm) [Cunningham, 1987]. Acute pyelonephritis can trigger uterine 
contractions and preterm labour, so the tocolytic therapy should be used carefully if there 
are cervical changes. Pregnant women suspected of acute pyelonephritis should be admitted 
in hospital for treatment. Those presenting in shock need to be referred to the intensive care 
unit. The treatment is empiric first, with intravenous antibiotic until sensibilities of blood 
and urine cultures are known. Usually these patients associate a degree of renal impairment, 
thrombocytopenia, and hemolysis, suggesting that alveolar capillary endothelium is 
damaged by endotoxin [Winf, 2001]. As the Gram-Negative bacteria usually causing 
pyelonephritis are often resistant to ampicilin the first choice of antibiotics should be 
intravenous cephalosporins, such as cefuroxime 750 mg to 1.5 g every 8 hours, until cultures 
results are known. Gentamicin can also be used. Intravenous antibiotics should be used 
until the patient is afebrile for 24 hours, and then the treatment should be followed by oral 
antibiotics for 7-10 days, as if for lower urinary infections. Following one episode of acute 
pyelonephritis, the pregnant woman should have monthly urine cultures for the recurrence 
screen [Dunlow, 1990].  
4.5 Acute renal failure and renal cortical necrosis in pregnancy 
Acute renal failure in pregnancy is largely a preventable problem usually resulting from 
obstetric complications and not intrinsic renal disease. With this in mind, pregnancy related 
acute renal failure (AFR) can be viewed more as a public health problem than a nephrologic 
problem [Hou, 1998]. Acute renal failure (ARF) represents a plurietiological syndrome 
characterized by the kidney incapacity to clear the metabolism products of the organisms. It 
is a very severe condition, fortunately rare in nowadays. Acute renal failure (ARF) and 
septic abortion is the most frequent form of ARF in early pregnancy especially in developing 
countries, where pronatality policies forbidden abortion. Such a case was also in Romania 
during the communist regime (in the seventies and eighties) when the maternal mortality 
got to ~ 500-600/100000 women. ARF appears due to the severe toxico- infectious syndrome 
(usually caused by anaerob bacteria- Clostridium velchii) after an abortive maneuver. Renal 
injuries are represented by acute tubular necrosis, and in very severe cases cortical bilateral 
necrosis. Evolution is characterized by initial oligoanuria followed by septicemic signs. 
Treatment addresses the primary septicemic reservoir (hysterectomy, massive 
antibiotherapy), dialysis. Global mortality I this pathology remain at high levels ~15-20%.  
Around the time of delivery, ARF is commonly caused by gestational syndromes such as 
preeclampsia/hemolysis, elevated liver enzymes and low platelets (HELLP syndrome) and 
abruption placentae [Spargo, 1959; Redman, 1999; Poston, 2002]. ARF multiple etiologies 
recognize common causes such as: urinary tract infections (especially acute pyelonephritis), 
intoxications with drugs or nephrotoxic substances, septicemic states, shock, major hidro-
electrolitic disequilibrium, posttransfusion accidents, urological causes (lithiasis, tuberculosis, 
ureteral obstructions). Specific etiological factors connected to the pregnancy status are: 
placental abruption, severe preeclampsia/HELLP syndrome, septic abortion, hyperemesis 
gravidarum, ovarian hyperstimulation syndrome, amniotic fluid embolus, hemolytic uremic 
syndrome/ thrombotic thrombocytopenic purpura, acute fatty liver of pregnancy and acute 
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obstruction of real tracts. The most common renal lesion is acute tubular necrosis and cortical 
necrosis usually appears in non pregnant patients. Positive diagnosis of ARF is based on 
oligoanury (less than 100 ml urine/24 hours) and association of uremic retention, 
hypercalcemia, hypermagnesemia, metabolic acidosis. ARF is a severe complication that 
triggers other complications: infectious (pneumopathy, thromboembolism, parotiditis), 
hidroelectrolitical (edema, hypertension, congestive cardiac failure), hemorragical. Treatment 
of ARF concentrates on finding the cause and treat it dialysis has more indications nowadays. 
The obstetric management of the patient has to take into account the gestational age and the 
fact that pregnancy related acute renal failure has a more severe evolution and prognosis than 
other causes.  
Acute renal cortical necrosis is a rare complication of pregnancy nowadays. In western 
countries, the frequency of renal cortical necrosis range from 1.9% to 2% [Schreiner, 1979]. 
Obstetric complications such as abruptio placentae, septic abortion, eclamptic toxemia, post-
partum hemorrhage, intrauterine fetal demise, amniotic fluid embolism and puerperal 
sepsis can cause renal cortical necrosis [Ali, 2003]. By all, the most common obstetric cause is 
abruptio placentae, responsible for 50–60% of cases [Jeong, 2002]. Acute renal cortical 
necrosis should be suspected if anuria persists. Definitive diagnosis can be made only by 
renal biopsy. Incidence of maternal and fetal mortality is still increased [Chugh, 1994].  
Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are 
very similar syndromes characterized by microangiopathic hemolytic anemia and 
thrombocytopenia. They appear more likely in the third trimester of pregnancy and 
determine a multiorgan disorder, women with these pathology present gastrointestinal or 
neurological abnormalities.  Maternal survival from HUS/TTP has greatly improved since 
treatment with plasmapheresis [Greer, 2007]. Steroids are often added to the plasma 
exchange, but there are no randomized controlled trials of their use [Rosene-Montella, 2008]. 
Antiplatelet regimen with aspirin may also be beneficial [McMinn, 2001].  
4.6 Diabetic nephropathy in pregnancy 
In the last 10 years an increased number of people with type 2 diabetes mellitus appeared. 
Diabetes mellitus (DM) is the most common medical complication of pregnancy and it 
carries a significant risk to the fetus and the mother [Abourawi, 2006]. Gestational DM 
represents approximately 90% of these cases and affects 2-5% of all pregnancies and varies 
in direct proportion to type 2 diabetes mellitus in the background population [Ben-Haroush, 
2004]. There is a clear association between obesity and adverse pregnancy outcomes 
(cesarean section, gestational diabetes, hypertensive disorders, birth defects and 
prematurity) [McIntyre, 2009]. Pregnant women with diabetes are at risk of progression to 
microvascular diabetic complications, early pregnancy loss, pre-eclampsia, polyhydramnios 
and premature labour. Glycemic control before and during pregnancy is critical and the 
benefit may result in a viable, healthy off spring [Hertzel, 2001]. The risk of neonatal 
macrosomia and hypoglycemia can be reduced by proper management of gestational DM. 
Appropriate counseling in women with gestational DM and post-partum evaluation of 
glucose tolerance may help decrease the high risk of subsequent type 2 diabetes in the long-
term [Kitzmiller, 2007]. Metabolic changes occur in normal pregnancy in response to the 
increase in nutrient needs of the fetus and the mother. There are two main changes which 
are seen during pregnancy, progressive insulin resistance that begins near mid-pregnancy 
and progresses through the third trimester to the level that approximates the insulin 
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resistance seen in individuals with type 2 diabetes mellitus [Abourawi, 2006]. The insulin 
resistance appears to result from a combination of increased maternal adiposity and the 
placental secretion of hormones (progesterone, cortisol, placental lactogen, prolactin and 
growth hormone). The fact that insulin resistance rapidly abates following delivery suggests 
that the major contributors to this state of resistance are placental hormones. The second 
change is the compensatory increase in insulin secretion by the pancreatic beta-cells to 
overcome the insulin resistance of pregnancy [Ben-Ziv, 2008]. Circulating glucose levels are 
maintained normal. If there is maternal defect in insulin secretion and in glucose utilization, 
then GDM will occur as the diabetogenic hormones rise to their peak levels. Maternal 
diabetes complications are frequent in women with both type 1 and type 2 diabetes 
[Abourawi, 2006]. Diabetic retinopathy and diabetic nephropathy may progress or start de 
novo during the pregnancy. 
Diabetic pregnant woman can have maternal complications such as: diabetic ketoacidosis, 
hypoglycemia, and retinopathy, deterioration of nephropathy, vomiting (gastric 
neuropathy), miscarriages, preeclampsia, polyhydramnios, and premature delivery. In 
order that diabetic pregnant women have a healthy baby and avoid maternal morbidity it is 
recommended a multidisciplinary pre-pregnancy consult. Ideally this is carried out by a 
team, which includes an obstetrician, a nephrologist and a diabetologist for optimum care. 
Clinical trials of pre-conception care to achieve stringent blood glucose control in the pre-
conception period and during the first trimester of pregnancy have demonstrated striking 
reductions in rates of malformation compared with infants of diabetic women who did not 
participate in pre-conception care [Ray, 2001]. In approximately two thirds of women with 
diabetes, may appear pregnancy, without an adequate pre-conception care and a lot of 
malformations in their infants. Oral hypoglycemic agents should be interrupted before 
pregnancy and insulin started if needed, and also statins and ACE-inhibitors should be 
discontinued. Safer drugs like Methyldopa, Nifedipine or Labetalol should be administered 
for arterial hypertension. It is necessary be evaluated and treated all the diabetic 
complications. Regular self-monitoring should be encouraged to optimize control. At least at 
four weeks pre-conception it should be administered Folic acid. Glycemic control should be 
optimized with the aim of pre-prandial blood glucose < 5.5 mmol/l (< 95 mg/dl) and 
HbA1c < 7%. Home blood glucose monitoring is an essential part of maintaining euglycemic 
state and its goal is to detect glucose concentration to allow fine-tuning of insulin 
adjustment, pre-prandial glucose level < 5.5 mmol/l (< 95mg/dl), and postprandial level 
glucose < 7.8 mmol/ l (<140 mg/dl). Post-prandial glucose levels have been shown to 
correlate more with macrosomia than do fasting levels. Diabetes in early pregnancy studies 
found that third trimester post-prandial glucose levels were the strongest predictors of 
percentile birth weight [Setji, 2005]. Diet in pregnancy should provide an adequate nutrition 
for both mother and fetus, with sufficient calories for appropriate maternal weight gain, for 
maintaining normal glycemia and avoiding ketosis. It is recommended that pregnant 
women with diabetes to eat three small to moderate size meals and three snacks per day. 
Monitoring with a pre-breakfast ketone measurement is recommended for patients who are 
on a hypo-caloric or carbohydrate restricted diet [Franz, 2002]. Before conception, a baseline 
assessment of renal function by serum creatinine and some measure of urinary protein 
excretion (urine albumin/creatinine ratio or 24-hour albumin excretion) should be done. 
Women with microalbuminuria may experience transient worsening during pregnancy; 
however, those with established nephropathy with overt proteinuria are at increased risk of 
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pre-eclampsia and intra-uterine growth retardation and premature delivery [Abourawi, 
2006]. A frequent associated pathology of diabetes is arterial hypertension. Patients with 
type 1 diabetes frequently develop hypertension in association with diabetic nephropathy, 
as manifested by the presence of overt proteinuria. Patients with type 2 diabetes more 
commonly have hypertension as a concomitant disease. In addition, pregnancy induced 
hypertension is a potential problem for the women with diabetes. In pregnancy, arterial 
hypertension may worse diabetic nephropathy and retinopathy. ACE-inhibitors, beta-
blockers and diuretics should be avoided in women contemplating pregnancy if are used for 
hypertension. Methyl-Dopa or Labetalol should be substituted. Considering the earlier 
studies in this domain [Purdy, 1996; Reece, 1998; Ekbom, 2001; Rossing, 2002], the 
management of diabetic nephropathy should follow: 
- Prepregnancy: advise that pregnancy with diabetic nephropathy and SCr > 124 μmol/L 
is associated with 40% risk of gestational decline in renal function; advise that increase 
risk of adverse pregnancy outcome; try and achieve euglycemia  
- Prenatal: every 4-6 week monitor blood pressure, blood urea nitrogen, glucose, 
midstream urinalysis until 24 week of gestation, then every 2 week until 32 weeks of 
pregnancy and after that weekly; try and achieve euglycemia; give aspirin 75 mg once 
daily to reduce the risk of preeclampsia, control hypertension to < 140/90 mmHg; 
screen for preeclampsia; fetal surveillance; give LMW heparin when > 1-3 g 
proteinuria/24 hour and hipoalbuminemia; a diuretic may be necessary for 
symptomatic relief of gross edema with nephrotic syndrome 
- Postnatal: reassess the renal function (GFR) postpartum 
Treatment with medical nutrition therapy, close monitoring of glucose levels, and  
insulin therapy if glucose levels are above goal can help to reduce these complications  
[Setji, 2005]. 
4.7 Unique surgical kidney and pregnancy 
Women undergoing nephrectomy (despite the cause of the surgical procedure) will have a 
pregnancy evolution in normal parameters if the remaining kidney has its morph functional 
integrity. Multidrug resistant urinary infection can be an indication for ending the 
pregnancy in order to preserve the renal function. Authors consider that pregnancy won’t 
influence the renal function and evolution of the renal disease if the blood pressure can be 
controlled and urinary infection treated promptly if they appear.  
4.8 Renal calculi and pregnancy 
Renal calculi, congenital renal tract abnormalities or a gestational overdistension syndrome 
can produce renal obstruction in pregnancy [Rosene-Montella, 2008]. The incidence of renal 
calculi in pregnant women appears to be no greater than in the nonpregnant population. 
Their presence and especially their migration in the urinary tract are associated with renal 
colic, UTI. Treatment and management of renal colic is similar as for nonpregnant women. 
Women born with congenital obstructive urophaties are at increased risk for urine outflow 
obstruction in second trimester of pregnancy and also for recurrent UTI [Meyers, 1985].  
Overdistension of urinary tracts isn’t very frequent in pregnancy. The patients will present 
severe loin pain, most commonly on the right part and radiating to the lower abdomen. 
Spontaneous rupture of the kidney is uncommon, and in severe cases ureteric stent or 
nephrostomy is performed. 
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pre-eclampsia and intra-uterine growth retardation and premature delivery [Abourawi, 
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hypertension may worse diabetic nephropathy and retinopathy. ACE-inhibitors, beta-
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daily to reduce the risk of preeclampsia, control hypertension to < 140/90 mmHg; 
screen for preeclampsia; fetal surveillance; give LMW heparin when > 1-3 g 
proteinuria/24 hour and hipoalbuminemia; a diuretic may be necessary for 
symptomatic relief of gross edema with nephrotic syndrome 
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Renal calculi, congenital renal tract abnormalities or a gestational overdistension syndrome 
can produce renal obstruction in pregnancy [Rosene-Montella, 2008]. The incidence of renal 
calculi in pregnant women appears to be no greater than in the nonpregnant population. 
Their presence and especially their migration in the urinary tract are associated with renal 
colic, UTI. Treatment and management of renal colic is similar as for nonpregnant women. 
Women born with congenital obstructive urophaties are at increased risk for urine outflow 
obstruction in second trimester of pregnancy and also for recurrent UTI [Meyers, 1985].  
Overdistension of urinary tracts isn’t very frequent in pregnancy. The patients will present 
severe loin pain, most commonly on the right part and radiating to the lower abdomen. 
Spontaneous rupture of the kidney is uncommon, and in severe cases ureteric stent or 
nephrostomy is performed. 
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4.9 Acute fatty liver of pregnancy  
Acute fatty liver of pregnancy was first described in 1940 by H. L. Sheehan as an "acute 
yellow atrophy" of the liver. Acute renal failure due to acute fatty liver of pregnancy is a 
rare life-threatening complication, specific to pregnancy. If unrecognized or untreated, the 
disorder may progress to fulminant hepatic failure with jaundice, encephalopathy, 
disseminated intravascular coagulation, uncontrollable gastrointestinal and uterine 
bleeding, and death [Kaplan, 1994]. Although the exact pathogenesis is unknown, it seems 
to be caused by a disordered metabolism of fatty acids by mitochondria in the mother, 
caused by deficiency in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase enzyme 
[Bellig, 2004]. Acute fatty liver of pregnancy may be confused with acute hepatitis or 
toxemia on both clinical and histological grounds [Burroughs, 1982]. The diagnosis of acute 
fatty liver of pregnancy is suggested by jaundice with a lesser elevation of liver enzymes, 
elevated white blood cell count, disseminated intravascular coagulation, and a clinically 
unwell patient [Riely, 1999]. Usually such patients will present with nausea, vomiting, and 
abdominal cramps. First appear an impaired renal function and reduced plasma 
antithrombin levels, liver dysfunction following this [Castro, 1999]. Maternal renal 
impairment is aggravated by hypotension secondary to hemorrhage, which it is most likely 
to follow an emergency cesarean section. Renal dysfunction, hemorrhage, and disseminated 
intravascular coagulation secondary to liver failure require a complex intensive therapy in a 
multidisciplinary team. Treatment includes supportive care in order to maintain adequate 
fluid balance for renal perfusion, replacing blood, correcting the coagulopathy. Temporary 
dialysis might be necessary [Pereira, 1997]. 
4.10 Pregnancy in women on dialysis 
End-stage renal disease requiring dialysis is associated with a marked decrease in fertility. 
Pregnancy occurs in approximately 1% of women, usually within the first few years of 
starting dialysis. The cause of infertility is not entirely clear, but it is probably multifactorial. 
An estimated 42% of women receiving dialysis who are of childbearing age have regular 
menses, but many more are likely anovulatory. Anemia probably also plays a role. In fact, 
some investigators suggest that the regular use of erythropoietin improves the pregnancy 
rate. Generally pregnancy is a contraindication in women on dialysis. The fetal outcome is 
quite poor. Only 23-55% of pregnancies result in surviving infants, and a large number of 
second-trimester spontaneous abortions occur. In addition, surviving infants have 
significant morbidities. Approximately 85% of surviving infants are born premature,  
and 28% are born small for gestational age. Maternal complications occur as well, including 
reports of several maternal deaths. Hypertension worsens in more than 80% of pregnant 
females on dialysis and is a major concern. The diagnosis of pregnancy in these patients  
is also difficult, because levels of beta-human chorionic gonadotropin (beta-hCG) are 
normally elevated in patients receiving dialysis. If pregnancy is considered likely and  
the beta-hCG level is high, obtain an ultrasonogram to aid in diagnosis. Some general 
recommendations apply to patients who become pregnant while receiving dialysis. Place the 
patient on a transplant list (if not on already), because outcomes with allograft transplant 
patients are markedly better. During hemodialysis, pursue uterine and fetal monitoring  
and make every attempt to avoid dialysis-induced hypotension. Some evidence indicates 
that judicious use of erythropoietin may improve fetal survival; however, no findings  
from randomized studies support this. Erythropoietin can also increase hypertension and 
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must be used cautiously. An increased frequency of dialysis may improve mortality and 
morbidity. Aggressive dialysis to keep blood urea nitrogen levels less than 50 mg/dL may 
be pursued with daily dialysis. Controlling uremia in this fashion may avoid 
polyhydramnios, control hypertension, and improve the mother's nutritional status [Hou, 
1998; Holley, 2003].  
4.11 Pregnancy after renal transplantation 
The first reported successful pregnancy occurred in a recipient of a kidney transplant from 
an identical twin sister performed in 1958 [Murray, 1963]. Fertility is usually restored  
in women with renal transplants. Pregnancy is then common, occurring in 12% of women at 
childbearing age in one series [Sturgiss, 1992]. Pregnancy success rates are also quite good, 
with more than 90% fetal survival rates after the first trimester. Pregnancy can  
be anticipated, planned, and even encouraged. In patients with chronic renal insufficiency, 
factors such as uncontrolled or worsening hypertension, worsening proteinuria, and  
poor prepregnancy renal function are important prognostic indicators for the risk of renal 
function deterioration. Whether pregnancy itself induces a significant risk to the 
transplanted kidney's function is unclear. Obstruction of the transplant ureter by the 
pregnant uterus is quite rare but has been reported. Further long-term studies are  
indicated. Current opinion holds that the graft function is not adversely affected by 
pregnancy in the setting of women with a creatinine level of less than 1.4 mg/dL who are 
treated with prednisone and/or azathioprine. An elevated prepregnancy creatinine  
level (> 1.4 mg/dL) is associated with a higher risk of renal decline but also with a 
decreased fetal survival rate. The fetal survival rate is approximately 74% in patients with a 
creatinine level of more than 1.4 mg/dL, whereas it increases to about 96% in patients with a 
creatinine level of less than 1.4 mg/dL [EBPG Expert Group on Renal Transplantation, 2002; 
Davison, 1995].  
5. Conclusion 
In pregnancy associated with different renal diseases, laboratory tests play an important  
role Pregnant women with any renal disease must be prepregnancy counseled,  
prenatal monitored, and receive a skilled obstetric management in a multidisciplinary 
manner, since the most common cause of mortality and morbidity in these cases is preterm 
labor. 
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1. Introduction 
The past decade has witnessed enormous advances in understanding the association 
between arterial hypertension and renal disease. This chapter aims to provide a 
comprehensive review about new insights generated from recent experimental and clinical 
studies that should shed light on the role of the kidney in causing hypertension but also the 
role of hypertension in causing renal disease. It will focus on pathogenic mechanisms that 
connect arterial hypertension with target renal damage and new markers able to identify 
subclinical target-renal damage.   
Nowadays, the most important causes of renal failure and dialysis in the world arterial are 
hypertension and diabetes mellitus. The kidneys have a central role in the control of sodium 
homeostasis through the important mechanism of regulation of blood pressure. Arterial 
hypertension is also a well known consequence of chronic kidney disease (CKD), and at the 
same time one of the main factors causing diabetic and/or non-diabetic chronic renal failure 
progression (Ljutić, 2003).  
Kidneys can be damaged by arterial hypertension by several mechanisms. Because 
autoregulation of glomerular pressure is impaired in CKD, elevations in systemic blood 
pressure are associated with increased glomerular capillary pressure. Glomerular 
hypertension results in increased protein filtration and endothelial damage, causing 
increased release of cytokines and other soluble mediators, promoting replacement of 
normal kidney tissue by fibrosis. An important factor contributing to progressive renal 
disease is activation of the renin-angiotensin system, which tends to increase blood pressure 
and also promotes cell proliferation, inflammation, and matrix accumulation (Dworkin, 
1999). An important part of the standard of care in clinics is the evaluation of 
microalbuminuria in order to detect renal organ damage that may influence the occurrence 
of future cardiovascular events.  Screening for renal organ damage is part of classification 
schemes and clinical assessment process and influences the therapy to prevent disease 
progression and delay or prevent future cardiovascular events. The presence of target organ 
damage defines a high-risk population that develops complications due to suboptimal 
disease control or accelerated development and progression of the atherosclerotic process 
(Lockhart, 2009).  
The renin-angiotensin system (RAS) is the most important mechanism for blood pressure 
regulation and electrolyte homeostasis. It was suggested that the major fraction of 
angiotensin II present in renal tissues is locally generated from angiotensinogen delivered to 
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the kidney as well as from angiotensinogen locally produced by the proximal tubule cells 
(Kobori, 2007). Renin is produced by the cells of the juxtaglomerular apparatus cells and 
then delivered in the renal interstitium and vascular compartment resulting local generation 
of angiotensin. Angiotensin-converting enzyme is abundant in the kidney and is present in 
the proximal tubules, distal tubules, and collecting ducts (Kobori, 2010). Angiotensin I 
delivered to the kidney can also be converted to angiotensin II (Komlosi, 2003). All of the 
components necessary to generate intrarenal angiotensin II are present along the nephron 
(Navar, 2002; Kobori, 2007). Recently, in the Bogalusa Heart Study was proved that urinary 
level of angiotensinogen can be a new and potential marker of intrarenal RAS status in 
kidney disease due to arterial hypertension (Kobori, 2010). An important role in progression 
of inflammation and fibrosis seems to involve the renin-angiotensin system, and specifically 
the angiotensin-converting enzyme (ACE)-angiotensin (Ang) II-AT1 receptor axis. ACE2, a 
new component of the renin-angiotensin system, has emerged as a key enzyme that 
selectively degrades Ang II and generates Ang-(1-7), a bioactive peptide with anti-
inflammatory and anti-fibrotic actions (Chappell, 2010). The deficiency of angiotensin-
converting enzyme 2 is associated with elevated tissue and circulating levels of angiotensin 
II, reduced levels of angiotensin and progressive glomerulosclerosis in the kidneys (Tikellis, 
2011). Definitely, the overexpression of angiotensin-converting enzyme 2 may produce 
adverse cardiac effects, and angiotensin-converting enzyme 2 and its metabolic products 
may promote epithelial-to-mesenchymal transition (Tikellis, 2011). 
Increased activity of the intrarenal RAS is another concept considered responsible for initiating 
and maintaining an elevated blood pressure in patients with hypertension and it is 
sustained by a lot of studies (Mitchell, 1992; Navar, 1999; Navar, 2002; Guyenet, 2006; 
Kobori, 2007). 
Since current European guidelines on hypertension (Mancia, 2007), stratify individuals 
based on both known risk factors and early markers of subclinical target-organ damage, the 
chapter focuses further on new and old available biomarkers that can detect renal damage in 
arterial hypertension. Blood urea nitrogen and creatinine clearance are well-established 
biomarkers of renal function that can be measured cheaply and easily. Reduced glomerular 
filtration rate (GFR) and increased urinary albumin excretion are manifestations of target 
organ damage in hypertension. New renal biomarkers include: urinary level of 
angiotensinogen, plasma aldosterone concentration, hyperhomocysteinemia and cystatin C.  
Antihypertensive agents like diuretics, angiotensin converting enzyme (ACE) inhibitors, 
angiotensin II (Ang II) receptor antagonists, ß-blockers, or calcium channel blockers (CCBs) 
can improve end organ damage and effectively reduce hypertension (Cohuet, 2006). 
2. From arterial hypertension to renal organ damage  
The increasing prevalence of arterial hypertension in general population is caused by a sum 
of factors involved in renal disease progression like atherogenic dyslipidemia, metabolic 
syndrome, type II diabetes, anemia, and disorders of mineral metabolism.  
The first form of hypertension most commonly observed in early or borderline hypertension 
is characterized by salt-resistance, normal or only slightly decreased GFR, relatively normal 
or mild renal arteriolosclerosis, and normal renal autoregulation. The patients affected by 
this form of hypertension are at minimal risk for renal progression.  
The second form of hypertension, characterized by salt-sensitivity, renal arteriolar disease, 
and blunted renal autoregulation, defines a group at highest risk for the development of 
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microalbuminuria, albuminuria, and progressive renal disease. This second form is more 
likely to be observed in blacks, in subjects with gout or hyperuricemia, with low level lead 
intoxication, or with severe obesity/metabolic syndrome (Johnson, 2005). 
Essential hypertension is frequently associated with arteriolar thickening, fibrinoid 
deposition in the glomeruli, and proteinuria (Cohuet, 2006). The deleterious effects of 
systemic hypertension on renal vascular bed depend on the degree to which the 
microcirculation is exposed to elevated pressures. Renal injury occurs when the 
preglomerular autoregulatory mechanism is insufficient to maintain flow and pressure in 
the kidney (Griffin, 2003). 
Chronic hypertension can lead to nephrosclerosis, a common cause of CKD (Porth, 2011). 
Clinicians use different terms to identify renal damage caused by hypertension like 
nephrosclerosis, benign nephrosclerosis, hypertensive kidney disease, or 
nephroangiosclerosis. Two clinicopathologic patterns have been described until now. The 
first form is benign nephrosclerosis or simply nephrosclerosis, characterised by microvascular 
changes with hyalinosis of the preglomerular vessel walls and thickening of the intima and 
reduplication of the internal elastic lamina of the arcuate and interlobar arteries. These 
modifications can lead to glomerular damage, glomerulosclerosis, patchy tubular atrophy, 
and interstitial fibrosis. The second form is malignant nephrosclerosis, associated with 
accelerated or malignant hypertension, characterized by fibrinoid necrosis and myointimal 
hyperplasia and left untreated can cause progressive renal insufficiency. It becomes a rare 
entity today due to improvements of antihypertensive management (Marin, 2005). Brenner 
established the central role for nephron injury and loss in glomerular hypertension. The 
remaining nephrons develop glomerular capillary hypertension accompanied with 
hyperfiltration (Brenner, 1982). Nephrosclerosis has actually been seen as a form of 
intrarenal renovascular disease (Marín, 2005). Beside benign and malignant nephrosclerosis, 
the spectrum of hypertension-induced renal damage is larger. The pathogenetic 
mechanisms involved in hypertensive renal damage seems to be the systemic blood 
pressure “load”, the degree to which such load is transmitted to the renal vascular bed and 
the local tissue susceptibility to any given degree of barotrauma (Bidani, 2004).  
In 2009 was proposed a new theory about nephrosclerosis induced by hypertension that 
involves the genetic MYH9 polymorphisms. The presence of MYH9 polymorphisms in 
individuals leads to products that disrupt normal podocyte function, causing podocyte 
injury, which ultimately leads to glomerulosclerosis (Freedman, 2009). The presence of 
genetic polymorphisms leading to intrinsic kidney injury suggest that the failure of strict 
blood-pressure control to prevent CKD progression does not relate to blood pressure alone, 
but rather relates to factors intrinsic to the kidney that are yet to be defined. In African 
American Study of Kidney Disease (AASK) could be observed that blood-pressure control 
alone cannot reverse existing kidney damage or stop progressive kidney damage (AASK) 
(Appel, 2008). 
Tubulointerstitial injury seems to be one of the main histological determinants of 
hypertension-related kidney damage. This fact is of particular importance because the 
pathology correlates with the degree and progression of renal impairment, regardless of the 
type and origin of kidney injury. Long time it was supposed that interstitial and tubular 
damage is secondary to glomerular and vascular injury and occurs in the final stages of 
hypertensive nephropathy. However, experimental studies have demonstrated that this 
type of kidney damage can be present in hypertensive patients before any changes in 
glomerular vessels (Mai, 1993). Considering the results of these studies, it may be 
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microalbuminuria, albuminuria, and progressive renal disease. This second form is more 
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Tubulointerstitial injury seems to be one of the main histological determinants of 
hypertension-related kidney damage. This fact is of particular importance because the 
pathology correlates with the degree and progression of renal impairment, regardless of the 
type and origin of kidney injury. Long time it was supposed that interstitial and tubular 
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hypothesized that the tubulointerstitium may be an initial site of renal injury in primary 
hypertension. This hypothesis is based only on animal studies, however, and has not been 
finally confirmed in clinical research (Tylicki, 2003). 
Endothelium seems to be at the crossroads of the risk for renal impairment and 
cardiovascular complications in individuals with essential hypertension, therefore, 
combined effects of low-grade inflammation, oxidative stress and hyperuricemia may be the 
link between arterial hypertension and renal organ damage. Different studies showed that 
endothelial dysfunction is associated with renal function decline in hypertensive patients 
with normal or only mildly impaired baseline renal function (Perticone, 2010). It is possible 
that a reduction of GFR could induce endothelial dysfunction, establishing a vicious circle 
which, if not interrupted, promotes the progression of both renal and vascular damage. 
Therefore, systemic endothelial dysfunction represents an important physiopathological 
mechanism for the appearance and progression of mild renal dysfunction in hypertensive 
status. Interstitial inflammation together with oxidative stress participates to the 
development and maintenance of hypertension by reducing the number of nephrons, 
limiting therefore the sodium filtration (Brenner, 1988). Ultimately, these effects lead to end 
stage renal disease. In hypertension, the permeability of the glomeruli is altered which leads 
to an excess of protein infiltration. The toxicity of this protein load generates tubular 
damage, inflammation and scarring (Cohuet, 2006). 
Novel biomarkers of renal damage are currently investigated and could be used to identify 
the first signs of hypertension-associated renal injury. There are a number of definitions of 
the term “biomarker”. In general, they have in common three components:  
1. They are objectively measured indicators of specific anatomic, physiologic, biochemical, 
or molecular events; 
2. They are associated with normal biological processes or accompany the onset, 
progression and/or severity of specific pathological or toxic conditions;  
3. They are useful to assess the progress of injury, disease or the effects of therapeutic 
intervention. 
2.1 Low grade inflammation 
The degree of inflammation and fibrosis of the tubulointerstitial compartment are 
considered strong predictors of the renal function loss and the risk of progression to end-
stage renal disease (Leemans, 2009). Tissue fibrosis and chronic inflammation are common 
causes of progressive renal damage, leading to loss of physiological functions. Renal 
fibrosis can be defined by the accumulation of interstitial leukocytes and fibroblasts, 
contributing to abnormal accumulation of extracellular matrix (ECM) and, eventual, 
tubular atrophy and loss of renal function (Iwano, 2004). Interestingly, the concept of 
renal inflammation in progressive kidney disease is intertwined with the concept of 
hemodynamically induced renal injury (Stuveling, 2005). In the last years, low-grade 
inflammation has acquired progressive recognition as a mechanism facilitating the 
occurrence of both glomerular and tubulo-interstitial renal damage. Recently, it was 
shown that Toll-like receptor 2 (TLR2) is expressed in the kidney and activated by 
endogenous danger signals (Leemans, 2009). The renal fibrosis is considered to be the 
common final pathway by which kidney diseases with variable etiology progresses to 
end-stage renal failure. It is therefore important to identify factors that participate in the 
initiation of tubulointerstitial inflammation and subsequent interstitial fibrosis during 
progressive renal injury. Toll-like receptor 2 (TLR2) and 4 plays a crucial role in the 
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induction of acute inflammation and early tubular injury in the kidney in a reversible 
model of acute renal injury (Leemans, 2009). 
Among inflammatory markers, high-sensitive C-reactive protein levels has been recently 
associated with early kidney damage and seems to best identify the subgroup of 
hypertensive patients at risk for renal involvement (Zoccali, 2006). Subtle elevations in 
plasma concentration of high-sensitive C-reactive protein, a reliable marker of inflammation, 
were associated with similarly subtle reductions in creatinine clearance in the Prevention of 
Renal and Vascular Endstage Disease (PREVEND) study (Stuveling, 2003). 
2.2 Oxidative stress 
The role of reactive oxygen species (ROS) has been documented in both experimental and 
human hypertension (Romero, 1999). It was observed that ROS can have direct and indirect 
effects on the vascular reactivity (Cohuet, 2006). Indeed, by inactivating endothelial nitric 
oxide, ROS impair vasodilation and can also have direct effects on vascular tone in function 
of the quantity of ROS produced and the involved vascular bed. The major ROS is the 
superoxide anion O2− and the most common response to its stimulus is vasoconstriction 
directly or potentiation of the constriction due to angiotensin II (Ang II), thromboxane A2, 
endothelin-1 (ET-1), and norepinephrine by increasing intracellular calcium in smooth 
muscle and endothelial cells. In addition, tubulointerstitial inflammation (infiltration and 
accumulation of lymphocytes and macrophages) appears to be responsible for the mediation 
of sodium retention in salt-sensitive models of hypertension. Moreover, oxidative stress may 
have an influence on sodium retention through tubulointerstitial accumulation of Ang II-
positive cells. These 2 mechanisms for hypertension pathogenesis are related by their effects 
on sodium retention via intrarenal Ang II activity. In the kidney, Ang II decreases 
glomerular filtration rate, increases tubular sodium reabsorption, and impairs pressure–
natriuresis contributing to renal insufficiency. Additionally, oxidative stress has 
proinflammatory effects: firstly, it activates NF-κB, a transcription factor for 
proinflammatory genes, which promotes leucocytes infiltration by increasing the expression 
of adhesion molecules and secondly, it induces the expression of heat shock proteins, 
resulting in cell death and apoptosis in an inflammatory environment.   
2.3 Hyperuricemia 
Uric acid may mediate aspects of the relationship between hypertension and kidney disease 
via renal vasoconstriction and systemic hypertension (Weiner, 2008).  Hyperuricemia is 
present in 25–40% of untreated hypertensive individuals, in 50% of those treated with 
diuretics, and in over 80% of those with malignant hypertension and is associated with 
cardiovascular disease, but is not clear if it is an independent risk factor or just a marker 
associated with cardiovascular risk factors like insulin resistance, obesity and arterial 
hypertension (Feig, 2008).  The high serum uric acid levels in hypertension have been 
attributed to several mechanisms:  
1. The reduced renal blood flow that often accompanies the hypertensive state stimulates 
urate reabsorption in the proximal tubule;  
2. The hypertensive microvascular disease leads to local tissue ischemia, the release of 
lactate that blocks urate secretion in the proximal tubule and increases uric acid 
synthesis. Tissue ischemia leads to ATP degradation to adenosine and xanthine oxidase. 
Both increased xanthine and xanthine oxidase result in increased generation of uric acid 
and oxidant (O2–) formation; 
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associated with cardiovascular risk factors like insulin resistance, obesity and arterial 
hypertension (Feig, 2008).  The high serum uric acid levels in hypertension have been 
attributed to several mechanisms:  
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3. Additional factors can contribute to hyperuricemia in hypertension such as alcohol 
abuse, lead intoxication, and diuretic use.  
Animal model studies have shown that hyperuricemia activates the renin-angiotensin 
system, induces oxidative stress and reduces renal function. In experimental rat models of 
hypertension it was shown that hyperuricemia is associated with renal vasoconstriction and 
is positively correlated with plasma renin activity, these data suggest that uric acid may 
have adverse effects that are mediated by activated RAS (Lee, 2006). Few studies 
demonstrated an association between hyperuricemia and microalbuminuria in hypertensive 
patients (Viazzi, 2007). Recent studies proved that hyperuricemia predicts the development 
of new-onset kidney disease (Obermayr, 2008) and is considered a risk factor for the 
development and progression of renal disease (Kang, 2002; Johnson, 2005; Nagakawa, 2006; 
Feig, 2009). 
3. From chronic kidney disease to arterial hypertension 
Although the relationship between hypertension and CKD has been recognized for several 
hundred years, the prevalence of CKD among patients with normal blood pressure has not 
been assessed in randomly sampled populations. Crews et al reported recently that 13.4% of 
people who have normal blood pressure have CKD (Agarwal, 2010). 
From a clinical point of view, kidney diseases can be classified into two categories according 
to the onset of the renal pathology (but irrespective of the etiology of injury): (i) Acute 
kidney injury (AKI) and (ii) Chronic kidney disease (CKD).  
AKI, also known as acute renal failure or acute kidney failure, is a rapid loss of renal 
function, with variable evolution (full, partial or no recovery of a normal renal function), 
resulting in failure of urinary elimination of nitrogenous waste products (urea nitrogen and 
creatinine). This impairment of renal function results in elevations of blood urea nitrogen 
and serum creatinine concentrations. While there is no disagreement about the general 
definition of ARF, there are substantial differences in diagnosis criteria of ARF (eg, 
magnitude of rise of serum creatinine concentration). From a clinical perspective, for 
persons with normal renal function and serum creatinine concentration, GFR must be 
dramatically reduced to result in even modest increments (eg, 0.1 to 0.3 mg/dL) in serum 
creatinine concentration (Dwinnell, 1999).  
AKI and CKD affect patients worldwide and both are associated with a high morbidity and 
mortality rate (Prunotto, 2011). AKI community-based incidence has increased by 60% in the 
past few years, affecting up to 15.3% of all hospitalized patients. CKD is a major public 
health problem throughout the world. CKD affects more than 13% of the population in the 
USA and in Europe (Prunotto, 2011). The worldwide impact of CKD is significant, yet 
underestimated. According to the World Health Report 2002 and the global burden of 
disease project, kidney and urinary tract diseases contribute to 850,000 deaths per year and 
15,010,167 in disability-adjusted life years (Staples, 2010). 
Chronic kidney failure, also known as chronic renal failure, chronic renal disease, or chronic 
kidney disease, is a slow progressive loss of kidney function over a period of several years. 
The definition of CKD is kidney damage or a GFR below 60 mL per minute per 1.73 m2 for 
three months or more (National Kidney Foundation, 2004). It has been appreciated for 
several decades that once GFR has decreased below a critical level, CKD tends to progress 
relentlessly toward ESRD (Taal, 2006). Earlier recognition of CKD could slow progression, 
prevent complications, and reduce cardiovascular-related outcomes (Plantinga, 2010). Due 
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to the asymptomatic nature of this disease, CKD is not frequently detected until its later 
progress, resulting in loss of prevention opportunities. Progress to kidney failure or other 
adverse outcomes could be prevented or delayed through early detection and treatment of 
CKD (Locatelli, 2002).  
Until now the available literature exploring the epidemiology of CKD overall has not 
classified individuals according to the underlying etiology. Rather, the available population 
cohort data gathered via NHANES and the national Kidney Foundation’s KEEP have 
provided information on comorbid conditions associated with CKD, including 
hypertension, as opposed to providing accurate estimates of CKD resulting from 
hypertension; as a result, only estimates of CKD associated with hypertension can be 
provided. The 2010 USRDS report summarizes the NHANES data on CKD and comorbid 
conditions. Compared to individuals without CKD, individuals with any stage of CKD 
(stages 1–5) have higher rates of hypertension (Udani, 2011). The strong association of 
hypertension with CKD was confirmed by data from KEEP. However, the KEEP data 
suggest that hypertension is more prevalent at early stages of CKD and that individuals 
with CKD have even higher rates of hypertension than NHANES data suggest. The KEEP 
investigators found that the overall prevalence of hypertension exceeded 50% in all 
individuals with CKD, regardless of GFR, and in those with ‘normal’ renal function (GFR 
>100 ml/min/1.73 m2) the prevalence of hypertension was 57%. The two databases, 
however, included different methods of sampling individuals and, overall, have different 
demographical data (Udani, 2011). 
The attention paid globally to CKD is attributable to five factors: the rapid increase in its 
prevalence, the enormous cost of treatment, recent data indicating that overt disease is the 
tip of an iceberg of covert disease, an appreciation of its major role in increasing the risk of 
cardiovascular disease, and the discovery of effective measures to prevent its progression 
(Barsoum, 2006). Furthermore, a gender-different prevalence of CKD was revealed in most 
included studies. Females had a higher prevalence of CKD than males. Females have less 
muscle mass as compared to males and the muscle mass is a major determinant of serum 
creatinine concentration (Heimsfiled, 1983). 
Hypertension is present in more than 80% of patients with CKD and contributes to 
progression of kidney disease toward end stage (ESRD) as well as to cardiovascular events 
such as heart attack and stroke (Toto, 2005). In fact the risk for cardiovascular death in this 
patient population is greater than the risk for progression to ESRD. Proteinuria is an 
important co-morbidity in hypertensive patients with CKD and increases the risk of disease 
progression and cardiovascular events.  
3.1 Pathogenesis 
Hypertension has long been recognized as a consequence of renal impairment and an 
important factor in the progression of CKD. The RAS together with genetic background, 
renal anemia, altered mineral homeostasis, atherogenic dyslipidemia, chronic inflammation, 
and oxidative stress and others cardiovascular risk factors such as diabetes, smoking, and 
obesity are the main contributors in the pathogenesis (Wühl, 2008). CKD pathogenesis is 
characterized by a progressive loss of renal function, and an excessive deposition of 
extracellular matrix in the glomeruli and tubular interstitium (López-Novoa, 2011). Chronic 
glomerulonephritis and interstitial nephritis are currently the principal causes of CKD in 
developing countries, reflecting the high prevalence of bacterial, viral, and parasitic 
infections affecting the kidneys (Barsoum, 2006).   
 
Diseases of Renal Parenchyma 
 
98
3. Additional factors can contribute to hyperuricemia in hypertension such as alcohol 
abuse, lead intoxication, and diuretic use.  
Animal model studies have shown that hyperuricemia activates the renin-angiotensin 
system, induces oxidative stress and reduces renal function. In experimental rat models of 
hypertension it was shown that hyperuricemia is associated with renal vasoconstriction and 
is positively correlated with plasma renin activity, these data suggest that uric acid may 
have adverse effects that are mediated by activated RAS (Lee, 2006). Few studies 
demonstrated an association between hyperuricemia and microalbuminuria in hypertensive 
patients (Viazzi, 2007). Recent studies proved that hyperuricemia predicts the development 
of new-onset kidney disease (Obermayr, 2008) and is considered a risk factor for the 
development and progression of renal disease (Kang, 2002; Johnson, 2005; Nagakawa, 2006; 
Feig, 2009). 
3. From chronic kidney disease to arterial hypertension 
Although the relationship between hypertension and CKD has been recognized for several 
hundred years, the prevalence of CKD among patients with normal blood pressure has not 
been assessed in randomly sampled populations. Crews et al reported recently that 13.4% of 
people who have normal blood pressure have CKD (Agarwal, 2010). 
From a clinical point of view, kidney diseases can be classified into two categories according 
to the onset of the renal pathology (but irrespective of the etiology of injury): (i) Acute 
kidney injury (AKI) and (ii) Chronic kidney disease (CKD).  
AKI, also known as acute renal failure or acute kidney failure, is a rapid loss of renal 
function, with variable evolution (full, partial or no recovery of a normal renal function), 
resulting in failure of urinary elimination of nitrogenous waste products (urea nitrogen and 
creatinine). This impairment of renal function results in elevations of blood urea nitrogen 
and serum creatinine concentrations. While there is no disagreement about the general 
definition of ARF, there are substantial differences in diagnosis criteria of ARF (eg, 
magnitude of rise of serum creatinine concentration). From a clinical perspective, for 
persons with normal renal function and serum creatinine concentration, GFR must be 
dramatically reduced to result in even modest increments (eg, 0.1 to 0.3 mg/dL) in serum 
creatinine concentration (Dwinnell, 1999).  
AKI and CKD affect patients worldwide and both are associated with a high morbidity and 
mortality rate (Prunotto, 2011). AKI community-based incidence has increased by 60% in the 
past few years, affecting up to 15.3% of all hospitalized patients. CKD is a major public 
health problem throughout the world. CKD affects more than 13% of the population in the 
USA and in Europe (Prunotto, 2011). The worldwide impact of CKD is significant, yet 
underestimated. According to the World Health Report 2002 and the global burden of 
disease project, kidney and urinary tract diseases contribute to 850,000 deaths per year and 
15,010,167 in disability-adjusted life years (Staples, 2010). 
Chronic kidney failure, also known as chronic renal failure, chronic renal disease, or chronic 
kidney disease, is a slow progressive loss of kidney function over a period of several years. 
The definition of CKD is kidney damage or a GFR below 60 mL per minute per 1.73 m2 for 
three months or more (National Kidney Foundation, 2004). It has been appreciated for 
several decades that once GFR has decreased below a critical level, CKD tends to progress 
relentlessly toward ESRD (Taal, 2006). Earlier recognition of CKD could slow progression, 
prevent complications, and reduce cardiovascular-related outcomes (Plantinga, 2010). Due 
 
Arterial Hypertension and Renal Disease 
 
99 
to the asymptomatic nature of this disease, CKD is not frequently detected until its later 
progress, resulting in loss of prevention opportunities. Progress to kidney failure or other 
adverse outcomes could be prevented or delayed through early detection and treatment of 
CKD (Locatelli, 2002).  
Until now the available literature exploring the epidemiology of CKD overall has not 
classified individuals according to the underlying etiology. Rather, the available population 
cohort data gathered via NHANES and the national Kidney Foundation’s KEEP have 
provided information on comorbid conditions associated with CKD, including 
hypertension, as opposed to providing accurate estimates of CKD resulting from 
hypertension; as a result, only estimates of CKD associated with hypertension can be 
provided. The 2010 USRDS report summarizes the NHANES data on CKD and comorbid 
conditions. Compared to individuals without CKD, individuals with any stage of CKD 
(stages 1–5) have higher rates of hypertension (Udani, 2011). The strong association of 
hypertension with CKD was confirmed by data from KEEP. However, the KEEP data 
suggest that hypertension is more prevalent at early stages of CKD and that individuals 
with CKD have even higher rates of hypertension than NHANES data suggest. The KEEP 
investigators found that the overall prevalence of hypertension exceeded 50% in all 
individuals with CKD, regardless of GFR, and in those with ‘normal’ renal function (GFR 
>100 ml/min/1.73 m2) the prevalence of hypertension was 57%. The two databases, 
however, included different methods of sampling individuals and, overall, have different 
demographical data (Udani, 2011). 
The attention paid globally to CKD is attributable to five factors: the rapid increase in its 
prevalence, the enormous cost of treatment, recent data indicating that overt disease is the 
tip of an iceberg of covert disease, an appreciation of its major role in increasing the risk of 
cardiovascular disease, and the discovery of effective measures to prevent its progression 
(Barsoum, 2006). Furthermore, a gender-different prevalence of CKD was revealed in most 
included studies. Females had a higher prevalence of CKD than males. Females have less 
muscle mass as compared to males and the muscle mass is a major determinant of serum 
creatinine concentration (Heimsfiled, 1983). 
Hypertension is present in more than 80% of patients with CKD and contributes to 
progression of kidney disease toward end stage (ESRD) as well as to cardiovascular events 
such as heart attack and stroke (Toto, 2005). In fact the risk for cardiovascular death in this 
patient population is greater than the risk for progression to ESRD. Proteinuria is an 
important co-morbidity in hypertensive patients with CKD and increases the risk of disease 
progression and cardiovascular events.  
3.1 Pathogenesis 
Hypertension has long been recognized as a consequence of renal impairment and an 
important factor in the progression of CKD. The RAS together with genetic background, 
renal anemia, altered mineral homeostasis, atherogenic dyslipidemia, chronic inflammation, 
and oxidative stress and others cardiovascular risk factors such as diabetes, smoking, and 
obesity are the main contributors in the pathogenesis (Wühl, 2008). CKD pathogenesis is 
characterized by a progressive loss of renal function, and an excessive deposition of 
extracellular matrix in the glomeruli and tubular interstitium (López-Novoa, 2011). Chronic 
glomerulonephritis and interstitial nephritis are currently the principal causes of CKD in 
developing countries, reflecting the high prevalence of bacterial, viral, and parasitic 
infections affecting the kidneys (Barsoum, 2006).   
 




Hyperuricemia is highly prevalent in patients with CKD, reflecting reduced efficiency in 
renal excretion of uric acid associated with hypouricosuria. Evaluating the role of uric acid 
in the development or progression of CKD is difficult due to the number of confounders to 
any study (Feig, 2009). A decline in GFR is associated with increased values of serum uric 
acid because uric acid is predominantly cleared by the kidneys (Marangella, 2005). The role 
of uric acid in the initiation and progression of CKD remains controversial. Recent 
epidemiological and experimental evidence suggested that uric acid might be involved in 
the development of CKD. In animal studies, experimental hyperuricemia is associated with 
increasing proteinuria, impaired renal function, glomerulosclerosis, renal interstitial fibrosis 
and preglomerular vasculopathy (Kang, 2002). Increased renal renin expression appears to 
be involved in these adverse effects of uric acid on renal function. In humans, hyperuricemia 
also appears to be associated with activation of the intrarenal RAS (Kobori, 2007). In the 
Cardiovascular Health Study, SUA levels did not predict incident CKD but were 
independently associated with the progression of pre-existing CKD (Tziomalos, 2010). 
3.3 Assessment of kidney function 
Blood urea nitrogen and creatinine clearance are well-established biomarkers of kidney 
function that can be measured cheaply and easily (Tesch, 2010). Increases levels of serum 
creatinine are the main manifestations of hypertension-associated renal dysfunction. 
Persistent increases of serum creatinine levels reflect an important renal parenchymal 
damage and some degree of irreversible kidney dysfunction (Udani, 2011). CKD from 
glomerular disease associated with arterial hypertension can be detected by markers of renal 
parenchymal disease, like proteinuria. The evidence of early kidney injury is elusive without 
overt glomerular disease that can be found in hypertensive nephrosclerosis or early diabetic 
nephropathy. The diagnosis and staging of CKD is nowadays based upon the presence of 
signs of kidney damage together with the estimation of the GFR (Montañés, 2011).  
3.3.1 Albuminuria 
Albumin is the most abundant protein in the circulation and during normal kidney function 
very little intact albumin is excreted by the kidney (<30 mg/day in humans) (Tesch, 2010). It 
is known that a slight increase of urinary albumin excretion (microalbuminuria) is a 
predictor of renal and cardiovascular events in hypertensive patients (Hillege, 2002). 
Albuminuria is frequently used as an early marker of renal injury because it often precedes 
a decline in renal function (Tesch, 2010). In arterial hypertension, an increased 
transglomerular passage of albumin may result from several mechanisms—hyperfiltration, 
glomerular basal membrane abnormalities, endothelial dysfunction, and nephrosclerosis 
(Redon, 2002). Microalbuminuria can also be considered a marker of underlying generalized 
endothelial or vascular dysfunction. The presence of a single measurement 
microalbuminuria does not confirm the presence of glomerular disease or parenchymal 
kidney injury (Udani, 2011). A 2010 debate questioned the relevance of microalbuminuria 
measurements in the diagnosis of kidney disease and controversies regarding its use as a 
marker of CKD still exist. The results of the Avoiding Cardiovascular events through 
Combination therapy in Patients living with systolic Hypertension (ACCOMPLISH) study 
highlights the limits of microalbuminuria as a marker of kidney disease and predictor of 
CKD progression (Jamerson, 2004). 
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3.3.2 Serum creatinine and estimated glomerular filtration rate 
In clinical practice, serum creatinine became the almost universal biomarker of choice for 
GFR (Dalton, 2010). Now it appears to be a rather unreliable marker of GRF because 
creatinine serum concentrations are affected by tubular secretion, age, sex, muscle mass, 
physical activity, and diet, and therefore creatinine does not have a direct relationship with 
the GFR (Hsu, 2002). The Cockcroft-Gault and the Modification of Diet in Renal Disease 
(MDRD) equations, both based on serum creatinine, are being used increasingly because 
they overcome, at least in part, some of the limitations of creatinine measurements 
(Cockcroft, 1976; Levey, 1999). Both equations are currently recommended for the estimation 
of GFR, which is an established method for detection and classification of CKD in clinical 
practice (National Kidney Foundation, 2002). The development of formula for estimating 
GFR and disease staging based on serum creatinine reiterate the continuing importance of 
this biomarker (Dalton, 2010). 
3.3.3 Urinalysis 
Urinalysis is considered the major noninvasive diagnostic tool available to the clinician. 
Although examination of the urine can also provide some information about disease 
severity, such a direct relationship between the urinalysis and disease severity is not always 
present (Post, 2006). A normalization of the urinalysis in patients with acute 
glomerulonephritis can be considered the resolution of the active inflammatory process, a 
recovery or healing with irreversible glomerular scarring and nephron loss. In this setting, 
repeated renal biopsy may be required to accurately estimate the status of the renal disease. 
Despite potential limitations, a complete urinalysis should be performed in all patients with 
renal disease (Post, 2003). 
3.3.4 Aldosterone 
Aldosterone, the main mineralocorticoid synthesized by the adrenal gland, has an essential 
function in sodium and water homeostasis and urinary excretion of potassium (Roldán, 
2010). It is an important mediator of collagen turnover, stimulating the expression of various 
profibrotic molecules and inhibiting other antifibrotic molecules, thereby assuming a 
decisive role in the development of renal fibrosis. Aldosterone also has an important 
pathogenic role in hypertension and vascular remodeling, in left ventricular hypertrophy, 
and in renal disease, specifically proteinuria and glomerulosclerosis in patients with 
hypertension (Roldán, 2010). A lot of experimental studies analysed the damage caused by 
aldosterone in the mesangium, basement membrane, and renal tubule and indicated an 
important pathologic role of the hormone in renal function impairment. The contribution of 
aldosterone to the development of arterial hypertension in the general population has been 
shown recently by the Framingham Offspring Study in which serum plasma aldosterone 
levels in normotensive subjects predicted subsequent increases in blood pressure and in the 
development of incident hypertension (Vasan, 2004). Plasma aldosterone concentration can 
be used as a marker of impaired renal function in the initial phases of arterial hypertension 
(Roldán, 2010). 
3.3.5 Hyperhomocysteinemia 
Another marker of renal damage is hyperhomocysteinemia. Serum homocysteine 
concentrations are significantly elevated in patients with albuminuria and low GFR 
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(Ikeyaga, 2005). In the Horn study, high plasma homocysteine was associated with 
microalbuminuria independently of other risk factors (Hoogeveen, 1998). Several 
biochemical mechanisms have been proposed to explain the presumed vasculotoxic effects 
of homocysteine. The main theory is that high homocysteine levels lead to endothelial 
dysfunction. Impaired endothelial vasomotor responses have been ascribed to a reduced 
bioavailability of nitric oxide due to auto-oxidation of homocysteine in plasma which leads 
to oxidative inactivation of nitric oxide (Welch, 1998). Alternatively, homocysteine may lead 
to the accumulation of asymmetric dimethylarginine by inhibiting its catabolizing enzyme 
dimethylarginine dimethylaminohydrolase (van Guldener, 2006). Hyperhomocysteinemia 
could cause subclinical renal interstitial injury, and reduced renal function promotes further 
rise in plasma homocysteine (Ikegaya, 2005). Both hyperhomocysteinemia and renal injury 
are associated as pathogenic processes, creating a vicious cycle that results in further 
impairment of renal function. 
3.3.6 Cystatin-C 
Recently, Cystatin-C, a protein member of the family of cysteine proteinase inhibitors, was 
proposed as a new reliable marker of renal function. Because of its small size, cystatin C is 
freely filtered by the glomerulus. It is not secreted but reabsorbed by tubular epithelial cells 
and subsequently catabolized so that it does not return to the blood flow (Abrahamson, 
1990). It is the product of a gene expressed in all nucleated cells and is produced at a 
constant rate, therefore permitted calculation of a cystatin C clearance using urine 
concentrations. Serum levels of cystatin C is a promising early marker of hypertension-
associated kidney dysfunction and may accurately reflect eGFR in various populations 
(Udani, 2011). The use of serum cystatin C to approximate eGFR is based on the same logic 
as the use of blood urea nitrogen and creatinine, but because it does not return to the 
bloodstream and is not secreted, the eGFR obtained may be more reflective of actual renal 
filtration function (McMurray, 2009). The cystatin C concentration is converted and reported 
in milliliters per minute giving a direct estimation of the GFR. Unlike serum creatinine, it is 
not influenced by age, sex, muscle mass, exercise or diet. A study from the Prevention of 
Renal and Vascular End-Stage Renal Disease (PREVEND) cohort found that cystatin C was 
significantly associated with C-reactive protein (CRP), smoking and body mass index, even 
after adjustment for creatinine clearance levels (Knight, 2004). The authors concluded that 
cystatin C levels were influenced by these factors in addition to kidney function. Other 
longitudinal studies have shown that cystatin C has a stronger and more linear association 
with cardiovascular disease and mortality outcomes compared to creatinine-based 
measures. These findings led to the hypothesis that cystatin C`s link to inflammation could 
explain its advantage over creatinine as a prognostic marker (Singh, 2007). 
3.3.7 Advanced Glycation End Products (AGE) 
Advanced glycation end products (AGEs) are a heterogeneous group of proteins and lipids 
covalently bound to sugar residues. It appears that activation of the RAS may contribute to 
AGE formation through various mechanisms (Bohlender, 2005). Although AGEs could 
nonspecifically bind to basement membranes and modify their properties, they also induce 
specific cellular responses including the release of profibrogenic and proinflammatory 
cytokines by interacting with the receptor for AGE (Bohlender, 2005). AGE levels are grossly 
elevated in CKD and hemodialysis as a result of decreased clearance, resulting in an 
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increased tissue accumulation. The accumulation of AGE in renal failure is even greater than 
in diabetes (Noordzij, 2008). 
3.3.8 Resistin 
Resistin, a newly discovered low molecular weight plasma protein, promotes endothelial 
dysfunction and proinflammatory activation, contributing to subclinical atherosclerosis 
(Dimitriadis, 2009). Although classified as an adipokine, resistin in humans is mainly 
produced by blood-derived leukocytes and mononuclear cells, both within and outside the 
adipose tissue (Ellington, 2007). Resistin directly induces endothelin-1 production, 
upregulates adhesion molecules and chemokines, and downregulates TNF receptor-
associated factor-3 (Verma, 2003). Resistin-induced mitochondrial dysfunction and 
imbalance in cellular redox enzymes may be the underlying mechanisms of oxidative stress 
(Chen, 2010). The humoral factors induced by resistin and their downstream effectors could 
potentiate mesangial proliferation and interstitial fibrosis, thereby affecting both glomerular 
and tubular processes. Recently, elevated levels of resistin were proposed to be a risk factor 
for kidney disease or may even represent overt kidney damage in asymptomatic adults with 
essential hypertension (Ellington, 2007).  
3.3.9 Kidney injury molecule-1 (KIM-1) 
The kidney injury molecule-1 (designated as Kim-1 in rodents, KIM-1 in humans) mRNA 
was identified using techniques of representational difference analysis, a PCR-based 
technique (Hubank, 1994; Bonventre, 2009). KIM-1 is a type 1 transmembrane protein that is 
not detectable in normal kidney tissue but is expressed at high levels in human and rodent 
kidneys with dedifferentiated proximal tubule epithelial cells after ischemic or toxic injury 
(Han, 2005).  KIM-1 is strongly up-regulated in dedifferentiated proximal tubule kidney 
epithelial cells after an ischemic or toxic injury. It may also play a role in epithelial adhesion, 
growth, and differentiation (Malyszko, 2010). KIM-1 not only functions as a biomarker but 
also has predictive value for acute renal injury, but was predictive for adverse clinical 
outcome in a cohort of 201 hospitalized patients with acute renal failure (Lock, 2010). 
Urinary Kim-1 levels may serve as a noninvasive, rapid, sensitive, reproducible, and 
potentially high-throughput method to detect early kidney injury in pathophysiological 
studies and in preclinical drug development studies for risk-benefit profiling of 
pharmaceutical agents (Vaidya, 2006). 
3.3.10 Asymmetric dimethylarginine 
Asymmetric dimethylarginine (ADMA) is a naturally occurring L-arginine analogue, found 
in plasma and various types of tissues, acting as an endogenous NO synthase inhibitor in 
vivo (Ueda, 2007). Further, plasma level of ADMA is elevated in patients with CKD and 
found to be a strong biomarker or predictor for future cardiovascular events (Ueda, 2007). In 
addition, plasma level of ADMA could predict the progression of renal injury in these 
patients, as well. These findings suggest that elevation of ADMA may be a missing link 
between CVD and CKD. ADMA levels are markedly elevated in renal impairment, together 
with the experimental evidence showing ADMA to be a CKD progression factor in animals; 
four prospective studies have found an association between ADMA level and CKD 
progression in humans (Kronenberg, 2009). 
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four prospective studies have found an association between ADMA level and CKD 
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3.3.11 Interleukin-18 (IL-18) 
Interleukin-18 (IL-18) is a proinflammatory cytokine which is induced in PCT and is 
detected in urine following AKI. It was found to be an early predictor of AKI in patients 
with adult respiratory distress syndrome with an area under the curve (AUC) of 0.73 (Soni, 
2009). It was also found to be an independent predictor of mortality in this study. In another 
study on patients undergoing cardiac surgery, urinary IL-18 levels increased 6 h after 
cardiopulmonary bypass (CPB) and peaked at 12 h in patients who were diagnosed to have 
AKI 2 days later by creatinine criteria (Han, 2009). Elevated urinary IL-18 is more specific for 
ischemic AKI and its levels are not deranged in CKD, urinary tract infections or nephrotoxic 
AKI. However, a study by Haase et al. did not find IL-18 to be a useful early predictor of 
AKI in a group of 100 adult patients undergoing cardiac surgery (Soni, 2009). 
3.3.12 Urinary Netrin-1 (Ntn-1) 
Netrin-1 (Ntn-1), a laminin-related axon guidance molecule, is highly induced and excreted 
in the urine after acute kidney injury (AKI) in animals (Ramesh, 2010). Previous studies 
proved that Ntn-1 is involved in the orchestration of inflammatory responses in vitro or in 
vivo (Ly, 2005; Rosenberger, 2009). The kidney has one of the highest levels of netrin-1 
expression, and administration of recombinant netrin-1 before ischemia reperfusion reduces 
kidney injury and inflammation (Wang, 2008). 
3.3.13 Urinary neutrophil gelatinase-associated lipocalin (NGAL) 
Urinary neutrophil gelatinase-associated lipocalin (NGAL) is a small (25 kDa) protein, 
expressed in renal tubular cells and released into the blood and urine after exposure to 
ischemia or toxicity (Devarajan, 2010) and represent a promising new renal biomarker able 
to diagnose acute kidney injury (AKI). It is rapidly induced and released from the injured 
renal distal nephrons in experimental studies and various human diseases. The changes of 
body water content could, thus, influence the urinary concentration, like for other urinary 
biomarkers, too. The release of NGAL occurs within hours after the stimulus and long 
before an increase in serum creatinine level. Urinary and plasma concentrations of NGAL 
increase proportionally to severity and duration of renal injury and rapidly decrease with its 
attenuation. However, NGAL release is not specific to the kidney. Measurements may be 
readily and easily performed in urine and plasma using clinical laboratory platforms or 
point of care devices (Haase, 2011). Therefore, the NGAL level was proposed to be a real-
time indicator of active kidney damage, whereas creatinine level and GFR are markers of 
functional nephron number (Kronenberg, 2009). 
3.3.14 Liver-type fatty acid binding protein (L-FABP) 
Clinical data on associations between liver-type fatty acid binding protein (L-FaBP) and 
kidney disease are sparse (Kronenberg, 2009). This protein is expressed in proximal tubular 
cells and increased expression and higher levels are seen in the urine of patients with kidney 
disease and is considered a promising indicator of tubular but not glomerular damage 
(Kamijo-Ikemori, 2011). A large health screening program in more than 900 individuals 
revealed that average urinary levels of L-FaBP were approximately 50% higher in patients 
with diabetes mellitus, hypertension or chronic hepatitis than in controls. A study 
investigating L-FaBP levels in patients with type 2 diabetes and different stages of 
nephropathy showed that urinary L-FaBP was associated with the severity of diabetic 
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nephropathy (Nakamura, 2005). Small studies in patients with mild kidney dysfunction 
suggest that urinary L-FaBP concentrations are increased in patients whose renal function 
deteriorates further (Kamijo, 2004). 
3.4 Lifestyle modifications 
In the general population, the strategies that lower blood pressure include dietary and 
lifestyle modifications in order to prevent and treat arterial hypertension. Blood pressure 
and CKD management rely heavily upon the patient's ability to self-manage and willingness 
to change or maintain health-promoting behaviors. The prevalence of hypertension may be 
also reduced also by measures like eight loss, sodium restriction, fluid restriction, exercise, 
and limitation of alcohol intake (Miller, 2003).  
The Intersalt Cooperative Research Study, which measured urinary sodium in over 10,000 
individuals from 32 countries, found that consumption of more than 100 mmol/day sodium 
was associated with significantly higher blood pressures (Miller, 2003). Sodium restriction is 
also a crucial component to dietary intake for patients with CKD. In CKD, extracellular 
volume expansion as a result of impaired natriuresis is thought to play an important role in 
the pathogenesis of hypertension. It is therefore recommended that dietary sodium intake 
should be less than 100 mmol/day. Exercise and weight loss (if body mass index is more 
than 25 kg/m2) are also recommended (Thuraisingham, 2011). 
The Dietary Approaches to Stop Hypertension (DASH) diet has been shown to produce 
most benefits in blood pressure reduction through sodium restriction and weight loss,  
and can also decrease LDL cholesterol. The DASH diet is a result of a feeding study of 459 
adults (49% women, 60% African American) with high normal or elevated blood pressure 
(Sacks, 2001). 
3.5 Pharmacologic intervention 
The discussed pathophysiology of hypertensive renal damage suggests three broad targets 
for therapeutic interventions: (1) reduction of BP load; (2) reduction of pressure transmission 
to the renal microvasculature; and (3) interruption and/or modification of the local 
cellular/molecular pathways that mediate eventual tissue injury and fibrosis (Bidani, 2004). 
Antihypertensive therapy significantly decreases the vascular damage in the kidneys of 
hypertensive patients. Therapy of hypertension is therefore imperative. The National 
Kidney Foundation clinical practice guidelines recommend a blood pressure goal of <130 
mmHg systolic and <80 mmHg diastolic for all CKD patients. Post-hoc analyses of the 
Modification of Diet in Renal Disease study indicate that lower blood pressure may provide 
long-term kidney protection in patients with nondiabetic kidney disease. Specifically a mean 
arterial pressure < 92 mmHg (e.g. 120/80 mmHg) compared to 102-107 mmHg (e.g. 140/90 
mmHg) is associated with a reduced risk for ESRD (Toto, 2005). Citing KDOQI, the seventh 
report from the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) also recommends a target BP of < 130/80 mmHg 
for all patients with CKD defined as an GFR<60 ml/min per 1.73m 2 or protein-to-creatinine 
ratio ≥ 200 mg/g.1 A target BP < 130/80 mmHg is also recommended by the American 
Diabetes Association (ADA) and by JNC 7 for all patients with diabetes (O’Hare, 2009). 
The inhibition of the effects of angiotensin II is necessary to ensure the best degree of renal 
protection by the simultaneous control of blood pressure (BP) and the achievement of the 
maximal antiproteinuric capacity. The inhibition can be attained through the administration 
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2009). It was also found to be an independent predictor of mortality in this study. In another 
study on patients undergoing cardiac surgery, urinary IL-18 levels increased 6 h after 
cardiopulmonary bypass (CPB) and peaked at 12 h in patients who were diagnosed to have 
AKI 2 days later by creatinine criteria (Han, 2009). Elevated urinary IL-18 is more specific for 
ischemic AKI and its levels are not deranged in CKD, urinary tract infections or nephrotoxic 
AKI. However, a study by Haase et al. did not find IL-18 to be a useful early predictor of 
AKI in a group of 100 adult patients undergoing cardiac surgery (Soni, 2009). 
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Netrin-1 (Ntn-1), a laminin-related axon guidance molecule, is highly induced and excreted 
in the urine after acute kidney injury (AKI) in animals (Ramesh, 2010). Previous studies 
proved that Ntn-1 is involved in the orchestration of inflammatory responses in vitro or in 
vivo (Ly, 2005; Rosenberger, 2009). The kidney has one of the highest levels of netrin-1 
expression, and administration of recombinant netrin-1 before ischemia reperfusion reduces 
kidney injury and inflammation (Wang, 2008). 
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Urinary neutrophil gelatinase-associated lipocalin (NGAL) is a small (25 kDa) protein, 
expressed in renal tubular cells and released into the blood and urine after exposure to 
ischemia or toxicity (Devarajan, 2010) and represent a promising new renal biomarker able 
to diagnose acute kidney injury (AKI). It is rapidly induced and released from the injured 
renal distal nephrons in experimental studies and various human diseases. The changes of 
body water content could, thus, influence the urinary concentration, like for other urinary 
biomarkers, too. The release of NGAL occurs within hours after the stimulus and long 
before an increase in serum creatinine level. Urinary and plasma concentrations of NGAL 
increase proportionally to severity and duration of renal injury and rapidly decrease with its 
attenuation. However, NGAL release is not specific to the kidney. Measurements may be 
readily and easily performed in urine and plasma using clinical laboratory platforms or 
point of care devices (Haase, 2011). Therefore, the NGAL level was proposed to be a real-
time indicator of active kidney damage, whereas creatinine level and GFR are markers of 
functional nephron number (Kronenberg, 2009). 
3.3.14 Liver-type fatty acid binding protein (L-FABP) 
Clinical data on associations between liver-type fatty acid binding protein (L-FaBP) and 
kidney disease are sparse (Kronenberg, 2009). This protein is expressed in proximal tubular 
cells and increased expression and higher levels are seen in the urine of patients with kidney 
disease and is considered a promising indicator of tubular but not glomerular damage 
(Kamijo-Ikemori, 2011). A large health screening program in more than 900 individuals 
revealed that average urinary levels of L-FaBP were approximately 50% higher in patients 
with diabetes mellitus, hypertension or chronic hepatitis than in controls. A study 
investigating L-FaBP levels in patients with type 2 diabetes and different stages of 
nephropathy showed that urinary L-FaBP was associated with the severity of diabetic 
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nephropathy (Nakamura, 2005). Small studies in patients with mild kidney dysfunction 
suggest that urinary L-FaBP concentrations are increased in patients whose renal function 
deteriorates further (Kamijo, 2004). 
3.4 Lifestyle modifications 
In the general population, the strategies that lower blood pressure include dietary and 
lifestyle modifications in order to prevent and treat arterial hypertension. Blood pressure 
and CKD management rely heavily upon the patient's ability to self-manage and willingness 
to change or maintain health-promoting behaviors. The prevalence of hypertension may be 
also reduced also by measures like eight loss, sodium restriction, fluid restriction, exercise, 
and limitation of alcohol intake (Miller, 2003).  
The Intersalt Cooperative Research Study, which measured urinary sodium in over 10,000 
individuals from 32 countries, found that consumption of more than 100 mmol/day sodium 
was associated with significantly higher blood pressures (Miller, 2003). Sodium restriction is 
also a crucial component to dietary intake for patients with CKD. In CKD, extracellular 
volume expansion as a result of impaired natriuresis is thought to play an important role in 
the pathogenesis of hypertension. It is therefore recommended that dietary sodium intake 
should be less than 100 mmol/day. Exercise and weight loss (if body mass index is more 
than 25 kg/m2) are also recommended (Thuraisingham, 2011). 
The Dietary Approaches to Stop Hypertension (DASH) diet has been shown to produce 
most benefits in blood pressure reduction through sodium restriction and weight loss,  
and can also decrease LDL cholesterol. The DASH diet is a result of a feeding study of 459 
adults (49% women, 60% African American) with high normal or elevated blood pressure 
(Sacks, 2001). 
3.5 Pharmacologic intervention 
The discussed pathophysiology of hypertensive renal damage suggests three broad targets 
for therapeutic interventions: (1) reduction of BP load; (2) reduction of pressure transmission 
to the renal microvasculature; and (3) interruption and/or modification of the local 
cellular/molecular pathways that mediate eventual tissue injury and fibrosis (Bidani, 2004). 
Antihypertensive therapy significantly decreases the vascular damage in the kidneys of 
hypertensive patients. Therapy of hypertension is therefore imperative. The National 
Kidney Foundation clinical practice guidelines recommend a blood pressure goal of <130 
mmHg systolic and <80 mmHg diastolic for all CKD patients. Post-hoc analyses of the 
Modification of Diet in Renal Disease study indicate that lower blood pressure may provide 
long-term kidney protection in patients with nondiabetic kidney disease. Specifically a mean 
arterial pressure < 92 mmHg (e.g. 120/80 mmHg) compared to 102-107 mmHg (e.g. 140/90 
mmHg) is associated with a reduced risk for ESRD (Toto, 2005). Citing KDOQI, the seventh 
report from the Joint National Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure (JNC 7) also recommends a target BP of < 130/80 mmHg 
for all patients with CKD defined as an GFR<60 ml/min per 1.73m 2 or protein-to-creatinine 
ratio ≥ 200 mg/g.1 A target BP < 130/80 mmHg is also recommended by the American 
Diabetes Association (ADA) and by JNC 7 for all patients with diabetes (O’Hare, 2009). 
The inhibition of the effects of angiotensin II is necessary to ensure the best degree of renal 
protection by the simultaneous control of blood pressure (BP) and the achievement of the 
maximal antiproteinuric capacity. The inhibition can be attained through the administration 
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of either an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor 
blocker (ARB). Uptitration of antihypertensive therapy is frequently required to achieve the 
desired BP goal in patients presenting with renal disease, with or without proteinuria. 
Control of BP is good for both cardiovascular and renal protection (Segura, 2003).  
RAS inhibitors have been shown to reduce proteinuria and the rate of loss of renal function 
in patients with CKD (Ito, 2010). However, the benefits of RAS inhibition seem to depend on 
the degree of proteinuria at baseline. Namely, RAS inhibition has been shown to be 
beneficial in patients with at least 0.5 g per day proteinuria, whereas no convincing evidence 
exists to demonstrate the benefits extended to patients with a lower level of proteinuria 
(Jafal, 2001). An “adequate” BP control with standard antihypertensive therapy, the kidney 
is well protected and very few hypertensive patients, less than 2%, will develop renal 
damage as a consequence of arterial hypertension (Ruilope, 2002). Interestingly, data from 
the ACCOMPLISH trial demonstrated that use of an ACE inhibitor in combination with a 
calcium antagonist was associated with a reduced requirement for dialysis than use of an 
ACE inhibitor and a diuretic in individuals > 65 years of age (Backris, 2010). 
Identifying individuals with early signs of CKD might help the targeting of therapies to 
more effectively prevent disease progression and associated complications. Identifying an 
appropriate marker of early renal dysfunction, however, remains challenging and depends 
on the underlying etiology of kidney disease.  Early diagnosis on the basis of presence of 
proteinuria or reduced estimated GFR could permit early intervention to reduce the risks of 
cardiovascular events, kidney failure, and death that are associated with chronic kidney 
disease. In developed countries, screening for the disorder is most effective when targeted at 
high-risk groups including elderly people and those with concomitant illness (such as 
diabetes, hypertension, or cardiovascular disease) or a family history of chronic kidney 
disease, although the role of screening in developing countries is not yet clear. Different 
strategies available now aimed to slow the progression of CKD and to reduce cardiovascular 
risk (James, 2010). Treatment of high blood pressure is recommended for all individuals 
with, or at risk of, chronic kidney disease. Use of angiotensin-converting-enzyme inhibitors 
or angiotensin-receptor blockers is preferred for patients with diabetic CKD or those with 
the proteinuric non-diabetic disorder (Matthew, 2010). 
4. Conclusion 
In conclusion, hypertension-associated renal damage would paradoxically originate from 
subtle, focal renovascular damage, where hypertension would be another mere consequence 
acting as a magnifying amplifier in the vicious circle of malignancy. The therapeutic strategy 
aims, at targeting the pathophysiological processes mentioned in this chapter, to prevent, 
reduce or reverse the renal organ damage due to arterial hypertension.  
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theories of evolution were postulated, namely- single mutation theory and multiple 
mutation theory. A single mutation occurring in Neolithic times in the then fertile Arabian 
Peninsula was favoured by Lehmann (1954), who postulated that the changing climatic 
conditions and conversion of this area to a desert caused a migration of peoples that could 
have carried the gene to India, Eastern Saudi Arabia and to Africa. Lehmann and Hunstan 
(1974) supported this hypothesis by citing the distribution of certain agricultural practices 
and anthropological evidence as well as the geographical distribution of the gene within 
Africa which manifested a decline in gene frequency from East to West Africa together with 
higher levels on the north compared to the south bank of the Zambesi River. This is 
compatible with the fact that the river acted as a barrier to a southern migration (Serjeant, 
1992). This theory was also supported by Gelpi (1973), who considered that the evidence 
from blood groups and other genetic markers was more compatible with an origin in 
Equatorial Africa and subsequent diffusion of the gene to India, Arabia and the 
Mediterranean by the East Africa slave trade (Kamel and Awny, 1965). 
The multiple mutation theory recently received support from the studies of DNA 
polymorphism. The use of restriction endonucleases to recognize and cut DNA at specific 
sequence has identified variations in DNA structure (polymorphism) that are inherited and 
may be used as genetic markers (Serjeant, 1992). The first of such polymorphism to be 
reported was a variation in the recognition site of the restriction endonuclease HPa 1 to the 
3’ side of the β-globin gene (Kan and Dozy, 1978). In most normal human DNA digested 
with HPa 1, the β-globin gene occurred on a DNA fragment 7.6 kd long. Polymorphism at 
this site in West African population resulted in β–gene occurring on the fragments 7.0 and 
13.0 kd long. Subsequently the 13.0kd fragment was found to be relatively lightly linked to 
the β-gene, the frequency of the 13.0 kd fragment in the AS genotype being 0.31 and in the 
SS genotype 0.87(Kan and Dozy,1978). The immediate application of this observation was in 
antenatal diagnosis (Kan and Dozy, 1978), but it was also of potential value as a genetic 
marker in anthropological studies. The 13.0 kb fragment was found to be linked to the βc 
gene (Feldenzer et al., 1979). 
3. Study of the kidney 
The study of nephrology as a major discipline in medicine dates back to about five decades 
ago. The discipline has its origin in the writing of pioneers who used their observational 
skills to establish its basic framework. From their observations and analyses came the 
realization of the vital role of the kidney in the maintenance of health, particularly in 
relation to homeostasis of body fluids and electrolytes (Travis et al., 1984). These pioneers 
recorded the profound changes in health that occurred with any of a variety of kidney 
disorders. While imaginative postulates about the physiology of the kidney in health and 
disease were beginning to evolve, detailed construct of the precise mechanisms by which 
various renal events took place were not easily obtainable. Opportunities to explore in detail 
the postulates were limited primarily by the primitive technology which was available then. 
Only recently when technological advances were made and applied that the theoretical 
bases and principles of renal physiology and molecular biology established and an 
understanding reached of the alterations that occurred in the disease state (Travis et al., 
1984). With technological advancement, there has been a deeper insight into the 
pathophysiologic mechanisms that interact to create renal disease. 
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The kidneys are essential for life. Normally more water and ions are ingested than the body 
requires. This excess intake is excreted in urine. The kidneys therefore regulate both the 
volume and the composition of the body fluids. As well as the surplus water and 
electrolytes, the urine contains metabolic waste products, foreign substances and their 
metabolic derivatives (Bray et al., 1999).The kidneys also produce a variety of humoral 
agents, including erythropoietin, active metabolites of vitamin D, renin and prostaglandins. 
Each human kidney has about one million functional units- the nephrons; arranged in 
parellel (Risdon, 1985). The renal regulation of the volume and composition of the body 
fluids involves each of these nephrons in three processes:  filtration at the glomerulus, 
tubular reabsorption and tubular secretion. 
4. Renal manifestations in sickle cell disease 
The kidney in SCD is affected by both the haemodynamic changes of a chronic anaemia and 
by the consequences of vaso-occlusion which are especially marked within the renal 
medulla. As a result, there are many abnormalities in renal structure and function (sergeant, 
1992). Renal size in SCD varies with age of the patients and the method of examination. 
Renal weight at autopsy was normal in young children (Alleyne et al., 1975), increased in 
older children and young adults and decreased in patients over 40years (Morgan et al., 
1987). In children, bilateral renal enlargement was common in intravenous urography 
(Minkin et al., 1997; Odita et al., 1983) and in adults; renal length exceeded 15cm in at least 
one kidney in about 10% Jamaicans (McCall et al., 1987) and Nigerians (Odita et al., 1983). In 
the Nigerian study, the mean kidney length in patients with SCD was significantly greater 
than in normal controls. Renal structure on imaging in SCD revealed that intravenous 
urography in 189 Jamaican adults showed mild cortical scarring, the frequency increasing 
from 8% in the 16-25years old, to 45% in those over 35years (McCall et al.,1987). Calyceal 
abnormalities included calyceal cysts, blunting and clubbing, which also increased with age. 
Radiological evidence of renal papillary necrosis occurred in 44 (26%) of adults patients in 
the Jamaican study. This high prevalence was also noted in Nigerians (Odita et al., 1983). 
Functional changes occur with increasing age in patients with SCD. In children and young 
adults there are increases in effective renal blood flow (ERBF), effective renal plasma flow 
(ERPF) and glomerular filtration rate (GFR), although the filtration fraction is decreased 
(Hatch et al., 1970). With age, there is a progressive decline in ERBF, ERPF and GFR and in 
patients over the age 40years; GFR and ERPF tend to decline (Morgan and sergeant, 1981). 
But normal or above normal values may persist in some patients (Alleyne et al., 1975). 
Progressive renal failure at older ages is a major cause of illness and death (Morgan et al., 
1987).     Glomerular disease is common (15 – 30 percent) in homozygotes for sickle cell 
disease. Glomerular hyperfiltration and hypertrophy occur within the first 5years of life. 
Approximately 15 – 30 % of patients develop proteinuria in the first three decades, and 5% 
develop ESRD. The glomerular pathology is usually focal segmental glomerulosclerosis, 
probably due to sustained glomerular capillary hypertension or membrane proliferative 
glomerulonephritis (MPGN). Predictors of chronic renal failure are worsening anaemia, 
proteinuria, nephrotic syndrome and hypertension (Powars et al., 2005). 
5. Sickle cell disease and glomerulopathy. 
Patients with sickle cell anaemia (SCA) may develop glomerulopathy with proteinuria and 
progressive renal insufficiency leading to End Stage Renal Disease(ESRD) (Gausch et al., 
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2006). These authors observed that the patients with sickle cell haemoglobin (Hb SS) have a 
more severe disease than individuals with other sickling haemoglobinopathies using 
clinical, haematologic and biochemical parameters in a group of patients with sickle cell 
haemoglobinopathies. It was reported that increased albumin excretion rate (AER) occurs in 
68% of the patients; macroalbuminuria was present in 26% and microalbuminuria in 42% 
while only 32% of adults with ‘SS’ disease had normoalbuminuria. There was no gender 
differences reported in the prevalence of albuminuria. In a study of proteinuria among SCA 
patients in Nigeria, male predominance of sickle cell nephropathy was reported (Abdu et 
al., 2011). The concentration of 24hours urine protein in the SCA male subjects with 
proteinuria was significantly higher (0.25g/day;p<0.001) compared with the SCA female 
patients with proteinuria (0.09g/day)(Emokpae et al.,2010a). The sex differences in the 
mechanisms underlying renal injury suggest that androgens may permit or accelerate renal 
damage while estrogen may provide renoprotection (Ji et al., 2005; Standberg, 2008). The 
female sex hormone (estradiol) is thought to have antioxidant properties. Estradiol is 
capable of increasing superoxide dismutase and glutathione peroxidase expression as well 
as decreases NADPH oxidase enzyme activity and superoxide production (Lopez-Ruiz et 
al., 2008). The graded albuminuria according to age hence duration of disease showed that, 
in ‘SS’ disease the prevalence of abnormal AER increased from 61% in patients aged 18 to 30 
years to as high as 79% in patients older than 40 years. Albumin excretion rate was reported 
to have increased as creatinine clearance decreased, but there was a large variability and a 
significant number of patients had increased AER despite a preserved creatinine clearance. 
In a four decade observational study of 1056 patients with sickle cell disease, Powars et al.,( 
2005) reported that 73% of the patients had one or more clinically recognized forms of 
irreversible organ damage. By the fifth decade, nearly one-half of the surviving patients 
(48%) had documented irreversible organ damage. ESRD (glomerulosclerosis), chronic 
pulmonary disease with pulmonary hypertension, retinopathy and cerebral micro 
infarctions were manifestations of arterial and capillary microcirculation obstructive 
vasculopathy. In an earlier report on chronic renal failure in sickle cell disease : risk factors, 
clinical course and mortality indicated that histologic studies showed characteristic lesion of 
glomerular “drop out” and glomerulosclerosis, in thirty six patients with sickle cell disease 
who developed sickle cell renal failure (Powards et al., 1991; Powards et al., 2002). Table 1 
shows changes in biochemical parameters in sickle cell disease patients with or without 
proteinuria in northern Nigeria.   
Renal insufficiency in SCA was defined as a creatinine clearance <90ml/min using 
Crockcroft- Gault, (1976) equation. It was reported that 21% of patients with SCA had renal 
insufficiency while 27% of patients with other sickling disorders also had renal insufficiency 
but the percentage of patients with renal insufficiency and advanced kidney failure (chronic 
kidney disease stage 3 or higher) was higher in SS disease  than other sickling disorders 
(Guasch et al., 2006). Guasch et al.(1997) previously showed renal insufficiency in SCA 
results from a glomerulopathy, which can be detected by the presence of albumin and other 
large molecular weight proteins in urine. Recently it was observed that glomerular 
involvement is extremely common in Nigerian sickle cell haemoglobinopathies (Abdu et 
al.2011). Increased AER occurs in approximately 70% of adults with haemoglobin SS disease 
and about 40% in adults with other sickling disorders. There was an indication of sickle cell 
glomerulopathy in a majority of older adults with SS disease and its prevalence was much 
higher than previously reported on the basis of a positive urinary dipstick for protein (Falk 
et al., 1992).   
 


















subjects 68 32  76 24  
Age 
(Years) 22.2 ± 3.8 26.4 ± 7.3 P < 0.005 21 ± 3.0 20.4 ± 7.6 NS 
Weight 
(Kg) 45 ± 12.3 50 ± 7.2 P < 0.001 42 ± 7.6 47.4 ± 5.3 P < 0.001 
Na+ 
mmol/l 134.7 ± 3.4 140 ± 3.8 P < 0.001 136 ± 5.4 141 ± 5.3 P < 0.001 
K + mmol/l 4.2 ± 0.5 3.9 ± 0.5 P < 0.05 4.05 ± 0.35 3.9 ± 0.13 NS 
Cl- mmo/l 97.4 ± 2.3 103 ± 4.1 P < 0.001 98.2 ± 5.3 101 ± 3.9 NS 
Hco3- 
mmo/l 97.4 ± 2.3 103 ± 4.1 NS 22.3 ± 1.55 20.2 ± 3.0 p < 0.05 
Urea 
mmol/l 2.46 ± 0.88 8.07 ± 2.2 P < 0.001 2.79 ± 1.77 2.46 ± 1.22 NS 
CR μmol/l 59.2 ± 10.2 280 ± 22.3 P < 0.001 61.2 ± 12.4 67 ± 23.7 NS 
eGFR 
ml/min 104 ± 22.8 70 ± 6.9 P < 0.001 97 ± 3.5 101 ± 2.5 NS 
CR = creatinine, eGFR = estimated glomerular filtration rate, NS = not significant, Adapted from Abdu 
et al.,2011. 
Table 1. Urea, electrolytes, creatinine and estimated glomerular filtration rates in sickle cell 
anaemia patients with proteinuria and those with no proteinuria. 
The pathogenesis of glomerular damage in SCA is not well understood. Children with 
sickle cell anaemia have renal haemodynamic alterations characterized by renal 
hyperperfusion and glomerular hyperfiltration. These probably resulted from renal vaso-
dilation associated with chronic anaemia. In some patients, these changes are followed by 
the development of glomerular proteinuria and progressive renal disease. Histologically, 
patients with SCA may develop glomerular hypertrophy and focal segmented 
glomerulosclerosis, features that are suggestive of haemodynamically mediated injury 
(Falk et al., 1992). The causes of the haemodynamic injury to the glomerulus in SCA are 
unclear, but anaemia could cause glomerular damage by increasing blood flow. Other 
factors that are related to the rheology or stickness of sickle erythrocyte could cause 
glomerular damage independently or in conjunction with the haemodynamic changes that 
are associated with anaemia (Guasch et al., 1999). In the analysis of significance of 
abnormal albuminuria in SCA, several authors demonstrated by physiologic and 
pathologic studies that macroalbuminuria is the clinical manifestation of an underlying 
glomerulopathy (Falk et al., 1992; Guasch et al., 1999; Emokpae et al., 2010a;Abdu et 
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2006). These authors observed that the patients with sickle cell haemoglobin (Hb SS) have a 
more severe disease than individuals with other sickling haemoglobinopathies using 
clinical, haematologic and biochemical parameters in a group of patients with sickle cell 
haemoglobinopathies. It was reported that increased albumin excretion rate (AER) occurs in 
68% of the patients; macroalbuminuria was present in 26% and microalbuminuria in 42% 
while only 32% of adults with ‘SS’ disease had normoalbuminuria. There was no gender 
differences reported in the prevalence of albuminuria. In a study of proteinuria among SCA 
patients in Nigeria, male predominance of sickle cell nephropathy was reported (Abdu et 
al., 2011). The concentration of 24hours urine protein in the SCA male subjects with 
proteinuria was significantly higher (0.25g/day;p<0.001) compared with the SCA female 
patients with proteinuria (0.09g/day)(Emokpae et al.,2010a). The sex differences in the 
mechanisms underlying renal injury suggest that androgens may permit or accelerate renal 
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subjects 68 32  76 24  
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(Kg) 45 ± 12.3 50 ± 7.2 P < 0.001 42 ± 7.6 47.4 ± 5.3 P < 0.001 
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the development of glomerular proteinuria and progressive renal disease. Histologically, 
patients with SCA may develop glomerular hypertrophy and focal segmented 
glomerulosclerosis, features that are suggestive of haemodynamically mediated injury 
(Falk et al., 1992). The causes of the haemodynamic injury to the glomerulus in SCA are 
unclear, but anaemia could cause glomerular damage by increasing blood flow. Other 
factors that are related to the rheology or stickness of sickle erythrocyte could cause 
glomerular damage independently or in conjunction with the haemodynamic changes that 
are associated with anaemia (Guasch et al., 1999). In the analysis of significance of 
abnormal albuminuria in SCA, several authors demonstrated by physiologic and 
pathologic studies that macroalbuminuria is the clinical manifestation of an underlying 
glomerulopathy (Falk et al., 1992; Guasch et al., 1999; Emokpae et al., 2010a;Abdu et 
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al.,2011). Twenty eight percent of patients with SCD patients were observed to have 
significant proteinuria in Nigerian SCD patients (Abdu et al.,2011), confirming the fact 
that proteinuria is a more sensitive marker than elevated serum creatinine values in 
detecting glomerular injury and early manifestation of sickle cell nephropathy. From that 
study, 50% of SCA male patients with proteinuria had CKD. However, it was observed 
that the high prevalence of CKD reported may be due to the fact that the study was 
conducted in a tertiary health care referral centre where there is likelihood of having 
patients population with more severe disease (Abdu et al., 2011). Table 2 shows 
haematological changes in SCD patients with or without proteinuria and those with 







P-value CKD P-value 
No. of subjects 144 40 - 16 - 
Age (years) 21.6±3.2 20.8±4.2 - 32.6 P<0.001 
Haematocrit (%) 20.1±5.9 19.1±3.9 NS 18.7±1.19 NS 
Haemoglobin (g/dl) 7.0±2.1 6.25±0.9 P<0.001 6.1±0.2 P<0.001 
Total leukocyte 
Count (x109/L) 11.7±4.05 11.8±3.2 NS 11.9±1.04 NS 
Red blood cells 
Count (x1012/L) 2.43±0.6 2.19±1.0 NS 2.07±0.2 P<0.001 
Platelet count 
(x109/L) 373±135 348±92 NS 428±221 P<0.001 
Mean cell 
Hemoglobin (pg) 29.6±2.6 35.7±3.3 NS 36.6±1.5 NS 




36.4±2.1 35.7±3.3 NS 36.6±1.5 NS 
Absolute lymphocyte 
Count (x109/L) 4.0±1.3 3.2±0.6 P<0.001 2.8±0.4 P<0.001 
Absolute neutrophil 
Count (x109/L) 5.2±1.7 6.0±0.8 P<0.001 6.4±0.6 P<0.001 
Absolute Monocyte 
Count (x109/L) 0.5±0.2 0.4±0.03 P<0.001 0.4±0.04 P<0.001 
Absolute eosinophil 
Count (x109/L) 0.2±0.1 0.2±0.02 NS 0.2±0.1 NS 
Adapted from Emokpae et al., 2010a 
Table 2. Haematological indices in SCD patients with macroalbuminuria, CKD and controls 
In patients with macroalbuminuria but preserved GFR, the glomerular ultrafiltration 
coefficient was reduced versus normalbuminuric sickle cell control subjects; indicating that 
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macroalbuminuria irrespective of the level of GFR reflects an underlying glomerular 
pathology (Guasch et al., 2006). It was reported that in children the development of 
microalbuminuria follows an age dependent manner. In a study by Dhranidharka et 
al.(1998) in a group of sicklers, It was observed that microalbuminuria was not present in 
children who were younger than 7years but reached 43 percent in the second decade of life. 
In another similar study, Wigfall et al.(2000) observed an age-dependent occurrence of 
dipstick proteinuria: proteinuria was not present in children who were less than 6years, but 
occurs in 7% of children aged 7-10years and 10% of children who were aged 13 to 17years. It 
was therefore speculated that sickle cell glomerulopathy could evolve in five clinical stages. 
 A normoalbuminuric stage of variable duration followed by a stage of  
 Microalbuminuria which could lead to 
 Macroalbuminunnia but with preserved GFR and to 
 Macroalbuminuna and progressive renal insufficiency and  
 ESRD.  
However, evidence of progression from micro to macroalbuminuria is lacking and such 
classification may remains a hypothesis (Guasch et al , 2006). It was concluded that the 
prevalence of glomerular damage in SCA is much higher than previously thought; a 
majority of patients with SS disease are at risk for the development of progressive renal 
insufficiency and late renal failure especially because the life expectancy in patients with SS 
disease has improved with better medical care. Secondly, in contrast to most glomerular 
disease, the glomerulopathy in SS disease is not accompanied by the development of 
significant systemic hypertension. Lastly, the haemodynamic changes that are associated 
with chronic anaemia per se are not solely responsible for the development of sickle cell 
glomerulopathy and indicate that other mechanisms are involved in the pathogenesis of the 
glomerular damage in this population. 
There is a large variability in the severity of the clinical manifestation of sickle cell anaemia 
(SCA), including renal involvement. Some patients develop multiorgan failure while others 
have relatively few end-organ complications (Guasch et al., 1999). Epigenetic and 
environmental factors have been implicated to explain these differences in clinical severity. 
In children, lower haemoglobin levels and a relatively high degree of haemolysis are 
associated with a poorer clinical outcome while the persistence of high levels of foetal 
haemoglobin (HbF) is associated with less aggressive clinical manifestation (Platt et al., 
1994). Epidemiologic studies in African and Asian countries have suggested that differences 
in the degree of clinical severity are related to the geographical origin of the sickle cell 
mutation (Adedeji, 1988). The β-globin gene cluster is located on chromosome 11 and 
consists of a long segment of DNA (approximately 60,000 bp) that contains the β-globin 
gene and other globin genes. Distinct polymorphism in this gene cluster can be identified by 
restriction endonucleases that cleave the DNA at specific sites. When the restriction sites 
patterns are arranged by alleles, they form a haplotype. In the African, specific haplotypes 
are associated with different groups from different geographic area and define an 
individual’s origin from Benin, Central African Republic, Senegal, Saudi Arabia or 
Cameroun (Nagel et al., 1985). Since substitution of valine for glutamic acid at position six 
arose on different haplotypes, it must have arisen in different ethnic groups (Guasch et al., 
1999). Some studies have suggested that the severity of SCA varied with haplotype, with the 
Central African Republic (CAR) haplotype associated with a higher incidence of stroke, leg 
ulcer, acute chest syndrome, bone infarcts and kidney failure compared with non-CAR 
haplotypes (Powars et al., 1990; Powars et al., 1991). Guasch et al., (1996) have emphasized 
 
Diseases of Renal Parenchyma 
 
118 
al.,2011). Twenty eight percent of patients with SCD patients were observed to have 
significant proteinuria in Nigerian SCD patients (Abdu et al.,2011), confirming the fact 
that proteinuria is a more sensitive marker than elevated serum creatinine values in 
detecting glomerular injury and early manifestation of sickle cell nephropathy. From that 
study, 50% of SCA male patients with proteinuria had CKD. However, it was observed 
that the high prevalence of CKD reported may be due to the fact that the study was 
conducted in a tertiary health care referral centre where there is likelihood of having 
patients population with more severe disease (Abdu et al., 2011). Table 2 shows 
haematological changes in SCD patients with or without proteinuria and those with 
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In patients with macroalbuminuria but preserved GFR, the glomerular ultrafiltration 
coefficient was reduced versus normalbuminuric sickle cell control subjects; indicating that 
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macroalbuminuria irrespective of the level of GFR reflects an underlying glomerular 
pathology (Guasch et al., 2006). It was reported that in children the development of 
microalbuminuria follows an age dependent manner. In a study by Dhranidharka et 
al.(1998) in a group of sicklers, It was observed that microalbuminuria was not present in 
children who were younger than 7years but reached 43 percent in the second decade of life. 
In another similar study, Wigfall et al.(2000) observed an age-dependent occurrence of 
dipstick proteinuria: proteinuria was not present in children who were less than 6years, but 
occurs in 7% of children aged 7-10years and 10% of children who were aged 13 to 17years. It 
was therefore speculated that sickle cell glomerulopathy could evolve in five clinical stages. 
 A normoalbuminuric stage of variable duration followed by a stage of  
 Microalbuminuria which could lead to 
 Macroalbuminunnia but with preserved GFR and to 
 Macroalbuminuna and progressive renal insufficiency and  
 ESRD.  
However, evidence of progression from micro to macroalbuminuria is lacking and such 
classification may remains a hypothesis (Guasch et al , 2006). It was concluded that the 
prevalence of glomerular damage in SCA is much higher than previously thought; a 
majority of patients with SS disease are at risk for the development of progressive renal 
insufficiency and late renal failure especially because the life expectancy in patients with SS 
disease has improved with better medical care. Secondly, in contrast to most glomerular 
disease, the glomerulopathy in SS disease is not accompanied by the development of 
significant systemic hypertension. Lastly, the haemodynamic changes that are associated 
with chronic anaemia per se are not solely responsible for the development of sickle cell 
glomerulopathy and indicate that other mechanisms are involved in the pathogenesis of the 
glomerular damage in this population. 
There is a large variability in the severity of the clinical manifestation of sickle cell anaemia 
(SCA), including renal involvement. Some patients develop multiorgan failure while others 
have relatively few end-organ complications (Guasch et al., 1999). Epigenetic and 
environmental factors have been implicated to explain these differences in clinical severity. 
In children, lower haemoglobin levels and a relatively high degree of haemolysis are 
associated with a poorer clinical outcome while the persistence of high levels of foetal 
haemoglobin (HbF) is associated with less aggressive clinical manifestation (Platt et al., 
1994). Epidemiologic studies in African and Asian countries have suggested that differences 
in the degree of clinical severity are related to the geographical origin of the sickle cell 
mutation (Adedeji, 1988). The β-globin gene cluster is located on chromosome 11 and 
consists of a long segment of DNA (approximately 60,000 bp) that contains the β-globin 
gene and other globin genes. Distinct polymorphism in this gene cluster can be identified by 
restriction endonucleases that cleave the DNA at specific sites. When the restriction sites 
patterns are arranged by alleles, they form a haplotype. In the African, specific haplotypes 
are associated with different groups from different geographic area and define an 
individual’s origin from Benin, Central African Republic, Senegal, Saudi Arabia or 
Cameroun (Nagel et al., 1985). Since substitution of valine for glutamic acid at position six 
arose on different haplotypes, it must have arisen in different ethnic groups (Guasch et al., 
1999). Some studies have suggested that the severity of SCA varied with haplotype, with the 
Central African Republic (CAR) haplotype associated with a higher incidence of stroke, leg 
ulcer, acute chest syndrome, bone infarcts and kidney failure compared with non-CAR 
haplotypes (Powars et al., 1990; Powars et al., 1991). Guasch et al., (1996) have emphasized 
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the development of proteinuria and progressive renal insufficiency, leading to end-stage 
renal disease in a subset of SCA patients. It was observed that glomerulopathy is the cause 
of the progressive renal insufficiency and can be detected as increased excretion of albumin 
in the urine.              
The prevalence of renal insufficiency in patients with SCA has been reported to be low 
(<5%), based on the serum creatinine (Powars et al., 1991). However, Guasch et al (1996) 
found that serum creatinine is a very insensitive marker of renal insufficiency in SCA, 
becoming abnormal only after GFR is reduced to <30 to 40mL/min per 1.73m2 
6. Renal matrix alterations in glomerulosclerosis 
Progressive renal disease of many etiologies is characterized by increased accumulation of 
acellular material within the glomerular mesangium. Initially, this process is characterized 
by focal areas of glomerular hyalinosis, acellular material that stains with eosin but not with 
periodic acid Schiff, together with capillary collapse and adhesions of the glomerular tuft to 
Bowman’s capsule. With time, the mesangial compartment is occupied by material that 
stains positively with both periodic acid Schiff and silver. Ultimately, the capillary tuft is 
replaced by this sclerotic material and ceases filtration (Rennke and Klein, 1989).Other 
features of progressive glomerulosclerosis are more variable. The mesangial compartment is 
in some cases occupied by an increased number of cells both mesangial cells and resident 
macrophages. In the case of diabetic nephropathy, there is an associated thickening and 
wrinkling of the glomerular basement membrane which contributes to compromised 
capillary lumens. In addition to an expanded mesangial compartment, some patients with 
diabetic nephropathy also exhibit a characteristic nodular glomerulosclerosis (Kimmelstiel-
Wilson lesion)(Rennke and Klein, 1989).    
The mesangial components that are expressed as a consequence of inflammation or the 
sclerotic process belong to two classes. First, normal mesangial matrix molecules accumulate 
in excess quantities. These include laminin, type IV collagen, heparin sulphate proteoglycan 
and fibronectin. Second, the sclerotic mesangium contains matrix molecules that are not 
usually present in this location. These include interstitial collagens, particularly type III 
collagen and the small proteoglycan decorion. These matrix consistuents are typical 
products of fibroblasts and related cell types. In a sense, the reappearance of these 
interstitial matrix products represents a return to biosynthethic activity of the embryonic 
renal interstitial mesenchyme (Yoshioka et al., 1989).    
Studies of matrix protein distribution in various primary renal diseases suggest that the 
proteins expressed and the regional pattern of expression differ considerably between 
different renal diseases (Oomura et al., 1989; Yoshioka et al., 1989).  In all, with progressive 
glomerulosclerosis particularly with a mesangial proliferative component, the mesangial 
contains increased amounts of fibronectin, laminin, heparin sulphate proteoglycan and type 
III and IV collagen. Despite the widespread use in experimental animals of the nephron 
ablation model of progressive glomerulosclerosis, relatively little is known about the nature 
of or the mechanisms responsible for the accumulated glomerular matrix components.      
Alterations in the renal expression of chondroitin sulphate proteoglycans are another 
component of the sclerosing process. The normal glomerulus expresses the small 
proteoglycan biglycan. In experimental glomerulonephritis induced by antibodies to the 
Thy-1-antigen, there is increased synthesis of biglycan as well as of another related 
proteoglycan, decorin by isolated glomeruli (Okuda et al., 1990). Activated mesangial cells 
are a possible source for these proteoglycans. 
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Diabetes mellitus in humans and experimental animals is associated with evidence of 
deregulation of renal extracellular matrix proteins expression. More is known about the 
matrix alterations in this disorder than other forms of glomerulosclerosis, perhaps in part 
due to the availability of animal models. Biochemical investigation has shown increased 
accumulation of basement membrane components in diabetes glomeruli from experimental 
animals. Thus glomeruli from streptozotocin-diabetic rats contain more type IV collagen 
compared with glomeruli from normal rats (Hasslacher et al., 1986). On the other hand, the 
data for glomerular content of heparin sulphate proteoglycan are conflicting, with an 
increase reported in streptozocin-diabetic rats and a decrease reported in diabetic human 
patients (Klein et al., 1986; Shimonura and Spiro, 1987). The discrepancy underscores the 
need for caution in extrapolating from studies of diabetic rodents to mechanisms of human 
disease.      
Immunohistochemical investigation of the sclerotic regions of human diabetic glomeruli 
show evidence of an increase in laminin, fibronectin and types IV and V collagen (Karttunen 
et al., 1986). 
While our understanding of the protein constituents of the sclerotic process has improved, 
the molecular mechanisms responsible for their accumulation are just being understood. It is 
likely that many factors including capillary physical forces, dietary constituents, metabolic 
injury and the effects of local growth factors and products of inflammation converge on a 
common pathway that generates matrix components within the glomerulus and 
mesangium. The process whereby matrix accumulates in response to injury, likely parallel 
the process of scarring and wound healing critical for the survival of other tissue types. In 
the kidney, however the generation of matrix may sufficiently disrupt the normal nephron 
architecture to render it useless. It may be possible in the future to modify the normal 
healing process in the glomerulus so that a loss of functioning nephrons does not hold the 
remaining glomeruli at increased risk for sclerosis.   
7. Mechanisms whereby proteinuria cause progressive renal disease 
The possibility that proteinuria may accelerate kidney disease progression  to end stage 
renal failure has received support from the results of increasing numbers of experimental 
and clinical studies (Abbate et al., 2006). Researches in nephrology in recent times have 
yielded substantial information on the mechanisms by which persisting dysfunction of an 
individual component cell in the glomerulus is generated and signaled to other glomerular 
cells and to the tubule. Spreading of disease is central to processes by which nephropathies 
of different types progress to end stage renal disease (ESRD). Independent of the underlying 
causes, chronic proteinuric glomerulopathies have in common a sustained or permanent 
loss of selectivity of the glomerular barrier to protein filtration. Glomerular sclerosis is the 
progressive lesion beginning at the glomerular capillary wall, the site of abnormal filtration 
of plasma proteins. Injury is transmitted to the intestitium favouring the self destruction of 
nephrons and eventually of the kidney (Abbate et al., 2006). Baseline proteinuria was an 
independent predictor of renal outcome in patients with diabetes, non-diabetes as well as 
sickle cell nephropathies (Peterson et al., 1995; Breyer et al., 1996; Abdu et al.,2011). Clinical 
trials consistently showed renoprotective effects of proteinuric reduction and led to the 
recognition that, the antiproteinuric treatment is instrumental to maximize renoprotection 
(Peterson et al., 1995; Wapstra et al., 1996). Findings that the rate of GFR decline correlated 
negatively with proteinuria reduction and positively with residual proteinuria provided 
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the development of proteinuria and progressive renal insufficiency, leading to end-stage 
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usually present in this location. These include interstitial collagens, particularly type III 
collagen and the small proteoglycan decorion. These matrix consistuents are typical 
products of fibroblasts and related cell types. In a sense, the reappearance of these 
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renal interstitial mesenchyme (Yoshioka et al., 1989).    
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contains increased amounts of fibronectin, laminin, heparin sulphate proteoglycan and type 
III and IV collagen. Despite the widespread use in experimental animals of the nephron 
ablation model of progressive glomerulosclerosis, relatively little is known about the nature 
of or the mechanisms responsible for the accumulated glomerular matrix components.      
Alterations in the renal expression of chondroitin sulphate proteoglycans are another 
component of the sclerosing process. The normal glomerulus expresses the small 
proteoglycan biglycan. In experimental glomerulonephritis induced by antibodies to the 
Thy-1-antigen, there is increased synthesis of biglycan as well as of another related 
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further evidence for a pathogenic role of proteinuria (Ruggenenti et al., 2003). It was 
documented that whenever proteinuria is decreased by treatments, progression to ESRD is 
reduced (Brenner et al., 2001).     
7.1 Glomerular proteinuria as signal for interstitial inflammation         
In vitro studies using proximal tubular cells as a model to assess effects of apical exposure to 
plasma proteins proved highly valuable to approaching direct casual relationships. In 
monolayers of proximal tubular cells, the load with plasma proteins (albumin, IgG and 
transferrin) induced the synthesis of the vasoconstrictor peptide endothelin-1 (ET-1), a 
mediator of progressive renal injury by virtue of ability to stimulate renal cell proliferation 
and extracellular matrix production and to attract monocytes (Zoja et al., 1995). Other 
investigators confirmed and extended the stimulatory effects of a diversity of plasma 
proteins on the expression of proinflammatory and profibrotic mediators in renal tubular 
cells (Yard et al., 2001; Tang et al., 2003). Among molecules attracted are 
monocytes/macrophages and T-lymphocytes, monocyte chemoattractant protein-1 (MCP-1) 
and RANTES which were over-expressed in proximal tubular cells that were challenged 
with plasma proteins (Wang et al., 1997; Zoja et al., 1998). Albumin upregulated tubular gene 
expression and production of interleukin 8(IL-8), a potent chemotatic agent for lymphocytes 
and neutrophils (Tang et al., 1999).The releases of ET-1 and chemokines in response to proteins 
was polarized mainly toward the basolateral compartment of the cell as to mirror a directional 
secretion that favoured the interstitial inflammatory reaction that was observed in-vivo. 
Protein overloading of human proximal tubular cells induced the synthesis of fractalkine, 
which in its membrane-anchored form promotes mononuclear cell adhesion via CX3CR1 
receptor (Danadelli et al., 2003). Fractalkine mRNA was overexpressed in kidneys of mice with 
protein overload proteinuria, and the gene product was detected in tubular epithelial cells 
mainly in the basal region. Treatment of mice with an antibody against CX3CR1 limited the 
interstitial accumulation of monocytes /macrophages (Danadelli et al., 2003). 
Investigation of the molecular mechanisms underlying chemokine upregulation in proximal 
tubular cells or protein challenge had initial focus on the activation of transcriptional NF-β 
(Zoja et al., 1998). Other studies confirmed the pathway and revealed reactive oxygen as a 
secondary messenger (Drumm et al., 2003). Protein overload elicited rapid generation of 
hydrogen peroxide in human proximal tubular cells, an effect that together with NF-β 
activation was prevented by antioxidants (Morigi et al., 2002). Specific inhibitors of proteins 
kinase C (PKC) prevented hydrogen peroxide generation, NF-β activation and MCP-1 and 
IL-8 genes up regulation that was induced by protein overload (Tang et al., 2003), suggesting 
a cascade of signals from PKC- dependent oxygen radical generation to nuclear 
translocation of  NF-β and consequent gene up regulation. A link also has been made 
between induction of NF-β activity by protein and mitogen-activated protein kinases, 
including p38 and extracellular signal-regulated kinase 1 and 2 (ERK1/ERK2) that are 
involved in chemokine synthesis (Dixon et al., 2000; Danadelli et al, 2003). In support of the 
hypothesis of protein overload as a key activator of signaling in proximal tubule is the 
finding that albumin activated the signal transducer and activator of transcription (STAT) 
proteins in cultured proximal tubular cells. Because the STAT pathway is the principal 
mechanism that converts the signal from a wide array of cytokines and growth factors into 
gene expression programs that regulate cell proliferation, differentiation, survival and 
apoptosis, it was suggested that albumin may stimulate proximal tubular cells in the 
manner of a cytokine (Rawlings et al., 2004; Brunskill et al., 2004).                 
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Despite evidence that albumin overload elicits several responses by tubular cells in-vitro, it 
has been argued that albumin per se may not be toxic to the proximal tubular epithelium. 
Compounds that are bound to albumin, such as free fatty acids (FFA), instead have been 
implicated to be causative in pro inflammatory activation or injury of cultured proximal 
tubular cells (Schreiner, 1995). It was also observed that among various fatty acids, oleic acid 
and linoleic acids exert the most toxic and profibrogenic effects in human proximal tubular 
cells in culture. These studies collectively indicate that the ability of albumin to act as a 
carrier enhances the pro inflammatory activation of proximal tubular cells. In addition, in-
vivo gene expression profile analysis of proximal tubules from mice with protein overload 
proteinuria identified 2000 genes that were differentially regulated by excess proteins. More 
than half of them were upregulated (Nakajima et al., 2002). They included thymic shared 
antigen -1, the fibroblast-associated gene GS188 and glia maturation factor-B, a protein that 
originally was purified as a neurotrophic factor (Kaimori et al., 2003). The expression of glia 
maturation factor-β was induced in renal proximal tubular cells of mice with protein 
overload proteinuria (Kaimori et al., 2003). Proximal tubular cells that over expressed glia 
maturation factor-β acquired more susceptibility to death by sustained oxidative stress 
through p38 pathway activation.  
There was a controversial issue relating to the concentration of albumin that was used in 
various in-vitro studies. Burton et al. (1999) discovered that the apical exposure of human 
proximal tubular cells to 1mg/ml albumin or transferrin did not increase MCP-1 or PDGF-
AB release, an effect that  was observed after exposure to a human serum fraction (40 to 100 
KD) in the molecular weight range similar to albumin and transferrin. Studies that reported 
the effects of protein overload on NF-β activation showed responses from 0.5mg/mL in 
some experiments and usually >2.5 - >5mg/mL (Zoja et al., 1995; Wang et al., 1997). The 
latter concentration seems too far exceed the concentration reached in the proteinuric 
ultrafiltrate in-vivo (Gekle, 2005).   
The proximal tubule bears other receptors for ultrafiltered proteins such as 
immunoglobulins and complement molecules (Braun et al., 2004). The functional role of such 
receptors has not been established. It is likely that filtered proteins other than or in addition 
to albumin induces tubular dysfunction and injury in conditions of non selective 
proteinuria, in which large molecular weight proteins are a significant component. In 
contrast, relatively selective albuminuria induces delayed mononuclear cells infiltration and 
usually is associated with or mild chronic tubulo-interstitial injury. In this respect, the case 
of minimal-change disease has been considered sometimes an exception to the rule that 
interstitial infiltrates develop with time in proteinuric glomerulopathies. In addition, in 
minimal-change disease, a substantial percentage of patients respond to steroid and the 
regression of proteinuria prevents inflammation and renal function deterioration (Remuzzi 
and Giachelli, 1995).  
7.2 Key role for the intra-renal activation of complement    
Complement activation is a powerful mechanism underlying tubular and interstitial injury 
via cytotoxic, proinflammatory and fibrogenic effects. Abnormal complement, C3 and C5b-9 
staining in proximal tubular cells and along the brush border is a long known feature both 
in human chronic proteinuric diseases and experimental models. Glomerular permeability 
dysfunction of proteinuric nephropathies allows complement factors to be ultrafiltered 
abnormally across the altered glomerular barrier into the Bowman’s space and tubular 
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lumen. Plasma- derived C3 (molecular weight 180kd) is likely to reflect more loss of 
glomerular permselectivity and to enhance cell dysfunction in the presence of abnormally 
filtered plasma proteins. Renal tubular cells also synthesize C3 and other complement 
factors in ways that may have critical importance in disease, as found in experimental renal 
transplant rejection and post ischemic acute renal failure (Pratt et al.,2002; Farrar et al., 2006). 
Therefore both excess ultrafiltration and proximal tubular cell synthesis of complement 
could underlie complement – mediated injury in chronic proteinuric renal disease. Recent 
findings of C3 mRNA upregulation and C3 accumulation in proximal tubular cells in 
kidneys of mice with protein overload proteinuria are in support of a role for the local 
synthesis of complement (Abbate et al., 2004). Complement is an important effector of 
interstitial mononuclear cell infiltration and fibrogenesis in this model as shown by 
significant attenuation of injury in C3 deficient mice (Abbate et al., 2004). A direct role for 
protein overload as a stimulus was indicated by findings that the exposure of cultured 
proximal tubular cells to total serum proteins at the apical surface upregulated C3 mRNA 
expression and protein biosynthesis (Tang et al., 1999). 
7.3 Profibrogenic signal from proximal tubular cells in response to protein overload 
Local recruitment of macrophages by tubular cells that are loaded with ultrafiltered plasma 
proteins may contribute to interstitial fibrosis by engaging matrix producing interstitial 
myofibroblasts. Macrophages also regulate matrix accumulation via release of growth 
factors such as TGF-β and PDGF, ET-1 and PAI-1, TGF-β stimulates the transformation of 
interstitial cells into myofibroblasts. In addition, proximal tubular epithelial cells 
communicate with interstitial fibroblasts to promote fibrogenesis via paracrine release of 
TGF-β. (Abbate et al.,2006).  
8. Pathogenesis of lipoprotein abnormalities in chronic kidney disease 
Regardless of the aetiology of renal disease, patients with CKD develop complex qualitative 
and quantitative abnormalities in lipid and lipoprotein metabolism. These damages and the 
underlying molecular mechanism has been the subject of some reviews (Vaziri, 2006; Chan 
et al., 2006). Classical uraemic dyslipidaemia is characterized by raised triglyceride, low high 
density lipoprotein (HDL) and normal total cholesterol. These qualitative defects become 
more pronounced with advancing renal failure and modified by renal replacement therapy, 
renal transplantation, co-morbid conditions such as diabetes mellitus and concurrent 
medication (for example steroids, cyclosporine) (Vaziri,200) Lipoprotein metabolism is a 
dynamic system that can be disturbed owing to alterations in apolipoprotein receptors. 
When GFR falls below 60ml/min, there is a fall in the ratio of apolipoprotein AI (apo A) to 
apolipoprotein C – III (apo C – III) in spite of normal cholesterol and triglyceride 
concentrations (Batsta et al., 2004). As renal function deteriorates in non- nephrotic patients 
with CKD, triglyceride concentrations increase while HDL concentrations decline 
(Farbekhsh and Kasiske, 2005) and there is accumulation of the more atherogenic small 
dense low-density lipoprotein (LDL) particles. 
In advanced CKD, there is decreased concentration of apoA-containing lipoproteins, 
increased concentrations of triglyceride-rich apo B containing lipoproteins and serum 
lipoprotein(a). Reduced catabolism and clearance of triglyceride-rich apo B containing 
lipoproteins is a consequence of : (a) decreased activity of lipolytic enzymes, such as 
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lipoprotein lipase (LPL)and hepatic lipase (HL), (b) reduced receptor- mediated uptake via 
hepatic LDL- receptor related protein(LRP) and VLDL receptors (c) accumulation of certain 
inhibitors of LPL such as pre -  β HDL (Chan et al., 2006). Impaired clearance of triglyceride-
rich lipoproteins is further compounded by reductions in apolipoprotein C-11 (apo C- II) 
and apolipoprotein E (apo E). Impaired divalent ion metabolism arising from parathyroid 
gland hyperplasia in CKD (stage 3–4) may also adversely affect lipoprotein metabolism by 
suppressing LPL and hepatic lipase activities (Nishizawa et al., 1997). Post prandial 
lipoprotein metabolism is also impaired in CKD, resulting in accumulation of chylomicron 
particles and their remnants. Reduction in the expression of HL and down regulation of LRP 
in uremia may also account for the accumulation of remnant lipoprotein (Kim and Vaziri, 
2005). Maturation of HDL is impaired due to decreased plasma lecithin: cholesterol 
acyltransferase (LCAT) activity and gene expression. Plasma HDL concentration also falls in 
uremia due to decreased expression of both apo AI and AII. (Vaziri et al., 2001). These 
abnormalities can lead to impaired HDL mediated cholesterol uptake from the vascular 
tissue and contribute to the cardiovascular disease. In addition, LCAT deficiency can in part, 
account for elevated serum free cholesterol, reduced HDL/total cholesterol and elevated  
pre – β HDL in CRF. The latter can in turn depress lipolytic activity and hinder triglyceride- 
rich lipoprotein clearance in CRF (Vaziri et al., 2001; Emokpae et al.,2010a). Statistically 
significant decrease in LCAT and lipoprotein lipase (LPL) activities were observed in SCA 
subjects in steady state compared with HbAS and HbAA controls in both males and 
females. The activities of LCAT and LPL were lower in subjects with SCA than sickle cell 
trait and normal haemoglobin. It was concluded that this may contribute to the changes 
observed in lipid metabolism in SCA(Emokpae et al.,2010b) Although Dyslipidaemia is 
present in patients with SCD and patients with renal insufficiency irrespective of the 
haemoglobin genotype, it was reported that the lipoprotein levels observed in Nigerian 
adults with SCA patients were more lower compared with the lipid levels observed in both 
African Americans and Saudi Arabian patients with SCD. The potential effects of lipids on 
cardiovascular disease risk as measured by three predictor ratios were higher in SCA 
compared to HbAS and HbAA patients with kidney disease (Emokpae et al.,2010c).Plasma 
total cholesterol is frequently low to normal and only occasionally elevated in CRF patients. 
In addition 3-hydroxyl-3- methyl-glutaryl- coA (HMG COA) reductase, the rate-limiting 
step in cholesterol biosynthesis and cholesterol 7 α-hydrolase, the rate limiting step in 
cholesterol catabolism, are unaffected by CRF (Liang and Vaziri., 1997). Moreover, LDL 
receptor and scavenger receptor B1, the primary pathways of hepatic cholesterol uptake are 
normal in CRF (Vaziri et al., 1999). 
The dyslipidaemia of CKD has similar feature to the metabolic syndrome. The metabolic 
syndrome, including type 2 diabetes, is known to predispose to CKD (Kurella et al., 2005), 
which in turn aggravates insulin resistance and promotes dyslipidaemia. Insulin 
resistance increases free fatty acid (FFA) supply from adipocytes to increase hepatic 
lipogenesis and this stimulates hepatic secretion of apo B-100 containing lipoprotein 
specifically large triglyceride rich VLDL particles (Prinsen et al., 2004). Impaired insulin 
signaling in skeletal muscles and adipose tissue also slows the catabolism of all 
triglycerides–rich containing lipoproteins. Expansion in the VLDL particle pool size 
impacts on the remodeling of LDL and HDL in an atherogenic direction (Chang et al., 
2006). Table 3 indicates changes in lipoproteins, lecithin: cholesterol acyltransferase and 
lipoprotein lipase in subjects with sickle cell anaemia, sickle cell trait and normal 
haemoglobin in northern Nigeria.  
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 HbSS males 
HbAS 
males p-value HbAA males p-value 
No of subjects 68 25 - 25 - 
Age in years 22.2±3.8 28.7±7 - 28.8±7 - 
Triglyceride (mmol/L) 1.10±0.4 1.19±0.18 NS 1.4±0.12 P<0.001 
T. Cholesterol (mmol/L) 3.06±0.5 4.05±0.06 P<0.001 4.3±0.12 P<0.001 
HDL Cholesterol (mmol/L) 0.72±0.17 1.18±0.03 P<0.001 1.2±0.06 P<0.001 
LDL Cholesterol (mmol/L) 1.92±0.54 2.15±0.14 NS 2.52±0.16 P<0.001 
VLDL Cholesterol (mmol/L) 0.48±0.06 0.42±0.07 NS 0.41±0.08 NS 
LPL (umolglycerol 
liberated/hr/l Plasma) 4.12±1.2 5.12±0.4 P<0.001 5.56±0.23 P<0.001 
LCAT (umolcholesterol 
liberated/hr/l Plasma) 66.8±2.8 69.2±3.0 P<0.001 70.2±2.96 P<0.001 
Adapted from  
Emokpae et al.,2010b      
Table 3. Lipid, lipoproteins, LCAT and LPL in male sickle cell disease subjects compared 
with HbAS and HbAA controls. 
9. Effect of oxidative stress 
Reactive oxygen species or free radicals are highly reactive entity and very short-lived 
molecules which are constantly produced in a wide variety of normal physiological 
functions, they are however toxic when generated in excess (Parke and Sapota, 1996). The 
most important characteristic of toxic free radicals either in vivo or in vitro is peroxidation 
of lipid resulting in tissue damage and death of affected cells (Bandyopadhyay et al., 1999). 
There are profound evidence implicating free radicals  in induced lipid peroxidation in the 
pathogenesis of several pathological conditions including chronic inflammation 
(Vijayakumar et al., 2006), renal disease (Dakshinamurty et al., 2006; Suryawanshi et al., 
2006),sickle cell renal disease (Emokpae et al.,2010d) and cardiovascular disease (Kaysen et 
al., 2004). Table 4 indicates changes in oxidative stress and lipid peroxide parameters in 
control SCD, proteinuria and chronic kidney disease while table 5 shows inflammatory 
markers in subjects with SCD in northern Nigeria. 
The harmful effect of reactive oxygen species is neutralized by a broad species of 
protective agents termed antioxidants which prevent oxidative damage by reacting with 
free radicals before any other molecules can become a target.   The non enzymatic 
antioxidants are vitamins E, C and reduced glutathione while the antioxidant enzymes 
include superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX). 
They all play important roles in the protection of cells and tissues against free radical 
mediated tissue damage (Yu et al., 1994; Airede and Ibrahim, 1999; Ray and Hussain, 
2002).There was a significant reduction in the activity levels of antioxidant enzymes in the 
serum of SCD patients compared with control sickle cell trait and normal haemoglobin 
(Emokpae et al.,2010d). This is an indication that SCA patients produce greater quantities 
of reactive oxygen species than controls. In SCD, the production of reactive oxygen 
species can be grossly amplified in response to variety of pathophysiological conditions 
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such as inflammation immunologic disorders, hypoxia, metabolism of drugs or alcohol 
and deficiency in antioxidant enzymes. Sickle cell anaemia patients showed low activity 
levels of antioxidant enzymes which may be due to the consumption of these substances 
by pro-oxidants in SCA. This therefore place SCA patients at increased risk of oxidative 
stress and injury. The oxidative stress may contribute to sickling process with the 
formation of dense cells, the development of vaso-occlussive and shortened red blood cell 
survival. We also demonstrated increased serum levels of some acute phase proteins in 
SCA, which may be as a result of sub-clinical vaso-occlusion which in turn can lead to a 
hidden inflammatory response (Emokpae et al.,2010d). Based on the results of the study, 
increased level of malondialdehyde compared significantly with lower activities level of 
antioxidant enzymes and increased acute phase proteins. In SCD patients with CKD, it 
was observed that there were increases in stress and inflammatory markers. C-reactive 
protein and fibrinogen were increased in subjects with renal insufficiency and were 
associated with increased urea and creatinine levels. Proteinuria as observed in SCA 
patients with renal insufficiency may act in synergy with oxidative stress and 
inflammation to initiate and accelerate the progression of renal disease. Chronic exposure 
of renal tubular epithelium to high levels of filtered plasma proteins may cause tissue 
injury (Emokpae et al.,2010a).   
In certain diseases such as renal disease and sickle cell disease, the toxic material produced 
by activated phagocytes during reaction can cause maximal damage to the membrane 
because they are active in the lipid phase. The damaging effects of elevated toxic radical are 
due to an increase in the formation of superoxide radicals within the cells which cause 
inactivation of superoxide dismutase enzyme (Suryawanshi et al., 2006).  Oxidative stress 
occurs when there is an imbalance between production and scavenging. Increase in lipid 
peroxidation in sickle renal disease is due to excess formation of free radicals. Glycosylated 
protein, auto-oxidation, reduced superoxide dismutase enzyme and ascorbic acid and lack 
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P-value 
 
No of subjects 144 40  16   
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32.5±4.2 25.4±4.6 P<0.001 18.3±2.8 P<0.001 
Catalase (μmol/min/ml) 156±5.9 152±1.9 P<0.001 148±1.06 P<0.001 
Adapted from Emokpae et al., 2010a 
Table 4. Oxidative stress markers in serum of SCD patients with macroalbuminuria, CKD 
and controls (mean ± SD)	
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control SCD, proteinuria and chronic kidney disease while table 5 shows inflammatory 
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include superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPX). 
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such as inflammation immunologic disorders, hypoxia, metabolism of drugs or alcohol 
and deficiency in antioxidant enzymes. Sickle cell anaemia patients showed low activity 
levels of antioxidant enzymes which may be due to the consumption of these substances 
by pro-oxidants in SCA. This therefore place SCA patients at increased risk of oxidative 
stress and injury. The oxidative stress may contribute to sickling process with the 
formation of dense cells, the development of vaso-occlussive and shortened red blood cell 
survival. We also demonstrated increased serum levels of some acute phase proteins in 
SCA, which may be as a result of sub-clinical vaso-occlusion which in turn can lead to a 
hidden inflammatory response (Emokpae et al.,2010d). Based on the results of the study, 
increased level of malondialdehyde compared significantly with lower activities level of 
antioxidant enzymes and increased acute phase proteins. In SCD patients with CKD, it 
was observed that there were increases in stress and inflammatory markers. C-reactive 
protein and fibrinogen were increased in subjects with renal insufficiency and were 
associated with increased urea and creatinine levels. Proteinuria as observed in SCA 
patients with renal insufficiency may act in synergy with oxidative stress and 
inflammation to initiate and accelerate the progression of renal disease. Chronic exposure 
of renal tubular epithelium to high levels of filtered plasma proteins may cause tissue 
injury (Emokpae et al.,2010a).   
In certain diseases such as renal disease and sickle cell disease, the toxic material produced 
by activated phagocytes during reaction can cause maximal damage to the membrane 
because they are active in the lipid phase. The damaging effects of elevated toxic radical are 
due to an increase in the formation of superoxide radicals within the cells which cause 
inactivation of superoxide dismutase enzyme (Suryawanshi et al., 2006).  Oxidative stress 
occurs when there is an imbalance between production and scavenging. Increase in lipid 
peroxidation in sickle renal disease is due to excess formation of free radicals. Glycosylated 
protein, auto-oxidation, reduced superoxide dismutase enzyme and ascorbic acid and lack 









P-value CKD HbSS 
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No of subjects 144 40  16   
Age (years) 21.6±3.2 20.8±4.2 NS 32.6±3.0 P<0.001 
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Table 4. Oxidative stress markers in serum of SCD patients with macroalbuminuria, CKD 
and controls (mean ± SD)	
 










P-value CKD HbSS P-value 
No of subjects 144 40  16  
C-reactive protein 
(μg/ml) 1.120±0.02 1.23±0.1 P<0.001 1.81±0.05 P<0.001 
Fibrinogen (mg/dl) 299±9.1 307±6.0 P<0.001 317±4.1 P<0.001 
Urea (mmol/l) 2.6±0.25 3.4±0.2 NS 14.0±2.8 P<0.001 
Creatinine 
(μmol/l) 59.2±10.2 63±27 NS 496±78 P<0.001 
eGFR (ml/min) 103±22 101±2.5 NS 14.5±2.0 P<0.001 
Adapted from Emokpae et al., 2010a 
Table 5. Serum levels of inflammatory markers, urea, creatinine and eGFR in SCD patients 












No. of subjects 144 20 16 20 
Age (years) 21.6±3.2 22.0±2.6 32.6±3.0* 48.6±15.2* 
Malondialdehyde (mmol/l) 2.5±0.4 2.4±0.2 5.8±0.4* 5.03±0.8* 
Glutathione Peroxidase (mU/ml) 9.6±0.9 10.3±2.7 2.81±0.24* 4.35±1.8* 
Superoxide Dismutase (ng/ml) 32.5±4.2 34.5±1.6** 18.3±2.8* 17.2±12.0* 
Catalase (μmol/min/ml) 156±5.9 163±5.8* 148±1.06* 153±3.0* 
*P<0.001     
Adapted from Emokpae et al., 2010a 
Table 6. Oxidative stress markers in controls HbSS, HbAA, CKD HbSS and CKD HbAA 
Sickle cell anaemia patients in both steady state and renal impairments undergo constant 
inflammatory process which may in turn leads to inflammatory response (Bourantas et 
al.,1998; Emokpae et al., 2010d). Haemoglobin S containing red blood cells auto-oxidize 
faster thereby generating more superoxide, hydrogen peroxide, hydroxyl radicals and lipid 
peroxides than HbAA. Reactive oxygen species can cause damage to biological 
macromolecules and membrane lipids readily react and undergo peroxidation. Studies have 
shown that there were increases in stress and inflammatory markers in SCD patients with 
renal insufficiency.  
The mechanisms by which inflammation may lead to decline in renal function is not clear 
but cytokine could act directly on the endothelium and mesangium of the glomerulus (Fried 
et al.,2004). Studies in animal model have shown that kidney in SCD is susceptible to 
hypoxia because of occlusion of blood flow in the vasa recta which may lead to medullary 
and papillary necrosis and fibrosis (Emokpae et al.,2010a). There are evidence to suggest 
that prolonged glomerular hyperfiltration due to any cause especially in SCD could lead to 
glomerular damage resulting to glomerular sclerosis, proteinuria and progressive renal 
disease. It was suggested that filtered plasma proteins taken up by tubular epithelium 
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stimulate inflammatory genes, release inflammatory and vaso-active substances into the 
renal interstitium that induce scarring and sclerosis (Remuzzi and Bertani,1998).We also 
showed a solid association of chronic inflammation with CKD in SCA and this observation 
supported the hypothesis that inflammatory and oxidative stress markers contribute to the 
pathophysiology of glomerulopathy in SCD. Other contributing factors to the 
pathophysiology of glomerulopathy in SCD are possible iatrogenic acceleration by analgesic 
medication. There are indication that morphine induces mesangial cell proliferation and 
glomerulopathy via kappa-opioid receptors as well as the effect of nonsteroidal anti-
inflammatory drug-induced damage (Allon et al.,1998;Weber et al.,2005).  
Lipid metabolism in SCA patients appears to be different from sickle cell trait and normal 
haemoglobin in both steady state and renal disease. Alterations in lipid metabolism are 
often observed in all three Hb genotypes with CKD but marked differences in pattern and 
severity of lipid disorder differ and thus appear to be more severe in SCD subjects with 
CKD. Since proteinuria is observed in the early stages of SCD nephropathy, it is the 
hallmark of future deterioration of renal failure. It is therefore important to detect this early 
so that intervention at this early stage may prevent or delay renal damage in SCD patients 
more so as this group of subjects do not do well with renal replacement therapies. 
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1. Introduction  
In 2010 alone there were an estimated 54,000 new diagnoses and 12,000 deaths attributable 
to renal cell carcinoma (RCC), with the vast majority of these tumors consituting small renal 
masses incidentially detected on cross-sectional imaging.(2010; Chow, Dong, and Devesa, 
2010)  Renal cortical tumors include a complex family of neoplasms with unique histology, 
cytogenetic effects, and metastatic potential; the differential presentation of symptomatic, 
locally advanced disease as opposed to small renal tumors (median tumor size <4cm, T1a) 
evokes different management paradigms.(Lee et al., 2010; McKiernan et al., 2002b; Mitchell 
et al., 2006; Russo et al., 2002)  This large subcategory of patients with localized RCC have 
historically been treated with radical nephrectomy, and this management has continued in 
many regions of the United Stes and the world.(Hollenbeck et al., 2006)  Nevertheless, a 
paradigm shift has occured in the surgical management of renal cortical tumors over the last 
10 years, favoring nephron-sparing surgery or partial nephrecotmy whenever this approach 
is feasible from a technical and oncologic standpoint.  The rationale underpinning this shift 
has involved the observed non-inferiority in terms of cancer control and operative morbidity 
as well as the superior renal functional outcomes.  Within the neprhology and urology 
communities, the last decade has also witnessed a increased understanding of how renal 
volume effects renal function, and how this in turn affects cardiovascular competence.  It 
now is evident that having less renal parenchyma does not only worsen renal function, but 
it also is a poor prognosticator of cardiac function and overall survival.  It is within this 
context that a review of renal functional outcomes following surgery for renal coritcal 
tumors can be undertaken.       
2. Renal cancer: Changing epidemiology 
Approximately 75-80% of patients in the United States with renal cancer are now diagnosed 
incidentally and with organ-confined disease.  This shift is largely attributable to the 
increasing use of cross-sectional imaging with the utilization of CT and MRI increasing by 
73% during 1986-1994 among the Medicare population.  Furthermore, depending on the 
histologic sub-type, the prognosis ranges from 75-100% of patients achieving long-term 
survival, and an estimated 30% of patients over 70 years of age dying of unrelated causes 
within 5 years of surgery for a renal cortical neoplasm.(Jewett and Zuniga, 2008)  The 
increased incidence and detection of these cancers is largely due to the diagnosis of small 
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localized renal lesions, many of which have low metastatic potential.  This finding is 
reflected in the fact that mortality as a result of renal cancer has not changed over time 














Fig. 1. Trends in Renal Cancer Over Time, American Cancer Society, Facts & Figures,  
1997-2006 
In parallel with the impetus underlying the increased detection of renal neoplasms, the 
detection of benign renal lesions, defined chiefly as oncocytoma, angiomyolipoma, and 
simple renal cysts, has also increased.  In fact, a contemporary review of the Columbia 
University experience identified 775 patients with a tumor diameter of less than or equal to 
7.0 cm.  Of these patients the proportion of patients undergoing renal surgery for benign 
tumors increased annually: 5% before 1998, 15.2% from 1998-2003, and 21.2% from 2004 to 
2007.  The mean tumor diameter was found to decrease significantly during the study 
period (p=0.006) and year of surgery and tumor diameter were found to be independent 
predictors of benign histologic features (p<0.05).(Murphy et al., 2009) 
This combination of observations thus underscores the changing phenomenology of renal 
cortical lesions, as an increase in the use of cross-sectional imaging has resulted in a higher 
proportion of patients with incidentally detected small renal masses and in turn the clinical 
recognition of benign renal pathology.   
2.1 Renal cortical tumors: Heterogeneous presentations and oncologic implications 
Renal cortical tumors are members of a complex category of histologic entities which 
includes the benign oncocytoma, the indolent papillary and chromophobe carcinomas, and 
also the potentially aggressive clear cell carcinoma.  While published urological series 
consist predominantly of small, localized renal masses, approximately 90% of the medical 
oncology series reporting metastatic renal cancers consist of tumors of conventional clear 
cell histology.  In fact, a retrospective review by McKiernan et al featured 246 consecutive 
partial nephrectomy specimens, and characterized the relative distribution of histologic 
subtypes in small renal masses.(McKiernan et al., 2002b)  Within this series from Memorial 
Sloan Kettering Cancer Center, the most frequent finding was conventional clear cell 
carcinoma in 148 cases (51%), followed by papillary carcinoma in 54 (18%), oncocytoma in 
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The World Health Organization (WHO)/ Heidelberg classification subdivides renal cell 
tumors into benign and malignant neoplasms based on documented genetic 
abnormalities.(Kovacs et al., 1997)  In fact, studies focusing on sporadic and hereditary 
forms of renal cancer have suggested that abnormalities in the von Hippel-Lindau 
(chromosome 3p) and met genes are among the earliest alterations in conventional clear cell 
and papillary renal cancers, respectively.  Table 1 highlights the major chromosomal 
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Oncocytoma -1, -Y, 11q rearrangement  
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Table. 1. Genetic Findings in Renal Carcinoma Subtypes. Zambrano et al. J Urol 1999; 163 (4): 
1246-58 adapted by P. Russo, MD.  
Later work demonstrated that pathologic tumor diameter may be useful in the prediction of 
conventional subtype in small renal cortical lesions.  One retrospective review involved 393 
patients who underwent radical or partial nephrectomy at one institution; logistic regression 
analysis demonstrated that for every 1cm increase in tumor diameter up to 4cm, the renal 
cortical lesion was 1.27 times more likely to be conventional clear cell (p=0.020).(Laudano et 
al., 2008)  These findings were extrapolated to show that a 4cm renal cortical tumor was 
approximately 2 times more likely to be conventional clear cell than tumors 0.6-1.5cm in 
size. (Figure 2) 
3. Partial nephrectomy is the standard of care for small renal masses (T1a) 
Radical nephrectomy became the standard of care for renal cortical neoplasms approximately 
40 years ago. In the 1980s this approach was challenged by reports demonstrating favourable 
results of partial nephrectomy in imperative cases (i.e. cases in which nephron-sparing surgery 
was mandatory to conserve adequate renal function such as in patients with a solitary 
kidney).(Novick et al., 1989; Zincke et al., 1985)  During the last 10 years partial nephrectomy 
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Fig. 2. The percentage of conventional clear cell renal carcinomas based on largest tumor 
diameter (*rounded to the nearest cm). Laudano et al. BJU Int. 2008; 102 (10): 1385-8. 
has become the standard of care for the management of most small renal masses even in the 
presence of a normal contralateral kidney.(Becker et al., 2006b; Huang et al., 2006; Patard et 
al., 2004; Thompson et al., 2005)  In addition to the benefits of preserving renal function and 
preventing cardiovascular complications, topics discussed in detail in the ensuing sections, 
evidence strongly supports the notion that cancer control and risk of cancer-related death 
are not compromised when a partial nephrectomy is performed instead of a radical 
procedure.(Dash et al., 2006; Leibovich et al., 2004)  
Although data from the National Cancer Institute SEER program demonstrated that partial 
nephrectomy was underutilized at the beginning of this century (2000-2002), with only 20% 
of patients with tumors 2-4cm in size receiving this procedure, these rates are changing in 
favour of a nephron-sparing approach.(Hollenbeck et al., 2006; Miller et al., 2006)  In fact, a 
retrospective review of 1,533 patients treated with partial or radical nephrectomy between 
2000-2007 at Memorial Sloan Kettering Cancer Center reported that nephron-sparing 
surgery was performed in approximately 90% of patients with T1a tumors.(Thompson et al., 
2009)  A similar analysis at the national level is documented in Figure 3, demonstrating that 
the use of partial nephrectomy is increasing, albeit at a relatively modest rate, with 66% of 
patients presenting with a renal cortical tumor <2cm in size receiving a partial nephrectomy 
in 2007.    
3.1 Partial nephrectomy is increasingly being utilized in medium-sized tumors (T1b) 
The current size determination for renal tumors that forms the basis for the 2010 TNM 
staging classification was founded on the basis of several studies demonstrating improved 
survival in patients undergoing surgery for tumors less than 4cm as opposed to those that 
exceeded this dimension.(Gofrit et al., 2001; Hafez, Fergany, and Novick, 1999)  More 
contemporary analyses have shown that regardless of the form of surgical intervention, 
namely partial or radical nephrectomy, patients with tumors larger than 4cm have a higher 
risk of relapse.(Lau et al., 2000; Lesage et al., 2007; Margulis et al., 2007; Mitchell et al., 2006; 
Zini et al., 2009)  On the basis of these precedents, there has been a clear impetus to 
determine whether elective nephron-sparing surgery may be an option for patient with 
localized T1b (4-7cm) tumors.   
 




Fig. 3. The Current Standard of Care for the Treatment of Tumors <2cm based on 
Surveillance, Epidemiology, and End Results (SEER) estimates.  The use of PN steadily 
increased over the study period, from 27% of all cases in 1998 to 66% in 2007. Kates et al.  
J Uro 2011 IN PRESS. 
In fact, several antecedent investigations have indicated partial nephrectomy can safely be 
expanded to include patients with T1bN0M0 tumors.(Becker et al., 2006a; Kim et al., 2010; 
Mitchell et al., 2006; Patard et al., 2004)  Leibovich and colleagues reported cancer-specific 
survival rates at 5 years of 98% for those receiving nephron-sparing surgery and 86% for 
patients treated with radical nehrectomy; and, after adjusting for several covariates 
including tumor grade and histologic subtype, this difference was found to no longer be 
statistically significant (risk ratio 1.60, 95% CI 0.50-5.12, p=0.430).(Leibovich et al., 2004)  In a 
similar vein, Patard et al noted that 3 year disease-specific survival rates were comparable at 
98% and 97% (p=0.8) when partial nephrectomy patients were stratified by tumor size less 
than and greater than 4cm, respectively.(Patard et al., 2007)  Last, recent work has 
expounded upon these findings as it pertains to the laparoscopic management of T1bN0M0 
tumors, documenting comparable cancer-specific mortality (3% vs 3%) and recurrence rates 
RN 3% vs PN 6%, p-0.40) for both procedures over a median follow-up of 57 
months.(Simmons, Weight, and Gill, 2009)  These studies thus set the precedent that 
nephron-sparing surgery is a viable option form an oncologic standpoint in an 
appropriately selected subset of patients with a medium-sized tumors when treated at 
centers experienced with these techniques. 
Last, a subsequent investigation by Badalato et al. extended these findings regarding 
nephron-sparing surgery for T1b patients to the population level, utilizing data from the 
Surveillance, Epidemiology, and End Results (SEER) registry.(Badalato et al., 2011)  Using 
propensity scoring, a statistical test that controls for measured variables between partial and 
radical nephrectomy cohorts, this study determined that no overall survival difference was 
noted within a matched cohort of pT1bN0M0 patients treated with either surgical 
alternative. (Figure 4)  These findings thus lend support to the aforementioned growing 
 




Fig. 2. The percentage of conventional clear cell renal carcinomas based on largest tumor 
diameter (*rounded to the nearest cm). Laudano et al. BJU Int. 2008; 102 (10): 1385-8. 
has become the standard of care for the management of most small renal masses even in the 
presence of a normal contralateral kidney.(Becker et al., 2006b; Huang et al., 2006; Patard et 
al., 2004; Thompson et al., 2005)  In addition to the benefits of preserving renal function and 
preventing cardiovascular complications, topics discussed in detail in the ensuing sections, 
evidence strongly supports the notion that cancer control and risk of cancer-related death 
are not compromised when a partial nephrectomy is performed instead of a radical 
procedure.(Dash et al., 2006; Leibovich et al., 2004)  
Although data from the National Cancer Institute SEER program demonstrated that partial 
nephrectomy was underutilized at the beginning of this century (2000-2002), with only 20% 
of patients with tumors 2-4cm in size receiving this procedure, these rates are changing in 
favour of a nephron-sparing approach.(Hollenbeck et al., 2006; Miller et al., 2006)  In fact, a 
retrospective review of 1,533 patients treated with partial or radical nephrectomy between 
2000-2007 at Memorial Sloan Kettering Cancer Center reported that nephron-sparing 
surgery was performed in approximately 90% of patients with T1a tumors.(Thompson et al., 
2009)  A similar analysis at the national level is documented in Figure 3, demonstrating that 
the use of partial nephrectomy is increasing, albeit at a relatively modest rate, with 66% of 
patients presenting with a renal cortical tumor <2cm in size receiving a partial nephrectomy 
in 2007.    
3.1 Partial nephrectomy is increasingly being utilized in medium-sized tumors (T1b) 
The current size determination for renal tumors that forms the basis for the 2010 TNM 
staging classification was founded on the basis of several studies demonstrating improved 
survival in patients undergoing surgery for tumors less than 4cm as opposed to those that 
exceeded this dimension.(Gofrit et al., 2001; Hafez, Fergany, and Novick, 1999)  More 
contemporary analyses have shown that regardless of the form of surgical intervention, 
namely partial or radical nephrectomy, patients with tumors larger than 4cm have a higher 
risk of relapse.(Lau et al., 2000; Lesage et al., 2007; Margulis et al., 2007; Mitchell et al., 2006; 
Zini et al., 2009)  On the basis of these precedents, there has been a clear impetus to 
determine whether elective nephron-sparing surgery may be an option for patient with 
localized T1b (4-7cm) tumors.   
 




Fig. 3. The Current Standard of Care for the Treatment of Tumors <2cm based on 
Surveillance, Epidemiology, and End Results (SEER) estimates.  The use of PN steadily 
increased over the study period, from 27% of all cases in 1998 to 66% in 2007. Kates et al.  
J Uro 2011 IN PRESS. 
In fact, several antecedent investigations have indicated partial nephrectomy can safely be 
expanded to include patients with T1bN0M0 tumors.(Becker et al., 2006a; Kim et al., 2010; 
Mitchell et al., 2006; Patard et al., 2004)  Leibovich and colleagues reported cancer-specific 
survival rates at 5 years of 98% for those receiving nephron-sparing surgery and 86% for 
patients treated with radical nehrectomy; and, after adjusting for several covariates 
including tumor grade and histologic subtype, this difference was found to no longer be 
statistically significant (risk ratio 1.60, 95% CI 0.50-5.12, p=0.430).(Leibovich et al., 2004)  In a 
similar vein, Patard et al noted that 3 year disease-specific survival rates were comparable at 
98% and 97% (p=0.8) when partial nephrectomy patients were stratified by tumor size less 
than and greater than 4cm, respectively.(Patard et al., 2007)  Last, recent work has 
expounded upon these findings as it pertains to the laparoscopic management of T1bN0M0 
tumors, documenting comparable cancer-specific mortality (3% vs 3%) and recurrence rates 
RN 3% vs PN 6%, p-0.40) for both procedures over a median follow-up of 57 
months.(Simmons, Weight, and Gill, 2009)  These studies thus set the precedent that 
nephron-sparing surgery is a viable option form an oncologic standpoint in an 
appropriately selected subset of patients with a medium-sized tumors when treated at 
centers experienced with these techniques. 
Last, a subsequent investigation by Badalato et al. extended these findings regarding 
nephron-sparing surgery for T1b patients to the population level, utilizing data from the 
Surveillance, Epidemiology, and End Results (SEER) registry.(Badalato et al., 2011)  Using 
propensity scoring, a statistical test that controls for measured variables between partial and 
radical nephrectomy cohorts, this study determined that no overall survival difference was 
noted within a matched cohort of pT1bN0M0 patients treated with either surgical 
alternative. (Figure 4)  These findings thus lend support to the aforementioned growing 
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body of evidence that partial neprhectomy may become the preferred management 





Fig. 4. Overall survival in a propensity-matched cohort of SEER patients receiving partial 
versus radical nephrectomy.  For the entire cohort, there was no difference in survival when 
groups were divided based on surgical treatment.  Badalato et al. BJU Int. 2011 IN PRESS 
4. Renal tumor patients may have unrecognized medical renal disease before 
intervention 
Patients with renal tumors are not a screened population and tend to be older (mean age 61 
years) with cardiovascular comorbidities.  Accordingly, clinical and pathological evidence 
has shown that this population of patients has a greater degree of underlying renal disease 
than previously appreciated.(Bijol et al., 2006; Kaplan et al., 1975)  In fact, a retrospective 
cohort study of patients with small renal tumors by Huang et al. showed that 26% of their 
patients with T1a RCC and normally functioning kidneys had pre-existing chronic kidney 
disease (CKD), defined as GFR <60 mL/min per 173 m2. (Huang et al., 2006)    
The most common renal diseases found in patients with renal tumors are due to 
hypertension and diabetes.  Bijol and colleagues reported that up to 60% of nephrectomy 
specimens show features of renal disease, most of which are due to changes from 
hypertension or diabetes. (Bijol et al., 2006) Other causes of renal disease include smoking, 
glomerulonephritis, cystic kidney diseases, congenital malformations, immune diseases, 
obstruction, and infection. 
Moreover, many of the risk factors that are implicated in the pathogenesis of renal disease 
overlap with the risk factors that contribute to renal cell carcinoma.  For example, although 
the pathophysiologic mechanism for this relationship is still unclear, there is a progressive 
increase in the risk of renal cell carcinoma in correlation with worsening hypertension. 
(Chow, Dong, and Devesa, 2010; Schlehofer et al., 1996; Setiawan et al., 2007) With regard to 
diabetes, the pre-surgical incidence of this disease ranges from 6.8% to 23%. (Hepps and 
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Chernoff, 2006; Lindblad et al., 1999; Schlehofer et al., 1996) Since diabetic nephropathy 
affects approximately one-third of patients with this condition, it is reasonable to extrapolate 
that a significant proportion of patients diagnosed with a renal cortical tumor will have pre-
existing diabetic nephropathy.  Last, smoking is another well-known risk factor prevalent 
within the population that contributes to an increased risk for the development of both renal 
disease and renal cell carcinoma. (Ejerblad et al., 2004; Hunt et al., 2005) 
Recent evidence by Donin et al. also demonstrated renal tumor diameter independently 
predicted decreased preoperative estimated GFR when controlling for hypertension and 
race on multivariable analysis. (Donin et al., 2011)  This study thus suggests that the growth 
of a renal neoplasm and perhaps the replacement of healthy renal parenchyma 
independently modulates renal functional deterioration to some degree. 
Cumulatively, the presence of underlying renal disease in patients diagnosed with a renal 
cortical neoplasm is significant because renal function plays an important role in the surgical 
management and overall survival associated with management. Therefore, it remains 
prudent to be aware of the risk of underlying renal disease in patients with RCC. 
4.1 Chronic kidney disease poses and independent risk factor for cardiovascular-
related death 
Approximately 26 million adults in the United States have CKD.  CKD is most commonly 
seen among African-Americans, Hispanics, Pacific Islanders, Native Americans, and the 
elderly. The National Kidney Foundation, American Heart Association, and the Seventh 
Joint National Committee on prevention, Detection, Evaluation, and Treatment of High 
Blood Pressure deemed CKD as an independent risk factor for cardiovascular disease.(2002; 
Chobanian et al., 2003; Sarnak et al., 2003) Similarly, cardiovascular disease is the leading 
cause of morbidity and mortality among patients with CKD. 
The criteria for CKD is defined by The National Kidney Foundation - Kidney Disease 
Outcomes Quality Initiative (NKF-K/DOQI) workgroup (See Table 2). 
 
 
Table 2. Criteria for Definition of Chronic Kidney Disease. Am J Kidney Dis 2002 39  
(2 Suppl 1), S1-266. 
Many studies have provided evidence that renal damage, assessed by markers of renal 
function such as serum creatinine, GFR, and albuminuria, is an independent risk factor for 
cardiovascular disease and cardiovascular mortality.   
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In a study of 1,120,295 patients in the San Francisco Bay Area, Go and colleagues 
demonstrated a progressively increased risk of death and/or a cardiovascular event as renal 
function declined.  They reported that the adjusted risk of a cardiovascular event increased 
by 43% with an estimated GFR of 45 to 59 ml/minute/1.73 m2 (HR 1.4; CI 1.4-1.5) and by 
343% with an estimated GFR of less than 15 ml/minute/1.73 m2 (HR 3.43; CI 3.1-3.8).  The 
presence of proteinuria was also an independent factor that predicted the risk of a 
cardiovascular event (HR1.3; CI 1.2-1.3). (Go et al., 2004)  
Level I evidence from the Heart Outcomes Prevention Evaluation (HOPE) trial 
demonstrated that the presence of kidney disease, defined as an increased serum creatinine 
>1.4 mg/dL and/or microalbuminuria, independently increased the risk of cardiovascular 
death, myocardial infarction, or stroke (HR, 1.40; CI, 1.16-1.69 for serum creatinine) (HR 
1.59; CI 1.37- 1.84 for microalbuminuria).  Moreover, compared to patients with neither risk 
factor, patients with both increased serum creatinine and microalbuminuria were at 
increased risk of having a cardiovascular death or cardiovascular event (28.6% vs 13.6%); 
this suggests the additive nature of these risk factors. (Mann et al., 2001)  
Cumulatively, the findings from these and similar studies qualify CKD alone as a risk factor 
for cardiovascular disease. 
5. Partial nephrectomy preserves renal function 
Emerging evidence strongly favors partial nephrectomy (PN), as opposed to radical 
nephrectomy (RN), for tumors that are 7cm or smaller as the best approach to preserve 
postoperative renal functional outcomes.  The data in support of this position stemmed from 
early work examining the prevalence and onset of CKD among postoperative renal cancer 
patients.  Then, as now, there is not standardized metric of renal function, although some 
precise mechanisms of assaying such function have gradually permeated the urologic 
literature.  McKiernan et al published one of the early papers on this subject, selecting a 
cohort of 290 patients with T1a (<4cm) renal cell carcinoma and a pre-operative serum 
creatinine of less than 1.5mg/dl and then longitudinally tracking the onset of chronic renal 
insufficiency (defined in the study as creatinine >2mg/dl) following surgical 
intervention.(McKiernan et al., 2002a)  In fact, at 5 years of follow-up the rate of freedom 
from CRI was 100% in the partial nephrectomy grouping and 84.8% in the radical 
nephrectomy cohort.  Huang et al. Later validated these findings in a level 2 prospective 
study using eGFR of less than 60mL/min per 1.73m2 as the index defining CKD Stage III or 
greater.(Lane et al., 2010b)  In a total of 662 patients with a normal serum creatinine prior to 
surgery for RCC, freedom from new onset CKD was determined to be 80% after partial 
nephrectomy as opposed to just 35% following radical nephrectomy.(Huang et al., 2006) 
(Figure 5)  Moreover, after controlling for relevant clinical and pathological differences 
between surgical groups, patients receiving a radical nephrectomy were found to be a t a 
four-fold higher risk of having CKD post-operatively as compared to their counterparts 
undergoing nephron-sparing surgery.  These findings were substantiated in similar work 
using creatinine clearance as an alternative measure of renal function.(Clark et al., 2008)   
Despite controversy related to the best metric for renal functional outcomes in the 
perioperative setting, the fact that partial nephrectomy results in improved long-term renal 
function compared to radical nephrectomy has continued to be validated in the 
literature.(Jeon et al., 2009; Lane et al., 2010c; Malcolm et al., 2009; Miller et al., 2008)  In fact, 
although there was initially concern that vascular clamping at the renal hilum during partial 
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nephrectomy might increase the rate of renal insufficiency due to the prolonged cold 
ischemia time, clamp time was shown not to be associated with long-term renal functional 
measures in patients who had a normal renal function at baseline.  Yossepowitch et al. went 
on to demonstrate that in healthy patients with two renal units, renal insufficiency is 
primarily a transient, postoperative entity.(Yossepowitch et al., 2006)  While non-modifiable 
factors such as preoperative eGFR as well as the amount and quality of the renal 
parenchyma left in situ may be prognostic of postoperative renal function, there is no level 1 




Fig. 5. Probability of freedom from new onset of GFR lower than 45 mL/min per 1.72m2 by 
operation type. Huang et al. Lancet Oncol 2006; 7: 735-40.  
5.1 Poor renal functional outcomes following nephrectomy increases the risk of 
cardiovascular sequelae and death  
Several prior studies have demonstrated the increase in non-cancer related deaths among 
patients undergoing radical as opposed to partial nephrectomy.(Thompson et al., 2008; 
Weight et al., 2010b)  Although it has been postulated that this increase in mortality was 
attributable to an increased rate of CKD and by extension cardiovascular disease, this theory 
had not been proven prior to the publication of recent work.  In fact, Weight, Novick, and 
colleagues examined the overall and disease-specific survival outcomes in 1,004 patients 
with T1b RCC (4-7cm) who underwent either partial or radical nephrectomy.  Over a 
median follow-up period of 4 years, a significantly decreased level of real function was 
observed in the radical nephrectomy cohort.(Weight et al., 2010a)  Furthermore, this 
difference in renal function correlated with a 25% increase in the risk of cardiovascular 
death and a 17% risk of death from any cause.  In subsequent work, Huang et al 
corroborated the results of this single-institution study with a population-level investigation 
involving Medicare beneficiaries; they found that radical nephrectomy was associated with 
an increased risk of cardiovascular events and non-cancer mortality within this 
grouping.(Huang et al., 2009)  Table 1 summarizes data that continues to emerge in 
contemporary work, substantiating the worsened overall and cardiovascular survival 
associated with radical as compared to nephron-sparing surgery. (Table 2)  
 
Diseases of Renal Parenchyma 
 
142 
In a study of 1,120,295 patients in the San Francisco Bay Area, Go and colleagues 
demonstrated a progressively increased risk of death and/or a cardiovascular event as renal 
function declined.  They reported that the adjusted risk of a cardiovascular event increased 
by 43% with an estimated GFR of 45 to 59 ml/minute/1.73 m2 (HR 1.4; CI 1.4-1.5) and by 
343% with an estimated GFR of less than 15 ml/minute/1.73 m2 (HR 3.43; CI 3.1-3.8).  The 
presence of proteinuria was also an independent factor that predicted the risk of a 
cardiovascular event (HR1.3; CI 1.2-1.3). (Go et al., 2004)  
Level I evidence from the Heart Outcomes Prevention Evaluation (HOPE) trial 
demonstrated that the presence of kidney disease, defined as an increased serum creatinine 
>1.4 mg/dL and/or microalbuminuria, independently increased the risk of cardiovascular 
death, myocardial infarction, or stroke (HR, 1.40; CI, 1.16-1.69 for serum creatinine) (HR 
1.59; CI 1.37- 1.84 for microalbuminuria).  Moreover, compared to patients with neither risk 
factor, patients with both increased serum creatinine and microalbuminuria were at 
increased risk of having a cardiovascular death or cardiovascular event (28.6% vs 13.6%); 
this suggests the additive nature of these risk factors. (Mann et al., 2001)  
Cumulatively, the findings from these and similar studies qualify CKD alone as a risk factor 
for cardiovascular disease. 
5. Partial nephrectomy preserves renal function 
Emerging evidence strongly favors partial nephrectomy (PN), as opposed to radical 
nephrectomy (RN), for tumors that are 7cm or smaller as the best approach to preserve 
postoperative renal functional outcomes.  The data in support of this position stemmed from 
early work examining the prevalence and onset of CKD among postoperative renal cancer 
patients.  Then, as now, there is not standardized metric of renal function, although some 
precise mechanisms of assaying such function have gradually permeated the urologic 
literature.  McKiernan et al published one of the early papers on this subject, selecting a 
cohort of 290 patients with T1a (<4cm) renal cell carcinoma and a pre-operative serum 
creatinine of less than 1.5mg/dl and then longitudinally tracking the onset of chronic renal 
insufficiency (defined in the study as creatinine >2mg/dl) following surgical 
intervention.(McKiernan et al., 2002a)  In fact, at 5 years of follow-up the rate of freedom 
from CRI was 100% in the partial nephrectomy grouping and 84.8% in the radical 
nephrectomy cohort.  Huang et al. Later validated these findings in a level 2 prospective 
study using eGFR of less than 60mL/min per 1.73m2 as the index defining CKD Stage III or 
greater.(Lane et al., 2010b)  In a total of 662 patients with a normal serum creatinine prior to 
surgery for RCC, freedom from new onset CKD was determined to be 80% after partial 
nephrectomy as opposed to just 35% following radical nephrectomy.(Huang et al., 2006) 
(Figure 5)  Moreover, after controlling for relevant clinical and pathological differences 
between surgical groups, patients receiving a radical nephrectomy were found to be a t a 
four-fold higher risk of having CKD post-operatively as compared to their counterparts 
undergoing nephron-sparing surgery.  These findings were substantiated in similar work 
using creatinine clearance as an alternative measure of renal function.(Clark et al., 2008)   
Despite controversy related to the best metric for renal functional outcomes in the 
perioperative setting, the fact that partial nephrectomy results in improved long-term renal 
function compared to radical nephrectomy has continued to be validated in the 
literature.(Jeon et al., 2009; Lane et al., 2010c; Malcolm et al., 2009; Miller et al., 2008)  In fact, 
although there was initially concern that vascular clamping at the renal hilum during partial 
 
Renal Cortical Neoplasms and Associated Renal Functional Outcomes 
 
143 
nephrectomy might increase the rate of renal insufficiency due to the prolonged cold 
ischemia time, clamp time was shown not to be associated with long-term renal functional 
measures in patients who had a normal renal function at baseline.  Yossepowitch et al. went 
on to demonstrate that in healthy patients with two renal units, renal insufficiency is 
primarily a transient, postoperative entity.(Yossepowitch et al., 2006)  While non-modifiable 
factors such as preoperative eGFR as well as the amount and quality of the renal 
parenchyma left in situ may be prognostic of postoperative renal function, there is no level 1 




Fig. 5. Probability of freedom from new onset of GFR lower than 45 mL/min per 1.72m2 by 
operation type. Huang et al. Lancet Oncol 2006; 7: 735-40.  
5.1 Poor renal functional outcomes following nephrectomy increases the risk of 
cardiovascular sequelae and death  
Several prior studies have demonstrated the increase in non-cancer related deaths among 
patients undergoing radical as opposed to partial nephrectomy.(Thompson et al., 2008; 
Weight et al., 2010b)  Although it has been postulated that this increase in mortality was 
attributable to an increased rate of CKD and by extension cardiovascular disease, this theory 
had not been proven prior to the publication of recent work.  In fact, Weight, Novick, and 
colleagues examined the overall and disease-specific survival outcomes in 1,004 patients 
with T1b RCC (4-7cm) who underwent either partial or radical nephrectomy.  Over a 
median follow-up period of 4 years, a significantly decreased level of real function was 
observed in the radical nephrectomy cohort.(Weight et al., 2010a)  Furthermore, this 
difference in renal function correlated with a 25% increase in the risk of cardiovascular 
death and a 17% risk of death from any cause.  In subsequent work, Huang et al 
corroborated the results of this single-institution study with a population-level investigation 
involving Medicare beneficiaries; they found that radical nephrectomy was associated with 
an increased risk of cardiovascular events and non-cancer mortality within this 
grouping.(Huang et al., 2009)  Table 1 summarizes data that continues to emerge in 
contemporary work, substantiating the worsened overall and cardiovascular survival 
associated with radical as compared to nephron-sparing surgery. (Table 2)  
 
Diseases of Renal Parenchyma 
 
144 





Study Year Age 
Tumor 
Size RN PN HR HR 
Thompson [22] 2008 <65 ≤4cm 140 187 2.16 — 
Huang [25] 2009 >65 ≤4cm 2547 556 1.38 1.4 
Weight [24] 2010 — 4-7cm 480 525 1.17 1.25 
Weight [23] 2010 — ≤7cm 111 388 2.5 — 
Table 2. Open series outcomes: Overall and Cardiovascular Mortality.  Kates et al. Curr Opin 
Urol 2011 IN PRESS 
5.1.1 Partial nephrectomy is underutilized, within certain populations: case in point – 
the elderly 
In the seminal articles on post-nephrectomy renal function published by McKiernan et al. 
and Huang et al., most of the with decompensating function were diagnosed less than 3 
years following their initial surgery.(Huang et al., 2006; McKiernan et al., 2002a)  Thus the 
concept of “long-term” benefit from a nephron-sparing approach is a fallacy, as this 
advantage is noted within a few years following surgical intervention.  An older patient, 
albeit with a shorter life expectancy may thus benefit from a partial nephrectomy.  This 
finding is especially pertinent since it has already been demonstrated that the risk of 
complication from a partial nephrectomy is no greater for patients over 75 years of age as 
compared to younger counterparts.(Lowrance et al., 2010)  This understanding is especially 
important due to urologists’ hesitation to perform a nephron-sparing procedure in the 
elderly – cumulatively a historic disparity which is not substantiated by an evidence-based 
approach and has persisted to this decade.(Hollenbeck et al., 2006; Kates et al., 2011) (Figure 6) 
Recently, Lane and colleagues demonstrated that a decline in renal function associated with 
a radical procedure in patients 75 years of age and older resulted in a corresponding 
increase in the risk of cardiovascular death.(Lane et al., 2010a)  In a cohort of elderly patients 
with local renal cell cancer 7cm or less, there was no statistically significant difference in 
survival for those receiving surgery, namely radical or partial nephrectomy, as opposed to 
those on active surveillance.  This finding suggests that no surgery or the proverbial 
“maximal nephron-sparing procedure” may be indicated for a carefully selected subset of 
the elderly patient population. 
6. Preoperative risk stratification schemata 
Comprehensive pre-operative risk stratification is important for patients undergoing kidney 
surgery in order to help approximate the best renal functional outcomes.  Remarkably, 
recent estimates have reported that up to one-third of patients with pre-existing Stage I or II 
CKD will progress to Stage II (GFR<60).(Clark et al., 2011)  Accordingly, several risk factors 
for the post-operative development of stage III CKD have been well described; chief among 
them involves having a prior diagnosis of diabetes.(Lane et al., 2011)  Composite  
risk profiles have been well-elucidated to predict a patients’ risk of CKD based on 
preoperative clinical parameters.  One such method is the Screening for Occult Renal 
Disease (SCORED) tool, a modified example of which is demonstrated in figure 7.  This 
prediction tool utilizes factors such as patient age, gender, and clinical characteristics (such 
as anemia, proteinuria, and cardiovascular comorbidities) to stratify patient into risk  
 




Fig. 6. Percentage of patients receiving radical nephrectomy for T1a RCC between 1998-2007 
according to tumor size.  A higher percentage of elderly patients consistently receive a 
radical nephrectomy for a given tumor size.  Kates et al. Urology 2011 IN PRESS. 
 
 
Fig. 7. Risk assessment chart for CKD using the SCORED model from Bang et al. Arch Intern 
Med 167(4), 374-81. 
 
Diseases of Renal Parenchyma 
 
144 





Study Year Age 
Tumor 
Size RN PN HR HR 
Thompson [22] 2008 <65 ≤4cm 140 187 2.16 — 
Huang [25] 2009 >65 ≤4cm 2547 556 1.38 1.4 
Weight [24] 2010 — 4-7cm 480 525 1.17 1.25 
Weight [23] 2010 — ≤7cm 111 388 2.5 — 
Table 2. Open series outcomes: Overall and Cardiovascular Mortality.  Kates et al. Curr Opin 
Urol 2011 IN PRESS 
5.1.1 Partial nephrectomy is underutilized, within certain populations: case in point – 
the elderly 
In the seminal articles on post-nephrectomy renal function published by McKiernan et al. 
and Huang et al., most of the with decompensating function were diagnosed less than 3 
years following their initial surgery.(Huang et al., 2006; McKiernan et al., 2002a)  Thus the 
concept of “long-term” benefit from a nephron-sparing approach is a fallacy, as this 
advantage is noted within a few years following surgical intervention.  An older patient, 
albeit with a shorter life expectancy may thus benefit from a partial nephrectomy.  This 
finding is especially pertinent since it has already been demonstrated that the risk of 
complication from a partial nephrectomy is no greater for patients over 75 years of age as 
compared to younger counterparts.(Lowrance et al., 2010)  This understanding is especially 
important due to urologists’ hesitation to perform a nephron-sparing procedure in the 
elderly – cumulatively a historic disparity which is not substantiated by an evidence-based 
approach and has persisted to this decade.(Hollenbeck et al., 2006; Kates et al., 2011) (Figure 6) 
Recently, Lane and colleagues demonstrated that a decline in renal function associated with 
a radical procedure in patients 75 years of age and older resulted in a corresponding 
increase in the risk of cardiovascular death.(Lane et al., 2010a)  In a cohort of elderly patients 
with local renal cell cancer 7cm or less, there was no statistically significant difference in 
survival for those receiving surgery, namely radical or partial nephrectomy, as opposed to 
those on active surveillance.  This finding suggests that no surgery or the proverbial 
“maximal nephron-sparing procedure” may be indicated for a carefully selected subset of 
the elderly patient population. 
6. Preoperative risk stratification schemata 
Comprehensive pre-operative risk stratification is important for patients undergoing kidney 
surgery in order to help approximate the best renal functional outcomes.  Remarkably, 
recent estimates have reported that up to one-third of patients with pre-existing Stage I or II 
CKD will progress to Stage II (GFR<60).(Clark et al., 2011)  Accordingly, several risk factors 
for the post-operative development of stage III CKD have been well described; chief among 
them involves having a prior diagnosis of diabetes.(Lane et al., 2011)  Composite  
risk profiles have been well-elucidated to predict a patients’ risk of CKD based on 
preoperative clinical parameters.  One such method is the Screening for Occult Renal 
Disease (SCORED) tool, a modified example of which is demonstrated in figure 7.  This 
prediction tool utilizes factors such as patient age, gender, and clinical characteristics (such 
as anemia, proteinuria, and cardiovascular comorbidities) to stratify patient into risk  
 




Fig. 6. Percentage of patients receiving radical nephrectomy for T1a RCC between 1998-2007 
according to tumor size.  A higher percentage of elderly patients consistently receive a 
radical nephrectomy for a given tumor size.  Kates et al. Urology 2011 IN PRESS. 
 
 
Fig. 7. Risk assessment chart for CKD using the SCORED model from Bang et al. Arch Intern 
Med 167(4), 374-81. 
 
Diseases of Renal Parenchyma 
 
146 
groupings for the development of CKD.  During the course of validating this instrument in 
the setting of patients with small renal masses undergoing surgery, Lucas et al determined 
that patients in high risk categories (SCORED>4) were 3 times more likely to develop Stage 
III CKD.(Bang et al., 2007; Lucas et al., 2008)  Other groups have followed suit with the 
proposal of alternative nomograms.  For example, Sorbellini et al have described a 
mechanism to predict renal insufficiency, which was defined as 2 or more values of a 
creatinine of 2.0mf/dl at least one month following surgery.(Sorbellini et al., 2006)  
Nevertheless, while this nomogram accounts for the change in renal volume, it relies on 
creatinine and does not include known predictors of CKD such as preoperative comorbidity 
information.      
Other systems of risk stratification have looked at the renal parenchyma in and of itself as a 
tool for predicting postoperative outcomes.  Notably, the presence and extent of 
glomerolosclerosis in normal parenchyma has been shown to be commensurate with 
deterioration in postoperative renal function, although this trend was not noted for features 
such as arteriosclerosis or interstitial fibrosis/ tubular atrophy.(Gautam et al., 2010; McCann 
et al., 2009) 
7. Conclusion  
Among patients diagnosed with a renal cortical neoplasm, those having a radical 
nephrectomy are at an increased risk for the development of CKD compared to those 
receiving nephron-sparing surgery or no surgery.  In parallel with these findings, the 
implications of radical nephrectomy and CKD also translate into adverse cardiovascular 
events and eventual end stage renal disease.  Accordingly, in patients presenting with a 
renal cortical mass, a comprehensive assessment of current and projected renal function is 
paramount in determining preferred management options.  
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groupings for the development of CKD.  During the course of validating this instrument in 
the setting of patients with small renal masses undergoing surgery, Lucas et al determined 
that patients in high risk categories (SCORED>4) were 3 times more likely to develop Stage 
III CKD.(Bang et al., 2007; Lucas et al., 2008)  Other groups have followed suit with the 
proposal of alternative nomograms.  For example, Sorbellini et al have described a 
mechanism to predict renal insufficiency, which was defined as 2 or more values of a 
creatinine of 2.0mf/dl at least one month following surgery.(Sorbellini et al., 2006)  
Nevertheless, while this nomogram accounts for the change in renal volume, it relies on 
creatinine and does not include known predictors of CKD such as preoperative comorbidity 
information.      
Other systems of risk stratification have looked at the renal parenchyma in and of itself as a 
tool for predicting postoperative outcomes.  Notably, the presence and extent of 
glomerolosclerosis in normal parenchyma has been shown to be commensurate with 
deterioration in postoperative renal function, although this trend was not noted for features 
such as arteriosclerosis or interstitial fibrosis/ tubular atrophy.(Gautam et al., 2010; McCann 
et al., 2009) 
7. Conclusion  
Among patients diagnosed with a renal cortical neoplasm, those having a radical 
nephrectomy are at an increased risk for the development of CKD compared to those 
receiving nephron-sparing surgery or no surgery.  In parallel with these findings, the 
implications of radical nephrectomy and CKD also translate into adverse cardiovascular 
events and eventual end stage renal disease.  Accordingly, in patients presenting with a 
renal cortical mass, a comprehensive assessment of current and projected renal function is 
paramount in determining preferred management options.  
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Systemic Lupus Erythematosus (SLE) is a multi-systemic autoimmune disorder that can 
have severe and potentially life-threatening manifestations. One such manifestation is lupus 
nephritis. While survival rates have improved significantly, SLE, and in particular lupus 
nephritis, continues to be associated with significant morbidity and mortality.  
The incidence of SLE varies greatly among different populations. As a whole, rates are 
highest in non-Caucasians. Estimated incidence rates of SLE are similar in the US and in 
Europe where Caucasians have rates of 3.5-4 per 100,000 and those of African descent have 
significantly higher rates of 9.2-11.4 per 100,000.1,2 While the disease is present to a certain 
degree in all populations, SLE affects primarily women in their child-bearing years with a 
ratio of 9:1 compared to men.3,4 When men do present with SLE there is evidence that they 
have worse disease outcomes including increased mortality.5,6 Regardless of race or gender, 
mortality in SLE has improved significantly since the 1950’s, where the 5-year survival rate 
was approximately 50%.7 
Currently, 10-year survival rates range between 85% and 95%.7 Despite improved overall 
survival, lupus nephritis (seen in upwards of 60% of all SLE patients) continues to 
significantly affect morbidity and mortality.8 While 5-year survival for those without 
nephritis is approximately 92%, those with this complication have a much lower rate of 
82%.8 Both in the US and in Europe, non-Caucasians have increased rates of nephritis, where 
not only is the condition more prevalent in these groups, it also tends to be more severe.5,9 In 
the US, risk factors for progression to end-stage renal disease include: being African 
American, Hispanic, male, less than 24 years old and having high activity and chronicity on 
renal biopsy.10 Risk factors notwithstanding, it has been shown that patients that receive 
early treatment have better outcomes.11,12  
However, even with early and aggressive treatment, one study has found no change in the 
incidence of end-stage renal disease from lupus nephritis.13 Therefore, it appears that while 
medications are usually effective in controlling renal inflammation, a substantial amount of 
patients fail treatment. In addition, conventional therapies are not target-specific and can 
lead to significant toxicity. Therefore, given that B cells play such an integral role in the 
pathogenesis of SLE and lupus nephritis, these cells are potential targets for more specific 
therapies. 
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2. Pathogenesis of lupus 
The etiology of SLE and specifically lupus nephritis is multi-factorial involving 
environmental, genetic and hormonal factors to name a few. Loss of tolerance and 
interactions between the innate and adaptive immune system, as well as T cells and B cells, 
all play a role in the development of SLE and lupus nephritis.  
2.1 Genetics 
SLE is a genetically complex disease that generally does not exhibit straightforward 
mendelian modes of inheritance. In several cases, SLE is associated with rare but highly 
penetrant mutations: homozygous deficiencies of the complement components C1q, C2 or 
C4, complete FcγRIIIb deficiency, and mutations in the DNA exonuclease TREX1.14-17 
Genes in the human leukocyte antigen (HLA) region of the short arm of chromosome 6 
exhibit the strongest association with the risk of developing SLE. Graham et al. identified 
HLA class II haplotypes containing DRB1 and DQB1 alleles as strong risk factors for 
human disease.18 
In a majority of cases, however, SLE genetic susceptibility is probably determined by relatively 
common variants that are found throughout the population. Each only contributes modestly to 
the risk of disease; hence the finding of 34% concordance rate in monozygotic twins and 3% in 
dizygotic twins.19,20 Genome-wide association studies have found hundreds of single 
nucleotide polymorphisms associated with SLE. A recent meta-analysis shows a total of 17 
well-validated common SLE risk variants including: HLA-DR3, DR2, PTPN22 and STAT4. 
These variants account for a fraction of the total genetic contribution to SLE. Initial pathway 
analyses of these risk alleles indicate an important role for B cell development and signalling, 
signaling through toll-like receptors 7 and 9, and neutrophil function.21 
2.2 Role of B-cells in SLE 
B cells play a major role in the development of SLE, where loss of B cell tolerance is 
presumed to be the basis of disease. The most common alteration seen is B cell hyperactivity 
and subsequent autoantibody production. The presence of autoantibodies, particularly anti-
nuclear antibodies, anti-Smith and anti-double stranded DNA (anti-DNA) antibodies, form 
part of the diagnostic criteria for SLE. 
Immunoglobulin genes undergo rearrangement during B cell development in the bone 
marrow, where many autoreactive B cell receptors (BCR) are generated. In lupus patients, 
many, if not all of the checkpoints that eliminate autoreactive B cells are breached.22 SLE 
patients also exhibit high levels of B cell activating factor (BAFF), a survival factor that 
contributes to the survival of these autoreactive cells. There is also overexpression of 
CD40L on B cells which results in excessive T cell co-stimulation, another mechanism for 
the survival of autoreactive B cells.23,24 However, they not only generate autoantibodies; B 
cells also act as antigen presenting cells (APC’s) providing costimulatory signals necessary 
for T cell activation, differentiation and expansion. In addition, B cells also produce 
cytokines like IL-10, IL-16, TNF-α and INF-γ that influence other cells in the immune 
system.25 (Figure 1.) 
2.3 Toll like receptors in SLE 
Toll-like receptors (TLRs) play a key role in innate responses to infections. When bound by 
endogenous or exogenous ligands, they are involved in acute and chronic inflammatory  
 




Fig. 1. B cell Function in Immune Responses. 
Figure reproduced with permission from Nature Immunology and Bob Crimi, 2001;2:764-6 
processes. Numerous in vitro studies have established that TLR-7 and TLR-9 are involved in 
immune complex recognition. It is hypothesized that nucleic acid-containing immune 
complexes are engaged simultaneously by both the BCR and TLR.27 This engagement of 
TLR-7 or TLR-9 by an immune complex induces a MYD88-dependent pathway that 
activates inflammatory transcription factors, including IRF-7, NF-κB and AP-1. This leads to 
B cell and plasmacytoid dendritic cell (PDC) activation. The activation of PDC’s stimulates 
the inappropriate production of many cytokines, particularly type I IFN which is intimately 
involved in the pathogenesis of SLE.26 
How TLRs gain access to nuclear antigens in SLE can be explained by two mechanisms. 
The first suggests that pre-existing anti-Smith and anti-DNA antibodies form immune 
complexes with endogenous RNA and DNA, that are then taken up by APCs via Fc 
receptors. In endosomes, these complexes are degraded into nucleic acid components. 
These exposed nucleic acids then interact with TLR-7 or TLR-9 resulting in type I IFN 
production from PDC’s and B cell activation. Another model hypothesizes that type I IFN 
production is induced by TLR recognition of nucleic acids from aberrant degradation of 
apoptotic cells.29 Regardless of the mechanism of upregulation of type I IFN, once 
increased it induces upregulation of TLRs in B cells and subsequent maturation into IgG-
secreting plasma cells.30,31 
3. Pathogenesis of lupus nephrtitis 
The serologic hallmark of SLE is the presence of autoantibodies against nuclear antigens.3 
Several antibodies, such as anti-DNA and anti-nucleosome antibodies, are highly specific for 
the disease.3,32 There is evidence to suggest that they play a significant role in the 
pathogenesis of lupus nephritis. 
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While there are several different classes of lupus nephritis, what all have in common is renal 
deposition of antibodies, immune complexes and complement.10 Immunofloresence 
typically shows staining for various immunoglobulins, where IgG is predominant, in 
addition to C3 and C1q.33 Several mechanisms have been proposed to explain the presence 
of immune complex disposition in lupus nephritis. The first is that extra-renal immune 
complexes form and are subsequently deposited in the kidney. The second theory postulates 
that there is direct binding of autoantibodies to renal targets. Finally, there is also the 
possibility that autoantibodies bind to autoantigens that have previously been bound to the 
glomerulus. It is likely that all three of these mechanisms explain the pathogenesis of lupus 
renal disease to some degree.34  
The antibody that has most consistently been associated with lupus nephritis is anti-DNA 
antibody. These antibodies were the first to be found in both humans with lupus nephritis 
and animal models of the disease.35,36 They are implicated in all postulated mechanisms of 
disease; however the true extent of the pathogenicity of anti-DNA antibodies is unclear. SLE 
patients have a dysregulation in apoptosis with decreased clearance of apoptotic bodies that 
are released in the serum.37,38 These circulating apoptotic bodies, double-stranded DNA 
fragments and nucleosomes likely serve as autoantigen for autoreactive B cells.39 Exposure 
to these antigens, subsequently causes the generation of anti-nuclear antibodies such as anti-
DNA.40 It is possible that anti-DNA antibodies and the above antigens form complexes in 
the serum that then deposit in the kidney.  
While interesting, several researchers have not been able to confirm the presence of 
substantial amounts of DNA-anti-DNA complexes in the serum or that these complexes are 
formed extra-renally and are then significantly deposited in the kidneys.41,42 Immune 
complexes injected into normal mice can cause transient depositions in the glomeruli 
resulting in the activation of mesangial cells, but this is unlikely to cause disease.43 If extra-
renal immune complexes are involved in lupus nephritis, they likely amplify inflammation 
as opposed to initiating it. 
What may in fact happen is that DNA fragments and nucleosomes bind to proteins in the 
glomerular basement membrane. They then act as “planted antigens” to which previously 
formed anti-nuclear antibodies can bind.43,44 Collagen, fibronectin and laminin all have 
binding sites for DNA. In addition, DNA may bind to previously captured immune 
complexes and nucleosomes in the basement membrane. Anti-DNA antibodies can then 
bind, leading to in situ immune complex formation.33,39 
Finally, there is significant evidence to show that anti-DNA antibodies bind directly to 
glomerular basement membrane proteins. Alpha-actinin, laminin, collagen and heparan 
sulfate can all directly bind anti-DNA antibodies.45 The pathogenicity of these antibodies that 
bind to planted antigens on the basement membrane and/or directly to glomerular antigens is 
likely the same. Both can cause direct renal toxicity via complement fixation and via FcR 
expression on infiltrating leukocytes.43 Neutrophils, macrophages and renal parenchymal cells 
are subsequently activated releasing inflammatory mediators and upregulating adhesion 
molecules, subsequently recruiting more leukocytes into the kidney.46 
Despite the role that B cells play in lupus nephritis through the generation of auto-
antibodies, they also exert their influence through immunoglobulin independent 
mechanisms. Several experiments using MRL-lpr/lpr (MRL-lpr) mice show that in the 
setting of B cell deficiency, mice do not develop nephritis while those with altered 
antibody production continue on to develop disease. Also B cell deficient lupus mice fail 
to activate CD4 T cells.47 Therefore, B cells can participate in the pathogenesis of nephritis 
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by acting as highly-efficient APC’s thereby activating T cells.48 CD4 T cells are activated 
through the MHC II molecule/T cell receptor interaction as well as through CD40/CD40 
ligand co-stimulation. When these interactions are blocked, significant improvement in 
SLE disease activity is observed.49 B/T cell interactions lead to an amplification of the 
immune response where activated CD4 T cells activate macrophages and drive 
autoreactive B cells to undergo somatic hypermutation and affinity maturation.50  
With the increased understanding of the role of B cells in SLE, new therapies have been 
developed to specifically target this cell type. Over the course of the next few sections we 
will discuss the current, less selective, standard of care for the treatment of lupus nephritis 
and move on to novel, more specific B cell targeted therapies. 
4. Current immunosuppressive therapy in lupus nephritis 
Treating lupus nephritis involves an induction period of intensive immunosuppressive 
therapy aimed at halting disease progression. This is followed by a period of maintenance 
therapy to maintain the response. The treatment of lupus nephritis has undergone a 
dramatic change from steroids as initial therapy to immunosuppressive therapy like 
cyclophosphamide. 
Steroids were the mainstay of treatment of lupus and lupus nephritis in the early 1960’s but 
such an approach was often unable to control the progression to renal failure and was 
associated with significant morbidity and mortality.51 Felson et al. conducted a pooled 
analysis of all published clinical trials where prednisone alone, or prednisone plus 
cyclophosphamide or azathioprine was used. They showed that patients receiving 
immunosuppressive therapy had less renal deterioration, were less likely to have end-stage 
renal disease, and had better survival rates compared to patients receiving steroids alone. 
When cyclophosphamide and azathioprine were considered separately, both were 
associated with a 40% reduction in the rates of adverse renal outcomes.52 
4.1 Cyclophosphamide 
Cyclophosphamide (CYP), an alkylating and cytotoxic agent, depletes both T and B cells 
reducing the production of pathogenic autoantibodies. Since the publication of studies by 
Austin et al. and Boumpas et al., CYP has become a mainstay for the treatment of lupus 
nephritis. 
Patients with lupus nephritis enrolled in trials at the NIH between 1969 and 1981 were 
randomized into one of five treatment protocols: (1) high-dose prednisone; (2) azathioprine 
+ low-dose prednisone; (3) oral CYP + low-dose prednisone; (4) combined oral azathioprine 
and oral CYP; and (5) intravenous CYP + low-dose oral prednisone. This study showed that 
renal function was better preserved in patients receiving immunosuppressive therapy, but 
the difference was statistically significant only for the intravenous CYP plus low-dose 
prednisone group as compared to the high-dose prednisone group.53 Boumpas et al. later 
showed that an extended course of pulse CYP is more effective than 6 months of pulse 
methylprednisolone in preserving renal function in patients with severe nephritis. The 
addition of a quarterly intravenous CYP maintenance regimen to monthly pulses also 
reduced exacerbation rates.54 These and several other studies established the NIH protocol 
for the treatment of lupus nephritis. However, this protocol can lead to significant morbidity 
with complications such infertility, and an increased risk of severe infections. 
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In response to increased morbidity rates attributable to CYP, the Euro-Lupus Nephritis Trial 
was developed to test lower doses of intravenous CYP (500 mg every 2 weeks for a total of 6 
doses) against the typical NIH protocol for induction. Houssiau et al. found that there was no 
significant difference between the high dose and low dose patients in renal remission rates, or 
in developing recurrent renal flares or renal failure. Severe infection was more than twice as 
frequent in the high-dose group, though the difference was not statistically significant.55 Ten 
year follow up data shows that death, sustained doubling of serum creatinine and end-stage 
renal disease rates did not differ between the low-dose and high-dose group nor did mean 
serum creatinine, 24 h proteinuria and damage score at last follow-up.56 
4.2 Mycophenolate mofetil 
Mycophenolate mofetil (MMF), the prodrug of mycophenolic acid, inhibits inosine 
monophosphate dehydrogenase which then suppresses DNA synthesis and the proliferation 
of T and B cells. Inspired by MMF’s efficacy in preventing renal transplant rejection, 
investigators began to evaluate the drug’s use in lupus nephritis. Several small trials showed 
that MMF was comparable to CYP in the treatment of proliferative LN.57,58 Ginzler et al. 
conducted a 24-week randomized, open-label, non-inferiority trial comparing oral MMF 
with monthly intravenous CYP as induction therapy. They showed that MMF was more 
effective in inducing remission of lupus nephritis and had a better safety profile.59 
A study by Chan et al. showed that for the treatment of diffuse proliferative lupus nephritis, 
one year of MMF therapy was as effective as a six months of CYP followed by six months of 
azathioprine. The MMF regimen was also found to be less toxic.60 In the long-term extension 
trial, serum creatinine in both groups remained stable and comparable. Creatinine clearance 
increased in the MMF group, but the difference was not statistically significant. MMF 
treatment was also associated with fewer severe infections. This study showed that MMF 
constitutes an effective continuous induction and maintenance therapy for lupus nephritis.61 
Given the reassuring data for the use of MMF, the Aspreva Lupus Management Study 
(ALMS), a large multicenter, randomized clinical trial, was developed to determine if MMF 
was in fact better than CYP therapy. They found no difference in response rates when 
comparing MMF to CYP pulse + azathioprine for maintenance. However, MMF was noted 
to be better in Hispanic and African American patients. Over the course of the maintenance 
phase, there was a higher failure rate in the azathioprine group versus in the MMF group 
(32% v 16%) at 3 years.62  
Induction therapy with MMF is associated with fewer side effects than with CYP. MMF may 
be particularly suitable as induction therapy in women of child bearing age where there are 
less concerns for infertility as compared to CYP treatment. It also may work particularly well 
in African American and Hispanic patients, two groups with a large burden of disease. 
Nevertheless, while often better tolerated than CYP, MMF can cause significant morbidity. 
Many patients experience gastro-intestinal side effects such as diarrhea, nausea and vomiting. 
Patients treated with MMF are at risk for severe and possibly lethal infections, and are at a 
higher risk for the development of lymphoma and skin malignancies.Also, while MMF may 
not affect fertility, the drug had been associated with an increased risk of birth defects. 
4.3 Azathioprine 
Azathioprine (AZA) is used as a steroid sparing agent in patients with active SLE and as an 
alternative to CYP for maintenance therapy in lupus nephritis. It is a purine analog and 
inhibits nucleic acid synthesis thereby affecting both cellular and humoral immune function. 
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In 1975, Hahn et al. found that there was no significant effect of the addition of AZA to 
steroids for the early treatment of lupus nephritis.63 In 2006, Grootscholten et al. showed that 
CYP pulse therapy was superior to AZA plus methylprednisolone with regards to relapses 
and short-term infections but renal function at the last visit did not differ between the 2 
groups.64 Although the MAINTAIN nephritis trial showed that MMF was not inferior to 
AZA in maintaining remission, there were fewer renal flares in patients on MMF.65 
Therefore AZA remains an option for therapy, particularly during pregnancy when other 
medications are contraindicated. Nevertheless, CYP and MMF continue to be the preferred 
treatment modalities for lupus nephritis. 
5. B-cell targeted therapies 
5.1 Rituximab 
Rituximab (RTX) is a chimeric antibody directed against CD20, a cell surface protein 
expressed on certain B cell subsets but not plasma cells. The mechanisms by which it 
induces B cell depletion is likely through the induction of apoptosis as well as through cell 
mediated toxicity.66 Initially used in non-Hodgkin’s lymphoma, off-label use in lupus has 
shown potential efficacy in SLE and lupus nephritis.67, 68  
Looney et al. conducted one of the first trials investigating the role of RTX in SLE. Eighteen 
SLE patients were recruited into a phase I/II dose escalation trial, where 7 of 18 patients had 
nephritis. Although those on CYP at baseline were excluded, the cohort overall had 
moderately active disease at baseline. Of the 10 patients that successfully depleted their B 
cells, all experienced some disease improvement. The SLE manifestations that experienced 
the most improvement were: rashes, mucositis, arthritis and alopecia. The authors do not 
comment on the overall efficacy in the nephritis patients but do mention one patient with 
class IV nephritis that entered remission, with remission, with resolution of proliferative 
changes on repeat biopsy.69 
An open label trial was then conducted looking at the combination of CYP and RTX in the 
treatment of refractory SLE. Although 21 of 32 patients had lupus nephritis, the authors do 
not comment on these patients specifically. Overall, 12 remained disease free after one cycle 
of RTX. Global British Isles Lupus Assessment Group (BILAG) scores significantly improved 
at 6 months. Therefore we assume that the nephritis patients did well after RTX, given the 
entire group did well post treatment. However we do not know if they responded to the 
same magnitude as the non-nephritis patients.70  
Jonsdottir et al. showed decreased disease activity scores at 6 months in 16 patients treated 
with RTX combined with CYP and steroids for refractory SLE. Of these 16 patients, 9 had 
nephritis, where 8 of 9 had failed treatment with CYP prior to starting RTX. All of the 
nephritis patients had BILAG scores of A before being given RTX. Response in these 16 
patients was good. Five of 9 nephritis patients had BILAG renal scores of C or D at 6 
months.71 Other small trials showed similar efficacy in both treating lupus as well as lupus 
nephritis.72-74 
Nevertheless, the results from recent randomized control trials were not as promising. 
The 52-week Exploratory Phase II/III SLE Evaluation of Rituximab trial, (EXPLORER), 
tested the efficacy and safety of RTX plus immunosuppressive therapy versus placebo 
plus immunosuppressive therapy in patients with moderate to severe extra-renal SLE.75 
This study showed that overall, there was no difference between the two groups in terms 
of both the primary or secondary efficacy endpoints. In subgroup analyses, Africans 
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Americans and Hispanics (approximately one-third of the study population), who 
received RTX had significantly better rates of both major and partial responses compared 
to placebo.  
A second large trial, the LUpus Nephritis Assessment with Rituximab trial (LUNAR) was 
conducted to specifically look at the role RTX therapy in the treatment of class III/IV lupus 
nephritis. In this trial 144 patients on MMF and corticosteroids were randomized to either 
the addition of RTX or placebo. Although there were more renal responders in the RTX 
group (57% v 45.9%), the difference was not statistically significant. Again, though under-
powered to detect a difference, the African American group had a higher proportion of 
patients that responded to RTX versus placebo (70% v 45%).76 While there may be some 
benefit to the addition of RTX in African Americans, the medication overall does not seem to 
grant any additional benefit to current regimens. 
Despite the failure of RTX for SLE as well as lupus nephritis in randomized clinical trials, 
data from the French Autoimmunity and Rituximab registry shows that overall 80 of 113 
patients in the cohort responded to RTX therapy. Of those patients with renal disease, 74% 
showed at least a partial, if not complete response.67 At the Hôpital Necker in Paris, good 
results were reported at 22 months of follow-up in the treatment of nephritis patients with 
concomitant RTX where 60% had a renal response.77 Recently, Roccatello et al. found that a 
regimen of 4 doses of RTX with 2 intravenous pulses of CYP in eight patients with severe 
multi-organ SLE involvement, including nephritis, led to significant improvements in 
proteinuria at 3,6, and 12 months of follow-up.78 While the use of RTX as first-line treatment 
or in patients with a mild form of the disease is not recommended, its off-label use in severe, 
refractory SLE appears to be sufficiently positive to warrant its use. 
5.2 Epratuzumab 
Another potential B cell depleting agent is epratuzumab (EPR), a humanized recombinant 
monoclonal antibody that targets CD22. CD22 is a co-receptor of the BCR and is present 
throughout B cell maturation, disappearing from the cell surface once it develops into a 
plasma cell.79 CD22 has two functions on B cells: it is a negative regulator of BCR signaling 
and it also acts as an adhesion molecule for the homing of IgD B cells to the bone marrow.80, 81 
Although EPR appears to be cytotoxic to B cells, particularly CD27 negative cells, the 
depletion is not as pronounced as with RTX.82,83 Therefore, the mechanism of action may be 
through the modification of action of CD22.83,84 
Fourteen moderately active SLE patients were included in the initial clinical trial of EPR. It 
was infused intravenously every other week for 4 doses, while the patients continued on 
their baseline immunosuppression. Patients did well; where most decreased their BILAG 
score ≥50% at 6 weeks, and 38% had a sustained decrease at 18 weeks.82 Although only four 
nephritis patients were included in this initial study, 3 of the 4 did show some improvement 
in BILAG scores. 
Data from the phase IIb, EMBLEM trial, shows that EPR continues to be a promising 
regimen for moderate to severe SLE. A group of 227 patients were randomized to either 
placebo or one of several doses of EPR where the primary endpoint was the reduction of 
baseline BILAG scores. A cumulative dose of 2400 mg, either given as 600 mg weekly or 
1200 mg every other week, was associated with significant improvements in general BILAG 
scores over placebo.85 It remains to be seen what effect the drug will have on lupus nephritis 
given that the phase III, EMBODY trial excludes patients with active renal disease.86 
 




B cell activating factor (BAFF), also known as B-lymphocyte stimulator (BLyS), and its 
homologue APRIL (a proliferation-inducing ligand), are members of the TNF-superfamily 
critical in the development of B cells. They are both widely expressed by neutrophils, 
macrophages, monocytes and dendritic cells as well as B and T cells.87 BAFF binds to three 
receptors: BAFF-R, transmembrane activator and calcium modulator ligand interactor 
(TACI), and B cell maturation antigen (BCMA). Where BAFF-R only binds BAFF, APRIL can 
bind to both TACI and BCMA.87 These receptors are expressed at different times of B cell 
development. BAFF-R is expressed by all B cells with the exception of plasma cells in the 
bone marrow. TACI is expressed by naïve and activated B cells, as well as CD27-positive 
memory B cells, and plasma cells. BCMA is found on tonsillar memory cells, germinal center 
B cells and plasma cells.87 Binding of BAFF to its receptor promotes B cell survival and 
development, allowing for progression past the T1 stage into follicular and marginal zone 
cells.88,89 Binding of BAFF and APRIL to TACI and BCMA allows for further survival and 
progression to class switching and somatic hypermutation, although BAFF is not necessary 
for this to occur.90 For further details regarding the effects of BAFF on B cell biology, please 
refer to a recent review by Liu and Davidson.88 
BAFF as well as BAFF-R and TACI have been implicated in murine models of SLE and 
nephritis. NZB/NZW mice have increased levels of circulating BAFF with increased B and T 
cell activation as well as short and long lived plasma cells.91 Early inhibition of BAFF-R and 
TACI in these mice leads to improved mortality, decreased renal inflammation and 
decreased glomerular immune complex deposition.92 Young MRL-lpr mice treated early 
with anti-TACI-Ig did not develop anti-DNA antibodies while older mice treated after the 
onset of disease had improved anti-DNA antibody levels.93  
BAFF levels have been found to be elevated in patients with SLE compared to normal 
controls.94 Whereas serum protein levels may be variable in patients, serum BAFF mRNA 
levels are less so and correlate better with disease activity.95 Nevertheless, in a group of 245 
patients followed over the course of 2 years, serum BAFF levels were significantly correlated 
with both disease activity scores and anti-DNA antibodies. In multivariate analyses, changes 
in disease activity were associated with changes in BAFF levels.96 
There is data indicating that targeting B cell survival factors may be a potential treatment in 
lupus nephritis. Neusser et al. recently found on microdissected renal biopsies of lupus 
nephritis patients that BAFF and APRIL mRNA levels were significantly increased in the 
glomeruli of patients with class III and IV nephritis when compared to pre-transplant living 
donor kidneys. There was also increased tubulointerstitial expression of BAFF, APRIL, 
BCMA and TACI.97  
Since BAFF levels correlate with disease activity, belimumab was designed as a recombinant 
fully human antibody, with a high affinity to soluble BAFF. In a phase II, 52 week placebo-
controlled trial, 449 SLE patients were randomized to several doses of belimumab versus 
placebo. Although patients had moderate disease activity at entry, active nephritis patients 
were excluded from this trial. The medication was well tolerated; however, this study failed 
to meet its primary end points of reduction of disease activity scores and decreased time to 
flare at 24 weeks.  
However a significant amount of these patients (38.5%) were ANA negative at enrollment. 
In subgroups analyses, seropositive patients performed significantly better on belimumab 
than on placebo with regards to disease activity, physician’s global assessment (PGA), and 
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Americans and Hispanics (approximately one-third of the study population), who 
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Short Form-36 (SF-36) physical component score.98 There were also decreases in IgM levels 
as well as anti-DNA antibody titers, in addition to increased C4 levels in those on 
belimumab.92 
Two multi-national phase III trials were conducted in ANA positive, SLE patients with a 
similar study design to the phase II study. One trial followed patients for 52 weeks (BLISS-52) 
while the other for 76 weeks (BLISS-76). In both studies, all patients were seropositive for anti-
nuclear antibodies and had moderate to severe disease activity. Patients were randomized to 
either standard of care + placebo, standard of care + belimumab 1 mg/kg, or standard of care 
+ belimumab 10 mg/kg. Again, patients with active nephritis were excluded, and less than 
15% of the patients randomized had a history of nephritis. The primary end point was the 
response rate at 52 weeks, as measured by the SLE Responder Index (SRI).89,99 
In both studies a total of 1684 patients were randomized to the 3 groups. In the combined 
results for both BLISS-52 and BLISS-76, SRI was significantly improved by week 52; 
however, the difference when compared to placebo was modest: belimumab 1 mg/kg v 
placebo: 46.2% v 38.8%, belimumab 10 mg/kg v placebo: 50.6% v 38.8%. In both belimumab 
groups, there was significant improvement in the PGA compared to placebo, and time to 
flare was prolonged in both treatment groups. Moreover, belimumab-treated patients were 
able to modestly reduce their prednisone dose as compared to placebo. Further details are 
given in Table 1. 
Although there was significant improvement in the SRI in both treatment groups at 52 
weeks, the effect appeared to wane. In BLISS-76, the SRI at 76 weeks was no longer 
significantly different in the treatment groups compared to placebo.89,99,100 In subgroup 
analyses by organ system, there was improvement and/or less worsening in several 
systems; however, renal parameters did not show any significant changes. This was likely 
due to the fact that lupus nephritis patients were under-represented in these studies.101 
Despite the modest improvement in disease activity, belimumab is the first medication for 
SLE approved by the Food and Drug Administration in 50 years. It remains to be seen 
though what role this drug will play in the treatment of lupus nephritis given that active 
nephritis patients were excluded from these studies. There is also a possibility that patients 
of African descent do not respond as well to belimumab. These patients, in both BLISS 52 
and 76, had less efficacy as measured by SRI compared to placebo. It is possible though that 
these are spurious results given the small amount of patients of African descent that were 
recruited into the BLISS trials. Yet, these results are worrisome given that this population 
tends to have a worse prognosis with regards to SLE and lupus nephritis. 
5.4 Atacicept 
As noted, both BAFF and APRIL bind to the TACI receptor. To inhibit the action of both, a 
fully human fusion protein of the extracellular domain of TACI and the Fc portion of IgG was 
created as a potential therapy for SLE.102 Binding of BAFF and APRIL to TACI contributes to 
short-lived plasma cell survival, resulting in decreased IgM and IgA levels.103,104 In a phase I 
trial of atacicept in SLE patients, subcutaneous administration of the medication was well 
tolerated. As expected, IgM and IgA levels were reduced by approximately 50% and 33% 
respectively. Both mature and total B cells counts were also reduced.105 Pena-Rossi et al. 
found similar findings in their phase I trial investigating the safety of intravenous and 
subcutaneous preparations of atacicept versus placebo.106 In these phase I trials, atacicept 
was well tolerated and appeared to be effective in suppressing B cell function. Two trials are  
 















SRI at Week 52, n(%) 218 (38.8) 258 (46.2) <0.01 285 (50.6) <0.0001 
 SS≥4-point 
reduction (%) 230 (40.9) 269 (48.1) <0.01 297 (52.8) <0.05 
 ≤0.3-point PGA 
worsening (%) 372 (66.2) 424 (75.8) <0.001 420 (74.6) <0.01 
 No new 1A/2B 
BILAG (%) 389 (69.2) 429 (76.7) <0.01 425 (75.5) <0.05 
Mean % PGA 
improvement at week 
24 
24.3 28.8 ns 32.3 <0.01 
Mean % PGA 
improvement at week 
52 
27.1 36.7 <0.01 37.8 <0.001 
SFI flare 
%(HR)/median time to 
first flare, days 
81.5/84 74.6 (0.82)/110 <0.01 74.6 (0.84)/110 <0.05 
Severe SFI flare, %(HR) 23.7 17.0 (0.71) <0.05 15.6 (0.64) <0.01 
New 1A/2B BILAG,  
% (HR) 32.0 27.2 (0.83) ns 24.9 (0.75) <0.05 
New 1A BILAG,  




by 25% or to 
≤7.5mg/day, during 
weeks 40-52, n (%) 
39 (12.3) 67 (20.1) <0.01 58 (17.9) <0.05 
Prednisone dose 
increase from ≤7.5 to 
>7.5mg/day at week 
52, n (%) 
82 (33.6) 58 (25.8) ns 62 (25.9) ns 
SF-36 PCS change from 
baseline at week 52, 
mean (SD) 
+2.9 (0.3) +4.3 (0.4) <0.01 +3.8 (0.3) <0.05 
FACIT-fatigue score 
change from baseline at 
week 52, mean (SD) 
+2.5 (0.4) +4.8 (0.4) <0.001 +4.7 (0.4) <0.001 
Table 1. Combined Efficacy Results Of Bliss-52 And Bliss-76** 
Abbreviations: BLISS: Belimumab International SLE Study: SRI: Systemic Response Index: 
SS: SELENA-SLEDAI; PGA, Physician’s Global Assessment; HR, Hazard Ratio; SD: 
Standard Deviation; SFI: SS Flare Index; SF-36, Short Form-36; PCS, Physical Component 
Score; SOC: Standard of Care.  
**Table reprinted from Biologics: Target and Therapy, Volume 5, Thanou-Stavraki, Sawalha 
AH, “An Update on Belimumab for the Treatment of Lupus”, 2011 with permission from 
Dove Medical Press Ltd, and with additional permission from John Wiley and Sons. 
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currently underway to study the potential efficacy in the treatment of SLE. The first is a 
phase II/III trial in SLE patients with moderate disease activity; active nephritis patients are 
excluded from this study. However, a phase Ib trial in active lupus nephritis patients failing 
MMF treatment is currently recruiting patients.86  
6. Possible future therapies 
6.1 Abatacept 
Binding of CD28 on T cells to its ligand CD80/86 on APCs and activated B cells provides the 
major costimulatory activation signal to T cells. Endogenous CTLA-4 is an inhibitory 
molecule on previously activated T cells that binds CD80/86 with higher affinity than CD28. 
Abatacept, a fusion protein of the extracellular portion of CTLA-4 with the Fc portion of 
IgG, takes advantage of this and blocks the interaction of CD28 with CD80/86, blocking T 
cell activation.107  
Abatacept has been studied extensively in mouse models of lupus. Administration of CTLA-
4 Ig to female NZB/NZW lupus-prone mice prevented the development of autoantibody 
production and kidney disease resulting in prolonged survival.108 Administration of CTLA-
4 Ig also prevented the onset of disease in SLE-prone NZB/NZW F1 mice.109 Schiffer et al. 
showed that short-term administration of CTLA-4 Ig and CYP induced remission of 
nephritis in NZW/W mice with the resolution of proteinuria.110 Treatment with abatacept 
increased lifespan of mice treated with CTLA-4 Ig plus CYP compared with those treated 
with CYP alone.  
A phase IIb, multicenter, randomized, placebo controlled trial was conducted to evaluate 
the efficacy and safety of abatacept versus placebo for the treatment of SLE. This study 
included only patients with non-life threatening manifestations where the primary endpoint 
was a new BILAG flare A or B over 12 months. 118 patients were randomized to receive 
abatacept and 57 to receive placebo. The percentage of new BILAG A/B flares over 12 
months did not different significantly between the groups (79.7% in the abatacept group and 
82.5% in the placebo group). Consequently, this study failed to meet its primary endpoints. 
However, improvements in certain measures were noted in the study. At each visit 
throughout the trial, investigators were asked to state if the patient was experiencing a 
disease flare. By this measure, a difference in flare rates between the abatacept group 
(63.6%) and placebo group (82.5%) was noted.111 Adverse events were comparable in the 
abatacept and placebo groups but serious adverse events were higher in the abatacept 
group. 
Abatacept potentially has some efficacy in SLE and is being studied in two ongoing trials for 
the treatment of lupus nephritis, one in conjunction with MMF and the other in conjunction 
with CYP.86 
6.2 TLR inhibitors 
As previously mentioned, there are several studies that point to Toll-like receptors as 
possible contributors to the pathogenesis of SLE. While there are multiple TLRs, there are 
two that are of particular interest: TLR-7 that recognizes single stranded viral RNA and 
TLR-9 that recognizes bacterial hypomethylated DNA.112 These two TLRs are implicated in 
both the activation of B cells in murine models and SLE patients, as well as in the generation 
of type I IFN, which can in turn also upregulate B cells.112 
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TLR-9 recognizes hypomethylated CpG-oligodeoxynucleotides (CpG-ODN), a motif present 
in bacterial DNA which has been found to induce T cell independent activation of B cells as 
well as the activation of other APCs such as dendritic cells.113 Humans recognize foreign 
DNA as foreign because it is not methylated as is human DNA. SLE patients though have 
abnormalities in DNA methylation leading to segments of hypomethylated DNA.112 
Theoretically, when SLE patients release apoptotic bodies and create immune complexes 
with chromatin, they are exposing this hypomethylated DNA to TLR-9.112 This has been 
shown in vitro where immune complexes containing DNA and IgG were bound to 
autoreactive B cells and induced the activation of the cell through TLR-9.114 
Administration of CpG-ODN in several murine models of SLE is associated with worse 
disease activity. In MRL-lpr mice, CpG-ODN precipitated the progression to cresenteric 
nephritis and an increase in anti-DNA antibodies where TLR-9 localized to glomerular, 
tubulointerstitial and perivascular infiltrates.115,116 TLR-9 localizes to the proximal tubules in 
NZB x NZW mice and is associated with increased proteinuria and tubular fibrosis when 
stimulated with CpG DNA and serum from lupus patients.117  
In mononuclear cells of SLE patients with moderate disease activity, TLR-9 expression is 
higher than in those with inactive disease or healthy controls. The percentage of memory B 
cells and plasma cells expressing TLR-9 is higher in those with active disease and correlates 
with anti-DNA antibody titers.118, 119 When B cells from active SLE patients were cultured 
with CpG-ODN, not only was there increased expression of TLR-9 but there was also 
increased anti-DNA antibody production. 
In patients with lupus nephritis, TLR-9 and the other TLRs that bind nucleic acids (TLR-3, -
7, and -8) are expressed throughout the kidney: in the glomeruli, proximal and distal 
tubules as well as in the capillaries.120 In proliferative disease, TLR-9 expression co-localizes 
to areas with immune complex deposition, and is increased in those with higher disease 
activity on pathology and with increased serum anti-DNA antibodies.26 
Autoimmunity via TLR-7 seems to function in a manner analogous to that of TLR-9. The 
RNA associated Smith and RNP proteins are common targets for auto-antibodies in SLE 
patients. RNA bound to these proteins are bound to immune complexes by anti-RNP 
antibodies causing activation of B cells through BCR as well as TLR signaling.121 
Activation by late apoptotic thymocytes generates anti-DNA antibodies  
via TLR-7 in B6 mice. In the Yaa murine lupus model, where autoimmunity is caused  
by a duplication of TLR-7 gene, when the receptor is deleted there is an improvement in 
auto-antibody levels and glomerulonephritis.122 Although TLR-7 has not been as 
extensively studied in human disease, there is increased TLR-7 mRNA expression relative 
to healthy controls and it is correlated with type I IFN levels.119 In patients with lupus 
nephritis there is moderate TLR-7 expression in the distal tubules and in Bowman’s 
capsule.120 
Given the apparent role that TLRs play in SLE and the likely role they play in nephritis, TLR 
inhibitors are now being investigated as possible treatments for SLE. This is especially 
important in light of recent findings that glucocorticoids in murine lupus models fail to 
inhibit TLR signaling in plasmacytoid dendritic cells.123 This may partially explain why 
certain patients do not respond sufficiently to steroid therapy.  
Several synthetic inhibitory oligonucleotides (INH-ODN) have been generated with the goal 
of blocking the activation of TLR-9 and TLR-7.124,125 These INH-ODNs have proven to be 
effective in various mouse models. In NZB/NZW mice, treatment with an INH-ODN 
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abatacept and 57 to receive placebo. The percentage of new BILAG A/B flares over 12 
months did not different significantly between the groups (79.7% in the abatacept group and 
82.5% in the placebo group). Consequently, this study failed to meet its primary endpoints. 
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with CYP.86 
6.2 TLR inhibitors 
As previously mentioned, there are several studies that point to Toll-like receptors as 
possible contributors to the pathogenesis of SLE. While there are multiple TLRs, there are 
two that are of particular interest: TLR-7 that recognizes single stranded viral RNA and 
TLR-9 that recognizes bacterial hypomethylated DNA.112 These two TLRs are implicated in 
both the activation of B cells in murine models and SLE patients, as well as in the generation 
of type I IFN, which can in turn also upregulate B cells.112 
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TLR-9 recognizes hypomethylated CpG-oligodeoxynucleotides (CpG-ODN), a motif present 
in bacterial DNA which has been found to induce T cell independent activation of B cells as 
well as the activation of other APCs such as dendritic cells.113 Humans recognize foreign 
DNA as foreign because it is not methylated as is human DNA. SLE patients though have 
abnormalities in DNA methylation leading to segments of hypomethylated DNA.112 
Theoretically, when SLE patients release apoptotic bodies and create immune complexes 
with chromatin, they are exposing this hypomethylated DNA to TLR-9.112 This has been 
shown in vitro where immune complexes containing DNA and IgG were bound to 
autoreactive B cells and induced the activation of the cell through TLR-9.114 
Administration of CpG-ODN in several murine models of SLE is associated with worse 
disease activity. In MRL-lpr mice, CpG-ODN precipitated the progression to cresenteric 
nephritis and an increase in anti-DNA antibodies where TLR-9 localized to glomerular, 
tubulointerstitial and perivascular infiltrates.115,116 TLR-9 localizes to the proximal tubules in 
NZB x NZW mice and is associated with increased proteinuria and tubular fibrosis when 
stimulated with CpG DNA and serum from lupus patients.117  
In mononuclear cells of SLE patients with moderate disease activity, TLR-9 expression is 
higher than in those with inactive disease or healthy controls. The percentage of memory B 
cells and plasma cells expressing TLR-9 is higher in those with active disease and correlates 
with anti-DNA antibody titers.118, 119 When B cells from active SLE patients were cultured 
with CpG-ODN, not only was there increased expression of TLR-9 but there was also 
increased anti-DNA antibody production. 
In patients with lupus nephritis, TLR-9 and the other TLRs that bind nucleic acids (TLR-3, -
7, and -8) are expressed throughout the kidney: in the glomeruli, proximal and distal 
tubules as well as in the capillaries.120 In proliferative disease, TLR-9 expression co-localizes 
to areas with immune complex deposition, and is increased in those with higher disease 
activity on pathology and with increased serum anti-DNA antibodies.26 
Autoimmunity via TLR-7 seems to function in a manner analogous to that of TLR-9. The 
RNA associated Smith and RNP proteins are common targets for auto-antibodies in SLE 
patients. RNA bound to these proteins are bound to immune complexes by anti-RNP 
antibodies causing activation of B cells through BCR as well as TLR signaling.121 
Activation by late apoptotic thymocytes generates anti-DNA antibodies  
via TLR-7 in B6 mice. In the Yaa murine lupus model, where autoimmunity is caused  
by a duplication of TLR-7 gene, when the receptor is deleted there is an improvement in 
auto-antibody levels and glomerulonephritis.122 Although TLR-7 has not been as 
extensively studied in human disease, there is increased TLR-7 mRNA expression relative 
to healthy controls and it is correlated with type I IFN levels.119 In patients with lupus 
nephritis there is moderate TLR-7 expression in the distal tubules and in Bowman’s 
capsule.120 
Given the apparent role that TLRs play in SLE and the likely role they play in nephritis, TLR 
inhibitors are now being investigated as possible treatments for SLE. This is especially 
important in light of recent findings that glucocorticoids in murine lupus models fail to 
inhibit TLR signaling in plasmacytoid dendritic cells.123 This may partially explain why 
certain patients do not respond sufficiently to steroid therapy.  
Several synthetic inhibitory oligonucleotides (INH-ODN) have been generated with the goal 
of blocking the activation of TLR-9 and TLR-7.124,125 These INH-ODNs have proven to be 
effective in various mouse models. In NZB/NZW mice, treatment with an INH-ODN 
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expressing either a TTAGGG motif or GpG not only delays the signs of nephritis but leads 
to increased survival.126,127 Treatment of MRL-lpr mice with INH-ODNs that are specific  
for TLR-7 (IRS 661) and TLR-7 and -9 (IRS 954) leads to improvement of nephritis and in the 
case of IRS 661, reduced levels of anti-dsDNA antibodies, and anti-Smith antibodies.116,128 
NZBxNZW mice injected twice weekly with IRS 954 from age 4-9 months showed lower 
levels of autoantibodies as compared to controls as well reduced proteinuria and nephritis 
on pathology.129  
Lenert et al. recently developed restricted activity-INH-ODNs (R-INH-ODN). They 
modified several INH-ODN constructs so that they no longer formed configurations, such 
as the G4 stack, that may have non-specific immune properties. In vitro, R-INH-ODNs 
were found to be 10 to 30 fold less potent in murine and human B cells. However, when 
encountering autoreactive B cells in vivo, R-INH-ODN were more potent than broad 
acting-INH-ODN. MRL-lpr mice treated with R-INH-ODN showed less proteinuria, 
improved renal score, and decreased renal IgG deposits as well as decreased anti- 
DNA and anti-Smith antibodies. Therefore R-INH-ODN are potentially more effective 
than other INH-ODNs when the BCR is activated in conjunction with either TLR-7 or 
TLR-9.130 
Although promising, there are currently no clinical trials looking at the safety and efficacy of 
INH-ODNs in the treatment of SLE. It is unknown what role these potential medications 
will play with regards to current regimens, given that blocking TLRs may cause a 
significantly increased risk of infection. Only time will tell if these molecules will be 
developed further for potential use in humans. 
7. Conclusion 
Lupus nephritis causes significant morbidity and mortality. While current regimens have 
reduced the burden of disease, many patients continue on to end-stage renal disease 
despite treatment with aggressive immunosuppression. Given that B cells play such an 
integral role in nephritis through the generation of pathogenic autoantibodies and by 
acting as APCs, they are a natural target for therapy. Despite the fact that rituximab 
causes profound B cell depletion, two phase III clinical trials have failed to show 
increased efficacy in SLE. Epratuzumab, on the other hand, also causes some level of B 
cell depletion and may possibly modify the actions of CD22 on B cells. So far early trials 
are positive for this medication, however lacking nephritis specific data, it is difficult to 
say if epratuzumab will add significantly to current nephritis regimens.  
Belimumab, while showing modest efficacy for the treatment of SLE, has also not been 
tested in patients with active lupus nephritis. Now that it has been approved by the FDA, it 
will be important to follow reports of its use in active nephritis patients, and to conduct 
nephritis specific trials to evaluate its use in this population. Nevertheless, belimumab is an 
exciting addition to our anti-B cell armamentarium. 
Abatacept failed to meet primary endpoints in a phase IIb clinical trial. Despite this there is 
sufficient positive data that clinical trials in lupus nephritis are currently being conducted. 
Hopefully this medication proves to have significant efficacy in the nephritis population. 
Lastly, TLR inhibitors such as INH-ODNs, may eventually become an option for the 
treatment of lupus nephritis. Currently data is limited to mouse lupus models; however, 
studies are showing promise in that they limit the progression of renal disease in these 
animals. 
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Figure 2 summarizes some of the possible B cell directed therapies that can be used in lupus 
nephritis. All in all, while B cells seem to be a logical target for the treatment of lupus 
nephritis, the best way to target them remains elusive. Further studies and medication 
development will hopefully lead to an optimal treatment regimen where end-stage renal 
disease will become a rarely seen complication of nephritis.  
 
 
Fig. 2. Potential B cell Targeted Therapies for SLE and Lupus Nephritis.* 
Rituximab: Chimeric, anti-CD20 monoclonal antibody; Epratuzumab: Humanized anti-CD 
22 monoclonal antibody; Belimumab: Humanized monoclonal antibody targeting soluble 
BAFF; Atacicept: Recombinant fusion protein of the extracellular portion of the TACI 
receptor to the Fc portion of IgG targeting both soluble BAFF and soluble APRIL; Abatacept: 
Recombinant fusion protein of the extracellular portion of the CTLA-4 inhibitory molecule 
to the Fc portion of IgG targeting interaction of CD80/86 with CD28, inhibiting T cell co-
stimulation; INH-ODN: Synthetic oligonucleotides that inhibit Toll-like Receptors, 
particularly TLR-7 and TLR-9.  
*For the sake of simplicity BCMA, a receptor that also binds to both BAFF and APRIL, has 
been left off of the schematic. 
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1. Introduction 
Diabetes is a metabolic disorder characterised by chronic hyperglycaemia, hypertension, 
dyslipidaemia, microalbuminuria and inflammation. Moreover, there are a number of 
vascular complications associated with this condition including retinopathy, neuropathy 
and nephropathy. Diabetic nephropathy is the major cause of end-stage renal disease in 
Western societies affecting a substantial proportion (25-40%) of patients with diabetes. 
Diabetic nephropathy is defined as a progressive decline in glomerular filtration rate, 
accompanied by proteinuria and other end-organ complications such as retinopathy. 
It is widely accepted, that diabetic nephropathy is the product of hemodynamic and 
metabolic factors which act in concert and drive its development and progression. Metabolic 
factors include hyperglycaemia, hyperlipidaemia and advanced glycation. Hemodynamic 
factors include alterations in flow and pressure and the activation of the Renin-Angiotensin 
system (RAS). Together, the hemodynamic and metabolic factors activate common 
downstream signalling pathways, which potentiate the activation of target growth factors 
and signalling pathways which likely drive the development of DN. At present the most 
effective therapeutics for the treatment of DN target the renin-angiotensin system. 
Unfortunately, whilst they slow down the progression of DN they do not prevent it and 
thus novel therapeutics and potential targets required.  
In recent times the downstream intracellular signalling pathways and their modulators have 
been central focus for the investigation of novel therapeutic targets for the treatment of DN. 
These targets include advanced glycation end products (AGEs) and their receptors, glucose 
transport molecules, NFB, ROS, PKC, inflammatory molecules, including adipokines, 
chemokines, adhesion molecules and pro-inflammatory cytokines. Moreover, pro-fibrotic 
molecules , including EGF, VEGF, CTGF and arguably the most important, TGF-β, which 
are known to potentiate the morphological alterations associated with DN have also been 
targeted.  Recently, epigenetic alterations, including histone, DNA methylation, metabolic 
memory and microRNA’s have demonstrated their potential as novel therapeutic targets in 
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the area of DN. Importantly a number of these potential therapies are the focus of clinical 
trials or are in pre-clinical investigations.  
In summary this chapter will investigate the hemodynamic, metabolic and epigenetic factors 
which drive the development of diabetic nephropathy and their subsequent downstream 
signalling pathways. Importantly, we will discuss the limitations of current therapeutic 
strategies and development of novel therapeutic targets which are presently in either pre-
clinical experimental investigations or clinical trials. 
2. Diabetes 
Today, it is estimated that approximately 180 million individuals worldwide have diabetes 
and WHO predicts that this is likely to double by the year 2030. The incidence of diabetes is 
increasing across the board, irrespective of age, sex or ethnicity (Sowers and Stump 2004). 
Diabetes is a metabolic disorder characterised by chronic hyperglycaemia, and often co-
morbidities such as hypertension, dyslipidaemia and inflammation, with the major types 
being type 1 (insulin-dependant) or type 2 (commonly non-insulin dependant) (Sowers and 
Stump 2004; O'Connor and Schelling 2005). Both forms of diabetes are associated with 
micro- and macrovascular complications which include retinopathy, neuropathy, 
cardio/cerebrovascular disease and nephropathy which are the major cause of mortality 
and morbidity in diabetic patients (Cooper, Gilbert et al. 1998; Giacchetti, Sechi et al. 2005).   
3. Diabetic nephropathy 
Diabetic nephropathy is defined as a progressive decline in glomerular filtration rate, 
accompanied by proteinuria and other end-organ complications such as retinopathy 
(O'Connor and Schelling 2005). Diabetic nephropathy progresses to end-stage renal disease 
via a number of stages including normoalbuminuria, microalbuminuria/incipient diabetic 
nephropathy, macroalbuminuria and finally end-stage renal disease (Giacchetti, Sechi et al. 
2005; O'Connor and Schelling 2005). Progression to end stage renal disease is enhanced by 
hyperglycaemia, hypertension and proteinuria, which are all common in diabetes (Cooper 
1998; Mene, Festuccia et al. 2001; Marshall 2004; Wolf 2004). 
Renal disease in diabetic patients is characterised by hemodynamic (hyperfiltration and 
hyperperfusion) as well as structural abnormalities (glomerulosclerosis, alterations in 
tubulointerstitium including interstitial fibrosis) and metabolic changes (Cooper 2001). More 
importantly, it appears that all renal cell types are affected by hyperglycaemic injury 
including glomerular podocytes, mesangial and endothelial cells, tubular epithelial cells, 
interstial fibroblasts, and vascular endothelia (Kanwar, Wada et al. 2008). Within glomeruli, 
there is thickening of basement membranes, mesangial expansion and hypertrophy and 
glomerular epithelial cell (podocyte) loss (Bohlender, Franke et al. 2005). In conjunction, 
disease progression is also seen in the tubulointerstitial compartment causing expansion of 
tubular basement membranes, tubular atrophy, interstitial fibrosis and arteriosclerosis 
(Marshall 2004).   
To date, the most effective clinical treatments to prevent the progression of diabetic 
nephropathy are strict blood glucose control and anti-hypertensives (1998; 2002; 2003). 
Unfortunately, present therapies have failed to prevent new cases of diabetic nephropathy 
and progression as such novel therapeutic approaches are required. It is widely accepted 
that there metabolic, hemodynamic and genetic components of diabetic nephropathy. Novel 
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therapeutics which are either in pre-clinical or clinical investigations target these factors in 
the hope of achieving the ultimate goal, prevention of diabetic nephropathy.  
4. Potential therpeutic targets and approaches  
4.1 Modulating hemodynamic pathways  
Hyperfiltration, which presents as a marked increase in glomerular filtration rate, is widely 
recognised as being an early marker of diabetic nephropathy (Kanwar, Sun et al.; Anderson 
and Brenner 1988).  Elevations in intra-renal pressure or glomerular capillary pressure are 
thought to induce the development of hyperfiltration thus highlighting the importance of 
the hemodynamic pathways in DN. Furthermore, the UK prospective diabetes study in type 
2 diabetic patients, highlights the importance of hemodynamic influences in the 
development of DN. Diabetic subjects randomised to receive tighter blood pressure control, 
exhibited a concomitant reduction in microalbuminuria and clinical proteinuria (1998) To 
date the most effective treatments for both type 1 and type 2 diabetic patients to retard the 
progression of diabetic complications, are anti-hypertensives which target the renin-
angiotensin system (Lewis, Hunsicker et al. 1993; Brenner, Cooper et al. 2001).  
4.2 The Renin-Angiotensin System (RAS) 
The renin-angiotensin system (RAS) is a co-ordinated hormonal cascade, which modulates 
vasoconstriction and facilitates renal-sodium absorption to maintain blood pressure control. 
The RAS cascade is initiated by the production of renin, which is released from renal 
juxtaglomerular cells, and converts angiotensinogen to angiotensin I. Angiotensin I, an 
inactive hormone, is subsequently cleaved into Angiotensin II by angiotensin converting 
enzyme (ACE). Angiotensin II drives the RAS and elicits its effects by binding to cellular 
receptors, the Angiotensin II type I receptor (AT1) or angiotensin type 2 receptor type II 
(AT2). It was originally postulated that AT1 was the primary receptor and modulator of the 
actions of Ang II, however in recent years it has been widely accepted that AT1 and AT2 
elicit opposing actions upon ligand interaction with Ang II.  The RAS is known to exist both 
systemically and locally in a number of different organs throughout the body including 
kidney, and vasculature (Wiecek, Chudek et al. 2003; Wolf 2004). Activation of the local 
renal RAS appears to be independent of the systemic RAS. In diabetes, the local RAS has 
been found to be up-regulated, in particular within the kidney, whilst the systemic RAS 
appears to be down-regulated (Gilbert, Krum et al. 2003; Wiecek, Chudek et al. 2003; 
Schrijvers, De Vriese et al. 2004; Forbes, Fukami et al. 2007).  
To date the most effective treatments for diabetic nephropathy target the RAS. Whilst they 
slow down the progression of nephropathy, Clinical studies such as the RENAAL have 
demonstrated that these compounds do not prevent the relentless progression to end stage 
renal disease. 
4.3 The endothelin pathway 
The endothelin pathway has also been shown to be involved in the development and 
progression of diabetic nephropathy.  There are three recognised endothelin proteins: ET-1, 
ET-2 and ET-3, all of which share a high level of homology and have demonstrated 
localisation in a variety of cell types. These vasoactive proteins bind to their receptors ETA, 
ETB, and ETC.  ETA receptors have been shown to induce vasoconstriction and mitogenesis 
whilst ETB receptors has been shown to induce vasoconstriction and vasodilatation (Seo, 
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the area of DN. Importantly a number of these potential therapies are the focus of clinical 
trials or are in pre-clinical investigations.  
In summary this chapter will investigate the hemodynamic, metabolic and epigenetic factors 
which drive the development of diabetic nephropathy and their subsequent downstream 
signalling pathways. Importantly, we will discuss the limitations of current therapeutic 
strategies and development of novel therapeutic targets which are presently in either pre-
clinical experimental investigations or clinical trials. 
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3. Diabetic nephropathy 
Diabetic nephropathy is defined as a progressive decline in glomerular filtration rate, 
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including glomerular podocytes, mesangial and endothelial cells, tubular epithelial cells, 
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disease progression is also seen in the tubulointerstitial compartment causing expansion of 
tubular basement membranes, tubular atrophy, interstitial fibrosis and arteriosclerosis 
(Marshall 2004).   
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that there metabolic, hemodynamic and genetic components of diabetic nephropathy. Novel 
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the hope of achieving the ultimate goal, prevention of diabetic nephropathy.  
4. Potential therpeutic targets and approaches  
4.1 Modulating hemodynamic pathways  
Hyperfiltration, which presents as a marked increase in glomerular filtration rate, is widely 
recognised as being an early marker of diabetic nephropathy (Kanwar, Sun et al.; Anderson 
and Brenner 1988).  Elevations in intra-renal pressure or glomerular capillary pressure are 
thought to induce the development of hyperfiltration thus highlighting the importance of 
the hemodynamic pathways in DN. Furthermore, the UK prospective diabetes study in type 
2 diabetic patients, highlights the importance of hemodynamic influences in the 
development of DN. Diabetic subjects randomised to receive tighter blood pressure control, 
exhibited a concomitant reduction in microalbuminuria and clinical proteinuria (1998) To 
date the most effective treatments for both type 1 and type 2 diabetic patients to retard the 
progression of diabetic complications, are anti-hypertensives which target the renin-
angiotensin system (Lewis, Hunsicker et al. 1993; Brenner, Cooper et al. 2001).  
4.2 The Renin-Angiotensin System (RAS) 
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(AT2). It was originally postulated that AT1 was the primary receptor and modulator of the 
actions of Ang II, however in recent years it has been widely accepted that AT1 and AT2 
elicit opposing actions upon ligand interaction with Ang II.  The RAS is known to exist both 
systemically and locally in a number of different organs throughout the body including 
kidney, and vasculature (Wiecek, Chudek et al. 2003; Wolf 2004). Activation of the local 
renal RAS appears to be independent of the systemic RAS. In diabetes, the local RAS has 
been found to be up-regulated, in particular within the kidney, whilst the systemic RAS 
appears to be down-regulated (Gilbert, Krum et al. 2003; Wiecek, Chudek et al. 2003; 
Schrijvers, De Vriese et al. 2004; Forbes, Fukami et al. 2007).  
To date the most effective treatments for diabetic nephropathy target the RAS. Whilst they 
slow down the progression of nephropathy, Clinical studies such as the RENAAL have 
demonstrated that these compounds do not prevent the relentless progression to end stage 
renal disease. 
4.3 The endothelin pathway 
The endothelin pathway has also been shown to be involved in the development and 
progression of diabetic nephropathy.  There are three recognised endothelin proteins: ET-1, 
ET-2 and ET-3, all of which share a high level of homology and have demonstrated 
localisation in a variety of cell types. These vasoactive proteins bind to their receptors ETA, 
ETB, and ETC.  ETA receptors have been shown to induce vasoconstriction and mitogenesis 
whilst ETB receptors has been shown to induce vasoconstriction and vasodilatation (Seo, 
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Oemar et al. 1994; Roux, Breu et al. 1999; Candido and Allen 2002). Importantly, within the 
diabetic kidney, ET-1 has been found to be elevated and altered expression of the receptors 
has also been reported. In addition, modulation of this pathway through the employment of 
ET antagonists has been shown to reduce renal extracellular matrix (ECM) accumulation 
diabetic rats (Jandeleit-Dahm, Allen et al. 2000; Fukami, Cooper et al. 2005). Bosentan, an 
ETA and ETB receptor antagonist has demonstrated renoprotective benefits in the diabetic rat 
which was comparable to enalapril. Currently there are number of clinical trials examining 
the benefits of ET antagonists such as bosentan in diabetic nephropathy.   
5. Modulation of metabolic pathways 
5.1 Glycaemic control  
A range of metabolic abnormalities in addition to hyperglycaemia, are seen in the diabetic 
milieu. However, it is obvious from studies in diabetic patients, that an elevation in 
circulating glucose is the predominant metabolic abnormality and strict glycaemic control, 
remains the ideal therapeutic approach to halt the progression of complications (1998; 2002). 
As well as promoting the formation of AGEs, chronic hyperglycaemia is also associated with 
increased inflammation and expression of associated inflammatory cytokines, such as MCP-
1 (monocyte chemoattractant protein-1) (Dragomir, Tircol et al. 2006), and CTGF (connective 
tissue growth factor) (Makino, Mukoyama et al. 2003), elevated production of ROS (reactive 
oxygen species) and activation of a number of signalling pathways which are involved in 
diabetic nephropathy. At present glycaemic control is achieved through a number of 
approaches including improving insulin sensitivity via agents such as glitazones, increasing 
pancreatic insulin production with sulfonylureas and meglitinides, reducing hepatic glucose 
production with the administration of biguanides, limiting post-prandial glucose absorption 
with α-glucosidase inhibitors (Wagman and Nuss 2001; Fukami, Cooper et al. 2005). 
A novel approach to modulate post-prandial glucose absorption is via targeting glucagon-
like peptide-1 (GLP-1). GLP-1 is an incretin hormone which is known to stimulate insulin 
secretion, increase pro-insulin biosynthesis and improve pacreatic beta-cell viability. 
Recently it has been demonstrated that GLP-1 also posesses a number of extra pancreatic 
functions including anti-apoptotic and anti-inflammatory effects. The actions of GLP-1 are 
also modulated via an endogenous circulating enzyme DPP IV (dipeptidyl peptidase 
inhibitors). At present GLP-1 analogues and inhibitors of DPP-IV are under pre-clinical 
investigation for diabetic nephropathy. Specifically, administration of GLP-1 in an 
experimental model of type-1 diabetes exhibited renoprotective benefits independant of 
glucose control thus warrant further investigation (Kodera, Shikata et al.)  
5.2 Modulation of glucose uptake 
The initial step of glucose signalling it thought to be the translocation of glucose into the 
cells. Glucose uptake into renal cells is facilitated by various glucose transporters 
including SGLT2 (sodium-glucose transporter-2) , GLUT-1(glucose transporter -1) and 
GLUT-4 (glucose transporter-4). Hyperglycaemia is thought to induce an increase in 
expression and /or activity of these receptors which results in elevated intracellular 
glucose, which is one of the fundamental drivers for the development of diabetic 
nephropathy. One of the pathological outcomes of increased glucose transport is 
increased aldose reductase expression and up-regulation of PKC-MAPK (Protein kinase 
C- mitogen activated protein kinase) pathways which lead subsequent elevation in ECM 
(extracellular matrix) proteins such as collagen IV and fibronectin which are pivotal to the 
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development of fibrotic lesions associated with DN (Kanwar, Sun et al.). Moreover, TGF-β 
(Transforming growth factor-β) is known to promote GLUT-1(glucose transporter-1) 
expression and facilitate elevations in intracellular glucose (Fukami, Yamagishi et al. 
2007). Inhibitors of facilitative glucose transporter-2 (SGLT-2) (T-1095), have 
demonstrated potential as therapeutics for diabetic nephropathy in experimental models 
of type 1 diabetes. Administration of T-1095, a synthetic inhibitor of SGLT,  reduced 
plasma glucose and urinary AER and a concomitant decrease in gene expression GLUT-2 
(Fukami, Yamagishi et al. 2007). Thus targeting glucose transporters has exhibited 
renoprotective benefits and further investigation is warranted. 
5.3 Advanced glycation end-products  
AGEs are a heterogeneous and complex group of modifications, which play an important 
role in the development of diabetic nephropathy. They often present as a yellow-brown 
pigmentation, may be fluorescent and a number are primarily cross-links between proteins 
(Brownlee 1992; Brownlee 1995; Kalousova, Zima et al. 2004). AGEs are formed as a result of 
non-enzymatic biochemical reactions initiated as part of the Maillard Reaction. This reaction 
is a multi-step process, where a reactive carbonyl from glucose or its derivatives, are 
attached commonly to lysine and arginine residues on proteins, amino acids and nucleic 
acids (Njoroge and Monnier 1989; Ziyadeh, Cohen et al. 1997). Following further 
condensation, rearrangement and other reactions, the intermediate compounds of which 
some are “Schiff” bases and amadori products, are further irreversibly modified to become 
advanced glycation end products (AGEs) (Njoroge and Monnier 1989; Schrijvers, De Vriese 
et al. 2004). Physiologically, advanced glycation is thought to play an important role in the 
identification of senescent molecules, which are then subsequently cleaved and cleared, 
primarily via the kidneys (Jakus and Rietbrock 2004). 
Within the body, AGEs accumulate from both endogenous and exogenous sources. 
Intracellularly, AGEs are formed as a by-product of a number of important biochemical 
reactions including oxidation of glucose to glyoxal, decomposition of amadori products and 
the fragmentation of glyceraldehydes. The reactive intracellular intermediates formed 
during these reactions, such as methylglyoxal, react with the amino groups of both 
intracellular and extracellular proteins to form AGEs (Brownlee 1992; Bierhaus, Hofmann et 
al. 1998).  
AGEs may be broadly categorised on the basis of their action and function as either non-
cross-linking adducts and cross-linking adducts such as hydroimidazoles (Bohlender, 
Franke et al. 2005). Some of the best characterised AGEs to date, include N-
carboxymethyllysine (CML), N-carboxyethyllysine (CEL), pentosidine, imidazole, 
glyoxallysine dimer (GOLD) and pyrraline (Brownlee 1992; Schrijvers, De Vriese et al. 2004; 
Wolf 2004; Bohlender, Franke et al. 2005). In addition, there are a number of exogenous 
sources of AGEs identified in recent times, including food and tobacco smoke, which also 
contribute to the body’s AGE pool (Cerami, Founds et al. 1997; Koschinsky, He et al. 1997).  
Under normal physiological conditions, AGEs are cleared from the body via the kidney, 
following their degradation by reductase enzymes within cells such as macrophages. The 
kidney via a multi-step process, filters AGE modified-peptides and proteins. Following 
filtration via the glomeruli, they are subsequently reabsorbed by the proximal tubules where 
they are often further degraded and then excreted into the urine (Kalousova, Zima et al. 
2004). In homeostasis, the rate of renal AGE removal is proportional to creatinine clearance, 
ensuring that there is no excess accumulation of tissue AGEs.  
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Oemar et al. 1994; Roux, Breu et al. 1999; Candido and Allen 2002). Importantly, within the 
diabetic kidney, ET-1 has been found to be elevated and altered expression of the receptors 
has also been reported. In addition, modulation of this pathway through the employment of 
ET antagonists has been shown to reduce renal extracellular matrix (ECM) accumulation 
diabetic rats (Jandeleit-Dahm, Allen et al. 2000; Fukami, Cooper et al. 2005). Bosentan, an 
ETA and ETB receptor antagonist has demonstrated renoprotective benefits in the diabetic rat 
which was comparable to enalapril. Currently there are number of clinical trials examining 
the benefits of ET antagonists such as bosentan in diabetic nephropathy.   
5. Modulation of metabolic pathways 
5.1 Glycaemic control  
A range of metabolic abnormalities in addition to hyperglycaemia, are seen in the diabetic 
milieu. However, it is obvious from studies in diabetic patients, that an elevation in 
circulating glucose is the predominant metabolic abnormality and strict glycaemic control, 
remains the ideal therapeutic approach to halt the progression of complications (1998; 2002). 
As well as promoting the formation of AGEs, chronic hyperglycaemia is also associated with 
increased inflammation and expression of associated inflammatory cytokines, such as MCP-
1 (monocyte chemoattractant protein-1) (Dragomir, Tircol et al. 2006), and CTGF (connective 
tissue growth factor) (Makino, Mukoyama et al. 2003), elevated production of ROS (reactive 
oxygen species) and activation of a number of signalling pathways which are involved in 
diabetic nephropathy. At present glycaemic control is achieved through a number of 
approaches including improving insulin sensitivity via agents such as glitazones, increasing 
pancreatic insulin production with sulfonylureas and meglitinides, reducing hepatic glucose 
production with the administration of biguanides, limiting post-prandial glucose absorption 
with α-glucosidase inhibitors (Wagman and Nuss 2001; Fukami, Cooper et al. 2005). 
A novel approach to modulate post-prandial glucose absorption is via targeting glucagon-
like peptide-1 (GLP-1). GLP-1 is an incretin hormone which is known to stimulate insulin 
secretion, increase pro-insulin biosynthesis and improve pacreatic beta-cell viability. 
Recently it has been demonstrated that GLP-1 also posesses a number of extra pancreatic 
functions including anti-apoptotic and anti-inflammatory effects. The actions of GLP-1 are 
also modulated via an endogenous circulating enzyme DPP IV (dipeptidyl peptidase 
inhibitors). At present GLP-1 analogues and inhibitors of DPP-IV are under pre-clinical 
investigation for diabetic nephropathy. Specifically, administration of GLP-1 in an 
experimental model of type-1 diabetes exhibited renoprotective benefits independant of 
glucose control thus warrant further investigation (Kodera, Shikata et al.)  
5.2 Modulation of glucose uptake 
The initial step of glucose signalling it thought to be the translocation of glucose into the 
cells. Glucose uptake into renal cells is facilitated by various glucose transporters 
including SGLT2 (sodium-glucose transporter-2) , GLUT-1(glucose transporter -1) and 
GLUT-4 (glucose transporter-4). Hyperglycaemia is thought to induce an increase in 
expression and /or activity of these receptors which results in elevated intracellular 
glucose, which is one of the fundamental drivers for the development of diabetic 
nephropathy. One of the pathological outcomes of increased glucose transport is 
increased aldose reductase expression and up-regulation of PKC-MAPK (Protein kinase 
C- mitogen activated protein kinase) pathways which lead subsequent elevation in ECM 
(extracellular matrix) proteins such as collagen IV and fibronectin which are pivotal to the 
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development of fibrotic lesions associated with DN (Kanwar, Sun et al.). Moreover, TGF-β 
(Transforming growth factor-β) is known to promote GLUT-1(glucose transporter-1) 
expression and facilitate elevations in intracellular glucose (Fukami, Yamagishi et al. 
2007). Inhibitors of facilitative glucose transporter-2 (SGLT-2) (T-1095), have 
demonstrated potential as therapeutics for diabetic nephropathy in experimental models 
of type 1 diabetes. Administration of T-1095, a synthetic inhibitor of SGLT,  reduced 
plasma glucose and urinary AER and a concomitant decrease in gene expression GLUT-2 
(Fukami, Yamagishi et al. 2007). Thus targeting glucose transporters has exhibited 
renoprotective benefits and further investigation is warranted. 
5.3 Advanced glycation end-products  
AGEs are a heterogeneous and complex group of modifications, which play an important 
role in the development of diabetic nephropathy. They often present as a yellow-brown 
pigmentation, may be fluorescent and a number are primarily cross-links between proteins 
(Brownlee 1992; Brownlee 1995; Kalousova, Zima et al. 2004). AGEs are formed as a result of 
non-enzymatic biochemical reactions initiated as part of the Maillard Reaction. This reaction 
is a multi-step process, where a reactive carbonyl from glucose or its derivatives, are 
attached commonly to lysine and arginine residues on proteins, amino acids and nucleic 
acids (Njoroge and Monnier 1989; Ziyadeh, Cohen et al. 1997). Following further 
condensation, rearrangement and other reactions, the intermediate compounds of which 
some are “Schiff” bases and amadori products, are further irreversibly modified to become 
advanced glycation end products (AGEs) (Njoroge and Monnier 1989; Schrijvers, De Vriese 
et al. 2004). Physiologically, advanced glycation is thought to play an important role in the 
identification of senescent molecules, which are then subsequently cleaved and cleared, 
primarily via the kidneys (Jakus and Rietbrock 2004). 
Within the body, AGEs accumulate from both endogenous and exogenous sources. 
Intracellularly, AGEs are formed as a by-product of a number of important biochemical 
reactions including oxidation of glucose to glyoxal, decomposition of amadori products and 
the fragmentation of glyceraldehydes. The reactive intracellular intermediates formed 
during these reactions, such as methylglyoxal, react with the amino groups of both 
intracellular and extracellular proteins to form AGEs (Brownlee 1992; Bierhaus, Hofmann et 
al. 1998).  
AGEs may be broadly categorised on the basis of their action and function as either non-
cross-linking adducts and cross-linking adducts such as hydroimidazoles (Bohlender, 
Franke et al. 2005). Some of the best characterised AGEs to date, include N-
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glyoxallysine dimer (GOLD) and pyrraline (Brownlee 1992; Schrijvers, De Vriese et al. 2004; 
Wolf 2004; Bohlender, Franke et al. 2005). In addition, there are a number of exogenous 
sources of AGEs identified in recent times, including food and tobacco smoke, which also 
contribute to the body’s AGE pool (Cerami, Founds et al. 1997; Koschinsky, He et al. 1997).  
Under normal physiological conditions, AGEs are cleared from the body via the kidney, 
following their degradation by reductase enzymes within cells such as macrophages. The 
kidney via a multi-step process, filters AGE modified-peptides and proteins. Following 
filtration via the glomeruli, they are subsequently reabsorbed by the proximal tubules where 
they are often further degraded and then excreted into the urine (Kalousova, Zima et al. 
2004). In homeostasis, the rate of renal AGE removal is proportional to creatinine clearance, 
ensuring that there is no excess accumulation of tissue AGEs.  
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In metabolic disorders, such as diabetes, there is a marked increase in a number of factors 
which promote the formation and accumulation of AGEs within various susceptible 
organs, in particular, the kidney. As a direct result of the hyperglycaemia characteristic of 
diabetes, there is marked increase in both carbonyl and oxidative stress, which each 
promote in vivo AGE accumulation (Miyata, Haneda et al. 1996; Miyata and van Ypersele 
de Strihou 2003).   
Excessive AGE accumulation can elicit a variety of deleterious effects on tissues and organs. 
These include altering the structure and function of both intracellular and extracellular 
molecules, increasing oxidative stress, modulation of cell activation, enhancement of signal 
transduction pathways and increasing the activation and expression of cytokines and 
growth factors. These actions have been shown to be mediated via both receptor dependant 
and independent mechanisms (Brownlee 1995; Schrijvers, De Vriese et al. 2004 Circulating 
levels of AGEs in diabetic patients are elevated with decreased renal function {Kubba, 2003 
#916). Furthermore, AGE accumulation in tissues correlate with the severity of organ injury, 
particularly within glomerular lesions (Shimoike, Inoguchi et al. 2000; Kanauchi, Nishioka et 
al. 2001).  
Dietary AGEs, are also thought to contribute to the development of diabetic nephropathy. 
Diets low in AGE content, when fed to non-obese diabetic mice (type 1) and db/db mice 
(type 2) reduced glomerular lesions, creatinine/albumin ratios and renal TGF1 expression 
when compared to their high AGE counterparts (Zheng, He et al. 2002). Moreover, diets 
high in AGE content are known to impair insulin sensitivity further confounding 
downstream complications (Hofmann, Dong et al. 2002). Harcourt et al, have recently 
demonstrated the benefits of low AGE diets on kidney function in pre-diabetic, obese 
individuals. Diets low in AGE content elicited improvements in renal function and 
reduction in inflammation (Harcourt, Sourris et al.). Various agents, including LR-90 
(Figarola, Scott et al. 2003), aminoguanidine (Youssef, Nguyen et al. 1999), and ALT-711 
(Forbes, Thallas et al. 2003) are potent in reducing AGE accumulation in renal tissues in 
experimental diabetic nephropathy, subsequently improving renal function. Many other 
agents have elicited similar benefits and have been extensively reviewed previously 
(Alderson, Chachich et al. 2004; Williams and Tuttle 2005; Williams 2006). In addition, 
pyridoxamine, an intermediate of vitamin B6, attenuated the progression of human diabetic 
nephropathy and concurrently reduced AGE and urinary TGF-β(Williams, Bolton et al. 
2007). Furthermore, benfotiamine (liposoluble vitamin B1 derivative), decreases AGE 
accumulation, inflammation and improves vascular function in type 2 diabetic patients 
consuming diets high in AGE content (Stirban, Negrean et al. 2006). To date there have been 
three clinical trials conducted which employed AGE-lowering therapies . Aminoguanidine 
and benfotiamine trials were stopped due to toxicity of the therapy. The third trial 
employed Alagaebrium in type 1 diabetic patients in addition to an ACE-inhibitor. This trial 
has now ended and results are pending.   
5.4 AGE-receptors  
The receptors for AGE are important modulators of the deleterious effects of these 
compounds. Receptors for AGEs may be loosely grouped as either inflammatory (RAGE, 
AGE-R2) or clearance type receptors (AGE-R1, AGE-R3, CD36, Scr-II, FEEL-1 and FEEL-2) 
(Vlassara and Bucala 1996; Vlassara 1997; Singh, Barden et al. 2001; Forbes, Yee et al. 2004; 
Schrijvers, De Vriese et al. 2004; Alikhani, Alikhani et al. 2005). Vascular, renal, neuronal and 
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haematopoietic cells are all known to express receptors for AGEs (Goldin, Beckman et al. 
2006; Sourris and Forbes 2009) AGEs contribute to the pathogenesis of diabetic nephropathy 
via receptor mediated mechanisms and indirectly via the generation of reactive oxygen 
species and by altering extracellular matrix (ECM) integrity.  
Diabetes alters the expression of a number of AGE-receptors thought to drive the 
development and progression of diabetic nephropathy, in particular, the expression of 
RAGE on cells such as podocytes and tubular epithelial cells (Soulis, Thallas et al. 1997; 
Wendt, Tanji et al. 2003; Gu, Hagiwara et al. 2006; Li, Nakamura et al. 2006).  
Another AGE receptor postulated to be involved in the development of diabetic 
nephropathy is AGE-R1, although converse to RAGE this is likely via a decrease in 
expression. In an experimental model of type 1 diabetes, renal AGE-R1 expression is 
reduced in association with a concurrent increase in AGE deposition and progression to 
diabetic nephropathy (He, Zheng et al. 2000; Vlassara 2001). In addition, we recently 
reported that in a small cohort of type 2 diabetic patients we found a positive correlation 
with AGE-R1 expression on the cell surface of peripheral blood mononuclear cells and renal 
function. We found that this was the most predictive biomarker for renal function and 
further investigation in a larger cohort is required {Sourris, #9145}.  
The contribution of AGE-R3 to the development and progression of diabetic nephropathy 
has not been extensively researched. However, AGE-induced increases in the expression of 
AGE-R3 has been demonstrated in cultured endothelial cells and within renal tissues in the 
diabetic milieu (Iacobini, Oddi et al. 2005; Kumar, Narang et al. 2006). This however, may 
indicate a protective role for AGE-R3 given that AGE-R3 deficient mice develop more severe 
renal disease and have marked increases in renal AGE deposition (Iacobini, Oddi et al. 
2005). Furthermore, AGE-R3 deficient mice develop albuminuria, mesangial expansion and 
fibrosis within the kidney cortex which is more pronounced with diabetes. Importantly, the 
deletion of AGE-R3 was also associated with a decrease in AGE-R1 and increased 
expression of RAGE demonstrating the existence of AGE-receptor cross talk. This study 
highlights that the role of AGE-R3 in the clearance of AGEs (Pugliese, Pricci et al. 2000) is 
likely more important in diabetic nephropathy than its ability to modulate immune 
function. The modulation of AGEs and their receptors have been extensively reviewed 
previously (Sourris and Forbes 2009). 
6. Hyperlipidaemia 
Hyperlipidaemia is a comorbidity often seen in diabetic patients and is thought to be an 
important contributor to progressive micro and macrovascular complications. This is most 
clearly demonstrated by the renoprotection which is seemingly afforded with HMG CoA 
reductase inhibitors (Tonolo, Ciccarese et al. 1997; Fujii, Inoguchi et al. 2007; Matsumoto, 
Tanimoto et al. 2008). Obesity is one the leading factors which drive the development of 
type 2 diabetes and its complications such as nephropathy. Moreover, it has also been 
shown to lead to kidney disease in the absence of diabetes. As one of the leading causes of 
chronic kidney disease, the WHO has recommended that lifestyle changes such as dietary 
and exercise are the most cost-effective approaches to combating this epidemic. We have 
recently reported the benefits of dietary intervention and renal function in a obese, non-
diabetic population (Harcourt, Sourris et al.). 
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In metabolic disorders, such as diabetes, there is a marked increase in a number of factors 
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organs, in particular, the kidney. As a direct result of the hyperglycaemia characteristic of 
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haematopoietic cells are all known to express receptors for AGEs (Goldin, Beckman et al. 
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with AGE-R1 expression on the cell surface of peripheral blood mononuclear cells and renal 
function. We found that this was the most predictive biomarker for renal function and 
further investigation in a larger cohort is required {Sourris, #9145}.  
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renal disease and have marked increases in renal AGE deposition (Iacobini, Oddi et al. 
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important contributor to progressive micro and macrovascular complications. This is most 
clearly demonstrated by the renoprotection which is seemingly afforded with HMG CoA 
reductase inhibitors (Tonolo, Ciccarese et al. 1997; Fujii, Inoguchi et al. 2007; Matsumoto, 
Tanimoto et al. 2008). Obesity is one the leading factors which drive the development of 
type 2 diabetes and its complications such as nephropathy. Moreover, it has also been 
shown to lead to kidney disease in the absence of diabetes. As one of the leading causes of 
chronic kidney disease, the WHO has recommended that lifestyle changes such as dietary 
and exercise are the most cost-effective approaches to combating this epidemic. We have 
recently reported the benefits of dietary intervention and renal function in a obese, non-
diabetic population (Harcourt, Sourris et al.). 
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7. Reactive oxygen species 
Reactive oxygen species are important intermediates in the formation of AGEs and are often 
excessively generated in the kidney in diabetes (Forbes, Coughlan et al. 2008). In addition, 
concomitant dysregulation of anti-oxidant enzymes in diabetes, leads to a state of oxidative 
stress (Forbes, Coughlan et al. 2008). To date, it is unclear as to why exogenous 
administration of antioxidants per se has demonstrated such poor renoprotection in humans, 
despite exciting positive preclinical research findings. However, it seems evident that 
therapies such as vitamins may not be the ideal antioxidant strategy in human DN. Vitamin 
B6 derivatives (Hammes, Du et al. 2003; Endo, Nishiyama et al. 2007), metformin (Rahbar, 
Natarajan et al. 2000), OPB-9195 (Wada, Nishizawa et al. 2001; Mizutani, Ikeda et al. 2002), 
ACEi (Miyata, van Ypersele de Strihou et al. 2002; Coughlan, Thallas-Bonke et al. 2007), AT1 
antagonists (Miyata, van Ypersele de Strihou et al. 2002), ALA (Coughlan, Thallas-Bonke et 
al. 2007) and sRAGE (Wautier, Zoukourian et al. 1996) have exhibited beneficial effects on 
excess superoxide generation within tissues, associated with improvements in the 
development and/or progression of diabetic complications.  
Vitamin B-related therapeutics are effective scavengers of ROS intermediates. Pyridoxamine, 
inhibits superoxide radical generation, as well as preventing the progression of neuropathy 
and retinopathy (Jain and Lim 2001). In addition benfotiamine and thiamine, Vitamin B1 
derivatives, have shown beneficial effects in normalising ROS production and reducing the 
activity of aldose reductase (Berrone, Beltramo et al. 2006). Paradoxically, thiamine 
administered to human with diabetic renal disease actually worsened renal function 
(Rabbani, Alam et al. 2009). The role of ROS in diabetic kidney disease has been extensively 
reviewed previously (Forbes, Coughlan et al. 2008).  
8. Inhibition of protein kinase C (PKC) activity  
There has been a growing body of evidence suggesting the central role of PKC, which is 
broadly involved in signal transduction from the plasma membrane to the nucleus, in 
diabetes induced vascular dysfunction (Inoguchi, Battan et al. 1992; Xia, Inoguchi et al. 
1994). PKC has 11 different isoforms, many of which have been shown to be involved in 
diabetic complications, in particular nephropathy. (Koya, Jirousek et al. 1997; Koya, Haneda 
et al. 2000; Meier, Park et al. 2003).  Of the 11 isoforms, PKC-α, -β, -δ, -ε, -ξ are expressed 
within the kidney (Kanwar, Sun et al.) PKC pathway is known to be activated by many 
factors including:  Elevations in diacylglycerol, hydrogen peroxide, increased activity of 
polyol pathway, mitochondrial superoxide activity (Geraldes and King) and following AGE-
RAGE interactions (Kanwar, Sun et al.). PKC isoforms have been associated with many 
cellular and vascular alterations and processes including: endothelial dysfunction, 
angiogenesis, vascular permeability, cell growth and apoptosis, basement membrane 
thickening, extracellular matrix (ECM) expansion. PKC pathway is known to be activation 
of numerous cellular pathways including NADH, ROS, Na+/K+ ATPase , Endothelin (ET-1), 
Ang II, MAPK and phospolipase A2 and VEGF (Geraldes and King; Kanwar, Sun et al.).  
We have recently reported the attenuation of PKC-α phosphorylation and translocation with 
ALA in both in vivo models of DN and in vitro studies (Thallas-Bonke, Lindschau et al. 2004).  
It remains to be determined if this action of alagebrium on PKCα phosphorylation partly 
explains its renoprotective actions. Modulation of PKC activity within the diabetic kidney 
has also been exhibited by various vitamin B derivatives (Babaei-Jadidi, Karachalias et al. 
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2003; Hammes, Du et al. 2003). Interestingly, both ACEi and aminoguanidine prevent 
diabetes associated increases in PKC  activation in renal glomeruli (Osicka, Yu et al. 2000).  
The effects of aminoguanidine and ACEi on PKC  activity were also observed at other sites 
of vascular injury including the retina and mesenteric vascular bed (Osicka, Kiriazis et al. 
2001; Miyata, van Ypersele de Strihou et al. 2002). In addition, AT-1 receptor antagonists, 
also attenuate diabetes induced increases in PKC -epsilon activity within the diabetic heart 
(Malhotra, Reich et al. 1997). Furthermore, modulation of PKC has been demonstrated in 
vascular endothelial cells with the insulin sensitizing agent metformin (Isoda, Young et al. 
2006) and the anti-thrombotic therapeutic, aspirin (Dragomir, Manduteanu et al. 2004). We 
have demonstrated that in our experimental models of diabetes translocation of PKC α to 
the membrane is associated with parallel increases in superoxide production and elevated 
urinary VEGF thus highlighting the importance of this pathway in DN. In the clinical 
setting, roboxistaurin, is a PKC inhibitor which Tuttle et al, demonstrated that 32mg/day in 
addition to an ACEi for 12 months reduced urinary ACR (Geraldes and King). Moreover, 
renal biopsies from diabetic patients exhibited almost 10-fold increase in PKC  gene 
expression compared to their control (Geraldes and King; Langham, Kelly et al. 2008).  In 
addition, the importance of PCK isoforms has been demonstrated in experimental models of 
diabetic nephropathy. PCK-α and β knockout mice exhibited a high level of resistance to the 
development of diabetic renal disease (Meier, Park et al. 2007; Meier, Menne et al. 2009; 
Tossidou, Starker et al. 2009).  
9. Nuclear transcription factor kappa-B (NF-B) 
NF-B is a transcription factor composed of two subunits, the most common of which are 
the p50 and p65 subunits (Barnes and Larin 1997) which are thought to be important 
modulators of diabetic complications. The active p65 subunit in particular, is thought to be 
central in the activation of numerous genes including cytokines, adhesion molecules, NO 
synthase, angiotensinogen and many other inflammatory and proliferative proteins 
implicated in the process of diabetic nephropathy (Barnes and Larin 1997; Bierhaus, 
Schiekofer et al. 2001). NF-B is activated by a range of stimuli including glucose (Pieper 
and Riazulhaq 1997) and ROS (Nishikawa, Edelstein et al. 2000). AGEs are also involved in 
activation of NF-B via a RAGE-dependent pathway leading to its translocation to the 
nucleus where it induces transcription of target genes such as IL-6 and TNF-α (Yan, Schmidt 
et al. 1994). The diverse actions of NF-κB and the capacity of various factors such as AII and 
AGEs to activate this transcription factor (Ruiz-Ortega, Lorenzo et al. 2000; Ruiz-Ortega, 
Lorenzo et al. 2000), are consistent with NF-B playing a pivotal role in the pathogenesis of 
diabetic complications. 
Pyrrolidine dithiocarbamate (PDTC) is a NF-B inhibitor which has been used in both 
diabetic (Lee, Cao et al. 2004) and non-diabetic animal models of renal disease where it is 
renoprotective (Rangan, Wang et al. 1999), although its toxicity does not allow for direct 
translation to the clinical setting. Indeed, our group has demonstrated the importance of NF-
B in the pathogenesis of early renal macrophage infiltration in experimental diabetes, 
which could be modulated by interruption of the RAS (Lee, Cao et al. 2004; Liu, Wei et al. 
2006). Moreover, diabetes-induced increases in NF-B activation are prevented by 
numerous therapeutics including Metformin (Isoda, Young et al. 2006) aspirin (Zheng, 
Howell et al. 2007) Vitamin B derivatives (Hammes, Du et al. 2003) carnosine (Odashima, 
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(Rabbani, Alam et al. 2009). The role of ROS in diabetic kidney disease has been extensively 
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diabetes induced vascular dysfunction (Inoguchi, Battan et al. 1992; Xia, Inoguchi et al. 
1994). PKC has 11 different isoforms, many of which have been shown to be involved in 
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RAGE interactions (Kanwar, Sun et al.). PKC isoforms have been associated with many 
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Ang II, MAPK and phospolipase A2 and VEGF (Geraldes and King; Kanwar, Sun et al.).  
We have recently reported the attenuation of PKC-α phosphorylation and translocation with 
ALA in both in vivo models of DN and in vitro studies (Thallas-Bonke, Lindschau et al. 2004).  
It remains to be determined if this action of alagebrium on PKCα phosphorylation partly 
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has also been exhibited by various vitamin B derivatives (Babaei-Jadidi, Karachalias et al. 
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2003; Hammes, Du et al. 2003). Interestingly, both ACEi and aminoguanidine prevent 
diabetes associated increases in PKC  activation in renal glomeruli (Osicka, Yu et al. 2000).  
The effects of aminoguanidine and ACEi on PKC  activity were also observed at other sites 
of vascular injury including the retina and mesenteric vascular bed (Osicka, Kiriazis et al. 
2001; Miyata, van Ypersele de Strihou et al. 2002). In addition, AT-1 receptor antagonists, 
also attenuate diabetes induced increases in PKC -epsilon activity within the diabetic heart 
(Malhotra, Reich et al. 1997). Furthermore, modulation of PKC has been demonstrated in 
vascular endothelial cells with the insulin sensitizing agent metformin (Isoda, Young et al. 
2006) and the anti-thrombotic therapeutic, aspirin (Dragomir, Manduteanu et al. 2004). We 
have demonstrated that in our experimental models of diabetes translocation of PKC α to 
the membrane is associated with parallel increases in superoxide production and elevated 
urinary VEGF thus highlighting the importance of this pathway in DN. In the clinical 
setting, roboxistaurin, is a PKC inhibitor which Tuttle et al, demonstrated that 32mg/day in 
addition to an ACEi for 12 months reduced urinary ACR (Geraldes and King). Moreover, 
renal biopsies from diabetic patients exhibited almost 10-fold increase in PKC  gene 
expression compared to their control (Geraldes and King; Langham, Kelly et al. 2008).  In 
addition, the importance of PCK isoforms has been demonstrated in experimental models of 
diabetic nephropathy. PCK-α and β knockout mice exhibited a high level of resistance to the 
development of diabetic renal disease (Meier, Park et al. 2007; Meier, Menne et al. 2009; 
Tossidou, Starker et al. 2009).  
9. Nuclear transcription factor kappa-B (NF-B) 
NF-B is a transcription factor composed of two subunits, the most common of which are 
the p50 and p65 subunits (Barnes and Larin 1997) which are thought to be important 
modulators of diabetic complications. The active p65 subunit in particular, is thought to be 
central in the activation of numerous genes including cytokines, adhesion molecules, NO 
synthase, angiotensinogen and many other inflammatory and proliferative proteins 
implicated in the process of diabetic nephropathy (Barnes and Larin 1997; Bierhaus, 
Schiekofer et al. 2001). NF-B is activated by a range of stimuli including glucose (Pieper 
and Riazulhaq 1997) and ROS (Nishikawa, Edelstein et al. 2000). AGEs are also involved in 
activation of NF-B via a RAGE-dependent pathway leading to its translocation to the 
nucleus where it induces transcription of target genes such as IL-6 and TNF-α (Yan, Schmidt 
et al. 1994). The diverse actions of NF-κB and the capacity of various factors such as AII and 
AGEs to activate this transcription factor (Ruiz-Ortega, Lorenzo et al. 2000; Ruiz-Ortega, 
Lorenzo et al. 2000), are consistent with NF-B playing a pivotal role in the pathogenesis of 
diabetic complications. 
Pyrrolidine dithiocarbamate (PDTC) is a NF-B inhibitor which has been used in both 
diabetic (Lee, Cao et al. 2004) and non-diabetic animal models of renal disease where it is 
renoprotective (Rangan, Wang et al. 1999), although its toxicity does not allow for direct 
translation to the clinical setting. Indeed, our group has demonstrated the importance of NF-
B in the pathogenesis of early renal macrophage infiltration in experimental diabetes, 
which could be modulated by interruption of the RAS (Lee, Cao et al. 2004; Liu, Wei et al. 
2006). Moreover, diabetes-induced increases in NF-B activation are prevented by 
numerous therapeutics including Metformin (Isoda, Young et al. 2006) aspirin (Zheng, 
Howell et al. 2007) Vitamin B derivatives (Hammes, Du et al. 2003) carnosine (Odashima, 
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Otaka et al. 2006) and thiazolidinediones (Marx, Walcher et al. 2004). It is possible that NF-
B, like PKC, is a central mediator which drives the downstream pathogenic consequences 
of interactions between hemodynamic and glucose dependent pathways in diabetic vascular 
complications. However, approaches to inhibit NF-B have not been explored fully in DN, 
most likely due to the intimate involvement of this transcription factor in a number of 
essential cellular processes including apoptosis.  
10. Inflammatory cytokines and growth factors 
Diabetic nephropathy was not traditionally considered to be an inflammatory condition, 
however, there is a growing body of evidence in recent times highlighting the central role of 
inflammation in its development and progression (Wu, Huang et al. 2002; Forbes, Cooper et 
al. 2003; Chow, Ozols et al. 2004; Chow, Nikolic-Paterson et al. 2004; Chow, Nikolic-Paterson 
et al. 2006; Nguyen, Ping et al. 2006; Chow, Nikolic-Paterson et al. 2007; Ninichuk, 
Khandoga et al. 2007; Giunti, Tesch et al. 2008; Hohenstein, Hugo et al. 2008). Indeed,  
both hemodynamic and metabolic factors involved in the development of diabetic 
complications such as nephropathy activate common downstream targets, including 
cytokines and growth factors (Cooper, Gilbert et al. 1998). In particular, Monocyte 
Chemoattractant Protein (MCP-1), Transforming Growth Factor-β1 (TGF-1), Connective 
Tissue Growth Factor (cTGF) and Vascular Endothelial Growth Factor (VEGF) have all been 
implicated in both experimental and human studies to be involved in the development and 
progression of diabetic nephropathy.  
10.1 Monoctye chemoattractant protein -1 (MCP-1) 
MCP-1 is a potent chemokine which encourages monocyte/macrophage infiltration into the 
kidney, which likely contributes to the progression of DN. MCP-1 production and secretion 
from damaged renal cells in diabetes are postulated to be a response to hyperglycaemia 
subsequently activating a number of signalling pathways including those mediated by PKC 
and NF-B (Tesch 2008). In an experimental model of type 2 diabetic nephropathy, a 
deficiency in MCP-1 resulted in a significant reduction in renal inflammatory infiltration and 
renoprotection, Furthermore administration of propagermanium, an antagonist of the MCP-1 
receptor, in model of diabetic nephropathy, resulted in reduced renal hypertrophy and 
macrophage infiltration in renal glomeruli (Kanamori, Matsubara et al. 2007). Indeed, it has 
been demonstrated that elevations in urinary excretion of MCP-1 may be a valid diagnostic 
marker of diabetic nephropathy in type 2 diabetic patients (Wang and Chen 2009). These 
studies suggest that MCP-1 is a central mediator of diabetic renal disease, although its utility 
as a therapeutic target remains to be determined (Chow, Nikolic-Paterson et al. 2007).  
10.2 Modulation of growth factors 
Growth factors such as transforming growth factor-β (TGF-β), a fibrogenic cytokine, and 
connective tissue growth factor (CTGF), which is primarily induced by TGF- β1, have been 
implicated as key effector molecules which promote diabetic renal disease. Transforming 
growth factor beta is a superfamily with three mammalian isoforms. The major isoform, 
TGF-1 is synthesised as an inactive or latent form, which subsequently is subjected to 
proteolytic cleavage leading to the generation of the active form. TGF-1 binds to the type II 
receptor and subsequently binds to the type I receptor (Wrana, Attisano et al. 1994) inducing 
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phosphorylation and intracellular signalling involving the SMAD proteins (Massague 1998). 
In vitro studies have shown that a range of stimuli increase TGF-1 expression including 
hyperglycaemia, AGEs, stretch, AII, endothelin, lipids and various products of oxidative 
stress such as F2 isoprostanes, all factors relevant to DN (Rocco, Neilson et al. 1992; Wolf, 
Ziyadeh et al. 1995; Herman, Emancipator et al. 1998; Gruden, Thomas et al. 1999; Jandeleit-
Dahm, Cao et al. 1999; Montero, Munger et al. 2000). Ziyadeh et al have previously 
examined the effects of long-term administration of a neutralizing TGF-β1 antibody on renal 
function and structure in diabetic db/db mice (Ziyadeh, Hoffman et al. 2000) and STZ 
diabetic mice (Sharma, Jin et al. 1996). Although most of the benefits have been attributed to 
TGF-β1, Hill et al. have suggested that another isoform, TGF-β2, is closely linked to 
fibrogenesis in diabetic nephropathy (Hill, Flyvbjerg et al. 2000). The utility of TGF-β1 as a 
target for therapeutic intervention in DN, however, is impeded by its essential role in 
inflammatory and immune processes. Therefore it may be preferable to modulate renal 
TGF-β1 levels by an alternative approach such as therapies which focus on upstream 
advanced glycation pathways.  A clinical trial in type 2 diabetic patients has recently ended 
and reports have been released. In this study by Sharma et al, they employed the anti-
fibrotic therapeutic, Pirfenidone at two different doses to investigate the benefits on renal 
function. Administration of Perfenidone at the lower dose of 1200mg resulted in a 
concurrent improvement in renal function and reduction in TGF-β thus demonstrating its 
benefits as a potential therapeutic for diabetic nephropathy (Sharma, Ix et al.). 
10.3 Connective tissue growth factor 
Another pro-sclerotic cytokine, connective tissue growth factor (CTGF) has increased renal 
(Riser, Denichilo et al. 2000; Twigg, Cao et al. 2002) and in particular, glomerular expression 
in diabetes (Murphy, Godson et al. 1999; Riser, Denichilo et al. 2000) and elevated in both 
early and late diabetic nephropathy in humans (Ito, Aten et al. 1998). Currently a Phase II 
study of FG-3019, a humanised anti-CTGF antibody, has been completed in patients with 
diabetic nephropathy (microalbuminuria) which was well tolerated and improved 
albuminuria. Subsequent, studies are planned in diabetic patients with macroalbuminuria 
(http://www.fibrogen.com/trials).  
CTGF expression is thought to be mediated by a number of factors common in diabetic 
nephropathy including TGF-1, hyperglycaemia or mechanical stretch (Riser, Denichilo et 
al. 2000). Interestingly, AGEs have been reported to specifically increase CTGF expression, 
initially in fibroblasts (Twigg, Chen et al. 2001) but subsequently in mesangial cells (Twigg, 
Chen et al. 2001). Moreover, aspirin has also been shown to prevent the diabetes-mediated 
increase in CTGF and mesangial expansion in experimental models of DN (Makino, 
Mukoyama et al. 2003).  
10.4 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a cytokine whose major role in diabetes was 
initially considered to be central for the pathogenesis of diabetic retinopathy and in 
particular retinal neovascularisation. Recent findings, however, have demonstrated the 
importance of VEGF within the diabetic kidney (De Vriese, Tilton et al. 2001; Wada, 
Nishizawa et al. 2001; Rizkalla, Forbes et al. 2003; Wendt, Tanji et al. 2003; Thallas-Bonke, 
Lindschau et al. 2004)]. We and others have previously shown both in vivo and in vitro 
decreases in VEGF expression with a number of therapies including alagebrium (Thallas-
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Otaka et al. 2006) and thiazolidinediones (Marx, Walcher et al. 2004). It is possible that NF-
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renoprotection, Furthermore administration of propagermanium, an antagonist of the MCP-1 
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receptor and subsequently binds to the type I receptor (Wrana, Attisano et al. 1994) inducing 
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phosphorylation and intracellular signalling involving the SMAD proteins (Massague 1998). 
In vitro studies have shown that a range of stimuli increase TGF-1 expression including 
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stress such as F2 isoprostanes, all factors relevant to DN (Rocco, Neilson et al. 1992; Wolf, 
Ziyadeh et al. 1995; Herman, Emancipator et al. 1998; Gruden, Thomas et al. 1999; Jandeleit-
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TGF-β1, Hill et al. have suggested that another isoform, TGF-β2, is closely linked to 
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advanced glycation pathways.  A clinical trial in type 2 diabetic patients has recently ended 
and reports have been released. In this study by Sharma et al, they employed the anti-
fibrotic therapeutic, Pirfenidone at two different doses to investigate the benefits on renal 
function. Administration of Perfenidone at the lower dose of 1200mg resulted in a 
concurrent improvement in renal function and reduction in TGF-β thus demonstrating its 
benefits as a potential therapeutic for diabetic nephropathy (Sharma, Ix et al.). 
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in diabetes (Murphy, Godson et al. 1999; Riser, Denichilo et al. 2000) and elevated in both 
early and late diabetic nephropathy in humans (Ito, Aten et al. 1998). Currently a Phase II 
study of FG-3019, a humanised anti-CTGF antibody, has been completed in patients with 
diabetic nephropathy (microalbuminuria) which was well tolerated and improved 
albuminuria. Subsequent, studies are planned in diabetic patients with macroalbuminuria 
(http://www.fibrogen.com/trials).  
CTGF expression is thought to be mediated by a number of factors common in diabetic 
nephropathy including TGF-1, hyperglycaemia or mechanical stretch (Riser, Denichilo et 
al. 2000). Interestingly, AGEs have been reported to specifically increase CTGF expression, 
initially in fibroblasts (Twigg, Chen et al. 2001) but subsequently in mesangial cells (Twigg, 
Chen et al. 2001). Moreover, aspirin has also been shown to prevent the diabetes-mediated 
increase in CTGF and mesangial expansion in experimental models of DN (Makino, 
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10.4 Vascular endothelial growth factor (VEGF) 
Vascular endothelial growth factor (VEGF) is a cytokine whose major role in diabetes was 
initially considered to be central for the pathogenesis of diabetic retinopathy and in 
particular retinal neovascularisation. Recent findings, however, have demonstrated the 
importance of VEGF within the diabetic kidney (De Vriese, Tilton et al. 2001; Wada, 
Nishizawa et al. 2001; Rizkalla, Forbes et al. 2003; Wendt, Tanji et al. 2003; Thallas-Bonke, 
Lindschau et al. 2004)]. We and others have previously shown both in vivo and in vitro 
decreases in VEGF expression with a number of therapies including alagebrium (Thallas-
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Bonke, Lindschau et al. 2004), ACE inhibitors (Thallas-Bonke, Lindschau et al. 2004), sRAGE 
(Wendt, Tanji et al. 2003) and OPB-9195 (Wada, Nishizawa et al. 2001). Despite this 
suppression of VEGF as a result of current therapeutics, the benefits of VEGF suppression 
remain controversial with some studies suggesting that VEGF blockade is renoprotective 
(De Vriese, Tilton et al. 2001), whereas recent studies, albeit in a non-diabetic context, 
suggest that VEGF is a critical renal survival factor and that blockade may in fact promote 
renal damage (Advani, Kelly et al. 2007). This is perhaps best demonstrated by the 
differential effects seen with anti-VEGF antibodies (192,193). Studies on the renal effects of 
blockade of VEGF receptor (VEGFR) signalling are currently being performed. Indeed, a 
recent preliminary report has shown that SU5416, a VEGFR tyrosine kinase inhibitor, 
reduces albuminuria in db/db mice (Sung 2004). In experimental models of DN, VEGF 
expression is also decreased by an inhibitor of AGE formation (Tsuchida, Makita et al. 1999) 
and with the AGE cross-link breaker, ALA (Thallas-Bonke, Lindschau et al. 2004) further 
confirming the link between AGEs and VEGF expression. 
11. Targeting genetic mediators of diabetic nephropathy 
Whilst, genetic factors and gene mutations have been implicated in the development and 
pathogenesis of diabetes for some time, recent evidence has implicated the involvement of , 
microRNA’s, histone methylation and metabolic memory in diabetes and specifically its 
complications. 
11.1 MicroRNAs (miRNAs) 
MiRNAs are regulatory RNAs that act as post-transcriptional repressors by binding to the 
3’untranslated region of target genes (Akkina and Becker; Guay, Roggli et al.). The 
mammalian genome encodes for several hundred miRNAs, and within the kidney, the 
miRNA profile differs from that of other tissues and indeed within different compartments 
of the kidney (Akkina and Becker; Guay, Roggli et al.). Initially miRNAs are transcribed as 
long pre-miRNA molecules which are subsequently modified to become their mature 
miRNA form, approximately 19-25 nucleotides in length, via a number of different 
processes. A strand of mature miRNA enters the RNA-inducing silencing complex (RISC) 
where it binds to the 3’ untranslated region of its target mRNA thus resulting in reduced 
expression of the targeted gene (Akkina and Becker) The miRNA which are in greatest 
abundance within the kidney include: miR-192, 194, 204, 215 and 216. Kantharidis et al have 
demonstrated in-vitro and ex-vivo potential of miRNA as therapeutic targets in diabetic 
nephropathy.  Specifically, they have demonstrated the role of microRNA’s in the fibrosis 
associated with diabetic nephropathy.  MicroRNA-192/215 was found to regulate the pro-
fibrotic protein e-cadherin whilst miRNA-200a was found to repress the expression of TGF-
ß2 (Wang, Herman-Edelstein et al.; Wang, Koh et al.)  Natarajan et al have alos extensively 
investigated microRNA in diabetic renal disease in experimental models (Kato, Arce et al.; 
Kato, Arce et al. 2009; Kato and Natarajan 2009; Kato, Putta et al. 2009). This therefore 
highlights the potential of microRNA’s as therapeutic targets for diabetic nephropathy and 
further pre-clinical work is warranted.  
11.2 Metabolic memory 
A number of pre-clinical and clinical trials have implicated the involvement of metabolic 
memory and the development of diabetic complications. Metabolic memory refers to an 
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earlier hyperglycaemic or erratic metabolic controlled state which is then followed by 
“normoglycaemia” or good glycaemia control.  This phenomenon is poorly understood, 
however it suggests that despite improved glycemic control, the original exposure to 
hyperglycaemia is enough to sustain prolonged deleterious effects and outcomes.  Metabolic 
memory has been demonstrated in both experimental and cell culture models of diabetes. In 
addition, numerous clinical trials, including the United Kingdom Prospective Diabetes 
Study (UKPDS) and The Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) demonstrated that intensive 
glycaemia control may help decrease micro and macrovasuclar complications thus 
suggesting the existence of metabolic memory (Villeneuve and Natarajan). Brassacchio et al 
have demonstrated the existence of “hyperglycaemic memory” in an in-vitro model of 
diabetes (Brasacchio, Okabe et al. 2009) however further investigation into this phenomenon 
is warranted and would undoubtedly reduce the onset and progression of diabetic 
complications, including nephropathy.  
11.3 Histone modifications 
Post-translational modifications that occur at the histone tails including: acetylation, 
methylation, and phosphorylation, one of the many methods through which regulation  
of gene transcription is achieved. Traditionally, post-translational modifications, such  
as DNA methylation have been extensively studied in the area of cancer. Recent reports 
have demonstrated the importance of histone modifications in diabetic complications.  
Pre-clinical studies in white blood cells including monocytes from diabetic patients  
have exhibited epigenetic modifications including increases in H3K9me2 AND H3K4me2 
which are associated with immune and inflammatory pathways (Villeneuve and Natarajan).  
In addition, TGF- ß treatment of renal mesangial cells were found to induce an increase  
in HMT SET7/9 which was associated with a profibrotic phenotype (Villeneuve and 
Natarajan). Histone modifications therefore demonstrate great potential as therapeutic 
targets.  
12. Clinical trials: The current state of affairs 
It is clearly evident that there is an abundance of potential therapeutic targets for the 
treatment of diabetic nephropathy. So why are we failing to translate these into positive 
outcomes in patients? We investigated the NIH database for clinical trials (completed and 
running) which targeted diabetic nephropathy. Of the 200 trials listed in the database, we 
categorised the interventions into their broad subject groups (Table 1). Our search found 
that 35% of all trials, employed interventional therapies which targeted the renin-
aldosterone-angiotensin system, which to date have proven to be the most beneficial 
therapeutic approach (Table 1). Approximately 13.5% of all clinical trials were investigating 
therapies which target glycaemic control (including insulin). Dietary intervention is a more 
cost effective therapeutic approach for the treatment of diabetic nephropathy constituted 
some 20% of all clinical trials registered within the NIH data base. It is evident that the 
wider research community is actively investigating novel therapeutic targets other than 
those which target the RAAS, demonstrated by the variety of interventions and categories. 
Of particular interest, is that of all of these trials, almost 10% of these targeted ROS whilst 
5% employed anti-inflammatories. In addition, 1.5% of all trials targeted AGEs and/or their 
receptors (Table 1). The remainder of the trials targeted thrombosis, fibrosis, erythropoiesis, 
 
Diseases of Renal Parenchyma 
 
190 
Bonke, Lindschau et al. 2004), ACE inhibitors (Thallas-Bonke, Lindschau et al. 2004), sRAGE 
(Wendt, Tanji et al. 2003) and OPB-9195 (Wada, Nishizawa et al. 2001). Despite this 
suppression of VEGF as a result of current therapeutics, the benefits of VEGF suppression 
remain controversial with some studies suggesting that VEGF blockade is renoprotective 
(De Vriese, Tilton et al. 2001), whereas recent studies, albeit in a non-diabetic context, 
suggest that VEGF is a critical renal survival factor and that blockade may in fact promote 
renal damage (Advani, Kelly et al. 2007). This is perhaps best demonstrated by the 
differential effects seen with anti-VEGF antibodies (192,193). Studies on the renal effects of 
blockade of VEGF receptor (VEGFR) signalling are currently being performed. Indeed, a 
recent preliminary report has shown that SU5416, a VEGFR tyrosine kinase inhibitor, 
reduces albuminuria in db/db mice (Sung 2004). In experimental models of DN, VEGF 
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MiRNAs are regulatory RNAs that act as post-transcriptional repressors by binding to the 
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long pre-miRNA molecules which are subsequently modified to become their mature 
miRNA form, approximately 19-25 nucleotides in length, via a number of different 
processes. A strand of mature miRNA enters the RNA-inducing silencing complex (RISC) 
where it binds to the 3’ untranslated region of its target mRNA thus resulting in reduced 
expression of the targeted gene (Akkina and Becker) The miRNA which are in greatest 
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nephropathy.  Specifically, they have demonstrated the role of microRNA’s in the fibrosis 
associated with diabetic nephropathy.  MicroRNA-192/215 was found to regulate the pro-
fibrotic protein e-cadherin whilst miRNA-200a was found to repress the expression of TGF-
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highlights the potential of microRNA’s as therapeutic targets for diabetic nephropathy and 
further pre-clinical work is warranted.  
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earlier hyperglycaemic or erratic metabolic controlled state which is then followed by 
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however it suggests that despite improved glycemic control, the original exposure to 
hyperglycaemia is enough to sustain prolonged deleterious effects and outcomes.  Metabolic 
memory has been demonstrated in both experimental and cell culture models of diabetes. In 
addition, numerous clinical trials, including the United Kingdom Prospective Diabetes 
Study (UKPDS) and The Action in Diabetes and Vascular Disease: Preterax and Diamicron 
Modified Release Controlled Evaluation (ADVANCE) demonstrated that intensive 
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have demonstrated the existence of “hyperglycaemic memory” in an in-vitro model of 
diabetes (Brasacchio, Okabe et al. 2009) however further investigation into this phenomenon 
is warranted and would undoubtedly reduce the onset and progression of diabetic 
complications, including nephropathy.  
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methylation, and phosphorylation, one of the many methods through which regulation  
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which are associated with immune and inflammatory pathways (Villeneuve and Natarajan).  
In addition, TGF- ß treatment of renal mesangial cells were found to induce an increase  
in HMT SET7/9 which was associated with a profibrotic phenotype (Villeneuve and 
Natarajan). Histone modifications therefore demonstrate great potential as therapeutic 
targets.  
12. Clinical trials: The current state of affairs 
It is clearly evident that there is an abundance of potential therapeutic targets for the 
treatment of diabetic nephropathy. So why are we failing to translate these into positive 
outcomes in patients? We investigated the NIH database for clinical trials (completed and 
running) which targeted diabetic nephropathy. Of the 200 trials listed in the database, we 
categorised the interventions into their broad subject groups (Table 1). Our search found 
that 35% of all trials, employed interventional therapies which targeted the renin-
aldosterone-angiotensin system, which to date have proven to be the most beneficial 
therapeutic approach (Table 1). Approximately 13.5% of all clinical trials were investigating 
therapies which target glycaemic control (including insulin). Dietary intervention is a more 
cost effective therapeutic approach for the treatment of diabetic nephropathy constituted 
some 20% of all clinical trials registered within the NIH data base. It is evident that the 
wider research community is actively investigating novel therapeutic targets other than 
those which target the RAAS, demonstrated by the variety of interventions and categories. 
Of particular interest, is that of all of these trials, almost 10% of these targeted ROS whilst 
5% employed anti-inflammatories. In addition, 1.5% of all trials targeted AGEs and/or their 
receptors (Table 1). The remainder of the trials targeted thrombosis, fibrosis, erythropoiesis, 
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heparin, PKC, calcium transport, endothelin and genetics (Table 1). A recent search into the 
diabetic nephropathy patent database has identified that other new novel therapeutics 
including vasohibin ( 20100113354), myostatin (20110008357), Oligotide ( 20100291098), 
modulators of prostacyclin (20110053872), inhibitors of galectin-3 (20080219973) and 
inhibitors of fatty acid oxidation ( 20110048980) are being considered for the treatment of 
diabetic renal disease. Moreover, novel biomarkers for the development and progression of 
diabetic nephropathy are also under investigation including urinary: precursor α-2-HS-




(including insulin and glucose transport ) 14.5% 
Advanced Glycation End-Products 1.5% 
Reactive Oxygen Species 9% 
Inflammation 5% 
Renin-aldosterone-angiotensin system 35% 
Endothelin 2.5% 
Dietary Interventions 17.5% 
Pro-fibrotic molecules 2% 
Anti-Thrombotic 1.5% 
Genetics 1% 
Protein Kinase C- inhibitors 1% 
Anti-Lipidaemic 4.5% 
Calcium Blockers 1.5% 
Others – diuretics, hormones, apoptosis, 5% 
Table 1. Therapeutics in clinical trials for treatment of diabetic nephropathy Representative 
table of Clinical Trials run to treat diabetic nephropathy and registered on NIH webpage. 
13. Conclusion  
Diabetic nephropathy is a multifaceted disease which encompasses hemodynamic, 
metabolic and genetic factors which are central to its development and progression. At 
present therapeutics which target the hemodynamic factors, specifically the renin-
aldosterone-angiotensin system are the most effective treatments. Unfortunately, their 
benefits are limited and as such additional novel therapeutics are required. In this chapter 
we have described an number of potential therapeutic targets which have been identified 
and which are either in clinical or pre-clinical investigation. In the future, it is hoped that 
current clinical trials will show benefits of some of these novel agents and that there will be 
significant advanced in our management of individuals with diabetic renal disease.  
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1. Introduction 
Diabetic kidney disease (DKD) is the single most common cause of end stage renal  
disease (ESRD) with the annual costs of caring for patients with DKD exceeding more  
than $9 billion in the United States (Centers of Disease Control and Prevention, 2005).  
Every diabetic patient has up to a 40% lifetime risk to develop DKD, if the patient does  
not die prematurely of cardiovascular disease (CVD) (Parving, Osterby, & Ritz, 2000).  
DKD can present as different phenotypes, progressive and nonprogressive (Figure 1  
and 2). 
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Fig. 1. A-B. The stages of CKD (A) and DKD (B). 
Approximately, a third of patients can have progressive DKD which presents with 
progressive proteinuria, mainly albuminuria, a subsequent decline in glomerular filtration 
rate (GFR), and in some patients, progression to ESRD. Clinical studies show that renal 
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vascular dysfunction can precede the onset of proteinuria in diabetes. Ishimura et al. 
demonstrated that patients with stage 1 DKD have increased resistive indices in the renal 
vasculature, indicating a diminished renal vasodilatory blood flow reserve (Ishimura et al., 
1997). Furthermore, Frauchiger et al. validated that patients with early DKD have a 
diminished renal blood flow response to nitroglycerin compared to healthy controls 
(Frauchiger, Nussbaumer, Hugentobler, & Staub, 2000). In addition, Epstein et al. elegantly 
demonstrated that renal blood flow oxygenation, as quantified by blood oxygenation level-
dependent magnet resonance imaging, is diminished in response to a water load in patients 
with stage 1 DKD compared to healthy controls, suggesting that oxygen delivery may be 
impaired in early stages of DKD, at least in part, due to vascular and/or endothelial 
dysfunction (Epstein, Veves, & Prasad, 2002). The cause for these observations is 
incompletely understood, but several studies suggest that inactivation of Nitric Oxide (NO) 
by increased reactive oxygen species (ROS) generation in diabetes may be an underlying 
mechanism. It has been suggested that increased generation of ROS in diabetes mellitus, 
namely of superoxide anion (O2-), reduces vascular endothelial function. This endothelial 
dysfunction is characterized by a decreased NO-dependent vasodilation which has been 
demonstrated in the renal vasculature of early DKD and may also contribute to the 
increased cardiovascular mortality in these patients (Dai, Diederich, Skopec, & Diederich, 
1993; Diederich, 1997; Kanwar et al., 2008). Any form of DKD is associated with a markedly 
increased cardiovascular mortality and in recent years, even low levels of albuminuria, 
which were previously thought to be normal, have been shown to be associated with up to 




   
 
Fig. 2. A-D. Different phenotypes of DKD including progressive (A-C) and non-progressive 
or slowly progressive DKD (D), GFR, glomerular filtration rate; UAE, Urine albumin 
excretion. 
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The therapeutic strategies for DKD are limited due to several factors: (1) Lack of screening 
for DKD, (2) Lack of implementation of optimal standard therapy for DKD, and (3) Current 
therapies primarily slow down, but do not halt the progression of DKD. These therapies 
include: blood pressure, lipid, glycemic, and weight control; diet and lifestyle modifications; 
antiplatelet aggregation therapy; and initiation of therapy with inhibition of the renin 
angiotensin system (RAS) by angiotensin converting enzyme inhibitors (ACEIs), angiotensin 
receptor blockers (ARBs), and renin inhibitors. 




Fig. 3. Sources of ROS Generation in DKD 
ROS are natural by-products of oxygen metabolism that are generated during oxidative 
phosphorylation and play an important role in cell signalizing, aging, cancer prevention 
and degenerative diseases. Oxidative radicals are highly reactive ROS capable of changing 
the form and function of many cellular components. Under normal conditions, common 
ROS, including superoxide anion (O2-), hydrogen peroxide (H2O2), hydroxyl radical (OH-) 
and hypochlorous acid (HClO) are detoxified via electron transfer by cellular antioxidant 
enzyme systems (superoxide dismutase, catalase, and glutathione peroxidase). However, 
during periods of stress, including environmental, physical (e.g. radiation, ultraviolet 
light), and chemical (e.g. hyperglycemia), these free radicals are produced in excess, 
overwhelming the detoxification capacity of cellular antioxidant enzymes and causing cell 
damage. This damage is mediated directly by electron shifts or due to cytokine-mediated 
signal transduction and amplification, DNA damage and structural changes of lipids and 
proteins. 
The overproduction of ROS in the kidney has been demonstrated in both animals (Koya et 
al., 2003) and humans with DKD (Brezniceanu et al., 2007). In addition, the products of 
increased ROS generation, such as 13-hydroxyoctadecadienoic acid, dimethylarginine,  
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8-hydroxyguanosine, and oxidized glutathione are increased in DKD (Aslam, Santha, Leone, 
& Wilcox, 2006). Vascular endothelium is especially prone to ROS-mediated damage 
(Inoguchi et al., 2003; H. B. Lee, Ha, & King, 2003; H. B. Lee, Yu, Yang, Jiang, & Ha, 2003; Li 
& Shah, 2003). Superoxide anion generation has been shown to inactivate NO-dependent 
vasodilation, likely by scavenging NO and generating the very potent ROS peroxynitrite: 
NO·+ O2-  ONOO (Figure 5A) (Hogg & Griffith, 1997). 
The challenges antioxidant therapy faces in the clinic are two-fold: (1) prevention of 
further ROS generation and, (2) achieving an appropriate and constant antioxidant level 
at the site of injury (mitochondria). Many antioxidant molecules get converted to oxidant 
radicals during the redox reaction involved in scavenging ROS. Moreover, the 
mitochondria are the major site of ROS generation and it is questionable if most 
antioxidants currently in clinical use (e.g. N-acetylcysteine, vitamin C, vitamin E) are 
reaching their target and acting within the mitochondria in order to effectively decrease 
ROS generation. Some newer antioxidants, such as ubiquinones, may be more 
mitochondria-specific and will be discussed later (James, Cocheme, Smith, & Murphy, 
2005; James et al., 2007). (Figure 3 & 4) 
 
 
Fig. 4. Amelioration of ROS by Antioxidants 
Both enzymatic (NADPH oxidase, G6PDH, xanthine oxidase, NO synthase and glycolysis 
pathway enzymes) and non-enzymatic reactions (glucose auto-oxidation and advanced 
glycation) are involved in hyperglycemia-induced overproduction of ROS. Glucose-induced 
protein kinase C (PKC), advanced glycosylation end-products (AGE), polyol pathways, and 
nuclear factor kappa B (NF-kB) activation are the 4 critical pathways involved in DKD. 
Agents with potential antioxidant effects currently investigated in animals and humans 
which will be discussed below include renin angiotensin inhibitors, protein kinase  
C inhibitors, TGF-B inhibitors, pentoxifylline, selective mitochondrial antioxidants, statins, 
vitamins C and E, sodium bicarbonate, N-acetylcysteine, bardoxolone methyl, omega-3 fatty 
acids, coenzyme Q10, and tempol. 
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2. Antioxidant therapy: ROS inhibition for the treatment of DKD 
Several studies have demonstrated that inhibition of ROS generation by various therapeutic 
strategies and targeting different pathways are beneficial in the prevention and/or 
progression of DKD. An ideal antioxidant agent would be one that targets several  
ROS-generating pathways, in particular, mitochondrial-derived ROS.  Such agents studied 
for the treatment of DKD are yet to be identified. Potential novel treatment strategies may 






Fig. 5. A-B. Mitochondrial pathways of ROS generation in non-diabetic (A) and diabetic 
conditions (B). 
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2.1 Glycemic control 
In hyperglycemia, excess glucose undergoes auto-oxidation and glycolysis to produce large 
amounts of NADH and FADH2 which feed into and overwhelm the electron transport 
chain, causing electron leaks and ROS overproduction in renal and other cells (El-Osta et al., 
2008). Currently, standard therapy for DKD includes tight glycemic control, directed by 
glycosylated hemoglobin A1c (HbA1c) levels to prevent hyperglycemia-induced, ROS-
related DKD. Target HbA1c levels of less than 7.0% have been recommended to improve 
DKD and/or prevent its progression in several trials (National Kidney Foundation, 2010). 
Generally, elevated HbA1c levels are indicative of chronic hyperglycemia, but insensitive to 
detect transient hyperglycemic episodes. However, events of transient hyperglycemia  
(as short as 6 hours of hyperglycemia) have been shown to induce long-lasting activation of  
NF-kB (El-Osta et al., 2008) and are now considered a risk factor for diabetic complications 
independent of HbA1c levels. 
2.2 Inhibition or blockade of Renin-Angiotensin System (RAS) 
Angiotensin II is a major constituent of the RAS and has been shown to be an important 
pathogenetic factor in DKD development (Andersen, Tarnow, Rossing, Hansen, & Parving, 
2000). Inhibition of the RAS by ACEIs, ARBs, and renin inhibitors have been shown to delay 
the onset and/or progression of DKD in numerous studies. A meta-analysis by Kunz et al 
analyzed 110 trials and found that ACEI and ARBs significantly decreased proteinuria, one 
of the early signs of DKD, in renal disease. No conclusions could be made, however, 
regarding preservation of kidney function from this analysis due to the variable quality of 
these studies and their short duration (Kunz et al 2008). Another meta-analysis of 24 studies 
found that RAS blockers reduce the risks of ESRD and doubling of serum creatinine in 
diabetic nephropathy patients, but do not affect all-cause mortality (Sarafidis et al 2008). The 
beneficial effects of RAS inhibitors in DKD may in part be due to their antioxidant 
properties (Onozato, Tojo, Goto, Fujita, & Wilcox, 2002). However, the use and benefit of 
these agents is limited by potentially harmful side effects such as hyperkalemia, reduction in 
the GFR, and failure to completely halt disease progression.  
2.3 Inhibition of protein kinase C (PKC) 
Hyperglycemia-mediated overexpression of protein kinase C (PKC)-β results in activation of 
NADPH oxidase, a lysosomal enzyme involved in ROS generation which is also increased in 
experimental models of DKD (Onozato et al., 2002). Ruboxistaurin, a PKC-β inhibitor, 
reduced proteinuria in animal models (Inoguchi et al., 2003) and humans (Tuttle et al., 2005). 
However, larger clinical trials are pending to confirm the safety and validate the prospective 
benefits of ruboxistaurin. Other PKC-β inhibitors are currently under investigation for 
possible use in the treatment of DKD. 
2.4 Inhibitors of transforming growth factor-β (TGF-β) 
Transforming growth factor-β is a family of growth and differentiation factors that includes 
TGF-β1, β-2, and β-3 , activins, and bone morphogenic proteins (Bottinger, 2007). TGF-β1 is 
a pleotrophic cytokine with complex biological activities that depend on cell type and cell 
context. Cell cycle control, regulation of early development, cell differentiation, 
angiogenesis, and immune system regulation are all activities ascribed to TGF-β1 (Schmidt-
Weber & Blaser, 2004{Ghosh, 2005 #132). TGF-β is also a major regulator of the extracellular 
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matrix and tissue repair. A highly validated deleterious action of TGF-β is its contribution to 
the progressive fibrosis of CKD (Bottinger & Bitzer, 2002) and DKD (Chen et al., 2001).  
TGF-β1 appears to be the predominant isotype mediating disease progression. Experimental 
evidence indcates that TGF-β1 is the most abundant isoform expressed in the kidney. The 
TGF-β2 and-β3 isoforms have been shown to mediate part of their effect through 
upregulation of β1 expression (Chen et al., 2001). In addition, it has been demonstrated in 
the db/db mouse model of DKD that a neutralizing monoclonical antibody (mAb) specific for 
TGF-β-1 was as effective in reducing renal damage as an mAb against all 3 TGF-β isoforms 
(Ziyadeh et al., 2000). Thus, modulation of TGF-β1 activity would be expected to retard 
DKD progression without interfering with either important regulatory roles of TGF-β2 and 
–β3. Humanized IgG4 mAb that has potent and selective neralizing activity against active 
TGF-β1 (known as CAT-192) is being tested for DKD therapy. Monoclonal antibodies 
against TGF-β are currently under clinical investigation for DKD. 
TGF-β is not only fibrogenic and causes glomerulosclerosis(Sharma, Jin, Guo, & Ziyadeh, 
1996) but can also generate ROS by inducting NADPH oxidase (Misra & Rabideau, 2000). 
Pirfenidone is an inhibitor of fibroblast growth factor, platelet derived growth factor, and 
TGF-β. Pirfenidone has antioxidant properities, and has been shown to slow the progression 
of glomerulosclerosis (Misra & Rabideau, 2000; RamachandraRao et al., 2009). Pirfenidone 
has been clinically used for the treatement of interstitial lung disease, and recently been 
shown to have beneficial effects for DKD (Sharma et al., 2011).  
2.5 Inhibition of non-enzymatic glycation 
Advance glycation end-product (AGE) are endogenous proteins which are non-
enzymatically glycated following auto-oxidation of glucose, primarily in diabetes. The 
interaction between AGE and their receptors (RAGE) in the kidney has been shown to 
activate expression of NF-kB which stimulates ROS production, contributing to DKD 
(Schmidt et al., 1995). Pyridoxamine inhibits glycation of proteins and decreases AGE 
deposition in animal models of DKD (Degenhardt et al., 2002). One clinical trial in DKD 
patients who were treated with pyridoxamine demonstrated a reduced progression of DKD 
defined as the improvement of the serum creatinine; however, a reduction of urinary 
albumin excretion was not observed (Williams et al., 2007). A multi-center, randomized 
controlled trial studying the effects of pyridoxamine in DKD is currently being conducted. 
2.6 Removal of catalytic iron 
Hyperglycemia-induced glycation of proteins increases their affinity for iron, forming 
glycochelates. Glycochelates, as well as catalytic iron, have also been implicated in DKD 
(Swaminathan, Fonseca, Alam, & Shah, 2007). Desferoxamine, a commonly used iron 
chelator(Miller, M.J., 1989), restores endothelial function mediated by inhibition of ROS 
(Koo, Casper, Otto, Gira, & Swerlick, 2003). The drug has the ability to penetrate cell 
membranes and chelate intracellular iron species. The role of iron chelators in decreasing 
ROS in DKD warrants evaluation in randomized controlled clinical trials. 
2.7 Role of pentoxifylline 
Pentoxifylline has numerous pharmacological roles, including antioxidant and platelet 
aggregation inhibitor. For example, tissue necrosis factor α (TNF-α) promotes the local 
generation of ROS in the glomerular capillary wall, increasing albuminuria in DKD 
(McCarthy et al., 1998). Pentoxifylline decreases TNF-α expression and reduces proteinuria 
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2000). Inhibition of the RAS by ACEIs, ARBs, and renin inhibitors have been shown to delay 
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these studies and their short duration (Kunz et al 2008). Another meta-analysis of 24 studies 
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properties (Onozato, Tojo, Goto, Fujita, & Wilcox, 2002). However, the use and benefit of 
these agents is limited by potentially harmful side effects such as hyperkalemia, reduction in 
the GFR, and failure to completely halt disease progression.  
2.3 Inhibition of protein kinase C (PKC) 
Hyperglycemia-mediated overexpression of protein kinase C (PKC)-β results in activation of 
NADPH oxidase, a lysosomal enzyme involved in ROS generation which is also increased in 
experimental models of DKD (Onozato et al., 2002). Ruboxistaurin, a PKC-β inhibitor, 
reduced proteinuria in animal models (Inoguchi et al., 2003) and humans (Tuttle et al., 2005). 
However, larger clinical trials are pending to confirm the safety and validate the prospective 
benefits of ruboxistaurin. Other PKC-β inhibitors are currently under investigation for 
possible use in the treatment of DKD. 
2.4 Inhibitors of transforming growth factor-β (TGF-β) 
Transforming growth factor-β is a family of growth and differentiation factors that includes 
TGF-β1, β-2, and β-3 , activins, and bone morphogenic proteins (Bottinger, 2007). TGF-β1 is 
a pleotrophic cytokine with complex biological activities that depend on cell type and cell 
context. Cell cycle control, regulation of early development, cell differentiation, 
angiogenesis, and immune system regulation are all activities ascribed to TGF-β1 (Schmidt-
Weber & Blaser, 2004{Ghosh, 2005 #132). TGF-β is also a major regulator of the extracellular 
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matrix and tissue repair. A highly validated deleterious action of TGF-β is its contribution to 
the progressive fibrosis of CKD (Bottinger & Bitzer, 2002) and DKD (Chen et al., 2001).  
TGF-β1 appears to be the predominant isotype mediating disease progression. Experimental 
evidence indcates that TGF-β1 is the most abundant isoform expressed in the kidney. The 
TGF-β2 and-β3 isoforms have been shown to mediate part of their effect through 
upregulation of β1 expression (Chen et al., 2001). In addition, it has been demonstrated in 
the db/db mouse model of DKD that a neutralizing monoclonical antibody (mAb) specific for 
TGF-β-1 was as effective in reducing renal damage as an mAb against all 3 TGF-β isoforms 
(Ziyadeh et al., 2000). Thus, modulation of TGF-β1 activity would be expected to retard 
DKD progression without interfering with either important regulatory roles of TGF-β2 and 
–β3. Humanized IgG4 mAb that has potent and selective neralizing activity against active 
TGF-β1 (known as CAT-192) is being tested for DKD therapy. Monoclonal antibodies 
against TGF-β are currently under clinical investigation for DKD. 
TGF-β is not only fibrogenic and causes glomerulosclerosis(Sharma, Jin, Guo, & Ziyadeh, 
1996) but can also generate ROS by inducting NADPH oxidase (Misra & Rabideau, 2000). 
Pirfenidone is an inhibitor of fibroblast growth factor, platelet derived growth factor, and 
TGF-β. Pirfenidone has antioxidant properities, and has been shown to slow the progression 
of glomerulosclerosis (Misra & Rabideau, 2000; RamachandraRao et al., 2009). Pirfenidone 
has been clinically used for the treatement of interstitial lung disease, and recently been 
shown to have beneficial effects for DKD (Sharma et al., 2011).  
2.5 Inhibition of non-enzymatic glycation 
Advance glycation end-product (AGE) are endogenous proteins which are non-
enzymatically glycated following auto-oxidation of glucose, primarily in diabetes. The 
interaction between AGE and their receptors (RAGE) in the kidney has been shown to 
activate expression of NF-kB which stimulates ROS production, contributing to DKD 
(Schmidt et al., 1995). Pyridoxamine inhibits glycation of proteins and decreases AGE 
deposition in animal models of DKD (Degenhardt et al., 2002). One clinical trial in DKD 
patients who were treated with pyridoxamine demonstrated a reduced progression of DKD 
defined as the improvement of the serum creatinine; however, a reduction of urinary 
albumin excretion was not observed (Williams et al., 2007). A multi-center, randomized 
controlled trial studying the effects of pyridoxamine in DKD is currently being conducted. 
2.6 Removal of catalytic iron 
Hyperglycemia-induced glycation of proteins increases their affinity for iron, forming 
glycochelates. Glycochelates, as well as catalytic iron, have also been implicated in DKD 
(Swaminathan, Fonseca, Alam, & Shah, 2007). Desferoxamine, a commonly used iron 
chelator(Miller, M.J., 1989), restores endothelial function mediated by inhibition of ROS 
(Koo, Casper, Otto, Gira, & Swerlick, 2003). The drug has the ability to penetrate cell 
membranes and chelate intracellular iron species. The role of iron chelators in decreasing 
ROS in DKD warrants evaluation in randomized controlled clinical trials. 
2.7 Role of pentoxifylline 
Pentoxifylline has numerous pharmacological roles, including antioxidant and platelet 
aggregation inhibitor. For example, tissue necrosis factor α (TNF-α) promotes the local 
generation of ROS in the glomerular capillary wall, increasing albuminuria in DKD 
(McCarthy et al., 1998). Pentoxifylline decreases TNF-α expression and reduces proteinuria 
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in DKD (Navarro et al., 1999). Clinical trials have demonstrated that pentoxifylline has 
additional mild benefits in reducing albuminuria in DKD patients who are already on ACEI 
or ARB therapy (Harmankaya, Seber, & Yilmaz, 2003; Navarro, Mora, Muros, & Garcia, 
2005). However, pentoxifylline has anti-platelet aggregating properties and as such, may 
increase the risk for bleeding in patients who are already on aspirin therapy (unpublished 
observations by the authors). 
2.8 Selective mitochondrial antioxidants 
Some of the newer developed antioxidants are the ubiquinones, and in particular, MitoQ10 
has been characterized as an effective mitochondrial antioxidant (Green, Brand, & Murphy, 
2004). Furthermore, MitoQ10 is not itself converted to a ROS after it scavenges ROS, making 
it a safer antioxidant (James et al., 2005; James et al., 2007). Thus, MitoQ10 might be a 
promising new agent for the treatment of DKD. Idebenone (Hausse et al., 2002), is another 
safe mitochondrial antioxidant which has a high mitochondrial uptake. Neither the role of 
Idebenone nor MitoQ10 have been studied yet in the treatment of DKD and remain to be 
elucidated. 
2.9 Statins 
Statins have been shown to have multiple antioxidant properties and improve vascular 
remodeling (Briones et al., 2009). Statins have also been shown to reduce proteinuria 
(Nakamura et al., 2005) and the progression of DKD (Agarwal, 2007). Therefore, patients 
with DKD may benefit from intensified statin therapy, even in the setting of an already 
controlled LDL cholesterol level. In our practice, we have observed a significant reduction in 
urinary albumin excretion in patients with progressive DKD who are taking statins and are 
either intolerable for ACEI/ARB therapy or who are already on maximal ACEI/ARB 
therapy (unpublished findings). Whether these benefits for the treatment of DKD are due to 
the antioxidant properties of statins, still needs to be determined. Furthermore, the recently 
published results of the Study of Heart and Renal Protection (SHARP trial) demonstrated 
the safety of statins in patients with DKD, however, no significant benefits with regard to 
improved kidney function have been demonstrated ( Baigent, C. et al. 2011). However, a 
population based cohort study demonstrated possible renal toxic effects of statin therapy, in 
that all statins were associated with acute renal failure over five years, however, the risk of 
that was extremely low (Hippisley-Cox and Coupland, 2010). For example, in women, the 
number needed to harm (NNH) for an additional case of acute kidney injury over years was 
434 (ranging from 284-783). 
2.10 Vitamin C and E 
Vitamin C activates vitamin E and each exhibits multiple antioxidant effects, including 
inhibition of monocyte adhesion. Their effects have been shown in animal models of 
experimental diabetes mellitus (E. Y. Lee, Lee, Hong, Chung, & Hong, 2007; Nakano et al., 
2008; Simsek, Naziroglu, & Erdinc, 2005). Furthermore, vitamin E protected against ROS-
induced DKD in diabetic mice with the haptoglobin (Hp) 2-2 genotype (Nakhoul et al., 
2009). A small randomized clinical trial of 69, type 2, diabetic patients with DKD, 
demonstrated a benefit with the administration of vitamin C (200 mg) and E (100 IU) in 
reducing urinary albumin excretion (Farvid, Jalali, Siassi, & Hosseini, 2005). Larger trials are 
warranted to further validate these findings. 
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2.11 Sodium bicarbonate 
The administration of sodium bicarbonate for patients with DKD has primarily been utilized 
for the prevention of contrast-induced acute kidney injury (CIAKI) (Brar et al., 2008; Maioli 
et al., 2008; Merten et al., 2004). The pathogenesis of CIAKI involves renal ischemia and ROS 
generation. Therefore, the use of sodium bicarbonate, a pro-oxidant, to countervail an ROS 
mediated and generated process such as CIAKI, would seem questionable and counter-
intuitive. Consistent with these biochemical observations (From et al., 2008), a retrospective 
cohort study of 7,977 patients undergoing contrast media (CM) procedures found that the 
administration of sodium bicarbonate for CIAKI prevention was associated with a 3-fold 
higher risk to develop CIAKI, compared to N-acetylcysteine alone. However, a recent study 
found a decrease in the progression of chronic kidney disease (CKD) and DKD in patients 
taking sodium bicarbonate for 2 years (de Brito-Ashurst, Varagunam, Raftery, & Yaqoob, 
2009). However, sodium bicarbonate did not change proteinuria in these patients. Further 
studies are needed to validate these findings and the underlying mechanism. 
2.12 N-acetylcysteine (NAC) 
NAC has several antioxidant properties, including induction of synthesis of glutathione, 
which is used by glutathione peroxidase to reduce H2O2. Furthermore, NAC has been 
successfully utilized for the prevention of CIAKI in patients with DKD, since both DKD  
and CIAKI are associated with increased ROS generation (A. Pflueger, Abramowitz, & 
Calvin, 2009). 
The first study of NAC for CIAKI prevention was conducted by Tepel and colleagues (Tepel 
et al., 2000). The investigators used 600 mg orally, twice daily, on the day before and the day 
of iodine CM administration and 0.45% saline intravenous hydration in comparison to 
0.45% saline hydration alone. Forty-eight hours after CM administration, CIAKI tended to 
occur and the serum creatinine tended to increase from 2.4 to 2.6 mg/dL (P=0.18) in the 
control group, whereas in the NAC group, serum creatinine decreased significantly from 2.5 
to 2.1 mg/dL (P=0.01). Several studies followed with conflicting results (Fishbane, 2008; 
Sterling, Tehrani, & Rudnick, 2008). Several factors have been postulated to contribute to 
these varying results, including different formulations of NAC. 
Dose and treatment duration are the most decisive factors in NAC’s prevention of CIAKI. 
NAC is commonly given for only two days (Tepel et al., 2000), and treatment duration may 
be too brief to effectively countervail CIAKI-induced ROS production. This treatment 
duration was chosen because ROS production was thought to occur only shortly after CM 
induction. However, this concept may need to be revised since the effects of ROS-induction 
may last much longer than previously assumed, particularly in diabetes. Recently, Michael 
Brownlee and his group (El-Osta et al., 2008) demonstrated that short-term exposure (1 
hour) of high glucose induces ROS-mediated, long-lasting activation of NF-kB subunit p65 
in aortic endothelial cells, both in vitro and in vivo. Interestingly, the effects of this short-
term ROS-mediated induction on transcription factor activation could be observed for at 
least six days after the initial induction. Therefore, CIAKI prevention strategies may need to 
be applied for longer than two days in order to countervail ROS production and induction 
of other cell signaling mechanisms. In our practice, we have given NAC as long as six days 
after CM administration with good tolerability and outcome (unpublished observation). 
Furthermore, like many antioxidants, NAC has a very short plasma half-life and plasma 
target levels are difficult to assess. Dosing twice daily may be insufficient to achieve 
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in DKD (Navarro et al., 1999). Clinical trials have demonstrated that pentoxifylline has 
additional mild benefits in reducing albuminuria in DKD patients who are already on ACEI 
or ARB therapy (Harmankaya, Seber, & Yilmaz, 2003; Navarro, Mora, Muros, & Garcia, 
2005). However, pentoxifylline has anti-platelet aggregating properties and as such, may 
increase the risk for bleeding in patients who are already on aspirin therapy (unpublished 
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has been characterized as an effective mitochondrial antioxidant (Green, Brand, & Murphy, 
2004). Furthermore, MitoQ10 is not itself converted to a ROS after it scavenges ROS, making 
it a safer antioxidant (James et al., 2005; James et al., 2007). Thus, MitoQ10 might be a 
promising new agent for the treatment of DKD. Idebenone (Hausse et al., 2002), is another 
safe mitochondrial antioxidant which has a high mitochondrial uptake. Neither the role of 
Idebenone nor MitoQ10 have been studied yet in the treatment of DKD and remain to be 
elucidated. 
2.9 Statins 
Statins have been shown to have multiple antioxidant properties and improve vascular 
remodeling (Briones et al., 2009). Statins have also been shown to reduce proteinuria 
(Nakamura et al., 2005) and the progression of DKD (Agarwal, 2007). Therefore, patients 
with DKD may benefit from intensified statin therapy, even in the setting of an already 
controlled LDL cholesterol level. In our practice, we have observed a significant reduction in 
urinary albumin excretion in patients with progressive DKD who are taking statins and are 
either intolerable for ACEI/ARB therapy or who are already on maximal ACEI/ARB 
therapy (unpublished findings). Whether these benefits for the treatment of DKD are due to 
the antioxidant properties of statins, still needs to be determined. Furthermore, the recently 
published results of the Study of Heart and Renal Protection (SHARP trial) demonstrated 
the safety of statins in patients with DKD, however, no significant benefits with regard to 
improved kidney function have been demonstrated ( Baigent, C. et al. 2011). However, a 
population based cohort study demonstrated possible renal toxic effects of statin therapy, in 
that all statins were associated with acute renal failure over five years, however, the risk of 
that was extremely low (Hippisley-Cox and Coupland, 2010). For example, in women, the 
number needed to harm (NNH) for an additional case of acute kidney injury over years was 
434 (ranging from 284-783). 
2.10 Vitamin C and E 
Vitamin C activates vitamin E and each exhibits multiple antioxidant effects, including 
inhibition of monocyte adhesion. Their effects have been shown in animal models of 
experimental diabetes mellitus (E. Y. Lee, Lee, Hong, Chung, & Hong, 2007; Nakano et al., 
2008; Simsek, Naziroglu, & Erdinc, 2005). Furthermore, vitamin E protected against ROS-
induced DKD in diabetic mice with the haptoglobin (Hp) 2-2 genotype (Nakhoul et al., 
2009). A small randomized clinical trial of 69, type 2, diabetic patients with DKD, 
demonstrated a benefit with the administration of vitamin C (200 mg) and E (100 IU) in 
reducing urinary albumin excretion (Farvid, Jalali, Siassi, & Hosseini, 2005). Larger trials are 
warranted to further validate these findings. 
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2.11 Sodium bicarbonate 
The administration of sodium bicarbonate for patients with DKD has primarily been utilized 
for the prevention of contrast-induced acute kidney injury (CIAKI) (Brar et al., 2008; Maioli 
et al., 2008; Merten et al., 2004). The pathogenesis of CIAKI involves renal ischemia and ROS 
generation. Therefore, the use of sodium bicarbonate, a pro-oxidant, to countervail an ROS 
mediated and generated process such as CIAKI, would seem questionable and counter-
intuitive. Consistent with these biochemical observations (From et al., 2008), a retrospective 
cohort study of 7,977 patients undergoing contrast media (CM) procedures found that the 
administration of sodium bicarbonate for CIAKI prevention was associated with a 3-fold 
higher risk to develop CIAKI, compared to N-acetylcysteine alone. However, a recent study 
found a decrease in the progression of chronic kidney disease (CKD) and DKD in patients 
taking sodium bicarbonate for 2 years (de Brito-Ashurst, Varagunam, Raftery, & Yaqoob, 
2009). However, sodium bicarbonate did not change proteinuria in these patients. Further 
studies are needed to validate these findings and the underlying mechanism. 
2.12 N-acetylcysteine (NAC) 
NAC has several antioxidant properties, including induction of synthesis of glutathione, 
which is used by glutathione peroxidase to reduce H2O2. Furthermore, NAC has been 
successfully utilized for the prevention of CIAKI in patients with DKD, since both DKD  
and CIAKI are associated with increased ROS generation (A. Pflueger, Abramowitz, & 
Calvin, 2009). 
The first study of NAC for CIAKI prevention was conducted by Tepel and colleagues (Tepel 
et al., 2000). The investigators used 600 mg orally, twice daily, on the day before and the day 
of iodine CM administration and 0.45% saline intravenous hydration in comparison to 
0.45% saline hydration alone. Forty-eight hours after CM administration, CIAKI tended to 
occur and the serum creatinine tended to increase from 2.4 to 2.6 mg/dL (P=0.18) in the 
control group, whereas in the NAC group, serum creatinine decreased significantly from 2.5 
to 2.1 mg/dL (P=0.01). Several studies followed with conflicting results (Fishbane, 2008; 
Sterling, Tehrani, & Rudnick, 2008). Several factors have been postulated to contribute to 
these varying results, including different formulations of NAC. 
Dose and treatment duration are the most decisive factors in NAC’s prevention of CIAKI. 
NAC is commonly given for only two days (Tepel et al., 2000), and treatment duration may 
be too brief to effectively countervail CIAKI-induced ROS production. This treatment 
duration was chosen because ROS production was thought to occur only shortly after CM 
induction. However, this concept may need to be revised since the effects of ROS-induction 
may last much longer than previously assumed, particularly in diabetes. Recently, Michael 
Brownlee and his group (El-Osta et al., 2008) demonstrated that short-term exposure (1 
hour) of high glucose induces ROS-mediated, long-lasting activation of NF-kB subunit p65 
in aortic endothelial cells, both in vitro and in vivo. Interestingly, the effects of this short-
term ROS-mediated induction on transcription factor activation could be observed for at 
least six days after the initial induction. Therefore, CIAKI prevention strategies may need to 
be applied for longer than two days in order to countervail ROS production and induction 
of other cell signaling mechanisms. In our practice, we have given NAC as long as six days 
after CM administration with good tolerability and outcome (unpublished observation). 
Furthermore, like many antioxidants, NAC has a very short plasma half-life and plasma 
target levels are difficult to assess. Dosing twice daily may be insufficient to achieve 
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consistent renoprotective effects. Moreover, the bioavailability of NAC by oral 
administration is limited by extensive first-pass metabolism, perhaps explaining why 
studies of intravenous NAC have tended to show greater efficacy in CIAKI prevention 
(Fishbane, 2008; Sterling et al., 2008). 
NAC has been successfully used for the treatment of acetaminophen-induced ROS liver 
toxicity, typically utilizing 40-fold higher doses than the current recommended dose of NAC 
(MW: 163.19) for CIAKI prevention, which is 1200 mg daily or 7 x 10-3 moles. The daily 
physiological production of superoxide anion (MW: 31.99) has been estimated to be 1.75 kg, 
or 5.5 x 104 moles (Frei, 1994). Furthermore, ROS production is increased in patients with 
diabetes and CIAKI. Therefore, it may be presumptuous to assume that 7 x 10-3 moles NAC 
would cause a meaningful reduction in a daily ROS generation of more than 5.5 x 104 moles 
of superoxide anion, which is a greater than 7 million-fold difference. Marenzi et al. have 
demonstrated that doubling the dose of NAC (1200 mg twice daily) improves CIAKI 
prevention rates (Marenzi et al., 2006). Thus, it would seem that higher doses of NAC and 
longer treatment periods are necessary for more efficacious CIAKI prevention. No clinical 
trials studying the long-term effects of NAC on DKD have been conducted, though given its 
low cost and good side-effect profile, they may well be worthwhile. 
2.13 Induction of transcription factor Nrf2: Bardoxolone methyl 
Bardoxolyne methyl, an inducer of transcription factor Nrf2, can induce the generation of 
over 250 antioxidant enzymes (Dinkova-Kostova et al., 2005). Recently, Bardoxolone methyl 
has been shown to significantly improve the creatinine GFR and cystatin C GFR in patients 
with DKD after only 4 weeks (Schwartz, Denham, Hurwitz, Meyer, & Pergola, 2009). 
However, Bardoxolone methyl did not improve urinary albumin excretion. Moreover, a 
recent landmark phase 2 trial of 227 adults with CKD and type 2 DM demonstrated that 
bardoxolone methyl improved GFR by at least 8.2 +/-1.5 ml/min over placebo after 24 
weeks of treatment and that this effect was maintained after a year of therapy. (Pergola, et 
al., 2011). Even though bardoxolone did not effect proteinuria in this trial.  
2.14 Role of haptoglobin (Hp) genotype 
Hp is a hemoglobin-binding protein that has a major role in protecting against heme-
induced ROS (Levy et al., 2010; Nakhoul, Miller-Lotan, Awaad, Asleh, & Levy, 2007). There 
are three common Hp genotypes: Hp 1-1, Hp 2-1, and Hp 2-2. The antioxidant protection 
provided by Hp in DKD has been shown to be genotype-dependent in animals (Miller-
Lotan et al., 2005) and humans (Burbea et al., 2004), with Hp 1-1 providing superior 
antioxidant protection compared with Hp 2-2. Diabetic patients with the genotype Hp 2-2 
are more likely to develop DKD than those with the Hp 2-1 or Hp 1-1 genotypes (Burbea et 
al., 2004; Levy et al., 2010; Nakhoul et al., 2007). However, no clinical therapeutic application 
has been studied in connection with Hp for DKD. 
2.15 Plant-derived omega-3 fatty acids: Alpha linolenic acid 
Omega-3 fatty acids are incorporated into cell membrane lipids, making them less 
susceptible to a free radical attack. Additionally, omega-3 fatty acids up-regulate the  
gene expression of antioxidant enzymes and down-regulate the gene expression of genes 
associated with ROS production (Takahashi et al., 2002). One of the most important plant-
derived omega-3 fatty acids is alpha linolenic acid, found in rapeseed (canola),  
 
Antioxidant Therapy for Diabetic Kidney Disease 
 
213 
chia, kiwifruit seed, soybean oil and in especially high content in flaxseed oil (Kris-
Etherton, Harris, & Appel, 2003). Alpha linolenic acid has been shown to prevent the 
progression of DKD including reduction of proteinuria, glomerular sclerosis, and tubular 
abnormalities in streptozotocin (STZ)-induced diabetic rats (Barcelli, Weiss, Beach, Motz, 
& Thompson, 1990). 
2.16 Animal-derived omega-3 fatty acids: Fish oil 
Important animal-derived fatty acids include eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) found primarily in fish oil. Among their many antioxidant 
effects, EPA has been shown to inhibit the production of phospholipase A2, an important 
pro-oxidant enzyme (von Schacky, Siess, Fischer, & Weber, 1985; Zhang et al., 2006), and 
DHA has been shown to decrease NADPH oxidase activity (Diep et al., 2002). However, 
these fatty acids are also susceptible to auto-oxidation and may, theoretically, increase ROS 
and lead to progression of DKD (Nenseter & Drevon, 1996). 
The antioxidant effects of fish oil-derived omega-3 fatty acids have also shown promising 
results in animal models of DKD. Several studies have noted a decrease in albuminuria 
(Garman, Mulroney, Manigrasso, Flynn, & Maric, 2009; Hagiwara et al., 2006; Zhang et al., 
2006) and general proteinuria (Velasquez et al., 2003) in rat and mouse models of diabetes 
mellitus. The percentage of glomerular abnormalities, defined as either mesangial expansion 
(Velasquez et al., 2003; Zhang et al., 2006) or glomerulosclerosis (Garman et al., 2009), was 
less in rodent diabetic models fed omega-3 fatty acids, versus placebo. The extent of 
tubulointerstitial fibrosis was also less in these animals (Garman et al., 2009; Velasquez et al., 
2003; Zhang et al., 2006). 
Fish oil-derived omega-3 fatty acid effects on human DKD subjects have been less 
impressive. Two double-blind, randomized controlled studies, each involving 29 type 1 
diabetic patients at a tertiary center, were performed comparing fish oil (4.6 g fish oil/d) 
with olive oil placebo (Myrup et al., 2001; Rossing et al., 1996). In one of these studies, 
although triglyceride and VLDL levels were lower in the fish oil group, total and LDL 
cholesterol were increased in that group, when compared to placebo (Rossing et al., 1996). 
There was no significant change in albuminuria,(Myrup et al., 2001; Rossing et al., 1996) nor 
in GFR (Rossing et al., 1996) between the fish oil and control groups in type 1 diabetic 
patients. Currently, the data in vivo concerning the antioxidant effect of omega-3 fatty acids 
is inconclusive. 
2.17 Red wine polyphenols 
The antioxidant renoprotective effects of red wine have largely been attributed to their 
polyphenol constituents, which include resveratrol, quercetin, anthocyanins, gallic acid, 
catechin, tannic acid and myercetin. Many other alcoholic beverages as well as tea, garlic, 
and other plants also are known to contain increased amounts of polyphenols (Rodrigo & 
Bosco, 2006). Among their antioxidant mechanisms, polyphenols have been shown to 
increase the activity of glutathione peroxidase and prevent deactivation of endothelial nitric 
oxide synthase (eNOS). eNOS is an isoenzyme of nitric oxide synthase (NOS) which uses 
NADPH to generate NO during oxidation of L-arginine and leads to vasodilation. Low 
starting reagent levels result in uncoupling of NOS and generation of superoxide via 
NADPH oxidase instead. Decreased NO-dependent renal vasodilation has been 
demonstrated in early DKD in both animals (Matsumoto, Koshiishi, Inoguchi, Nawata, & 
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consistent renoprotective effects. Moreover, the bioavailability of NAC by oral 
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or 5.5 x 104 moles (Frei, 1994). Furthermore, ROS production is increased in patients with 
diabetes and CIAKI. Therefore, it may be presumptuous to assume that 7 x 10-3 moles NAC 
would cause a meaningful reduction in a daily ROS generation of more than 5.5 x 104 moles 
of superoxide anion, which is a greater than 7 million-fold difference. Marenzi et al. have 
demonstrated that doubling the dose of NAC (1200 mg twice daily) improves CIAKI 
prevention rates (Marenzi et al., 2006). Thus, it would seem that higher doses of NAC and 
longer treatment periods are necessary for more efficacious CIAKI prevention. No clinical 
trials studying the long-term effects of NAC on DKD have been conducted, though given its 
low cost and good side-effect profile, they may well be worthwhile. 
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recent landmark phase 2 trial of 227 adults with CKD and type 2 DM demonstrated that 
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chia, kiwifruit seed, soybean oil and in especially high content in flaxseed oil (Kris-
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2006) and general proteinuria (Velasquez et al., 2003) in rat and mouse models of diabetes 
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cholesterol were increased in that group, when compared to placebo (Rossing et al., 1996). 
There was no significant change in albuminuria,(Myrup et al., 2001; Rossing et al., 1996) nor 
in GFR (Rossing et al., 1996) between the fish oil and control groups in type 1 diabetic 
patients. Currently, the data in vivo concerning the antioxidant effect of omega-3 fatty acids 
is inconclusive. 
2.17 Red wine polyphenols 
The antioxidant renoprotective effects of red wine have largely been attributed to their 
polyphenol constituents, which include resveratrol, quercetin, anthocyanins, gallic acid, 
catechin, tannic acid and myercetin. Many other alcoholic beverages as well as tea, garlic, 
and other plants also are known to contain increased amounts of polyphenols (Rodrigo & 
Bosco, 2006). Among their antioxidant mechanisms, polyphenols have been shown to 
increase the activity of glutathione peroxidase and prevent deactivation of endothelial nitric 
oxide synthase (eNOS). eNOS is an isoenzyme of nitric oxide synthase (NOS) which uses 
NADPH to generate NO during oxidation of L-arginine and leads to vasodilation. Low 
starting reagent levels result in uncoupling of NOS and generation of superoxide via 
NADPH oxidase instead. Decreased NO-dependent renal vasodilation has been 
demonstrated in early DKD in both animals (Matsumoto, Koshiishi, Inoguchi, Nawata, & 
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Utsumi, 2003; A. C. Pflueger, Larson, Hagl, & Knox, 1999; A. C. Pflueger, Osswald, & Knox, 
1999; A. C. Pflueger, Schenk, & Osswald, 1995) and humans (Frauchiger et al., 2000), also 
suggesting an uncoupling of the NO signal transduction pathway. 
Several studies have also been carried out on rodent DKD models. For example, direct 
quercetin administration resulted in reduced levels of oxidative stress and attenuation of 
diabetic proteinuria, polyuria, serum creatinine, and blood urea nitrogen in STZ-induced 
diabetic rats when compared to STZ diabetic controls (Anjaneyulu & Chopra, 2004). Green 
tea polyphenol with partially hydrolyzed gaur gum has also been shown to reduce 
oxidative stress and improve kidney weight, blood urea nitrogen levels, serum creatinine, 
and creatinine clearance in partially nephrectasized and STZ-induced diabetic rats 
(Yokozawa, Nakagawa, Oya, Okubo, & Juneja, 2005). Another study on STZ rats led by the 
Montilla group included administration of red wine four weeks after, as well as two weeks 
prior to STZ injection. Treatment with red wine significantly prevented changes induced by 
STZ, including decreased albuminuria, proteinuria, glucosuria, triglycerides, and total 
cholesterol, when compared with the control STZ rat group (Montilla et al., 2005). 
Several studies in humans suggest that chronic exposure to moderate amounts of red wine 
improve DKD. A large cross sectional study involving 157 type 1 diabetes patients with 
macroalbuminuria found that those who consume moderate amounts (30-70 g/week) of 
alcoholic beverages including red wine and beer, had a significantly lower incidence of 
macroalbuminuria than those who did not (Beulens et al., 2008). A randomized, controlled 
study involving moderate red wine versus white wine consumption (4 oz/day, for 6 
months) in type 2 diabetes patients with DKD showed a statistically significant decrease in 
proteinuria, as well as in excretion of 8-hydroxydeoxyguanosine and liver type fatty acid-
binding protein (markers of tubulointerstitial damage and of CKD, respectively) only in the 
red wine group (Nakamura, Fujiwara, Sugaya, Ueda, & Koide, 2009). Red wine has a higher 
content of polyphenols than white wine. Another randomized, controlled trial in diabetic 
patients showed that the administration of moderate amounts of red wine with a 
polyphenol-enriched, low-iron-available, carbohydrate-restricted diet was 40-50% more 
effective in improving renal and overall survival rates than the standard protein restriction 
diet (Facchini & Saylor, 2003). Further studies need to be conducted in order to investigate 
the full benefit of these compounds in patients with DKD. 
2.18 Berry polyphenols 
An important subgroup of polyphenol-containing foods are berries, such as acai berries, 
bilberries, raspberries, black currants, strawberries, blueberries, lingonberry extracts, and 
grapes (Pacheco-Palencia, Talcott, Safe, & Mertens-Talcott, 2008; Schauss et al., 2006; Seeram 
et al., 2008; Spada, de Souza, Bortolini, Henriques, & Salvador, 2008; Sun et al., 2010). 
The most beneficial antioxidant molecules in berries are polyphenolic acids, including gallic 
acid, hydroxybenzoic acids, and flavanoids, including flavan-3-ols along with cyaniding 3-
O- rutinoside and cyaniding 3-O-glucoside. One example is the acai fruit berry. Acai is a 
palm fruit from South America, and the pulp and oil extracts have been studied and shown 
to inhibit cell proliferation and demonstrate antioxidant properties (Mertens-Talcott et al., 
2008; Pacheco-Palencia et al., 2008). Acai extract has been shown to improve endothelium-
dependent vasodilatation in the mesenteric vascular bed of rats (Rocha et al., 2007). 
Furthermore, acai juice and pulp have been shown to increase plasma antioxidant capacity 
in humans up to threefold, albeit without an elevation in urinary antioxidants (Mertens-
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Talcott et al., 2008). The benefits of the acai berry from pulp and oil in vitro have been 
demonstrated in humans with a dual effect on ROS generation, in that lower concentrations 
of acai extract may increase ROS generation, whereas higher concentrations have 
antioxidant properties (Pacheco-Palencia et al., 2008). 
The antioxidant capacity of polyphenolics has further been demonstrated in freeze-dried 
acai extract (Schauss et al., 2006) and in other frozen fruits (Spada et al., 2008), suggesting 
that processed food items still retain antioxidant properties (Mertens-Talcott et al., 2008). 
In one study, the antioxidant property of acai extract, assessed by SOD-induced scavenging 
of superoxide anion, was remarkably higher than in other reported fruit and vegetables. 
Seeram and colleagues also compared the antioxidant properties of several polyphenol-rich 
beverages, including acai juice. Their analyses revealed that the highest antioxidant index 
and gallic acid equivalence occur in the following order, from highest to lowest antioxidant 
properties: pomegranate juice, red wine, grape juice, blueberry juice, blackberry juice, acai 
juice, cranberry juice, orange juice, apple juice, green tea, and black tea (Seeram et al., 2008). 
2.19 Role of heme oxygenase (HO) 
HO is a heme degradation enzyme which is expressed in several organs, including liver and 
kidney. It is involved in the production of several molecules known to have antioxidant 
properties including, carbon monoxide, biliverdin/bilirubin, and iron/ferritin (Stocker, 
Yamamoto, McDonagh, Glazer, & Ames, 1987). HO-2 is constituitively expressed, while the 
inducible isoform, HO-1 is generated in response to oxidative stress. HO’s specific functions 
in the kidney include maintaining renal blood flow, vasotonic equilibrium, and sodium and 
fluid absorption in the Loop of Henle (Abraham, Cao, Sacerdoti, Li, & Drummond, 2009). 
HO-1 has also been shown to enhance renal mitochondrial transport carriers and 
cytochrome c oxidase activity (Di Noia et al., 2006). CO, one of the products of heme 
degradation, has been shown to have both pro-oxidant (via vasoconstriction) and 
antioxidant (via vasodilation) effects (Abraham et al., 2009; Lamon et al., 2009). 
The antioxidant effects of HO-1 have also been demonstrated in rodent DKD models. 
Goodman, et al. examined the differences between HO-2 (-/-) knockout and HO-2 (+/+) 
wildtype mice. When diabetes was induced by STZ in both groups, HO-2 (-/-) mice 
demonstrated increased plasma creatinine levels, acute tubular damage and microvascular 
pathology when compared to their wildype HO-2 counterparts. An inverse relationship was 
demonstrated between HO and superoxide levels. These results clearly indicate that HO 
activity is essential in preserving renal function and morphology in STZ-induced diabetic 
mice (Abraham et al., 2009; Goodman et al., 2006). 
Although there are studies showing the causative role of pro-oxidants, including 
endothelin-1, TGF-β and platelet-derived growth factor (PDGF) in DKD patients (Gilbert, 
Akdeniz, Allen, & Jerums, 2001; Jandeleit-Dahm, Allen, Youssef, Gilbert, & Cooper, 2000; 
Langham et al., 2003) and HO-1 has been shown to inhibit these pro-oxidants (Abraham et 
al., 2009; A. Pflueger et al., 2005), no human studies have been performed demonstrating the 
direct effect of HO on alleviating DKD. 
2.20 Role of bilirubin 
As noted above, bilirubin is a degradation product of HO and is long known to have 
antioxidant properties (Stocker, Glazer, & Ames, 1987; Stocker, Yamamoto, et al., 1987). The 
ROS scavenging properties of bilirubin have been demonstrated in rat tissue samples. In rat 
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liver tissue exposed to oxidative stresses including UVA radiation, menadione bisulfite, or 
copper sulfate, the addition of low doses of bilirubin prevented lipid peroxidation and 
attenuation of glutathione reductase antioxidant enzyme (Ossola, Groppa, & Tomaro, 1997; 
Ossola, Kristoff, & Tomaro, 2000; Ossola & Tomaro, 1995, 1998). Bilirubin and biliverdin 
(bilirubin’s immediate precursor) inhibit CO-induced superoxide generation in rat renal 
arteries (Lamon et al., 2009). Bilirubin also demonstrated important effects on angiotensin II 
(AII) activity: in vitro, AII administration results in vascular smooth muscle contraction and 
generation of superoxide anion, a powerful ROS. Administration of bilirubin was shown to 
normalize the pressor and pro-oxidant effects of AII (A. Pflueger et al., 2005). 
Despite the aforementioned beneficial properties, high levels of bilirubin have also been 
associated with adverse effects in cells. In our own experiments, higher bilirubin 
concentrations (≥100 μM, ≥5.8 mg/dL) were associated with apoptosis (unpublished 
observations by the authors). Bilirubin has also been shown to inhibit mitochondrial 
enzymes, cause DNA damage, and inhibit protein synthesis (Chuniaud et al., 1996). 
Moreover, bilirubin has been shown to have inhibitory effects on ion exchange and water 
transport in the kidney (Sellinger, Haag, Burckhardt, Gerok, & Knauf, 1990). 
A few studies involving bilirubin and renal damage that may mimic DKD have been carried 
out in animal models. Recently, Adin and colleagues demonstrated that micromolar doses of 
bilirubin improved renal vascular resistance, urine output, GFR, tubular function, and 
mitochondrial integrity in rats exposed to ischemia/reperfusion renal injury (which can occur 
in DKD) (Abraham et al., 2009; Adin, Croker, & Agarwal, 2005). The attenuating effect of 
bilirubin on AII has also been shown in animal models although AII administration caused a 
significant decrease in GFR and impairment of both endothelium-dependent and 
endothelium-independent vasodilators in control rats, hyperbilirubinemic Gunn rats were 
resistant to such effects (A. Pflueger et al., 2005). Another study by Fujii et al. suggests a 
protective effect of bilirubin in diabetic animal models via downregulation of NADPH 
oxidase. Diabetic, hyperbilirubinemic Gunn j/j rats and biliverdin-treated diabetic db/db mice 
were found to have a lack of progression of mesangial expansion and less albuminuria than 
the control diabetic, j/+ Gunn rats and non-biliverdin-treated db/db mice, respectively, 
suggesting a bilirubin- and biliverdin-induced resistance to the development of DKD. In 
vascular endothelial and mesangial cells cultured from these animals, bilirubin and biliverdin 
were found to significantly inhibit NADPH-dependent superoxide production, as well as 
hyperglycemic- and AII-induced production of ROS, suggesting that this bilirubin- and 
biliverdin-induced protection is mediated by an antioxidant mechanism (Fujii et al., 2010). 
Several human studies have recently been conducted studying the antioxidant effects of 
bilirubin on DKD. A cross-sectional, population-based study of 93,909 Korean subjects found 
that CKD due to diabetes mellitus was significantly lower in women with higher bilirubin 
levels, but not in men (Han et al., 2010). However, another cross-sectional study using 
demographic data from 13,184 US patients found higher serum bilirubin levels to be 
associated with lower estimated GFR and higher albuminuria, but found no significant 
associations in diabetic patients (Targher et al., 2009). A recent case control study compared 
bilirubin levels of 32 type 2 diabetic patients with DKD to those of 32 likewise diabetic patients 
without DKD, matched for gender, age, and diabetes duration. Bilirubin was 5.5 +/-2.3 umol/l 
in cases versus 7.3+/- 3.3 umol/l in controls (P = 0.02), suggesting a protective effect of 
bilirubin on DKD in humans (Zelle, Deetman, Alkhalaf, Navis, & Bakker, 2011). 
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2.21 Role of coenzyme Q10 
Coenzyme Q10 (also known as ubiquinone, or “Q10”) is a lipid-soluble component of the 
electron transport chain. In its reduced form (ubiquinol-10), coenzyme Q10 acts as an 
antioxidant, inhibiting lipid peroxidation and free radical oxidative damage.  
Studies involving Q10’s renal effects have thus far been sparse. No rodent studies focusing 
on DKD have been performed. However, the effects of Q10 on renal function in human 
diabetics are beginning to be conducted. A 1998 study by Suzuki (Suzuki et al., 1998) and 
colleagues studied the effect of Q10 on 28 subjects with a rare form of diabetes called 
maternally inherited diabetes mellitus and deafness (MIDD), caused by a mutation of one of 
the tRNA genes in the mitochondrial DNA. The subjects were given daily doses of 150mg of 
Q10 over a period of three years. Results showed that Q10 improved insulin secretory 
response, post-exercise lactate levels, and progression of hearing loss in these patients. 
However, Q10 was not shown to improve diabetic complications in these patients, including 
DKD. 
A recent randomized, controlled 8-week trial involving 74 subjects by Mori and colleagues 
showed that when taken in conjunction with omega-3 fatty acids (4g/d), Q10 (200mg/d) 
improves systolic and especially diastolic blood pressure in (non-diabetic) moderate-to-
severe CKD patients. This effect on diastolic blood pressure using combination therapy was 
only marginally better than the results of omega-3 fatty acids being used alone (3.4 mm Hg 
decrease for combination therapy versus 2.9 mm Hg decrease for omega-3 alone), and thus, 
the effects of Q10 alone on blood pressure need confirmation. When Q10 was used alone on 
such patients, no benefit on blood pressure was observed; in fact, Q10 demonstrated a slight 
tachycardic effect.  Since hypertension is an important prognostic factor in the progression 
of CKD, the authors of this study suggested that Q10 may slow down CKD progression 
when used in conjunction with omega-3 fatty acids (Mori et al., 2009). However, more 
studies involving Q10 used alone and in combination with omega-3 fatty acids would have 
to be performed in order to elucidate its effect on CKD.  Studies involving Coenzyme Q10 
and diabetes-induced CKD and other manifestations of DKD would also need to be 
performed in order to investigate Q10’s effect on this aspect of diabetes. 
2.22 Tempol 
Nitroxides, also known as superoxide dismutase mimetics, are a class of potent, synthetic 
antioxidants. One of the nitroxides, tempol, has been studied extensively for its antioxidant 
properties. Tempol metabolizes superoxide anion to by a catalase-like action. Furthermore, 
nitroxides metabolize, detoxify, or prevent the formation or action of a wide range of other 
ROS (Wilcox & Pearlman, 2008). 
In animals, tempol has been shown to prevent the development of hypertension, 
proteinuria, oxidative ROS, podocyte damage, and upregulation of the aldosterone 
effector kinase-1 in glomerular podocytes of uni-nephrectomized rats (Ebenezer, 
Mariappan, Elks, Haque, & Francis, 2009). The authors have suggested that the beneficial 
effects of tempol on the reduction of proteinuria and glomerular damage are due to its 
antioxidant properties (Wilcox & Pearlman, 2008). Interestingly, tempol has been shown 
to improve renal oxygenation in rats and thereby may improve bioavailability of NO. 
Numerous studies have demonstrated blood pressure-reducing effects of tempol which 
are outlined in a detailed review article published by Wilcox and Pearlman (Wilcox & 
Pearlman, 2008). Tempol has also been demonstrated to reduce SOD activity in the renal 
cortical tissue of diabetic Zucker rats, thereby reducing the expression of numerous pro-
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bilirubin on DKD in humans (Zelle, Deetman, Alkhalaf, Navis, & Bakker, 2011). 
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2.21 Role of coenzyme Q10 
Coenzyme Q10 (also known as ubiquinone, or “Q10”) is a lipid-soluble component of the 
electron transport chain. In its reduced form (ubiquinol-10), coenzyme Q10 acts as an 
antioxidant, inhibiting lipid peroxidation and free radical oxidative damage.  
Studies involving Q10’s renal effects have thus far been sparse. No rodent studies focusing 
on DKD have been performed. However, the effects of Q10 on renal function in human 
diabetics are beginning to be conducted. A 1998 study by Suzuki (Suzuki et al., 1998) and 
colleagues studied the effect of Q10 on 28 subjects with a rare form of diabetes called 
maternally inherited diabetes mellitus and deafness (MIDD), caused by a mutation of one of 
the tRNA genes in the mitochondrial DNA. The subjects were given daily doses of 150mg of 
Q10 over a period of three years. Results showed that Q10 improved insulin secretory 
response, post-exercise lactate levels, and progression of hearing loss in these patients. 
However, Q10 was not shown to improve diabetic complications in these patients, including 
DKD. 
A recent randomized, controlled 8-week trial involving 74 subjects by Mori and colleagues 
showed that when taken in conjunction with omega-3 fatty acids (4g/d), Q10 (200mg/d) 
improves systolic and especially diastolic blood pressure in (non-diabetic) moderate-to-
severe CKD patients. This effect on diastolic blood pressure using combination therapy was 
only marginally better than the results of omega-3 fatty acids being used alone (3.4 mm Hg 
decrease for combination therapy versus 2.9 mm Hg decrease for omega-3 alone), and thus, 
the effects of Q10 alone on blood pressure need confirmation. When Q10 was used alone on 
such patients, no benefit on blood pressure was observed; in fact, Q10 demonstrated a slight 
tachycardic effect.  Since hypertension is an important prognostic factor in the progression 
of CKD, the authors of this study suggested that Q10 may slow down CKD progression 
when used in conjunction with omega-3 fatty acids (Mori et al., 2009). However, more 
studies involving Q10 used alone and in combination with omega-3 fatty acids would have 
to be performed in order to elucidate its effect on CKD.  Studies involving Coenzyme Q10 
and diabetes-induced CKD and other manifestations of DKD would also need to be 
performed in order to investigate Q10’s effect on this aspect of diabetes. 
2.22 Tempol 
Nitroxides, also known as superoxide dismutase mimetics, are a class of potent, synthetic 
antioxidants. One of the nitroxides, tempol, has been studied extensively for its antioxidant 
properties. Tempol metabolizes superoxide anion to by a catalase-like action. Furthermore, 
nitroxides metabolize, detoxify, or prevent the formation or action of a wide range of other 
ROS (Wilcox & Pearlman, 2008). 
In animals, tempol has been shown to prevent the development of hypertension, 
proteinuria, oxidative ROS, podocyte damage, and upregulation of the aldosterone 
effector kinase-1 in glomerular podocytes of uni-nephrectomized rats (Ebenezer, 
Mariappan, Elks, Haque, & Francis, 2009). The authors have suggested that the beneficial 
effects of tempol on the reduction of proteinuria and glomerular damage are due to its 
antioxidant properties (Wilcox & Pearlman, 2008). Interestingly, tempol has been shown 
to improve renal oxygenation in rats and thereby may improve bioavailability of NO. 
Numerous studies have demonstrated blood pressure-reducing effects of tempol which 
are outlined in a detailed review article published by Wilcox and Pearlman (Wilcox & 
Pearlman, 2008). Tempol has also been demonstrated to reduce SOD activity in the renal 
cortical tissue of diabetic Zucker rats, thereby reducing the expression of numerous pro-
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oxidant factors such as TNF, NF-kB and NADPH oxidase (Ebenezer et al., 2009). 
Furthermore, the reduction of renal SOD reduced the progression of DKD in the C57 BL\6 
Akita diabetic mouse model (Fujita et al., 2009). 
However, to date, tempol has never been studied in clinical trials for the treatment of DKD. 
Although tempol has potential properties to be effective in clinical trials, it can act as a pro-
oxidant when used in high doses. Therefore, appropriate dosing regimens have to be 
determined clinically (Wilcox & Pearlman, 2008). 
2.23 Other potential antioxidants for the treatment of DKD 
Other potential antioxidant agents for the treatment of DKD include the following, with the 
potential antioxidant mechanism in parenthesis: selenium (cofactor for glutathione 
peroxidase), reduced glutathione (reducing agent by virtue of an SH-group), ceruloplasmin 
(binding iron), transferrin (binding iron), albumin (binding iron and copper), uric acid 
(binding iron and copper), amino-steroids (e.g. methylprednisolone; inhibit lipid 
peroxidation by non-glucocorticoid action), metformin (inhibits lipid peroxidation, increases 
SOD and glutathione levels), thiazolidinediones (inhibit lipid peroxidation, decrease 
inflammatory mediators, decrease p47phox expression), folate (decreases eNOS and xanthine 
oxidase-mediated O2- production), estrogen (decreases eNOS transcription), NOS inhibitors 
(decrease NO and potentially ONOO-), endothelin receptor antagonists, and vitamin B. 
However, these agents have not been studied systematically to determine their clinical 
effects in the treatment of DKD and warrant further evaluation. 
3. Conclusions 
The increased generation of ROS production in diabetes plays a critical role in the 
pathogenesis of DKD. Appropriate and successful antioxidant therapy for the treatment of 
DKD will vitally depend on several factors, including: mechanism of action, site of action, 
auto-oxidation and conversion to ROS while serving as an antioxidant, plasma half-life, 
mode of delivery, safety, and tolerability. In the past, the benefits of antioxidant therapy 
have been limited by ineffective targeting of ROS pathways and ROS production at the site 
of injury or disease process. Antioxidant agents acting directly at the mitochondrial site may 
promise higher efficacy than non-specific antioxidant agents. However, clinical trials and 
the development of further appropriate and more effective antioxidant agents are 
warranted. 
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End stage renal disease (ESRD) and diabetes mellitus are independently associated with 
advanced atherosclerosis with extended arterial wall calcifications and occlusions in inferior 
limb arteries (Norgreen et al., 2007). A severe arterial affectation was commonly 
documented in critical inferior limb ischemic (CLI) wounds, particularly located in the tibial 
trunks of these patients (Casserly, 2008; Norgreen et al., 2007). The association of CLI in 
subjects with impaired renal function and particularly ESRD leads to a notable higher rate of 
subsequent morbidity and mortality (Andreoli et al., 2008; Casserly, 2008; Mlekusch et al., 
2004). Although revascularization indisputably represents the primary therapy for limb 
salvage (Casserly, 2008; Conrad et al., 2009; Norgreen et al., 2007), renal patients seem to 
require strikingly more challenging interventions, that focus hostile and diffusely diseased 
leg segments (Andreoli et al., 2008; Casserly, 2008; Conrad et al., 2009; Randon et al., 2010). 
Literature on arterial reconstruction (surgical and endovascular) reveals poor patency, tissue 
recovery and limb preservation data, coupled to high short and mid-term mortality rates for 
ESRD subjects (independently from other cardio-vascular risk factors) (Abou-Zamzam et al., 
2007; Bradbury et al., 2010; Casserly, 2008; Leers et al., 1998). Similar observations were 
independently documented in diabetic ischemic limbs that have the metabolic and 
neuropathic background, local sepsis and important amount of tissue loss (Apelqvist et al., 
1993; Dormandy et al., 1999; Edmonds, 2008; Norgreen et al., 2007).  However, despite 
progresses in both surgical and endovascular approaches, in 14%-20% of these patients 
exhibiting advanced crural and pedal occlusive disease, neither of the available procedures 
can provide appropriate distal arterial supply, turning to amputation (Abou-Zamzam et al., 
2007; Dormandy et al., 1999; Faglia et al., 2007). In these desperate cases, since all 
“conventional” arterial revascularization techniques were unsuccessful, the concept of 
“venous arterialization”, as extreme alternative for delivering the oxygenated blood to distal 
ischemic tissues was considered. These limb salvage alternatives for extreme CLI 
presentations (currently intended to amputation) were mostly described as using the 
available superficial veins of the affected limb (Jacop et al., 1999; Lengua et al., 2001).  
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While some reports claim encouraging limb salvage results (Jacop et al., 1999; Lengua et al., 
2001; Lu et al., 2006), others remain reserved (Matzke et al., 1999). 
Parallel efforts in CLI limb preservation were reported in the plastic reconstructive surgery 
field, by promoting the angiosomes model (AM) for reperfusion and tissue reconstruction 
upon specific arterial and venous bundles of blood supply (Attinger et al., 2001, 2006; Taylor 
& Pan, 1998). 
A schematic description of these tissue irrigation areas in the foot is illustrated in Fig. 1.  
 
 
Fig. 1. A simplified illustration of the main angiosomes (and  correspondent venosomes) 
related territories of the foot and ankle:   
MC: The Medial Calcaneal Artery,  
MP: The Medial Plantar Artery and LP:  The Lateral Plantar Artery angiosomes, dependent from 
the Posterior Tibial Artery territory, 
DP:  The Dorsalis Ppedis Artery angiosome,  from the Anterior Tibial  arterial and venous 
bundle,  and LC:  The Lateral Calcaneal Artery  angiosome from the Peroneal arterio-venous tract. 
We propose to examine in this chapter the clinical efficacy of a new hybrid limb salvage 
technique (surgical and endovascular) for deep venous selective arterializations in extreme 
diabetic CLI presentations, unfit for any of the common arterial reconstructive methods 
(Alexandrescu et al., 2011). The method also proposes an appended AM strategy for 
revascularization, in the hope to enhance appropriate wound healing in these challenging 
situations (Alexandrescu et al., 2011; Attinger et al., 2006 Taylor & Pan, 1998). 
2. Material and methods  
Patients. From January 2003 until October 2010, a series of 28 limbs with threatening 
ischemic foot wounds in 26 diabetic and ESRD patients were retrospectively studied. All 
subjects were at high risk for major limb amputation with no feasible conventional arterial 
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revascularizations. They were treated by hybrid (surgical and endovascular) deep calf veins 
arterialization following the AM concept. This method allows Selective Arterio-Venous 
Endoluminal Switch (the SAVES- technique, previously described by our group in the deep 
calf veins (Alexandrescu et al., 2011), following an AM strategy of perfusion (Attinger et al., 
2001, 2006; Taylor & Pan, 1998). Two patients received a staged bilateral intervention at 
eight and twelve months interval, respectively. The method’s aim is to provide a pulsatile 
flow to the foot by selective bypass arterialization of one of the paired either anterior, 
posterior or peroneal deep calf veins (according the AM distribution), with synchronous 
devalvulation and endoluminal coil-exclusion of the collaterals. The group gathered specific 
presentations with unfeasible or previously failed arterial reconstrucions, including lack of 
superficial vein material or inappropriate tissues conditions for distal bypasses (including 
eventual arterializations in the superficial venous network). Severe ischemic wounds 
(Rutherford categories 5-6.) (Dayal & Kent, 2005; Rutherford et al., 1997) confined to the foot 
(Wagner grades 3-4) (Driver et al., 2007) were noted in 22 limbs (79%), whereas 6 (21%) 
others presented complex below the knee trophic lesions. Advanced gangrene with 
irrecoverable tissue loss (Wagner grade 5 lesions) (Driver et al., 2007), preexisting severe 
cardiac insufficiency (LVEF < 30%) and eventual disagreement of patients for this type of 
intervention, represented the major exclusion criteria. 
There were 20 men and the mean age was 73.7 years (in the range 56-89). Nine (32%) cases 
were insulin dependent.  
Patient characteristics and risk factors are summarized in Table I:  
 
 
Table I.  
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The technical features of the 28 combined surgical and endovascular angiosome-oriented 
interventions are described in Table II:  
 
 
Table II.  
All patients were simultaneously followed in the nephrology-dialysis department. They 
underwent a preoperative complete inferior limbs arterial and venous Duplex scan, adding 
either DS-Arteriography (in our early experience) or preliminary Angio-CT assessment 
coupled to a per-operative angiography (in the recent years).  
Complementary Duplex notification concerning the valvular competence and the 
anatomical distribution (the level of vein duplication) concerning the deep venous system 
were collected.  
Following arterialization, adjuvant wound therapy was pursued in a multidisciplinary 
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Definitions.  Clinical grading of the inferior limb ischemia was evaluated according to the 
revised criteria of SVS/ISCVS (Rutherford et al., 1997) and the TASC (II) recommendations 
(Norgreen et al., 2007). Other specific clinical findings were guided by the Wagner revised 
classification (Driver et al., 2007) and the UK peripheral neuropathy screening score (Young 
et al., 1993).  
The technical success was considered if a direct arterialized axis starting from the iliac level 
through the selected deep calf veins till the peri-malleolar or foot level network was present 
after devalvulation and selective embolizations of venous side branches. This implied lack 
of deep vein narrowing or major steal phenomena, induced by venous tibial collaterals or 
perforators.   
Limb salvage implied no requirement of major amputation and if the functional autonomy 
of the patient was recovered (walking or standing) despite eventually minor amputations (at 
the metatarsal or toe level).  
Endpoints and statistical analysis.  All results were reported in an intention to treat 
analysis. Patency, clinical success, limb salvage and patients survival rates were studied 
using the Kaplan-Meier life-table method at sequential intervals. 
The surgical and endovascular “SAVES” method for deep calf vein arterializations. The 
“hybrid” technique for vascular reconstruction (Selective Arterio-Venous Endoluminal 
Switch - the “SAVES” method) followed a similar protocol, as previously described by our 
team (Alexandrescu et al., 2011). The pre-operative medication included a constant anti-
platelet therapy (160 mg aspirin daily or clopidogrel 75 mg/day). In this cohort, the 
treatment was already started in all patients before the procedure for previous 
miscellaneous cardio-vascular problems. General anaesthesia was applied in 21 cases (75%), 
local anaesthesia and slight sedation in 6 (21%), while sole local anaesthesic products were 
preferred in 1 (4%) of interventions. In the first stage of the procedures (surgical), a classical 
protocol for femoro-infragenicular PTFE bypass was undertaken (Fig. 2 and 3b).  
 
 
Fig. 2. Distal  “PTFE- graft” anastomosis at the popliteal level: 
a. The presence of a “twin popliteal veins” anatomical pattern white arrows), 
b. Termino-lateral anastomosis as to arterialize one of the two popliteal veins in a femoro 
(arterial) – popliteal (venous) PTFE graft during the first stage of the procedure. The synthetic 
graft allows the passage of a long 6F introducer from the groin, further enhancing the second 
stage of the intervention: selective devalvulation and collateral embolization of specific tibial 
deep veins, following the AM distribution. 
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Fig. 3. a) A brief illustration of the main deep venous trunks in the leg:  
PFv:  Profound  Femoral vein,  
SFv:  Superficial Femoral vein, 
Popl. vv:  Popliteal veins, 
AT. vv:  Anterior Tibial veins  
Peron. vv:  Peroneal veins  
PT. vv:  Posterior Tibial veins                     
b) The red curved arrow: schematic arterial in-flow from the groin. Below the knee twin veins 
and their correspondent venosomes: 
In red: appended  Anterior Tibial  Venosome, 
In yellow:  correspondent  Peroneal  Venosome, 
In blue: adjacent Posterior Tibial  Venosome. 
The common femoral artery was usually the chosen in-flow vessel (n= 16) albeit the SFA (n= 
7) and the popliteal artery (n= 5) was seldom employed. The location of the distal 
anastomosis, to induce direct arterial flow toward the deep calf veins (Fig. 2), was planned 
upon the Duplex findings on the level of duplication (Table II) and topographical 
specificities of the wounds (the angiosomes distribution) (Attinger et al., 2001, 2006; Taylor 
et al., 1990, 1998). This distal anastomosis was realised on one of the doubled deep veins in a 
termino-lateral (n = 23) (Fig. 2) or termino-terminal way (n = 5). In all the cases, 8mm PTFE 
armed prosthesis (n = 21/ Distaflow BARD co. USA, and n = 7/ GORE Medical Products 
co.USA) were placed. Before clamping the femoral artery, a 2500 IU heparin amount was 
given in order to promote anticoagulation yet, minimizing possible interferences with the 
second procedural stage (endovascular), the collateral embolizations. The cephalad segment of 
the twin vein was ligated, while side anastomosis was chosen. Although the distal popliteal 
vein was found more often paired than single (Fig. 2 and 3) according to other similar 
observations (Wind et al., 1991), in ten cases (35%) the distal anastomosis was performed 
directly in selected venous tibial trunks (Table II.) and oriented toward the main 
corresponding foot angiosome (venosome) (Fig. 1 and 3). After releasing the flow in the 
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PTFE arterio-venous bypass, an 80cm / 6-F introducer sheath (Cook, inc. UK) was 
antegradely mounted via the common femoral artery traversing the prosthetic graft. A road-
mapping of the infra-popliteal venous deep network was obtained, beyond the distal 
anastomosis. The competence of the deep valvular system was documented (often already 
affected by neuropathic “idiosyncratic deep venous distension” in this subset of patients) 
(Pureval et al., 1995). Although rarely needed, devalvulation was initially started by 
crossing each valve with a 0.035-inch hydrophilic guidewire (Terumo, Japan) and 
accomplished by the passage of the 6-F 80 cm long introducer sheath (occasionally 
necessitating few “back and forth” co-axially over the wire movements) (Fig. 4a and 5a).  
 
 
Fig. 4. Specific Anterior Tibial deep veins arterialization:  
a. Initial selective embolization of the Posteriof Tibial and twin veins with peculiar 
canulation of the Anterior Tibial vein, enabling to direct the arterialization toward the 
Anterior Tibial angiosome and correspondent venosome. 
b. Specific catheterization and devalvulation of the Anterior Tibial vein tovard the ankle, 
c. The newly induced arterial flow in the Anterior Tibial venosome, after specific collateral 
embolization. 
d. The initial clinical presentation featuring an extended ischemic and infected ulcer on the 
anterior tibial aspect of the calf. 
e. The clinical outcome following specific anterior tibial veins arterialization, at seven 
months after multidisciplinary follow-up.  
The long sheath was advanced until the ankle region in the angiosome-selected venous 
pathway. Contrast mapping demonstrated the principal collaterals or perforators of the 
chosen deep vein axis. Using a floppy tip 5-F vertebral or “Cobra 2-3” catheters (Cook inc., 
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(Pureval et al., 1995). Although rarely needed, devalvulation was initially started by 
crossing each valve with a 0.035-inch hydrophilic guidewire (Terumo, Japan) and 
accomplished by the passage of the 6-F 80 cm long introducer sheath (occasionally 
necessitating few “back and forth” co-axially over the wire movements) (Fig. 4a and 5a).  
 
 
Fig. 4. Specific Anterior Tibial deep veins arterialization:  
a. Initial selective embolization of the Posteriof Tibial and twin veins with peculiar 
canulation of the Anterior Tibial vein, enabling to direct the arterialization toward the 
Anterior Tibial angiosome and correspondent venosome. 
b. Specific catheterization and devalvulation of the Anterior Tibial vein tovard the ankle, 
c. The newly induced arterial flow in the Anterior Tibial venosome, after specific collateral 
embolization. 
d. The initial clinical presentation featuring an extended ischemic and infected ulcer on the 
anterior tibial aspect of the calf. 
e. The clinical outcome following specific anterior tibial veins arterialization, at seven 
months after multidisciplinary follow-up.  
The long sheath was advanced until the ankle region in the angiosome-selected venous 
pathway. Contrast mapping demonstrated the principal collaterals or perforators of the 
chosen deep vein axis. Using a floppy tip 5-F vertebral or “Cobra 2-3” catheters (Cook inc., 
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UK) or, in some other instances with a better adapted 4-F curved hydrophilic micro-catheter 
("Slip-cath" selective catheter, Cook inc. UK), the main venous collaterals were selectively 
catheterized and occluded using coils embolization material (5-F “Tornado”,  “Nester” or 
stainless steel 5-8mm coils /Cook inc., Medical UK) (Fig. 4 a, b, c, and 5 a, b). These coils 
were delivered mainly using the “coaxial” technique (and seldom only by the “anchor” 
method) (White & Pollak, 2006) in the principal deep venous ramifications. There was an 
average of 7.1 (n= 5-19) coils released per procedure. The side branches embolization 
stage was performed as distally as possible (Fig. 4c and 5c), toward the clinical venosome-
location of the wounds (White & Pollak, 2006). The progressing results were assessed by 
small contrast injections (Fig. 4c and 5c). Not all the collaterals were approachable during 
this stage of the procedure, particularly the medium-sized to small diameter veins, 
usually located in the peri-malleolar deep network (Fig. 5c). To avoid prolonged time and 
contrast consuming interventions, the selective branch embolizations were restricted 
below the ankle level, as the distal blood pressure measured through the 6-F introducer 
sheath edge exceeded 50 mm Hg. This observation allowed exclusion of residual CLI 
hemodynamic features (Norgreen et al., 2007; Rutherford et al., 1997). Hemostasis was 
directly performed at the arterial puncture level after the withdrawal of sheaths. All 
patients were prescribed aspirin (160 mg/day) after the procedure, unless intolerant or 
previous treatment with clopidogrel, ticlopidin or oral anticoagulation, in which case 
these last ones were prolonged.  
 
 
Fig. 5. Deep Posterior Tibial veins selective arterialization:  
a. Devalvulation in the main vein trunk using the 0.035-inch guidewire and the passage of 
the 6F long introducer sheath. 
b. Selective “coaxial” embolization of the main deep vein collaterals owing a 5F curved 
microcatheter. 
c. Regain of the arterial flow in the vein collaterals around the heel targeting the medial 
calcaneal angiosome  (and its appended venosome). 
d. The initial heel neuro-ischemic wound. 
e. Clinical result at five months providing the same multidisciplinary “diabetic foot” team 
surveillance. 
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Follow-up. In the post-operative period, patients were assessed by periodical clinical and 
hemodynamic (duplex scan) evaluations, focusing on tissue healing, bypass patency and the 
presence of arterial waves in the ankle or foot deep veins. Information was collected one 
month after discharge and every 6 months thereafter. In cases showing clinical tissue 
deterioration as primary end-point, corroborated by corresponding duplex findings, further 
Angio-CT or MRI evaluation was undertaken. Mean follow-up was 23.3 months (in the 
range 1-68 months). 
3. Results 
The initial technical success was achieved in 21/28 limbs (75%) with 96% corresponding 
thirty-day peri-operative mortality rate (one patient died from myocardial infarction). In 
seven instances, the procedure could not follow the scheduled protocol. In 2 cases, the distal 
venous anastomosis of the PTFE graft was unachievable either in a context of extensive 
fibrosis (multiple previous interventions) or by substantial inflammation. In 2 others, 
unexpected wall laceration of the selected venous conduit during the devalvulation stage 
required hemostasis by direct embolization of these veins. Since alternative deep veins 
arterializations without AM guidance were used, these cases were categorized as technical 
failures. There were 3 other situations when the distal embolization of collaterals could not 
be achieved: in two limbs, a rich network of fine branches with sharp angle and retrograde 
emergence rendered difficult all endovascular manoeuvres, while in other case the 
embolization stage was discontinued following an intolerance to contrast agents. For the 
whole 7 technical failures, 4 compulsory arterializations (non angiosomes-oriented) of 
miscellaneous deep or superficial veins, one minor and 2 major amputations were 
requested. During the first year of follow-up, there were 2 graft occlusions. In both 
instances, irregularities in the postoperative medication (modest compliance of patients) 
were noted. After eight months of surveillance one of these 2 limbs showed however, a 
correct tissue recovery despite the PTFE thrombosis, while major amputation was inevitable 
for the other.  
The cumulative primary and secondary patency were (+/-SEM): 71% (+/- 9%), 59% (+/- 
10%) and 59% (+/- 10%), at 12, 24 and 36 months, respectively. Limb salvage showed: 86% 
(+/- 7%) at one year and steady 77% (+/- 10%) afterwards, while the clinical success was: 
82% (+/- 7%), 71% (+/- 10%) and 71% (+/- 10%) at identical time intervals (Fig. 6).  
Deep venous system reflux was assessed in 19/28 (68%) limbs, whereas in only 10/28 (35%) 
previous evidence for clinical venous insufficiency was available. In all 28 treated limbs 
deep vein duplications were documented (preoperative Duplex) as follows: 20 in the distal 
popliteal (71%) (Fig. 2), 5 in the proximal popliteal (18%) and 3 concerning the superficial 
femoral (12%) deep veins. The overall 30-day peri-operative complication rate was 21% 
(6/28cases). Major complications were noted in three cases (11%): there were two temporary 
cardiac deficiencies after the initiation of the arterio-venous flow compensated by inotropic 
agents and diligent medical treatment and one secondary compartmental syndrome coupled 
to venous gangrene, ending in inevitable amputation. There were 3 other minor 
complication represented by 2 venous branch perforations of the collaterals with self 
limiting local effects and one causing secondary limb swelling, that needed prolonged 
postoperative physiotherapy before ambulation. Following the evoked AM strategy and 
appended venosome-model for arterialization (Fig. 1), we have noted: 10 limbs treated by 
preferential anterior tibial veins arterialization (trophic lesions located on the anterior leg 
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UK) or, in some other instances with a better adapted 4-F curved hydrophilic micro-catheter 
("Slip-cath" selective catheter, Cook inc. UK), the main venous collaterals were selectively 
catheterized and occluded using coils embolization material (5-F “Tornado”,  “Nester” or 
stainless steel 5-8mm coils /Cook inc., Medical UK) (Fig. 4 a, b, c, and 5 a, b). These coils 
were delivered mainly using the “coaxial” technique (and seldom only by the “anchor” 
method) (White & Pollak, 2006) in the principal deep venous ramifications. There was an 
average of 7.1 (n= 5-19) coils released per procedure. The side branches embolization 
stage was performed as distally as possible (Fig. 4c and 5c), toward the clinical venosome-
location of the wounds (White & Pollak, 2006). The progressing results were assessed by 
small contrast injections (Fig. 4c and 5c). Not all the collaterals were approachable during 
this stage of the procedure, particularly the medium-sized to small diameter veins, 
usually located in the peri-malleolar deep network (Fig. 5c). To avoid prolonged time and 
contrast consuming interventions, the selective branch embolizations were restricted 
below the ankle level, as the distal blood pressure measured through the 6-F introducer 
sheath edge exceeded 50 mm Hg. This observation allowed exclusion of residual CLI 
hemodynamic features (Norgreen et al., 2007; Rutherford et al., 1997). Hemostasis was 
directly performed at the arterial puncture level after the withdrawal of sheaths. All 
patients were prescribed aspirin (160 mg/day) after the procedure, unless intolerant or 
previous treatment with clopidogrel, ticlopidin or oral anticoagulation, in which case 
these last ones were prolonged.  
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a. Devalvulation in the main vein trunk using the 0.035-inch guidewire and the passage of 
the 6F long introducer sheath. 
b. Selective “coaxial” embolization of the main deep vein collaterals owing a 5F curved 
microcatheter. 
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Follow-up. In the post-operative period, patients were assessed by periodical clinical and 
hemodynamic (duplex scan) evaluations, focusing on tissue healing, bypass patency and the 
presence of arterial waves in the ankle or foot deep veins. Information was collected one 
month after discharge and every 6 months thereafter. In cases showing clinical tissue 
deterioration as primary end-point, corroborated by corresponding duplex findings, further 
Angio-CT or MRI evaluation was undertaken. Mean follow-up was 23.3 months (in the 
range 1-68 months). 
3. Results 
The initial technical success was achieved in 21/28 limbs (75%) with 96% corresponding 
thirty-day peri-operative mortality rate (one patient died from myocardial infarction). In 
seven instances, the procedure could not follow the scheduled protocol. In 2 cases, the distal 
venous anastomosis of the PTFE graft was unachievable either in a context of extensive 
fibrosis (multiple previous interventions) or by substantial inflammation. In 2 others, 
unexpected wall laceration of the selected venous conduit during the devalvulation stage 
required hemostasis by direct embolization of these veins. Since alternative deep veins 
arterializations without AM guidance were used, these cases were categorized as technical 
failures. There were 3 other situations when the distal embolization of collaterals could not 
be achieved: in two limbs, a rich network of fine branches with sharp angle and retrograde 
emergence rendered difficult all endovascular manoeuvres, while in other case the 
embolization stage was discontinued following an intolerance to contrast agents. For the 
whole 7 technical failures, 4 compulsory arterializations (non angiosomes-oriented) of 
miscellaneous deep or superficial veins, one minor and 2 major amputations were 
requested. During the first year of follow-up, there were 2 graft occlusions. In both 
instances, irregularities in the postoperative medication (modest compliance of patients) 
were noted. After eight months of surveillance one of these 2 limbs showed however, a 
correct tissue recovery despite the PTFE thrombosis, while major amputation was inevitable 
for the other.  
The cumulative primary and secondary patency were (+/-SEM): 71% (+/- 9%), 59% (+/- 
10%) and 59% (+/- 10%), at 12, 24 and 36 months, respectively. Limb salvage showed: 86% 
(+/- 7%) at one year and steady 77% (+/- 10%) afterwards, while the clinical success was: 
82% (+/- 7%), 71% (+/- 10%) and 71% (+/- 10%) at identical time intervals (Fig. 6).  
Deep venous system reflux was assessed in 19/28 (68%) limbs, whereas in only 10/28 (35%) 
previous evidence for clinical venous insufficiency was available. In all 28 treated limbs 
deep vein duplications were documented (preoperative Duplex) as follows: 20 in the distal 
popliteal (71%) (Fig. 2), 5 in the proximal popliteal (18%) and 3 concerning the superficial 
femoral (12%) deep veins. The overall 30-day peri-operative complication rate was 21% 
(6/28cases). Major complications were noted in three cases (11%): there were two temporary 
cardiac deficiencies after the initiation of the arterio-venous flow compensated by inotropic 
agents and diligent medical treatment and one secondary compartmental syndrome coupled 
to venous gangrene, ending in inevitable amputation. There were 3 other minor 
complication represented by 2 venous branch perforations of the collaterals with self 
limiting local effects and one causing secondary limb swelling, that needed prolonged 
postoperative physiotherapy before ambulation. Following the evoked AM strategy and 
appended venosome-model for arterialization (Fig. 1), we have noted: 10 limbs treated by 
preferential anterior tibial veins arterialization (trophic lesions located on the anterior leg 
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and ankle, the forefoot, dorsum of the toes and foot) (Fig. 4), 16 others having 
revascularizations in the posterior tibial veins territory (ulcers of the medial calcaneal, 
plantar, hallux, medial malleolar and Achillean teguments) (Fig. 5), while the remnant 2 
targeted a dominant peroneal in-flow (wounds located in the lateral calcaneal and lateral 
malleolar territories) (Table II.).  
 
 
Fig. 6. Patency, Limb Salvage and Clinical Success statistical data.  
Although complete healing with or without minor amputations was documented in 15 
treated limbs (54%) (Fig. 4e and 5e), notable trends for tissue recovery without complete 
cicatrization were observed in 7 others (25%). Major amputations were however, inevitable 
in the remnant 6 presentations (21%). Cyclic relapses of the wounds, albeit without ischemic 
Duplex features were documented in 11 (39%) cases, mostly between the 10th -15th months of 
follow-up. These limbs were invariably associated a severe neuropathic background. 
In the whole group of patients, six (21%) major amputations for miscellaneous clinical 
reasons were documented (2 technical failures, 2 major complications, 1bypass thrombosis 
and 1 progressively irreversible forefoot sepsis). 
The thirty-day peri-operative mortality rate was 0%. The cumulative survival rates were 
93%, 66% and 38% at 12, 24 and 36 months, respectively.    
4. Discussion  
The renal patient presents with unanimously recognized severe CLI features and consequent 
difficult revascularization patterns (Casserly, 2008; Conrad et al., 2009; Leers et al., 1998; 
Norgreen et al., 2007). A vast amount of contemporary literature shows the poor outcome 
commonly noted after surgical or endovascular arterial reconstruction in these patients 
(Arvela et al., 2010; Black et al., 2005; Casserly, 2008; Conrad et al., 2009; Leers et al., 1998). As 
the revascularization seems however feasible, particularly aggressive atherosclerosis coupled 
to long segment chronic occlusions, calcifications and depleted run-off, make further arterial 
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patency and limb preservation quite questionable in ESRD subjects (Arvela et al., 2010; Black et 
al., 2005; Casserly, 2008; Leers et al., 1998). These poor clinical results are often associated with 
a high co-morbidity and mortality, independently from diabetes and other cardio-vascular risk 
factors (Leers et al., 1998; Mlekusch et al., 2004; Norgreen et al., 2007). Similar observations 
were described in the diabetic CLI context that adds the metabolic and neuropathic 
background, local sepsis, poor immune response and variable amounts of foot tissue loss 
(Abou-Zamzam et al., 2007; Apelqvist et al., 1993; Norgreen et al., 2007).    
Moreover, the diabetic CLI “macro-angiopathic” atherosclerosis is characterised by enhance 
more aggressive and more distal occlusive lesions, with preferential tropism in the tibial 
trunks (Apelqvist et al., 1993; Dormandy et al., 1999; Faglia et al., 2007 Norgreen et al., 2007). 
A synchronous functional microcirculatory affectation induced by both neuropathic and 
septic entanglement, was also witnessed in this multifaceted pathology of the diabetic foot 
(Apelqvist et al., 1993; Boulton et al., 2006; Edmonds, 2008). Despite soaring progresses in 
technology and aggressive follow-up, long-term limb preservation seems however inferior 
in diabetic – ESRD subjects compared to other CLI patients, mainly due to extended 
infragenicular arterial thrombosis, calcifications and poor distal foot runoff (Abularrage et 
al., 2010; Dormandy et al., 1999).   
While non-diabetic subjects seem to express intima-layer, eccentric and patchy wall arterial 
calcifications, prevailing in the coronary also the peripheral vessels (the « type I » 
calcifications) (Irvin & Guzman, 2009), the diabetic also ESRD patients have media-layer, 
concentric and rather continuous wall calcifications (the “Mönckeberg sclerosis” or « type 
II » calcifications) (Irvin & Guzman, 2009). These particularly dense « type II » calcific 
deposits featuring the below-knee arterial trunks were independently associated with more 
severe CLI presentations (Irvin & Guzman, 2009 ; Leskinen et al., 2002), requiring additional 
technical challenges (Abou-Zamzam et al., 2007; Alexandrescu et al., 2011; Casserly, 2008; 
Leers et al., 1998) and consequent higher technical failures. They were also connected with 
low patency and discouraging limb loss rates (Casserly, 2008; Combe et al., 2009; Leers et al., 
1998; Ohtake et al., 2011). 
The reported 1-year survival rate after major amputations ranges between 50%-60% and 
seems to be worse for patients undergoing above- the-knee versus below-the-knee 
interventions (Dormandy et al., 1999; Toursarkissian et al., 2002). Despite undeniable 
progresses in both surgical and endovascular approaches, in about 14%-20% of patients 
featuring severe crural and pedal occlusive disease, neither of the available techniques can 
afford appropriate distal arterial supply, resulting amputation (Abou-Zamzam et al., 2007; 
Apelqvist et al., 1993; Combe et al., 2009 Norgreen et al., 2007; Toursarkissian et al., 2002). 
This assertion seems particularly valid regarding the ESRD subjects suffering from CLI 
(Abou-Zamzam et al., 2007; Apelqvist et al., 1993; Arvela et al., 2010; Black et al., 2005; 
Casserly, 2008; Conrad et al., 2009). 
Complementary efforts for limb preservation were achieved in the plastic reconstructive 
surgery field, by applying the AM policy for perfusion in tissue rebuilding. The concept 
delineates the human body in specific 3D blocks of tissue, fed by peculiar arterial and 
venous bundles of blood supply (Attinger et al., 2001, 2006; Taylor et al., 1990, 1998). 
Originally pioneered for the pediculated flaps techniques, the AM strategy (Attinger et al., 
2006; Taylor et al., 1998) was also applied to improve healing in lower limb ischemic ulcers 
(Alexandrescu et al., 2008; Neville et al., 2009; Varela et al., 2010; Setacci et al., 2010). Based 
on the anatomical studies of Taylor (Taylor et al., 1990, 1998) and Attinger (Attinger et al., 
2001, 2006), new preferential strategies for vascular access, revascularization or amputation 
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and ankle, the forefoot, dorsum of the toes and foot) (Fig. 4), 16 others having 
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patency and limb preservation quite questionable in ESRD subjects (Arvela et al., 2010; Black et 
al., 2005; Casserly, 2008; Leers et al., 1998). These poor clinical results are often associated with 
a high co-morbidity and mortality, independently from diabetes and other cardio-vascular risk 
factors (Leers et al., 1998; Mlekusch et al., 2004; Norgreen et al., 2007). Similar observations 
were described in the diabetic CLI context that adds the metabolic and neuropathic 
background, local sepsis, poor immune response and variable amounts of foot tissue loss 
(Abou-Zamzam et al., 2007; Apelqvist et al., 1993; Norgreen et al., 2007).    
Moreover, the diabetic CLI “macro-angiopathic” atherosclerosis is characterised by enhance 
more aggressive and more distal occlusive lesions, with preferential tropism in the tibial 
trunks (Apelqvist et al., 1993; Dormandy et al., 1999; Faglia et al., 2007 Norgreen et al., 2007). 
A synchronous functional microcirculatory affectation induced by both neuropathic and 
septic entanglement, was also witnessed in this multifaceted pathology of the diabetic foot 
(Apelqvist et al., 1993; Boulton et al., 2006; Edmonds, 2008). Despite soaring progresses in 
technology and aggressive follow-up, long-term limb preservation seems however inferior 
in diabetic – ESRD subjects compared to other CLI patients, mainly due to extended 
infragenicular arterial thrombosis, calcifications and poor distal foot runoff (Abularrage et 
al., 2010; Dormandy et al., 1999).   
While non-diabetic subjects seem to express intima-layer, eccentric and patchy wall arterial 
calcifications, prevailing in the coronary also the peripheral vessels (the « type I » 
calcifications) (Irvin & Guzman, 2009), the diabetic also ESRD patients have media-layer, 
concentric and rather continuous wall calcifications (the “Mönckeberg sclerosis” or « type 
II » calcifications) (Irvin & Guzman, 2009). These particularly dense « type II » calcific 
deposits featuring the below-knee arterial trunks were independently associated with more 
severe CLI presentations (Irvin & Guzman, 2009 ; Leskinen et al., 2002), requiring additional 
technical challenges (Abou-Zamzam et al., 2007; Alexandrescu et al., 2011; Casserly, 2008; 
Leers et al., 1998) and consequent higher technical failures. They were also connected with 
low patency and discouraging limb loss rates (Casserly, 2008; Combe et al., 2009; Leers et al., 
1998; Ohtake et al., 2011). 
The reported 1-year survival rate after major amputations ranges between 50%-60% and 
seems to be worse for patients undergoing above- the-knee versus below-the-knee 
interventions (Dormandy et al., 1999; Toursarkissian et al., 2002). Despite undeniable 
progresses in both surgical and endovascular approaches, in about 14%-20% of patients 
featuring severe crural and pedal occlusive disease, neither of the available techniques can 
afford appropriate distal arterial supply, resulting amputation (Abou-Zamzam et al., 2007; 
Apelqvist et al., 1993; Combe et al., 2009 Norgreen et al., 2007; Toursarkissian et al., 2002). 
This assertion seems particularly valid regarding the ESRD subjects suffering from CLI 
(Abou-Zamzam et al., 2007; Apelqvist et al., 1993; Arvela et al., 2010; Black et al., 2005; 
Casserly, 2008; Conrad et al., 2009). 
Complementary efforts for limb preservation were achieved in the plastic reconstructive 
surgery field, by applying the AM policy for perfusion in tissue rebuilding. The concept 
delineates the human body in specific 3D blocks of tissue, fed by peculiar arterial and 
venous bundles of blood supply (Attinger et al., 2001, 2006; Taylor et al., 1990, 1998). 
Originally pioneered for the pediculated flaps techniques, the AM strategy (Attinger et al., 
2006; Taylor et al., 1998) was also applied to improve healing in lower limb ischemic ulcers 
(Alexandrescu et al., 2008; Neville et al., 2009; Varela et al., 2010; Setacci et al., 2010). Based 
on the anatomical studies of Taylor (Taylor et al., 1990, 1998) and Attinger (Attinger et al., 
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were described. Schematically, in the foot and lower ankle were initially allocated 5 
angiosomes (Attinger et al., 2006; Taylor et al., 1998) depending on the three main tibial 
trunks : the anterior, the posterior tibial and the peroneal arteries. A succinct exemplification 
of the corresponding skin sectors is showed in Fig. 1. Each angiosome encompasses an 
arterial (arteriosome) and correspondent venous (venosome) participation (Taylor et al., 
1990, 1998). Particularly for this chapter, a specific venosome-orientation (concerning the 
venous facet of each angiosome) (Alexandrescu et al., 2011; Taylor et al., 1990) in deep calf 
veins arterialization was designed (Fig. 3b).  
Deep veins arterialization in ESRD and diabetic CLI patients may offer the advantage to 
direct flow in the deep calf venous conduits spared from typical type II calcifications (Irvin & 
Guzman, 2009) and extended chronic occlusions (Lu et al., 2006; Toursarkissian et al., 2002). 
This may enable to deliberately choose specific distal territories (Fig. 4 and 5) to be reperfused 
(Alexandrescu et al., 2011). It may also fit selected extreme situations for limb salvage, 
despite irrecoverable occlusions of the arterial network (Alexandrescu et al., 2011; Lu et al., 
2006). The concept of venous arterialization to treat advanced CLI presentations has 
emerged as an extreme therapeutic alternative in cases with impracticable conventional 
arterial reconstructions (Jacop et al., 1999; Lu et al., 2006). In Table I, are schematized the 
main features of the patients addressed for this technique. The majority of arterializations 
for “hopeless” CLI presentations intended for amputation were described in the literature 
using the available superficial venous system (Jacop et al., 1999; Lengua et al., 2001; Lu et al., 
2006). A growing number of contemporary reports seem to provide rather encouraging 
(Lengua et al., 2001; Lu et al., 2006) than pessimistic results (Matzke et al., 1999) concerning 
this evolving technique. In most of the published studies, the arterialized venous conduit 
and the distal anastomosis are located at different levels in the superficial saphenous 
system, usually adding destruction of the appended valves (Lengua et al., 2001; Lu et al., 
2006; Ozbek et al., 2005). In this setting, the arterialization of the superficial venous network 
carries however, some possible limitations: a) its availability (particularly in ESRD, diabetic 
CLI patients with huge dialysis-access and cardio-vascular surgical past) and b) the presence 
of surrounding inflammation, sepsis and edema. This latest factor affects the “quality” of the 
surounding venous bed and hampers further graft preparation or its accessibility to the 
distal foot anastomosis (Alexandrescu et al., 2011; Lu et al., 2006). Furthermore, in these 
situations the eventual affiliation of the AM concept may be problematic, as the saphenous 
network offers only limited choices in targeting specific areas for foot arterializations 
(Alexandrescu et al., 2011). Only odd reports are focusing until yet, on alternative deep 
veins arterialization for CLI limb salvage. This strategy was however previously proposed, 
either in experimental (Ozek et al. 1997) or as staged interventions (Chen et al., 1998; Lu et 
al., 2006), without systematic valvular avulsion.  
Although rational, the genuine concept for distal valves destruction in newly arterializated 
venous conduits, has give rise to different techniques assembling either metallic olives, 
retrograde balloon PTA or 0.035-inc guidewire-enhanced valvular disruption, sustained or 
not by Fogarty catheters (Lu et al., 2006). Other authors have promoted the sole hydraulic 
effect of the new arterial pulsatile flow, as to be adequate enough for counteracting the 
venous valves barrier, especially in the deep venous circulation (Chen et al., 1998; Krisnan & 
Rayman, 2008; Lu et al., 2006). In spite of recent supportive observations (44), this latest 
hypothesis remains controversial (Lu et al., 2006). 
In the author’s group experience, we stressed the concept of restoring limb perfusion in the 
deep venous pathway, for untreatable ESRD ischemic lesions deemed for “classical” arterial 
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reconstructions. Most of these cases featured characteristic infrapopliteal extensive 
occlusions (Casserly, 2008; Conrad et al., 2009; Norgreen et al., 2007; Toursarkissian et al., 
2002) and calcifications (Alexandrescu, 2009; Irvin & Guzman, 2009; Krisnan & Rayman, 
2008; Leskinen et al., 2002), when all types of conventional reconstructions have previously 
failed or were impracticable (Table I.).  
In this setting, bypassing the deep venous network towards the distal foot circulation 
seemed unconditioned neither by tegumental integrity, swelling or tissue infection, nor by 
the availability of saphenous versus other autologous bypass conduits. The current calf 
venous duplication (Wind et al., 1991), may offer the possibility to enhance precise 
arterializations (Fig. 3-5) in one of the twin tibial veins (Alexandrescu et al., 2011), by 
following a specific AM strategy (Alexandrescu et al., 2011; Taylor et al., 1990). To achieve 
this aim, acquiring effective valvular incompetence also proved to be indispensable in our 
experience. This was either primary induced by the first crossing of the 0.035-inch 
hydrophillic guidewire (Fig. 5), or complementary obtained with the passage of a 6-F, 80 cm 
long introducer sheath through the distal deep vein (Fig. 4b and 5b). Nevertheless, the lack 
of residual valvular tensile stress was documented in all the cases by injecting a small 
amount of contrast before proceeding to the embolization stage. A preexistent valvular 
incompetence by vein walls enlargement was witnessed in more than 25% of cases, 
oftentimes without previous evidence for chronic venous insufficiency. This finding may 
correlate the presence of up to 93% neuropathic limbs in this cohort (Table I.), that exhibit 
the previously described “idiosyncratic deep venous distension” context (Alexandrescu et al., 
2011; Boulton et al., 2006; Edmonds, 2008; Pureval et al., 1995). The existence of neuropathy-
associated capillary shunting in diabetic ESRD subjects (Krisnan & Rayman, 2008; Pureval et 
al., 1995), seems to allow local redistribution of the dermal, sub-dermal and muscular blood 
flow and by additional ascendant venous collectors (Calota et al., 2007). This makes possible 
the blood mass transfer from deep calf to the surface, especially as moderate venous 
hypertension appears (Calota et al., 2007; Edmonds, 2008; Krisnan & Rayman, 2008). 
Duplication in tibial veins may allow the arterialized flow to be deliberately oriented 
towards specific ulcerated zones of the distal leg (Alexandrescu et al., 2011; Taylor et al., 
1990) according to the AM policy (Fig. 1 and 2). First described by Taylor et al. (Taylor et al., 
1990, 1998), the “angiosomes model” for perfusion was further developed by Attinger et al. 
(Attinger et al., 2001, 2006) also in the plastic reconstructive surgery field. Although with 
limited contemporary evidence for CLI applications at the present time, this concept seems 
to gain more acceptance in the limb salvage domain (Neville et al., 2009; Varela et al., 2010; 
Setacci et al., 2010) and represents one of the current concerns of our multidisciplinary 
diabetic "foot-team" (Alexandrescu et al., 2008, 2009, 2011). According to their initial 
description, each angiosome encompasses twin arteriosomes and venosomes for blood supply, 
all being interconnected in a vast compensatory system (the”choke vessels”) (Attinger et al., 
2006; Taylor et al., 1998). The arterial side of this “rescue network” relying on adjacent 
angiosomes seems particularly damaged in ESRD/diabetic patients exhibiting peculiar 
medium-sized collaterals depletion by aggressive atherosclerosis joined to small arterial 
septic thrombosis (the already reported “end artery occlusive disease” pattern) (O’Neal, 2008). 
Unlike the arteries, deep calf veins and collaterals seem less affected by this occlusive 
process (Alexandrescu et al., 2011; Krisnan & Rayman, 2008). This important aspect may 
enable deep vein arterialization to access specific leg territories (angiosomes), throughout 
their appended venous communicants (venosomes), in areas although deprived from direct 
arterial connections (Alexandrescu et al., 2011).   
 
Diseases of Renal Parenchyma 
 
240 
were described. Schematically, in the foot and lower ankle were initially allocated 5 
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We used the venosomes orientation (Taylor et al., 1990) joined to the SAVES technique 
(Alexandrescu et al., 2011) in all these marginal candidates for common revascularizations 
and observed correct healing with or without minor amputations in 15 treated limbs (54%). 
Notable trends for tissue recovery however without complete cicatrization were 
documented in 7 others (25%). Major amputation were inevitable in the remnant 6 
presentations (21%).  
It has been stipulated that the “venosomes” allocation may be prone to anatomical 
variations (Taylor et al., 1990) according to the individual distribution of the deep venous 
system (Calota et al., 2007; Taylor et al., 1990; Wind et al., 1991) (Fig. 3). We believe that 
systematic preoperative Duplex assessment joining « on table » road-mapping, may provide 
important information in detecting these venous pecularities (26% limbs in our cohort). We 
also observed that staged embolizations of the major vein collaterals were technically more 
demanding in the posterior tibial territory (Fig. 5), by steady large perforators or 
communicants, sometimes appointing sharp retrograde emergences with more arduous 
cannulation. 
All treated patients expressed discrete to moderate lower limb edemas after arterializations. 
This phenomenon showed generally a spontaneous resolution during the postoperative first 
month. Similar observations in dedicated literature suggest that the more distal the location 
of the outflow anastomosis in long arterio-venous fistulas (femoro-infrapopliteal in our 
technique), the higher likelihood to enhance a better cardiac tolerance (Lengua et al., 2001; 
Ozek et al. 1997).  
As noticed, in one case (4%) persistent limb swelling joining calf compartmental syndrome 
and venous gangrene were documented, unfortunately ending with major amputation.  
In two other cases (8%), cardiac insufficiency symptoms were perceived: one precocious  
and reversible manifestation (in the 30-day complications subset) and one insidious and 
retarded presentation (two months after the procedure), in a severe and inoperable coronary 
context.  
The study presented in this chapter may express some clear limitations: beyond its 
retrospective nature and the small number of cases included, the results in terms of limb 
salvage are not easy to be compared with other series of conventional arterial 
reconstructions or venous arterializations, since the technique itself and the selection criteria 
are different. 
In addition, the “SAVES” method represent only an evolving therapeutic option, since 
specific difficulties and related complications (notably the collateral embolization stage), 
may be subject for further technical improvements. A larger clinical experience and skills, 
joining more sophisticated devices for endovascular navigation and collateral occlusion (like 
modular micro-catheters, specific pro-thrombotic substances or embolic microspheres) may 
probably contribute to further technical refinements. Finally, to accurately evaluate and 
compare limb preservation in this subset of diabetic and renal patients oftentimes implies 
(beyond reestablishing limb perfusion) the undeniable implication of multi-disciplinary 
team surveillance (Abularrage et al., 2010; Alexandrescu et al., 2008; Apelqvist et al., 1993; 
Boulton et al., 2006; Driver et al., 2007; Edmonds, 2008; Norgreen et al.). 
5. Conclusion 
Deep calf venous arterialization (the SAVES-method) may represent an extreme alternative 
for limb salvage in selected, inoperable presentations for conventional arterial 
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revascularization. The association of an angiosome strategy seems, at this stage of the 
available clinical experience, a possible useful method to enhance distal ulcer healing. 
Larger studies, providing comparative and randomized data are thus needed, as to ascertain 
these preliminary observations.  
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1. Introdution 
Diabetes and its devastating complications reduce life expectancy and adversely affect 
quality of life amongst those affected, thus, posing immense challenges to many societal 
sectors. The upsurge in the prevalence of diabetes from 171 million in 2000 to 366 million by 
2030 as projected by the World Health Organization threatens to overwhelm the economic 
and healthcare system globally.  
In type 1 diabetes the prevalence gradually increases from onset of disease (6% after 1–3 
years), reaching over 50% after 20 years [Warram, 1996]. In type 2 diabetes the prevalence is 
20–25% in both newly diagnosed and established diabetes [Mogensen, 1994]. Approximately 
40% of patients with type 1 diabetes and 20 to 40% of those with type 2 diabetes will 
eventually develop diabetic nephropathy, although the reason why not all patients with 
diabetes develop this complication is unknown.  
In both types of diabetes, chronic hyperglycemia is the primary cause of the disease. In type 
1 diabetes hyperglycemia starts in the first decades of life and is usually the only recognized 
cause of nephropathy. On the contrary, in type 2 diabetes  hyperglycemia starts after the 
forties, usually when the kidneys have already suffered the long‐term consequences of 
ageing and of other recognized promoters of chronic renal injury such as arterial 
hypertension, obesity, dyslipidemia, and smoking [Ruggenenti, 2000]. Similar histological 
and clinical courses in all diabetic individuals indicated that the pathogenesis of 
nephropathy is similar in patients with type 1 and type 2 diabetes mellitus. 
The kidney is an extremely complex organ with broad ranging functions in the body, 
including, but not restricted to, waste excretion, ion and water balance, maintenance of blood 
pressure, glucose homeostasis and generation of erythropoietin or activation of vitamin D. 
With diabetes, many of these integral processes are interrupted via a combination of 
hemodynamic and metabolic changes; hyperglycemia also activates a series of changes leading 
to glomerular and tubular dysfunction and accelerates glomerular cell apoptosis [Forbes, 
2010]. Different pathogenetic, hemodynamic and metabolic processes can lead to diabetic 
kidney disease. In recent years, great progress has been made in understanding the risk factors 
and pathogenetic processes in diabetic nephropathy. In addition, new insight into the 
pathophysiology of this chronic disease has lead to better preventive therapies, treatment 
possibilities and reduced progression to end stage renal disease. 
Diabetic kidney disease refers to a characteristic set of structural and functional kidney 
abnormalities in patients with diabetes. Classic glomerulosclerosis is characterized by 
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increased glomerular basement membrane width, diffuse mesangial sclerosis, hyalinosis, 
microaneurysm, and hyaline arteriosclerosis [Mauer, 1981]. The structural abnormalities 
include hypertrophy of the kidney, increase in glomerular basement membrane thickness, 
nodular and diffuse glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The 
functional alterations include an early increase in glomerular filtration rate with 
intraglomerular hypertension, subsequent proteinuria, systemic hypertension, and eventual 
loss of renal function [Ayodele - 2004].  
The management of patients with type 2 diabetes and progressive kidney disease requires a 
comprehensive approach that includes aggressive blood pressure control with agents that 
also lower urinary protein excretion and optimization of glucose and lipid control, 
considering the therapeutic limitations imparted by renal dysfunction. Clinicians must also 
address the comorbidities associated with renal failure such as anemia and secondary 
hyperparathyroidism. Diabetic nephropathy typically follows a slowly progressive course 
from albuminuria to azotemia. Consequently, optimal care includes planning for the 
management of impending renal failure long before the patient requires dialysis or 
transplantation. 
The aim of this chapter is to provide a comprehensive review about the risk factors, the 
histological changes and the pathogenic mechanisms that lead to diabetic 
nephropathy/diabetes kidney disease, diagnosis, new biomarkers and recent developments 
in the prevention and treatment of diabetes kidney disease, targeting the main risk factors 
and resulting in renal protection and reduced disease progression. 
2. Diabetic nephropathy or diabetic kidney disease?  
The phenomenon of albuminuria has been recognized for more than 200 yr, and its association 
with kidney disease dates to the epochal insights of Richard Bright in 1827 [Cameron, 1988]. 
The presence of microalbuminuria is associated with increased cardiovascular morbidity and 
mortality, and regular screening is recommended in guidelines for diabetes care. Albuminuria 
reflects functional and potentially reversible abnormalities initiated by glomerular 
hyperfiltration, proteinuria, a size-selective dysfunction of the glomerular barrier normally 
associated with glomerular filtration rate (GFR) decline that may result in end-stage renal 
disease [Ruggenenti, 2006].  
The Diabetes and Chronic Kidney Disease work group of the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative suggested that chronic kidney disease 
considered to be caused by diabetes should be named "diabetic kidney disease" and the term 
"diabetic nephropathy" should be reserved for kidney disease attributed to diabetes with 
histopathological changes, demonstrated by renal biopsy [Cavanaugh - 2007]. Progression 
from normoalbuminuria to microalbuminuria defines the initiation of diabetic nephropathy, 
and the transition from microalbuminuria to overt diabetic nephropathy resulting in 
deterioration of renal function and end-stage renal disease constitutes its progression.  
Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 
μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive 
decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an 
increased risk for cardiovascular morbidity and mortality. 
3. The initiation of diabetic kidney disease 
Generalized endothelial dysfunction and inflammation are important antecedents of 
microalbuminuria in both types of diabetes. Markers of endothelial dysfunction, including 
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elevated serum von Willebrand factor (vWF) and increased transcapillary albumin escape 
rate, are present before the onset of microalbuminuria in type 1 diabetes and worsen in 
association with it. Type 2 diabetes is often complicated by the presence of other risk factors 
for vascular disease, and discerning the contribution of hyperglycemia and its sequel to 
endothelial dysfunction in this condition is more difficult [Satchell, 2008]. While in some 
type 2 diabetic patients microalbuminuria may occur in the absence of evidence of 
endothelial dysfunction, in others, vWF levels predict its development [Stehouwer, 2002]. 
Markers of chronic low-grade inflammation, including C-reactive protein (CRP), are also 
correlated with microalbuminuria in type 1 and type 2 diabetes [Schalkwijk, 1999]. 
4. The natural progression of diabetic kidney disease 
In an initial phase, diabetic kidney disease is characterized by glomerular hyperfiltration 
due to a reduction in the resistance of the afferent and efferent glomerular arterioles, and 
consequent increased renal perfusion. The natural progression of diabetic nephropathy has 
been well studied in type 1 diabetes by Mogenson et al. There are 5 stages of diabetic kidney 
disease: 
Stage 1: Stage of hyperfiltration is characterized by renal hypertrophy and renal hyperfiltration. 
Increased glomerular filtration leads to increased urinary albumin excretion rate (increases by 
20- 40 percent) along with increase in renal blood flow by 9 -14 percent.  
Stage 2: Renal hyperfiltration with increased glomerular filtration pressure persists, but there 
is normalization of urinary albumin excretion rate and normal blood pressure.  
Stage 3: Incipient nephropathy or stage of microalbuminuria is characterised by urinary albumin 
excretion rate of 30 -300 mg per day, with a rise of blood pressure. More characteristic is the 
impaired nocturnal dip in blood pressure. Microscopically, the renal biopsy (or histology) 
shows increased basement membrane thickness and increased mesangium.  
Stage 4: Overt nephropathy is characterized by progressive drop in glomerular filtration rate 
by 10 ml per minute per year, while proteinuria increases at the rate of 15 – 40 percent per 
year and hypertension ensues.  
Stage 5: End stage renal disease occurs at about 7 -14 years from stage 4 requiring renal 
replacement therapy. 
However, it is often difficult to document these various stages in a diabetic patient in clinical 
practice because of confounding factors, such as blood pressure medications, which modify 
the natural course of diabetic nephropathy. 
A greater proportion of patients with type-2 diabetes compared with type-I diabetes have 
microalbuminuria and overt nephropathy at or shortly after diagnosis of diabetes. This is 
because the disease may have been present for several years before the diagnosis. In addition, 
concomitant presence of hypertension at the time of diagnosis also contributes to the high 
prevalence of microalbuminuria in type-2 diabetes. Progression from microalbuminuria to 
overt nephropathy occurs in 20-40% of Caucasians within a 10-year period, with 
approximately 20% of those with overt nephropathy progressing to ESRD over a period of 20 
years [Ayodele, 2004]. 
5. Epidemiology 
Diabetic kidney disease is one of the most serious complications of diabetes mellitus and is 
the leading cause of end stage renal disease both in the USA and in Europe, requiring renal 
 
Diseases of Renal Parenchyma 
 
248 
increased glomerular basement membrane width, diffuse mesangial sclerosis, hyalinosis, 
microaneurysm, and hyaline arteriosclerosis [Mauer, 1981]. The structural abnormalities 
include hypertrophy of the kidney, increase in glomerular basement membrane thickness, 
nodular and diffuse glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The 
functional alterations include an early increase in glomerular filtration rate with 
intraglomerular hypertension, subsequent proteinuria, systemic hypertension, and eventual 
loss of renal function [Ayodele - 2004].  
The management of patients with type 2 diabetes and progressive kidney disease requires a 
comprehensive approach that includes aggressive blood pressure control with agents that 
also lower urinary protein excretion and optimization of glucose and lipid control, 
considering the therapeutic limitations imparted by renal dysfunction. Clinicians must also 
address the comorbidities associated with renal failure such as anemia and secondary 
hyperparathyroidism. Diabetic nephropathy typically follows a slowly progressive course 
from albuminuria to azotemia. Consequently, optimal care includes planning for the 
management of impending renal failure long before the patient requires dialysis or 
transplantation. 
The aim of this chapter is to provide a comprehensive review about the risk factors, the 
histological changes and the pathogenic mechanisms that lead to diabetic 
nephropathy/diabetes kidney disease, diagnosis, new biomarkers and recent developments 
in the prevention and treatment of diabetes kidney disease, targeting the main risk factors 
and resulting in renal protection and reduced disease progression. 
2. Diabetic nephropathy or diabetic kidney disease?  
The phenomenon of albuminuria has been recognized for more than 200 yr, and its association 
with kidney disease dates to the epochal insights of Richard Bright in 1827 [Cameron, 1988]. 
The presence of microalbuminuria is associated with increased cardiovascular morbidity and 
mortality, and regular screening is recommended in guidelines for diabetes care. Albuminuria 
reflects functional and potentially reversible abnormalities initiated by glomerular 
hyperfiltration, proteinuria, a size-selective dysfunction of the glomerular barrier normally 
associated with glomerular filtration rate (GFR) decline that may result in end-stage renal 
disease [Ruggenenti, 2006].  
The Diabetes and Chronic Kidney Disease work group of the National Kidney Foundation 
Kidney Disease Outcomes Quality Initiative suggested that chronic kidney disease 
considered to be caused by diabetes should be named "diabetic kidney disease" and the term 
"diabetic nephropathy" should be reserved for kidney disease attributed to diabetes with 
histopathological changes, demonstrated by renal biopsy [Cavanaugh - 2007]. Progression 
from normoalbuminuria to microalbuminuria defines the initiation of diabetic nephropathy, 
and the transition from microalbuminuria to overt diabetic nephropathy resulting in 
deterioration of renal function and end-stage renal disease constitutes its progression.  
Diabetic kidney disease is characterized by persistent albuminuria (>300 mg/dl or >200 
μg/min) that is confirmed on at least 2 occasions 3 to 6 months apart, with a progressive 
decline in the glomerular filtration rate (GFR), elevated arterial blood pressure, and an 
increased risk for cardiovascular morbidity and mortality. 
3. The initiation of diabetic kidney disease 
Generalized endothelial dysfunction and inflammation are important antecedents of 
microalbuminuria in both types of diabetes. Markers of endothelial dysfunction, including 
 
Diabetes and Renal Disease 
 
249 
elevated serum von Willebrand factor (vWF) and increased transcapillary albumin escape 
rate, are present before the onset of microalbuminuria in type 1 diabetes and worsen in 
association with it. Type 2 diabetes is often complicated by the presence of other risk factors 
for vascular disease, and discerning the contribution of hyperglycemia and its sequel to 
endothelial dysfunction in this condition is more difficult [Satchell, 2008]. While in some 
type 2 diabetic patients microalbuminuria may occur in the absence of evidence of 
endothelial dysfunction, in others, vWF levels predict its development [Stehouwer, 2002]. 
Markers of chronic low-grade inflammation, including C-reactive protein (CRP), are also 
correlated with microalbuminuria in type 1 and type 2 diabetes [Schalkwijk, 1999]. 
4. The natural progression of diabetic kidney disease 
In an initial phase, diabetic kidney disease is characterized by glomerular hyperfiltration 
due to a reduction in the resistance of the afferent and efferent glomerular arterioles, and 
consequent increased renal perfusion. The natural progression of diabetic nephropathy has 
been well studied in type 1 diabetes by Mogenson et al. There are 5 stages of diabetic kidney 
disease: 
Stage 1: Stage of hyperfiltration is characterized by renal hypertrophy and renal hyperfiltration. 
Increased glomerular filtration leads to increased urinary albumin excretion rate (increases by 
20- 40 percent) along with increase in renal blood flow by 9 -14 percent.  
Stage 2: Renal hyperfiltration with increased glomerular filtration pressure persists, but there 
is normalization of urinary albumin excretion rate and normal blood pressure.  
Stage 3: Incipient nephropathy or stage of microalbuminuria is characterised by urinary albumin 
excretion rate of 30 -300 mg per day, with a rise of blood pressure. More characteristic is the 
impaired nocturnal dip in blood pressure. Microscopically, the renal biopsy (or histology) 
shows increased basement membrane thickness and increased mesangium.  
Stage 4: Overt nephropathy is characterized by progressive drop in glomerular filtration rate 
by 10 ml per minute per year, while proteinuria increases at the rate of 15 – 40 percent per 
year and hypertension ensues.  
Stage 5: End stage renal disease occurs at about 7 -14 years from stage 4 requiring renal 
replacement therapy. 
However, it is often difficult to document these various stages in a diabetic patient in clinical 
practice because of confounding factors, such as blood pressure medications, which modify 
the natural course of diabetic nephropathy. 
A greater proportion of patients with type-2 diabetes compared with type-I diabetes have 
microalbuminuria and overt nephropathy at or shortly after diagnosis of diabetes. This is 
because the disease may have been present for several years before the diagnosis. In addition, 
concomitant presence of hypertension at the time of diagnosis also contributes to the high 
prevalence of microalbuminuria in type-2 diabetes. Progression from microalbuminuria to 
overt nephropathy occurs in 20-40% of Caucasians within a 10-year period, with 
approximately 20% of those with overt nephropathy progressing to ESRD over a period of 20 
years [Ayodele, 2004]. 
5. Epidemiology 
Diabetic kidney disease is one of the most serious complications of diabetes mellitus and is 
the leading cause of end stage renal disease both in the USA and in Europe, requiring renal 
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replacement therapy. As the population of patients with diabetes of long duration grows, 
reports of a dramatically increasing burden of diabetic nephropathy are appearing. Globally 
the burden of diabetes is expected to double between 2000 and 2030, with the greatest 
increases in prevalence expected to occur in the Middle East, sub-Saharan Africa, and India 
(KDOQI Clinical Practice Guidelines). This increased risk and more rapid progression of 
diabetic nephropathy also has been reported in immigrants from developing to developed 
countries (KDOQI Clinical Practice Guidelines) [Burney, 2009].  
Diabetic kidney disease affects males and females equally and rarely develops before 10 
years’ duration of type 1 DM. The peak incidence (3%/year) is usually found in persons 
who have had diabetes for 10-20 years. The mean age of patients who reach end-stage 
kidney disease is about 60 years. Although in general, the incidence of diabetic nephropathy 
is higher among elderly persons who have had type 2 diabetes for a longer period, the role 
of age in the development of diabetic kidney disease is unclear. In Pima Indians with type 2 
diabetes, the onset of diabetes at a younger age was associated with a higher risk of 
progression to end-stage kidney disease.  
6. Risk factors 
Although diabetes is often accompanied by hyperglycemia, hypertension, and altered lipid 
profile, surprisingly, most individuals with type 1 or type 2 diabetes do not develop diabetic 
nephropathy. This suggests that other factors are involved [Hall, 2006]. Persuasive 
evidences have implicated also nontraditional risk factors including lipid disorders, chronic 
inflammation and anemia in the development of diabetic kidney disease. 
6.1 Race 
The incidence and severity of diabetic kidney disease are increased in blacks, Mexican 
Americans, Pima Indians, and Hispanics compared with Caucasians. Even after adjusting 
for confounding factors such as lower socioeconomic status and increased incidence of 
hypertension in blacks, there is still a 4.8 times greater risk of ESRD in blacks compared to 
Caucasians [Ayodele, 2004]. 
6.2 Aging 
Ageing is per se a cause of progressive glomerulosclerosis and combined with the risk factors 
may contribute to the specific arteriolosclerotic changes, that often coexist with, and 
occasionally overwhelm, the typical features of diabetic glomerulopathy, in particular in 
type 2 diabetes [Ruggeneti, 1998]. Renal blood flow and GFR diminish over time in elderly 
persons, minimized by a rise in the filtration fraction. In older diabetic patients, the decrease 
in kidney mass, particularly the renal cortex, and the histological changes of diabetic 
nephropathy are compounded by advanced vascular changes. Pathologically, the aging 
kidney may be associated with basement membrane thickening and mesangial expansion 
that are also key histological features of diabetic glomerulopathy. Global glomerulosclerosis 
affecting the kidneys of elderly persons may relate to hyperperfusion, also observed in 
diabetes. However, studies about the diagnosis and prevalence of diabetic kidney disease in 
the elderly are lacking [Williams, 2009]. 
6.3 Smoking 
Smoking is a risk factor for diabetic nephropathy and might contribute to its progression 
[64]. Although some studies did not confirm these observations, it is strongly recommended 
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to quit smoking in any phase of DN, also aiming to reduce the associated cardiovascular 
and cancer risk [Luk, 2008]. 
6.4 Genetic risk factors 
Genetic susceptibility is one of the determinants of progression and severity in diabetic 
kidney disease. Several genes predisposing to type 2 diabetes have recently been identified. 
In addition to the recognized and powerful effects of environmental factors, there is 
abundant evidence in support of genetic susceptibility to the microvascular complication of 
nephropathy in individuals with both type 1 and type 2 diabetes. Familial aggregation of 
phenotypes such as end-stage renal disease, albuminuria, and chronic kidney disease have 
routinely been reported in populations throughout the world, and heritability estimates for 
albuminuria and glomerular filtration rate demonstrate strong contributions of inherited 
factors. Recent genome-wide linkage scans have identified several chromosomal regions 
that likely contain diabetic nephropathy susceptibility genes, and association analyses have 
evaluated positional candidate genes under these linkage peaks. These complimentary 
approaches have demonstrated that polymorphisms in the carnosinase 1 gene on 
chromosome 18q, the adiponectin gene on 3q, and the engulfment and cell motility gene on 
7p are likely associated with susceptibility to diabetic nephropathy [Freedman - 2007]. 
6.5 Arterial hypertension 
Increase of arterial blood pressure is an early and frequent phenomenon in diabetic 
nephropathy as well as in the development of macrovascular lesions. There has been some 
recent evidence that genetic predisposition to hypertension may predispose to the 
development of diabetic kidney disease. In diabetic kidney disease hypertension is not 
merely the result of relentless kidney damage. There is considerable clinical evidence that 
the elevated arterial pressure is also important in the genesis of the glomerular lesion. 
Indeed the development of proteinuria is paralleled in most cases by a gradual increase in 
systemic blood pressure, and there is a significant correlation between the blood pressure 
levels and the rate of decline in glomerular filtration rate [Mogensen, 1985]. In type 2 
diabetes, lowering blood pressure, regardless of the used agent, retards the onset and 
progression of diabetic nephropathy [Schrier, 2002]. In type 1 diabetes, Lurbe et al. have 
noted that an insufficient decline in nighttime blood pressure (nondipping) preceded the 
onset of microalbuminuria [Lurbe, 2002]. Although the type 2 diabetic patient is usually 
hypertensive before the onset of nephropathy, nephropathy aggravates the severity of 
hypertension. 
6.6 Hyperglycemia 
The hyperglycemic state itself is a strong risk factor for diabetic kidney disease and causes 
the proliferation of mesangial cells and their matrix, as well as the thickening of the 
basement membrane. In recent years, many discoveries elucidated the mechanisms by 
which hyperglycemia affect the renal glomerular and tubulointerstitial cells and suggested 
that podocyte injury have a pivotal role in the pathogenesis of diabetic glomerulopathy. 
Molecular pathogenesis of diabetic podocyte injury is likely multifactorial involving a 
number of interrelated signaling pathways that have yet to be well understood. Sustained 
hyperglycemia affects the glomerular cells by various mechanisms. The changes lead to 
altered structure and function in the glomerulus.  
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hypertensive before the onset of nephropathy, nephropathy aggravates the severity of 
hypertension. 
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The hyperglycemic state itself is a strong risk factor for diabetic kidney disease and causes 
the proliferation of mesangial cells and their matrix, as well as the thickening of the 
basement membrane. In recent years, many discoveries elucidated the mechanisms by 
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number of interrelated signaling pathways that have yet to be well understood. Sustained 
hyperglycemia affects the glomerular cells by various mechanisms. The changes lead to 
altered structure and function in the glomerulus.  
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6.7 Lipid disorders 
Patients with diabetes have a variety of disorders of plasma lipids. These lipid abnormalities 
are known to contribute to cardiovascular risk. The role of lipids in diabetic nephropathy is 
not clear [Hall, 2006]. In type 2 DM, elevated serum cholesterol is a risk factor for the 
development of DN. In type 1 DM patients increased serum triglycerides, total and LDL-
cholesterol were associated with micro- and macroalbuminuria. High serum cholesterol also 
seems to be a risk factor for GFR loss in macroalbuminuric type 1 diabetic subjects [ 
Zelmanovitz - 2009]. 
For many decades, obesity has been known to cause structural changes to the renal 
parenchyma, and biopsies from obese subjects consistently showed glomerulomegaly with 
or without focal segmental glomerulosclerosis. Several mechanisms have been proposed to 
explain obesity-related renal changes. One explanation is the greater work load imposed on 
the kidneys as a direct result of larger body mass, as increased tissue turnover and toxic 
output place additional strains on the nephrons. Another hypothesis is lipotoxicity: the 
exposure of renal tissues to excess free fatty acid leads to generation of oxidative stress and 
cytotoxic lipid products. Recent attention has focused on adipose tissue as a rich source of 
pro-inflammatory cytokines and growth factors such as tumor necrosis factor a, interleukin-
6 and leptin. The plethora of circulating cytokines is believed to have direct effects on renal 
hemodynamics and glomerular cellularity [Luk, 2008]. 
Ravid et al. found that the level of cholesterol both at onset and after a five-year follow-up 
period was positively related with the subsequent increase in urinary albumin excretion in 
microalbuminuric patients with type-2 diabetes [Ravid, 1995]. Gall et al. found that total 
serum cholesterol was significantly associated with development of abnormally increased 
urinary albumin excretion [Gall, 1997]. Klein et al. in a study of type-I individuals, found 
that higher total serum cholesterol and lower HDL cholesterol were associated with 
incidence of renal insufficiency [Klein, 1999]. 
6.8 Increased protein intake 
Protein intake: 0.8 – 1.0 gram per kilogram body weight per day in patients with normal 
renal functions and decrease to 0.6-0.8 gram per kilogram body weight per day once 
proteinuria sets in. High intakes of animal protein have been shown to increase renal blood 
flow and glomerular filtration rate (GFR) whereas soy protein does not appear to have this 
effect. Substituting soy protein for animal protein has been found to decrease hyperfiltration 
in subjects with diabetes and may reduce urine albumin excretion [Song, 2004]. 
6.9 Chronic inflammation 
With the recognition of the central role played by inflammatory processes in cardiovascular 
disease and both type 1 and type 2 diabetes, the association between potentially modifiable 
inflammatory biomarkers and clinical outcomes such as nephropathy and cardiovascular 
disease in diabetes is of interest. Moreover, although diabetic nephropathy has traditionally 
not been considered an inflammatory nephritis, more recent evidence that macrophage 
accumulation is characteristic for diabetic glomerulosclerosis has challenged this perception 
[Foruta, 1993].  
Recent studies suggested that inflammatory processes and immune cells might be involved 
in the development and progression of diabetic nephropathy. Infiltrated macrophages are 
found within renal diabetic tissues, and recent studies demonstrated that macrophage-
derived products can induce further inflammation in the diabetic kidney. Furthermore, 
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activated T lymphocytes have been associated with diabetic nephropathy. One of the most 
striking features of leukocytes from patients with diabetes is the activated status of blood 
neutrophils. There is no doubt that immune cells participate in the vascular injury in the 
conditions of diabetic nephropathy, and their migration into the kidney is a crucial step in 
the progression of this disease [Galkina - 2006]. A few cross-sectional studies of individuals 
with type 1 diabetes have reported associations between increased albumin excretion rate 
and elevated levels of inflammatory markers including high-sensitivity (hs) C-reactive 
protein (CRP), soluble (s) tumor necrosis factor-α receptor-1 (TNFR-1), intercellular 
adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1), but 
whether the elevation of these inflammatory markers precedes nephropathy progression is 
not well described.  
Inflammatory cytokines and growth factors, mainly VEGF, TGF-ß, IL-1, IL-6, and IL-18, as 
well as TNF-α, are also involved in the development and progression of DKD [Navarro-
Gonzales, 2008]. If inflammation contributes to the development of nephropathy, it would 
represent a potential therapeutic target for slowing the microvascular and macrovascular 
complications of diabetes [Lin, 2008]. 
6.10 Anemia 
Anemia is a common finding in patients with diabetes, particularly in those with overt 
nephropathy or renal impairment. Anemia in patients with diabetes is not restricted to those 
with renal impairment, as about half have normal renal function. Failure to up-regulate 
erythropoietin production in response to a declining hemoglobin level has been suggested 
to be the primary mechanism leading to chronic anemia. Accordingly, the presence of 
anemia may be a distinctive marker for renal tubulointerstitial dysfunction even before 
overt nephropathy manifests [Luk, 2008]. The precise mechanisms by which diabetes 
impairs the renal erythropoietin response to reduced Hb remain to be established. While 
functional erythropoietin deficiency is clearly linked to renal dysfunction in diabetes, the 
reduction in synthesis of erythropoietin in response to anemia appears to be beyond that 
seen in other renal (and particularly glomerular) diseases. A number of mechanisms 
potentially contribute to the preferential development of anemia in patients with diabetes. 
For example, the predominance of damage to specific cells and to the vascular architecture 
of the renal tubulo-interstitium, and the resulting systemic inflammation, autonomic 
neuropathy, and induction of inhibitors of erythropoietin release, have all been suggested as 
contributors to impaired renal erythropoietin production and release [Thomas, 2006]. 
Although anemia can be considered a marker of kidney damage, reduced hemoglobin levels 
independently identify diabetic patients with an increased risk of microvascular 
complications, cardiovascular disease and mortality. Nevertheless, a direct role in the 
development or progression of diabetic complications remains to be clearly established and 
the clinical utility of correcting anemia in diabetic patients has yet to be demonstrated in 
randomized controlled trials. Correction of anemia certainly improves performance and 
quality of life in diabetic patients [Thomas, 2007]. 
6.11 Hyperuricemia 
Uric acid has been associated with renal disease, even though hyperuricemia may be a 
marker of or by itself be responsible for microvascular disease in diabetes. In animal models, 
elevated level of uric acid can lead to arteriolopathy of preglomerular vessels, impaired 
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activated T lymphocytes have been associated with diabetic nephropathy. One of the most 
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autoregulation, glomerular hypertension, as well as endothelial dysfunction. Kidney 
damage in hyperuricemic rats is not dependent on blood pressure, and instead involves the 
renin-angiotensin system. In patients with diabetes, serum uric acid early in the course of 
diabetes is significantly, and independent of confounders, associated with later 
development of persistent macroalbuminuria. Therefore, uric acid may be a novel and 
important player in the pathogenesis of microvascular complications in diabetes. A dose-
response relationship between serum uric acid and early decline in renal function has 
recently been demonstrated in patients with type-1 diabetes [Hovind, 2011].  
6.12 Aldosterone  
Another deleterious factor that has been underappreciated until recently is aldosterone. In 
addition to the classic effects of promoting sodium retention and volume expansion, 
aldosterone promotes inflammation, production of cytokines, growth factors and 
endothelial dysfunction, which acts on the renal vasculature, glomeruli and tubules and 
favors the emergence of proteinuria. In the setting of diabetes and longstanding 
hyperglycemia, free amino groups of proteins are non-enzymatically modified by glucose 
and its metabolites to form Schiff bases that eventually lead to the formation of advanced 
glycation end products (AGEs).  
6.13 The use of oral contraceptives 
Oral contraceptive (OC) use is associated with increased intrarenal renin–angiotensin–
aldosterone system (RAA System) activity and risk of nephropathy, though the contribution 
of progestins contained in the OC in the regulation of angiotensin-dependent control of the 
renal circulation has not been elucidated [Sarna, 2009]. 
7. Pathogenic mechanisms 
Multiple mechanisms contribute to the development and outcomes of diabetic nephropathy, 
such as an interaction between hyperglycemia induced metabolic and hemodynamic 
changes and genetic predisposition, which sets the stage for kidney injury [Dronavalli - 
2008]. Extracellular matrix accumulation is one of the hallmarks in the development of the 
disease that leads to the formation of glomerular and interstitial lesions [Deckert, 1981]. 
Multiple biochemical pathways have been postulated that explain how hyperglycemia 
causes tissue damage: nonenzymatic glycosylation that generates advanced glycosylation 
end products, activation of protein kinase C, and acceleration of the polyol pathway.  
8. Increased advanced glycation end products (AGEs) 
Advanced glycation end products (AGEs) are diverse group of molecules and are well 
known heterogeneous compounds formed nonenzymatically through an interaction of 
reducing sugar with free amino group of proteins, lipids and nucleic acids [Krishan, 2010]. 
AGEs form at a constant rate in the normal body; however, in diabetes, this process is 
drastically increased. Accumulation of AGEs in the kidney may contribute to the 
progressive alteration in renal architecture and loss of renal function in patients and rodents 
via various mechanisms, including their cross-linking properties of matrix proteins and 
activation of the downstream signaling. AGEs may produce functional changes in the 
kidney by cross-linking with the glomerular basement membrane and other vascular 
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membranes. AGE binding proteins may also be involved. The best defined is the receptor 
for AGEs (RAGE). Three main consequences have been found in association with AGEs 
inside cells: (1) functional alterations of intracellular proteins, (2) altered interaction with 
AGE receptors, and (3) altered interactions with matrix and other cells. Binding of AGEs to 
RAGEs activates cell signaling mechanisms coupled to increased transforming growth 
factor-ß (TGF-ß) and vascular endothelial growth factor (VEGF) expression, which are 
increased in diabetic nephropathy and are thought to contribute to diabetes complications. 
8.1 Increased transforming growth factor ß1  
Studies in rodent models have suggested that reduction in renal transforming growth factor 
(TGF)-β1 may underlie the renoprotective effects of the renin-angiotensin system (RAS) 
blockade [Langham, 2006]. Over the past several years, experimental evidence consistently 
has suggested a key role for TGF-β in the pathogenesis of the extracellular matrix 
accumulation that characterizes diabetic nephropathy and closely correlates with declining 
renal function [Mauer, 1984]. Angiotensin II potently induces synthesis of transforming 
growth factor (TGF)-β, a profibrotic growth factor consistently implicated in the 
pathogenesis of diabetic nephropathy [Border, 1996]. The mechanisms for this fibrogenic or 
prosclerotic action of TGF-β are multiple and include both stimulation of extracellular 
matrix synthesis and inhibition of its degradation [Bruijn, 1996]. 
8.2 Activation of protein kinase Cß (PKCß) 
Other proposed mechanisms by which hyperglycemia promotes the development of 
diabetic nephropathy include activation of PKC that involves de novo formation of 
diacylglycerol and oxidative stress. Hyperglycemia also increases the generation of 
advanced products of nonenzymatic glycosilation of proteins through activation of aldol 
reductase pathway and protein kinase C (PKC). The final products of non-enzymatic 
glycosilation are bound to collagen and proteins that constitute the glomerular basement 
membrane and make the glomerular barrier more permeable to the passage of proteins, 
resulting in increased urinary albumin excretion [Zelmanovitz, 2009]. Two clinical 
observations explain the possible mechanisms involved. The first is that the hyperglycemic 
state seems to sensitize the endothelium to injury from elevated blood pressure. The second 
observation is that successful pancreas transplant that results in normal insulin regulation 
and normoglycemia is associated with a reversal of the lesions of diabetic nephropathy 
[Lurbe, 2002]. Specifically, activation of this enzyme leads to increased secretion of 
vasodilatory prostanoids, which contributes to glomerular hyperfiltration. By activation of 
TGF-β1, PKC might also increase production of extracellular matrix by mesangial cells. PKC 
activation induces the activity of mitogen-activated protein kinases (MAPK) in response to 
extracellular stimuli through dual phosphorylation at conserved threonine and tyrosine 
residues. The coactivation of PKC and MAPK in the presence of high glucose concentrations 
indicates that these two families of enzymes are linked [Dronavalli, 2008]. 
8.3 Aldose reductase pathway/polyol pathway 
Aldose reductase (AR) is a monomeric reduced nicotinamide adenine dinucleotide (NAD) 
phosphate (NADPH)-dependent enzyme and a member of aldo-keto reductase superfamily. 
Aldose reductase (AR) is widely expressed aldehyde-metabolizing enzyme. The polyol 
pathway is implicated in the pathogenesis of diabetic nephropathy. A number of studies 
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2008]. Extracellular matrix accumulation is one of the hallmarks in the development of the 
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Multiple biochemical pathways have been postulated that explain how hyperglycemia 
causes tissue damage: nonenzymatic glycosylation that generates advanced glycosylation 
end products, activation of protein kinase C, and acceleration of the polyol pathway.  
8. Increased advanced glycation end products (AGEs) 
Advanced glycation end products (AGEs) are diverse group of molecules and are well 
known heterogeneous compounds formed nonenzymatically through an interaction of 
reducing sugar with free amino group of proteins, lipids and nucleic acids [Krishan, 2010]. 
AGEs form at a constant rate in the normal body; however, in diabetes, this process is 
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progressive alteration in renal architecture and loss of renal function in patients and rodents 
via various mechanisms, including their cross-linking properties of matrix proteins and 
activation of the downstream signaling. AGEs may produce functional changes in the 
kidney by cross-linking with the glomerular basement membrane and other vascular 
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membranes. AGE binding proteins may also be involved. The best defined is the receptor 
for AGEs (RAGE). Three main consequences have been found in association with AGEs 
inside cells: (1) functional alterations of intracellular proteins, (2) altered interaction with 
AGE receptors, and (3) altered interactions with matrix and other cells. Binding of AGEs to 
RAGEs activates cell signaling mechanisms coupled to increased transforming growth 
factor-ß (TGF-ß) and vascular endothelial growth factor (VEGF) expression, which are 
increased in diabetic nephropathy and are thought to contribute to diabetes complications. 
8.1 Increased transforming growth factor ß1  
Studies in rodent models have suggested that reduction in renal transforming growth factor 
(TGF)-β1 may underlie the renoprotective effects of the renin-angiotensin system (RAS) 
blockade [Langham, 2006]. Over the past several years, experimental evidence consistently 
has suggested a key role for TGF-β in the pathogenesis of the extracellular matrix 
accumulation that characterizes diabetic nephropathy and closely correlates with declining 
renal function [Mauer, 1984]. Angiotensin II potently induces synthesis of transforming 
growth factor (TGF)-β, a profibrotic growth factor consistently implicated in the 
pathogenesis of diabetic nephropathy [Border, 1996]. The mechanisms for this fibrogenic or 
prosclerotic action of TGF-β are multiple and include both stimulation of extracellular 
matrix synthesis and inhibition of its degradation [Bruijn, 1996]. 
8.2 Activation of protein kinase Cß (PKCß) 
Other proposed mechanisms by which hyperglycemia promotes the development of 
diabetic nephropathy include activation of PKC that involves de novo formation of 
diacylglycerol and oxidative stress. Hyperglycemia also increases the generation of 
advanced products of nonenzymatic glycosilation of proteins through activation of aldol 
reductase pathway and protein kinase C (PKC). The final products of non-enzymatic 
glycosilation are bound to collagen and proteins that constitute the glomerular basement 
membrane and make the glomerular barrier more permeable to the passage of proteins, 
resulting in increased urinary albumin excretion [Zelmanovitz, 2009]. Two clinical 
observations explain the possible mechanisms involved. The first is that the hyperglycemic 
state seems to sensitize the endothelium to injury from elevated blood pressure. The second 
observation is that successful pancreas transplant that results in normal insulin regulation 
and normoglycemia is associated with a reversal of the lesions of diabetic nephropathy 
[Lurbe, 2002]. Specifically, activation of this enzyme leads to increased secretion of 
vasodilatory prostanoids, which contributes to glomerular hyperfiltration. By activation of 
TGF-β1, PKC might also increase production of extracellular matrix by mesangial cells. PKC 
activation induces the activity of mitogen-activated protein kinases (MAPK) in response to 
extracellular stimuli through dual phosphorylation at conserved threonine and tyrosine 
residues. The coactivation of PKC and MAPK in the presence of high glucose concentrations 
indicates that these two families of enzymes are linked [Dronavalli, 2008]. 
8.3 Aldose reductase pathway/polyol pathway 
Aldose reductase (AR) is a monomeric reduced nicotinamide adenine dinucleotide (NAD) 
phosphate (NADPH)-dependent enzyme and a member of aldo-keto reductase superfamily. 
Aldose reductase (AR) is widely expressed aldehyde-metabolizing enzyme. The polyol 
pathway is implicated in the pathogenesis of diabetic nephropathy. A number of studies 
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have shown a decrease in urinary albumin excretion in animals administered aldose 
reductase inhibitors, but in humans these agents have not been studied widely and the 
results are inconclusive [Tilton, 1989]. The reduction of glucose by the AR-catalyzed polyol 
pathway has been linked to the development of secondary diabetic complications 
[Srivastava - 2005]. 
8.4 The protein kinase C (PKC) pathway 
The protein kinase C (PKC) superfamily comprises proteins that are activated in response to 
various pathogenic stimuli in the diabetic state. Hyperglycemia is the predominant stimulus 
that induces the activation of distinct PKC isoforms within a cell, each mediating specific 
functions, probably through differential subcellular localization. Craven and DeRubertis 
[Craven, 1989] and Lee et al. [Lee, 1989] were the first to provide data indicating that 
activation of the PKC system by hyperglycemia may represent an important pathway by 
which glucotoxicity is transduced in susceptible cells in diabetic nephropathy. The putative 
intracellular mechanism is the glucose induced de novo synthesis of diacylglycerol that is 
one of the intracellular activators of PKC [Menne, 2009]. PKC activation is involved in the 
regulation of vascular permeability and contractility, endothelial cell activation and 
vasoconstriction, extracellular matrix (ECM) synthesis and turnover, abnormal 
angiogenesis, excessive apoptosis, leukocyte adhesion, abnormal growth factor signaling 
and cytokine action, as well as abnormal cell growth and angiogenesis, all of which are 
involved in the pathophysiology of diabetic vascular complications [Meier, 2009]. 
8.5 Vascular endothelial growth factor (VEGF) pathway 
Vascular endothelial growth factor (VEGF) is a key regulator of vascular permeability and 
angiogenesis and is implicated in the pathogenesis of diabetic retinal neovascularisation. In 
the glomerulus it is produced in large amounts by podocytes and is thought to be important 
in maintaining glomerular endothelial cell fenestrations [Satchell, 2006]. Hyperglycemia 
increases the expression of vascular endothelial growth factor (VEGF) in podocytes causing 
increased vascular permeability. VEGF has the potential to induce the new vessel growth 
seen in early diabetic nephropathy and to alter the permeability characteristics of the 
endothelium [Kanesaki, 2005]. In human type 1 diabetes, serum VEGF concentrations vary 
according to glycemic control, and higher levels are associated with microvascular 
complications, including microalbuminuria [Chiarelli, 2000]. In type 2 diabetes, VEGF is 
upregulated early in the course of disease and urinary VEGF levels are correlated with 
microalbuminuria [Kim, 2005]. Further studies have confirmed initial upregulation of VEGF 
signalling in type 2 diabetes followed by a down-regulation with podocyte loss and sclerosis 
development [Hohenstein, 2006].  
8.6 Oxidative stress pathway 
A large body of evidence indicates that oxidative stress is the common denominator link for 
the major pathways involved in the development and progression of diabetic micro- as well 
as macrovascular complications of diabetes nephropathy. Both hyperglycemia and 
activation of the renin-angiotensin system play a role in the generation of reactive oxygen 
species (ROS) [Anjaneyulu, 2004]. There are a number of macromolecules that have been 
implicated for increased generation of reactive oxygen species (ROS), such as, NAD(P)H 
oxidase, advanced glycation end products (AGE), defects in polyol pathway, uncoupled 
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nitric oxide synthase (NOS) and mitochondrial respiratory chain via oxidative 
phosphorylation. Excess amounts of ROS modulate activation of protein kinase C, mitogen-
activated protein kinases, and various cytokines and transcription factors which eventually 
cause increased expression of extracellular matrix (ECM) genes with progression to fibrosis 
and end stage renal disease. Activation of renin-angiotensin system (RAS) further worsens 
the renal injury induced by ROS in diabetic nephropathy. Buffering the generation of ROS 
may represent a promising therapeutic to ameliorate renal damage from diabetic kidney 
disease; however, various studies have demonstrated minimal reno-protection by these 
agents [Kashihara - 2010]. These derangements, along with hemodynamic changes, activate 
various cytokines and growth factors such as vascular endothelial growth factor, 
transforming growth factor-β, Interleukin 1 (IL 1), IL-6 and IL-18. 
8.7 The activation of the transcription factor NF-kB  
Patients with diabetic kidney disease have higher monocyte NFκB activity than diabetic 
patients without renal complications. The transcription factor NF-kB helps to control the 
expression of numerous genes activated during inflammation. NF-kB is induced by various 
cell stress–associated stimuli including growth factors, vasoactive agents, cytokines, and 
oxidative stress. NF-kB in turn controls the regulation of genes encoding proteins involved 
in immune and inflammatory responses (i.e., cytokines, chemokines, growth factors, 
immune receptors, cellular ligands, and adhesion molecules) [Schmid - 2006]. Inhibition of 
NFκB reduces interstitial monocyte infiltration in rats with proteinuria, and NFκB is 
believed to play a key role in proteinuria-induced tubulointerstitial damage in diabetes 
[Remuzzi, 1998]. 
9. The histological changes 
Three major histological changes occur in the glomeruli of persons with diabetic kidney 
disease. First, mesangial expansion is directly induced by hyperglycemia, perhaps via 
increased matrix production or glycosylation of matrix proteins. Second, thickening of the 
glomerular basement membrane occurs. Third, glomerular sclerosis is caused by 
intraglomerular hypertension (induced by dilatation of the afferent renal artery or from 
ischemic injury induced by hyaline narrowing of the vessels supplying the glomeruli). These 
different histological patterns appear to have similar prognostic significance. All of these are 
part and parcel of microvascular complications of diabetes. A large body of evidence 
indicates that oxidative stress is the common denominator link for the major pathways 
involved in the development and progression of diabetic micro- as well as macro-vascular 
complications of diabetes. 
Light microscopy findings show an increase in the solid spaces of the tuft, most frequently 
observed as coarse branching of solid (positive periodic-acid Schiff reaction) material 
(diffuse diabetic glomerulopathy). Large cellular accumulations also may be observed 
within these areas. These are circular on section and are known as the Kimmelstiel-Wilson 
lesions/nodules.  
Electron microscopy provides a more detailed definition of the structures involved. In 
advanced disease, the mesangial regions occupy a large proportion of the tuft, with 
prominent matrix content. Further, the basement membrane in the capillary walls (ie, the 
peripheral basement membrane) is thicker than normal. Immunofluorescence microscopy 
may reveal deposition of albumin, immunoglobulins, fibrin, and other plasma proteins 
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have shown a decrease in urinary albumin excretion in animals administered aldose 
reductase inhibitors, but in humans these agents have not been studied widely and the 
results are inconclusive [Tilton, 1989]. The reduction of glucose by the AR-catalyzed polyol 
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that induces the activation of distinct PKC isoforms within a cell, each mediating specific 
functions, probably through differential subcellular localization. Craven and DeRubertis 
[Craven, 1989] and Lee et al. [Lee, 1989] were the first to provide data indicating that 
activation of the PKC system by hyperglycemia may represent an important pathway by 
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one of the intracellular activators of PKC [Menne, 2009]. PKC activation is involved in the 
regulation of vascular permeability and contractility, endothelial cell activation and 
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angiogenesis, excessive apoptosis, leukocyte adhesion, abnormal growth factor signaling 
and cytokine action, as well as abnormal cell growth and angiogenesis, all of which are 
involved in the pathophysiology of diabetic vascular complications [Meier, 2009]. 
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Vascular endothelial growth factor (VEGF) is a key regulator of vascular permeability and 
angiogenesis and is implicated in the pathogenesis of diabetic retinal neovascularisation. In 
the glomerulus it is produced in large amounts by podocytes and is thought to be important 
in maintaining glomerular endothelial cell fenestrations [Satchell, 2006]. Hyperglycemia 
increases the expression of vascular endothelial growth factor (VEGF) in podocytes causing 
increased vascular permeability. VEGF has the potential to induce the new vessel growth 
seen in early diabetic nephropathy and to alter the permeability characteristics of the 
endothelium [Kanesaki, 2005]. In human type 1 diabetes, serum VEGF concentrations vary 
according to glycemic control, and higher levels are associated with microvascular 
complications, including microalbuminuria [Chiarelli, 2000]. In type 2 diabetes, VEGF is 
upregulated early in the course of disease and urinary VEGF levels are correlated with 
microalbuminuria [Kim, 2005]. Further studies have confirmed initial upregulation of VEGF 
signalling in type 2 diabetes followed by a down-regulation with podocyte loss and sclerosis 
development [Hohenstein, 2006].  
8.6 Oxidative stress pathway 
A large body of evidence indicates that oxidative stress is the common denominator link for 
the major pathways involved in the development and progression of diabetic micro- as well 
as macrovascular complications of diabetes nephropathy. Both hyperglycemia and 
activation of the renin-angiotensin system play a role in the generation of reactive oxygen 
species (ROS) [Anjaneyulu, 2004]. There are a number of macromolecules that have been 
implicated for increased generation of reactive oxygen species (ROS), such as, NAD(P)H 
oxidase, advanced glycation end products (AGE), defects in polyol pathway, uncoupled 
 
Diabetes and Renal Disease 
 
257 
nitric oxide synthase (NOS) and mitochondrial respiratory chain via oxidative 
phosphorylation. Excess amounts of ROS modulate activation of protein kinase C, mitogen-
activated protein kinases, and various cytokines and transcription factors which eventually 
cause increased expression of extracellular matrix (ECM) genes with progression to fibrosis 
and end stage renal disease. Activation of renin-angiotensin system (RAS) further worsens 
the renal injury induced by ROS in diabetic nephropathy. Buffering the generation of ROS 
may represent a promising therapeutic to ameliorate renal damage from diabetic kidney 
disease; however, various studies have demonstrated minimal reno-protection by these 
agents [Kashihara - 2010]. These derangements, along with hemodynamic changes, activate 
various cytokines and growth factors such as vascular endothelial growth factor, 
transforming growth factor-β, Interleukin 1 (IL 1), IL-6 and IL-18. 
8.7 The activation of the transcription factor NF-kB  
Patients with diabetic kidney disease have higher monocyte NFκB activity than diabetic 
patients without renal complications. The transcription factor NF-kB helps to control the 
expression of numerous genes activated during inflammation. NF-kB is induced by various 
cell stress–associated stimuli including growth factors, vasoactive agents, cytokines, and 
oxidative stress. NF-kB in turn controls the regulation of genes encoding proteins involved 
in immune and inflammatory responses (i.e., cytokines, chemokines, growth factors, 
immune receptors, cellular ligands, and adhesion molecules) [Schmid - 2006]. Inhibition of 
NFκB reduces interstitial monocyte infiltration in rats with proteinuria, and NFκB is 
believed to play a key role in proteinuria-induced tubulointerstitial damage in diabetes 
[Remuzzi, 1998]. 
9. The histological changes 
Three major histological changes occur in the glomeruli of persons with diabetic kidney 
disease. First, mesangial expansion is directly induced by hyperglycemia, perhaps via 
increased matrix production or glycosylation of matrix proteins. Second, thickening of the 
glomerular basement membrane occurs. Third, glomerular sclerosis is caused by 
intraglomerular hypertension (induced by dilatation of the afferent renal artery or from 
ischemic injury induced by hyaline narrowing of the vessels supplying the glomeruli). These 
different histological patterns appear to have similar prognostic significance. All of these are 
part and parcel of microvascular complications of diabetes. A large body of evidence 
indicates that oxidative stress is the common denominator link for the major pathways 
involved in the development and progression of diabetic micro- as well as macro-vascular 
complications of diabetes. 
Light microscopy findings show an increase in the solid spaces of the tuft, most frequently 
observed as coarse branching of solid (positive periodic-acid Schiff reaction) material 
(diffuse diabetic glomerulopathy). Large cellular accumulations also may be observed 
within these areas. These are circular on section and are known as the Kimmelstiel-Wilson 
lesions/nodules.  
Electron microscopy provides a more detailed definition of the structures involved. In 
advanced disease, the mesangial regions occupy a large proportion of the tuft, with 
prominent matrix content. Further, the basement membrane in the capillary walls (ie, the 
peripheral basement membrane) is thicker than normal. Immunofluorescence microscopy 
may reveal deposition of albumin, immunoglobulins, fibrin, and other plasma proteins 
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along the GBM in a linear pattern most likely as a result of exudation from the blood vessels, 
but this is not immunopathogenetic or diagnostic and does not imply an immunologic 
pathophysiology. The renal vasculature typically displays evidence of atherosclerosis, 
usually due to concomitant hyperlipidemia and hypertensive arteriosclerosis.    
The severity of diabetic glomerulopathy is estimated by the thickness of the peripheral 
basement membrane and mesangium and matrix expressed as a fraction of appropriate 
spaces (eg, volume fraction of mesangium/glomerulus, matrix/mesangium, or 
matrix/glomerulus). The glomeruli and kidneys are typically normal or increased in size 
initially, thus distinguishing diabetic nephropathy from most other forms of chronic renal 
insufficiency, wherein renal size is reduced (except renal amyloidosis and polycystic kidney 
disease).  
10. Clinical diagnosis of diabetic kidney disease  
The clinical diagnosis of diabetic kidney disease is, mainly, based on detection of 
albuminuria from spot urine is recommended because the albumin-creatinine ratio by spot 
urine sample has demonstrated excellent correlation with the 24-hour urine albumin 
measurements. Estimated glomerular filtration rate (eGFR), has been added to the 
albuminuria also as a renal biomarker. Both are indeed associated with renal and 
cardiovascular disease in individuals with diabetes and may be used to identify individuals 
at risk of long-term complications. 
Microalbuminuria, which is an indicator of endothelial dysfunction, and an independent 
marker for cardiovascular morbidity and mortality in individuals with and without diabetes 
is defined as an albumin-creatinine ratio of 30-300 mg/g from a spot urine collection, 
urinary albumin excretion 30-300 mg/24 hours in a 24-hour urine collection, or 20-200 
µg/min in a timed urine collection. 
Macroalbuminuria is defined as an albumin/creatinine ratio (ACR) > 300 mg/g from a spot 
urine collection, urinary albumin excretion > 300 mg/24 hours in a 24-hour urine collection, 
or >200 µg/min in a timed urine collection. For initial screening of diabetic kidney disease, 
the measurement of albuminuria from spot urine is recommended because the ACR by spot 
urine sample has demonstrated excellent correlation with the 24-hour urine albumin 
measurements. 
If the determination of albuminuria cannot be performed at diagnosis, we can measure 
proteinuria. Microproteinuria is defined by a value between 300-500 mg/24 hours and 
macroproteinuria is defined by a value higher than 500 mg/24 hours. Serum markers of 
glomerular filtration rate and microalbuminuria identify renal impairment in different 
segments of the diabetic population, indicating that serum markers as well as 
microalbuminuria tests should be used in screening for nephropathy in diabetic patients.  
There is accumulating evidence suggesting that the risk for developing diabetic nephropathy 
and cardiovascular disease starts when UAE values are still within the normoalbuminuric 
range [Gerstein, 2001]. After the diagnosis of micro- or macroalbuminuria is confirmed, 
patients should undergo a complete evaluation, including a work-up for other etiologies and 
an assessment of renal function and the presence of other comorbid associations [Gross - 2005]. 
10.1 Glomerular filtration rate 
Although the best measure for glomerular filtration rate (GFR) is obtained by techniques 
that involve infusion of exogenous substances, GFR is usually estimated in clinical practice 
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by various formulae based on serum creatinine concentration, since this is much less 
invasive and time-consuming. The most popular equation used today is the Modification of 
Diet in Renal Disease (MDRD) equation [Levey, 1999 ]. 
Recent efforts to identify novel biomarkers in the diabetic population have been evolving 
either to detect early kidney injury or repair that ultimately lead to progression of diabetic 
kidney disease. 
10.2 Cystatin-C 
Cystatin-C, a cysteine protease inhibitor that is produced by virtually all nucleated cells and 
released into the bloodstream is entirely filtered by the kidney glomerulus and metabolized 
by the proximal tubule. Recently interest has developed in cystatin-C and was proposed as a 
potential endogenous filtration marker of GFR because it is a more sensitive indicator of 
mild renal impairment and may better estimate the GFR than serum creatinine. 
10.3 Retinol-binding protein 4 (RBP-4)  
Retinol-binding protein 4 (RBP-4) is a small visceral protein, mainly synthesized in the liver 
and catabolized in the kidneys after glomerular filtration. Initially reported as an adipokine 
that impairs insulin sensitivity, the concentrations of this adipokine are increased in diabetic 
patients as compared to normal subjects.  
Mechanistic studies have suggested that RBP-4 impaired insulin sensitivity by inhibition of 
insulin receptor substrate-1 phosphorylation and phosphatidylinositol 3-kinase activation in 
muscle and by induction of glucose production in liver via cytosolic phosphoenolpyruvate 
carboxykinase (PEPCK) stimulation [Yang, 2005]. Interestingly, urinary RBP-4 excretion is 
increased in early diabetic nephropathy and might even be a marker of early renal damage 
preceding microalbuminuria [Hong, 2000]. 
10.4 Connective tissue growth factor (CTGF)  
Connective tissue growth factor (CTGF) is a polypeptide with functions in extracellular 
matrix production and other profibrotic activity mediated by transforming growth factor-β1. 
Other biological functions of CTGF include angiogenesis, chondrogenesis, osteogenesis, and 
cell adhesion, migration, proliferation, and differentiation. The upregulation of CTGF has 
been observed in human and experimental diabetic nephropathy. 
10.5 Pigment epithelium-derived factor (PEDF) 
Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily 
of serine protease inhibitors with complex neurotrophic, neuroprotective, anti-angiogenic, 
anti-oxidative and anti-inflammatory properties, any of which could potentially be 
exploited as a therapeutic option for the treatment of vascular complications in diabetes. 
Recent studies suggest that PEDF could reduce proteinuria by suppressing podocyte 
damage and decreased nephrin as well as increased VEGF expression in the glomeruli of 
ADN rats. It has been reported that PEDF counteracts the effects of VEGF [Liu, 2004] and 
advanced glycation end products [Inagaki, 2003]. It is noteworthy in the future to determine 
whether PEDF may be used as a specific marker for screening incipient DN. 
10.6 Pentoxifylline (PTF)  
Pentoxifylline (PTF) is a methylxanthine derivative with favorable effects on microcirculatory 
blood flow as a result of its rheological properties. Recent studies have shown that PTF 
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an assessment of renal function and the presence of other comorbid associations [Gross - 2005]. 
10.1 Glomerular filtration rate 
Although the best measure for glomerular filtration rate (GFR) is obtained by techniques 
that involve infusion of exogenous substances, GFR is usually estimated in clinical practice 
 
Diabetes and Renal Disease 
 
259 
by various formulae based on serum creatinine concentration, since this is much less 
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Recent efforts to identify novel biomarkers in the diabetic population have been evolving 
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Cystatin-C, a cysteine protease inhibitor that is produced by virtually all nucleated cells and 
released into the bloodstream is entirely filtered by the kidney glomerulus and metabolized 
by the proximal tubule. Recently interest has developed in cystatin-C and was proposed as a 
potential endogenous filtration marker of GFR because it is a more sensitive indicator of 
mild renal impairment and may better estimate the GFR than serum creatinine. 
10.3 Retinol-binding protein 4 (RBP-4)  
Retinol-binding protein 4 (RBP-4) is a small visceral protein, mainly synthesized in the liver 
and catabolized in the kidneys after glomerular filtration. Initially reported as an adipokine 
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Mechanistic studies have suggested that RBP-4 impaired insulin sensitivity by inhibition of 
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carboxykinase (PEPCK) stimulation [Yang, 2005]. Interestingly, urinary RBP-4 excretion is 
increased in early diabetic nephropathy and might even be a marker of early renal damage 
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10.4 Connective tissue growth factor (CTGF)  
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matrix production and other profibrotic activity mediated by transforming growth factor-β1. 
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Pigment epithelium-derived factor (PEDF) is a glycoprotein that belongs to the superfamily 
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exploited as a therapeutic option for the treatment of vascular complications in diabetes. 
Recent studies suggest that PEDF could reduce proteinuria by suppressing podocyte 
damage and decreased nephrin as well as increased VEGF expression in the glomeruli of 
ADN rats. It has been reported that PEDF counteracts the effects of VEGF [Liu, 2004] and 
advanced glycation end products [Inagaki, 2003]. It is noteworthy in the future to determine 
whether PEDF may be used as a specific marker for screening incipient DN. 
10.6 Pentoxifylline (PTF)  
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reduces urinary protein excretion in individuals with diabetes, both with normal renal 
function and with renal insufficiency. In a previous study in patients with diabetes and 
nephropathy, was found that TNF-α concentrations were significantly elevated and related to 
the urinary protein excretion and, moreover, that the levels of this cytokine decreased after 
PTF administration, with a significant correlation between the decrease of TNF-α and the 
reduction of proteinuria. It was demonstrated in rats that Pentoxifylline reduces the 
accumulation and proliferation of glomerular macrophages in mesangial proliferative 
glomerulonephritis, and the recruitment of macrophages, lymphocytes, and major 
histocompatibility complex (MHC) class II antigen-positive cells into remnant kidney 
interstitium [Lin, 2002]. 
Emerging roles of urinary biomarkers have proven beneficial due to the ability to 
standardize the various markers to creatinine or peptides already present in the urine. The 
role of neutrophil gelatinase-associated lipoprotein, kidney injury molecule-1 and podocin 
derivatives have gained enormous significance in the process of early identification of 
kidney injury in the diabetic population [Buddineni - 2011]. 
11. Differential diagnosis 
Differential diagnosis is usually based on the history, physical examination, laboratory 
evaluation, and imaging of the kidneys. Renal biopsy is only recommended in special 
situations. The diagnosis of diabetic nephropathy is easily established in long-term type 1 
diabetic patients (>10 years diabetes duration), especially if retinopathy is also present. 
Typical diabetic nephropathy is also likely to be present in proteinuric type 2 diabetic 
patients with retinopathy. However, diagnostic uncertainty exists in some patients with 
type 2 diabetes since the onset of diabetes is unknown and retinopathy is absent in a 
significant proportion (28%) of these patients [Christensen, 2001]. 
Imaging of the kidneys, usually by ultrasonography, should be performed in patients with 
symptoms of urinary tract obstruction, infection, or kidney stones or with a family history of 
polycystic kidney disease [Levey, 2003]. 
12. Prevention and treatment of diabetic nephropathy 
Monitoring of type 2 diabetic patients for microalbuminuria at least once per year is 
recommended. Microalbuminuria in type 2 diabetic patients is not as potent a real risk 
predictor as in type 1 diabetic patients, but it is certainly the best available tool to identify 
patients in need of intensified treatment [Rugenetti, 1998].  
13. Glycemic and blood pressure control  
The interventions which proved to prevent the onset or attenuate the progression of diabetic 
nephropathy includes a combination of tight control of blood glucose (goal is < 7%), tight 
control of blood pressure (goal < 130/80 mmHg), lowering of urine albumin, and stopping 
of smoking (a well-established endothelial cell toxin that also affects progression of kidney 
disease), the specific blockage of the renin-angiotensin-aldosteron system (RAAS), with 
either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers 
(ARB) and lipid-lowering therapy, especially statins and fibrates.  
There is evidence that early therapeutic intervention in patients with chronic kidney disease 
or diabetes can delay onset of complications and improve outcomes [Atkins, 2010]. For 
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example, the UKPDS [Holman, 2008 Bilous, 2008], STENO-2 [Gaede, 2008], and ADVANCE 
studies [Patel, 2007, Patel, 2008, Zoungas, 2009]  demonstrated that tight control of blood 
glucose level, blood pressure (and lipids in STENO-2) significantly reduced incidence and 
progression of diabetic kidney disease. In people with type 2 diabetes, inhibition of the 
renin-angiotensin-aldosterone system using an ACE inhibitor or an ARB decreased the 
progression from normoalbuminuria to microalbuminuria [Ruggenenti, 2004], reduced the 
progression from micro albuminuria to macroalbuminuria, [Parving, 2001] and slowed the 
development of ESRD [Lewis, 2001]. Thus the use of an ACE inhibitor or ARB is now 
standard therapy for patients with diabetic nephropathy as well as glucose, lipid and blood 
pressure control. Effective management using evidence-based therapies is the fourth step in 
tackling diabetic kidney disease.   
Like other microvascular complications of diabetes, there are strong associations between 
glucose control (as measured by hemoglobin A1c [A1C]) and the risk of developing diabetic 
nephropathy. Patients should be treated to the lowest safe glucose level that can be obtained 
to prevent or control diabetic nephropathy [Fowler - 2008]. Glycemic control in both type 1 
and type 2 diabetes has been associated with reduced appearance of diabetic nephropathy 
(microalbuminuria) [Hall, 2006]. Control of glycemia in type 2 diabetic patients with 
nephropathy represents some peculiar aspects. Today there is no longer any doubt that tight 
glycemic control prevents the onset or progression of diabetic nephropathy in type 2 
diabetic patients as it does in type 1 diabetic patients. In the past, it had been thought that 
once clinically manifest nephropathy had developed, a point of no return was reached 
beyond which tight glycemic control failed to prevent the further decline in renal function. 
Nevertheless recent studies from the Steno Hospital showed that glycemic control had 
some, although less pronounced compared with tight BP control, effect on the rate of 
progression [Wolf, 2003]. 
The Diabetes Control and Complications Trial, the United Kingdom Prospective Diabetes 
Study and the Japanese Diabetes Intervention Study have confirmed that tight glycemic 
control can prevent the development of all microvascular complications including 
nephropathy [Looke, 2008]. 
Once albuminuria occurs, controlling blood pressure assumes critical importance. The use of 
renin–angiotensin blockade has been a major advance in the management of diabetic 
nephropathy. Major landmark studies including the Irbesartan Diabetic Nephropathy Trial 
[Louis, 2001] and RENAAL study [Brenner, 2001] have provided compelling evidence to 
support the renoprotective effect of angiotensin-II receptor antagonists, independent of 
blood pressure lowering [Looke, 2008]. 
The renin–angiotensin system (RAAS) is an important target for hemodynamic disturbances 
in diabetic kidney disease. Blocking the renin–angiotensin system in diabetes has 
pluripotent effects on modifying the systemic and glomerular hemodynamic as well as 
attenuating the pro-inflammatory and pro-fibrotic changes in renal parenchyma [Look, 
2008]. The pharmacological agents which block the RAAS slow the progression of renal 
dysfunction more effectively than other classes of antihypertensive agents. In addition to 
normalization of systemic and glomerular hypertension, it is now clear that inhibition of the 
RAAS at various levels have several renoprotective effects, including anti-inflammatory and 
antifibrotic mechanisms. 
Currently available therapies for this blockade are angiotensin converting enzyme inhibitor 
(ACE-I), angiotensin II type 1 receptor blocker (ARB) and direct renin inhibitor.  If the 
treatment with ACEI and/or ARB does not reach the blood pressure target levels, then they 
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nephropathy represents some peculiar aspects. Today there is no longer any doubt that tight 
glycemic control prevents the onset or progression of diabetic nephropathy in type 2 
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[Louis, 2001] and RENAAL study [Brenner, 2001] have provided compelling evidence to 
support the renoprotective effect of angiotensin-II receptor antagonists, independent of 
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The renin–angiotensin system (RAAS) is an important target for hemodynamic disturbances 
in diabetic kidney disease. Blocking the renin–angiotensin system in diabetes has 
pluripotent effects on modifying the systemic and glomerular hemodynamic as well as 
attenuating the pro-inflammatory and pro-fibrotic changes in renal parenchyma [Look, 
2008]. The pharmacological agents which block the RAAS slow the progression of renal 
dysfunction more effectively than other classes of antihypertensive agents. In addition to 
normalization of systemic and glomerular hypertension, it is now clear that inhibition of the 
RAAS at various levels have several renoprotective effects, including anti-inflammatory and 
antifibrotic mechanisms. 
Currently available therapies for this blockade are angiotensin converting enzyme inhibitor 
(ACE-I), angiotensin II type 1 receptor blocker (ARB) and direct renin inhibitor.  If the 
treatment with ACEI and/or ARB does not reach the blood pressure target levels, then they 
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can be combined with other drug classes, even before maximizing the dose of each agent. 
The combination of agents may include calcium channel blockers (especially 
nondihydropyridine), β-blockers, diuretics or central α2-agonist.  
Another concept of a dual blockade of the RAAS has been developed by Mogensen in 2000. 
Since ACEI and ARB interrupt the RAAS at different levels, the combination of these classes 
of drugs may have an additive effect on renoprotection. The renoprotective effects of dual 
blockade of the RAAS with ARB and direct renin inhibitor (aliskiren) may also be effective. 
Addition of diuretics has been strongly recommended by KDOQI guidelines to achieve 
target blood pressures of < 130 mmHg in cases of recalcitrant hypertension in diabetes 
kidney disease patients. The role for aldosterone antagonist (spironolactone) and statins in 
prevention of metabolic derangements consequent to RAAS overactivity in DKD is 
emerging. 
The BP-lowering arm of the Action in Diabetes and Vascular disease: preterAx and 
diamicroN-MR Controlled Evaluation (ADVANCE) study recently reported that the routine 
administration of a fixed combination of the angiotensin converting enzyme inhibitor 
perindopril and the diuretic indapamide to a broad cross-section of patients with type 2 
diabetes reduced the risk for cardiovascular and kidney outcomes, regardless of initial BP 
level. More recently, the glucose-lowering arm of ADVANCE reported that intensive 
glucose lowering based on gliclazide (modified release) reduced the risk for new or 
worsening nephropathy. 
While good glycemic control ameliorates the development of microalbuminuria in type 1 
and type 2 diabetes there is increasing evidence that angiotensin-converting enzyme 
inhibition and angiotensin receptor blockade are ineffective as primary prevention 
strategies. Blood pressure control remains the mainstay of treating established diabetic renal 
disease and a multi-factorial intervention approach in those with type 2 diabetes and 
microalbuminuria appears to be effective in reducing mortality based on data from one 
study [Walker, 2010]. 
14. Aldosterone receptor antagonists 
Experimental studies supporting aldosterone antagonists have shown anti-inflammatory 
effect, anti-fibrotic properties and suppression of markers of tubular injury, interstitial 
fibrosis and glomerulosclerosis [Kramer, 2007]. Aldosterone antagonists have generally been 
considered to have an antiproteinuric effect, and addition of spironolactone to an ACE 
inhibitor or ARB is associated with a marked and sustained antiproteinuric effect, with the 
rate of hyperkalemia being similar to placebo. These results are based on studies with small 
numbers of patients, mostly of very short follow-up. There are no long term data regarding 
benefit with the combination of ACE inhibitor or ARB and aldosterone antagonists in terms 
of slowing the progression of diabetic kidney disease. In clinical practice, the use of this 
combination of agents in patients with low GFR should be undertaken with careful 
instructions for dietary potassium restriction and avoidance of nonsteroidal anti-
inflammatory drugs and cyclooxy-genase-2 inhibitors [Satirapoj, 2010]. 
15. Peroxisome proliferator-activated receptors (PPAR)-gamma agonists 
Peroxisome proliferator activated receptor-γ (PPARγ) is a ligand activated transcription 
factor that regulates cell growth, inflammation, lipid metabolism and insulin sensitivity, 
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appear to have a role in regulating adipogenesis and blood pressure [Satirapoj, 2010]. 
PPARγ agonists may indirectly suppress the systemic production of a proinflammatory 
milieu mainly via inhibiting TNF-α, PAI-1, and IL-6 expression in adipose tissue. 
Additionally, PPARγ seems to have anti-inflammatory effects on monocytes. PPARγ 
activation can reduce the production of cytokines (TNF-α, IL-1, IL-6), probably through 
inhibiting the activity of proinflammatory transcription factors such as NF-κB. PPARs have 
also been implicated in many renal pathophysiological conditions, including diabetic 
nephropathy and glomerulosclerosis [Ruan, 2008]. Recently it was demonstrated that 
peroxisome proliferator activated receptor-γ (PPARγ) agonists block the deleterious effects 
of AGEs and exert beneficial actions on diabetic nephropathy. It has been successfully 
shown that PPAR-γ agonists limit high glucose-induced inflammation in proximal tubular 
cells. PPAR-γ agonists also exert anti-fibrotic effects in human proximal tubular cells under 
high glucose conditions by attenuating the increase in AP-1, TGF-β1 and downstream 
production of the extracellular matrix protein, fibronectin. PPAR-γ agonists can improve 
insulin sensitivity, reduce triglyceride levels and decrease the risk of atherosclerosis. PPARγ 
agonists have been shown to lower blood pressure in animals and humans, perhaps by 
suppressing the renin-angiotensin (Ang)-aldosterone system (RAAS), including the 
inhibition of Ang II type 1 receptor expression, Ang-II-mediated signaling pathways, and 
Ang-II-induced adrenal aldosterone synthesis/secretion [Sugawara, 2011]. 
16. Protein restriction 
Animal studies have shown that restriction of dietary protein intake also reduces 
hyperfiltration and intraglomerular and retards the progression of several models of renal 
disease, including diabetic glomerulopathy. Reduction of dietary protein has long been 
proposed as a treatment for CRF and this intervention has shown a modest benefit in slowing 
loss of filtration function, but adherence to this form of therapy is difficult in diabetes. 
17. Lipid control 
Clinical studies in patients with diabetic nephropathy showed that lipid control can be 
associated with an additional effect of reduction in proteinuria. Lipid-lowering agents 
(statins) showed renoprotection in a variety of proteinuric glomerular diseases [Agarwal, 
2007]. Although lipid-lowering treatment has been shown to be effective in reducing 
cardiovascular morbidity and mortality in diabetic patients with hyperlipidemia, their 
effects on diabetic nephropathy are still unclear due to lack of prospective randomized 
intervention studies [Chen, 2005]. Early studies have demonstrated that treatment with the 
HMG CoA reductase inhibitor pravastatin decreases albuminuria in patients with type 2 
diabetes [Sasaki, 1990]. Experimental studies demonstrated that lipid-lowering agents 
exerted a certain degree of renoprotection, through both indirect effects from lipid lowering 
and a direct effect on cell protection. Therefore, lipid control appears to be important in the 
prevention and treatment of diabetic nephropathy [Chen, 2005]. 
18. Antioxidants 
There have been multiple trials using vitamin E, vitamin C, probucol, taurine, n-
acetylcysteine, lipoic acid, and other antioxidant drugs in animals. Animal studies using 
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appear to have a role in regulating adipogenesis and blood pressure [Satirapoj, 2010]. 
PPARγ agonists may indirectly suppress the systemic production of a proinflammatory 
milieu mainly via inhibiting TNF-α, PAI-1, and IL-6 expression in adipose tissue. 
Additionally, PPARγ seems to have anti-inflammatory effects on monocytes. PPARγ 
activation can reduce the production of cytokines (TNF-α, IL-1, IL-6), probably through 
inhibiting the activity of proinflammatory transcription factors such as NF-κB. PPARs have 
also been implicated in many renal pathophysiological conditions, including diabetic 
nephropathy and glomerulosclerosis [Ruan, 2008]. Recently it was demonstrated that 
peroxisome proliferator activated receptor-γ (PPARγ) agonists block the deleterious effects 
of AGEs and exert beneficial actions on diabetic nephropathy. It has been successfully 
shown that PPAR-γ agonists limit high glucose-induced inflammation in proximal tubular 
cells. PPAR-γ agonists also exert anti-fibrotic effects in human proximal tubular cells under 
high glucose conditions by attenuating the increase in AP-1, TGF-β1 and downstream 
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proposed as a treatment for CRF and this intervention has shown a modest benefit in slowing 
loss of filtration function, but adherence to this form of therapy is difficult in diabetes. 
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associated with an additional effect of reduction in proteinuria. Lipid-lowering agents 
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2007]. Although lipid-lowering treatment has been shown to be effective in reducing 
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effects on diabetic nephropathy are still unclear due to lack of prospective randomized 
intervention studies [Chen, 2005]. Early studies have demonstrated that treatment with the 
HMG CoA reductase inhibitor pravastatin decreases albuminuria in patients with type 2 
diabetes [Sasaki, 1990]. Experimental studies demonstrated that lipid-lowering agents 
exerted a certain degree of renoprotection, through both indirect effects from lipid lowering 
and a direct effect on cell protection. Therefore, lipid control appears to be important in the 
prevention and treatment of diabetic nephropathy [Chen, 2005]. 
18. Antioxidants 
There have been multiple trials using vitamin E, vitamin C, probucol, taurine, n-
acetylcysteine, lipoic acid, and other antioxidant drugs in animals. Animal studies using 
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these compounds have been shown to be effective in reducing the development of diabetic 
kidney disease. It’s hard to translate these animal results to humans as many trials in mice 
and rats are very effective in the particular animal but often ineffective in humans. This may 
be due to short duration of animal studies, dose differences between animals and humans, 
and different pathophysiologic processes between animals and humans. Human studies 
with antioxidants for diabetic nephropathy are limited and have had variable results 
[Stanton, 2011]. 
Despite receiving optimal care to control blood pressure and metabolic risk factors as well as 
inhibition of the renin–angiotensin system in a clinical trial setting, there is a considerable 
residual risk for cardio-renal complications in patients with diabetic kidney disease. 
Understanding the molecular milieu of diabetic podocyte injury, an early event in diabetic 
nephropathy, remains a primary target in identifying novel avenues for early intervention 
and prevention of severe late complications of this increasingly prevalent disease. 
Decreasing hyperglycemia's toxic effects, stimulating the endogenous protective factors, 
controlling obesity and low grade inflammation as well as correction of anemia may 
represent also areas where novel strategies can be developed and tested to curb this rising 
global burden of cardio-renal complications in diabetic patients. Correction of anemia 
improves renal tissue oxygenation, reduces hypoxic damage and associated oxidative stress. 
There have been several reports suggesting that early erythropoietin treatment may retard 
the progression of renal diseases and delay the commencement of renal replacement 
therapy.  
Annual screening for microalbuminuria will allow the identification of patients with 
nephropathy at a point very early in its course. Improving glycemic control, aggressive 
antihypertensive treatment, and the use of ACE inhibitors or ARBs will slow the rate of 
progression of nephropathy. In addition, protein restriction and other treatment modalities 
such as phosphate lowering may have benefits in selected patients. 
In conclusion, there are very compelling reasons to better understand the mechanisms 
underlying diabetic kidney disease, to develop new treatments that can both prevent the 
development of kidney disease and slow or stop the progression. 
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and different pathophysiologic processes between animals and humans. Human studies 
with antioxidants for diabetic nephropathy are limited and have had variable results 
[Stanton, 2011]. 
Despite receiving optimal care to control blood pressure and metabolic risk factors as well as 
inhibition of the renin–angiotensin system in a clinical trial setting, there is a considerable 
residual risk for cardio-renal complications in patients with diabetic kidney disease. 
Understanding the molecular milieu of diabetic podocyte injury, an early event in diabetic 
nephropathy, remains a primary target in identifying novel avenues for early intervention 
and prevention of severe late complications of this increasingly prevalent disease. 
Decreasing hyperglycemia's toxic effects, stimulating the endogenous protective factors, 
controlling obesity and low grade inflammation as well as correction of anemia may 
represent also areas where novel strategies can be developed and tested to curb this rising 
global burden of cardio-renal complications in diabetic patients. Correction of anemia 
improves renal tissue oxygenation, reduces hypoxic damage and associated oxidative stress. 
There have been several reports suggesting that early erythropoietin treatment may retard 
the progression of renal diseases and delay the commencement of renal replacement 
therapy.  
Annual screening for microalbuminuria will allow the identification of patients with 
nephropathy at a point very early in its course. Improving glycemic control, aggressive 
antihypertensive treatment, and the use of ACE inhibitors or ARBs will slow the rate of 
progression of nephropathy. In addition, protein restriction and other treatment modalities 
such as phosphate lowering may have benefits in selected patients. 
In conclusion, there are very compelling reasons to better understand the mechanisms 
underlying diabetic kidney disease, to develop new treatments that can both prevent the 
development of kidney disease and slow or stop the progression. 
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1. Introduction 
Diabetic nephropathy (DN) is an important and often life-threatening microvascular 
complication of diabetes mellitus (DM). It is usually first manifested as an increase in 
urinary albumin excretion (microalbuminuria), which progresses to overt albuminuria and 
then to renal failure (Mogensen et al., 1983). However, the EDIC/DCCT study showed that a 
significant number of patients develop renal insufficiency without the presence of 
microalbuminuria (Molitch et al., 2006). 
The incidence of end-stage renal disease (ESRD) and type 2 DM as a co-morbid condition 
has increased continuously during the past decades (Ritz & Stefanski., 1996; Ritz & Orth., 
1999a) and has been named a medical catastrophe of worldwide dimensions (Ritz et al., 
1999b). Thus, the proportion of diabetic patients among patients with treated ESRD ranges 
between 12 and 95%, depending on nations and ethnicities investigated, with the majority 
(43-95%) usually being type 2 diabetic subjects (Ismail & Cornell, 1999). 
A similar increase in the incidence of ESRD secondary to DM has been demonstrated 
following analyses of the United States Renal Data System data (USRDS 2004 Annual Data 
Report). Between 1999 and 2003, diabetes was responsible for >44.8% of all new cases of 
ESRD in the United States. This increase could not be fully explained by changes in 
assignment of causes of ESRD, rising prevalence of DM, increased access to renal 
replacement therapy (RRT), increased acceptance of individuals with DM to ESRD 
programs, or increased survival of patients with DM (Jones et al., 2005). It has been 
suggested that external factors might be responsible for this growth in DN incidence.  
Although diabetes has long been identified as a cardiovascular disease (CVD) risk 
equivalent, only recently has chronic kidney disease (CKD) been more widely recognized as 
an independent risk factor for CVD and all-cause mortality (Kidney Disease Outcomes 
Quality Initiative, 2004; Levey et al., 2003; Weiner  et al., 2004; Go  et al., 2004). In a study of 
more than 1 million ambulatory adult patients, the risk of a cardiovascular event and death 
due to any cause increased at every level of CKD below a GFR of 60 mL/min per 1.73 m2, 
with a nearly 3.5-fold increased risk of a cardiovascular event and a 6-fold increased risk of 
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death for those with a GFR of less than 15 mL/min/1.73 m2 (i.e. CKD stage 5) (Go et al., 
2004). This has also been confirmed in diabetic subjects (Nag et al., 2007). In addition, 
microalbuminuria has been associated with an increased risk of CVD, both in patients with 
and without DM (Klausen et al., 2004; Gerstein et al., 2001; Dinneen & Gerstein, 1997). 
Therefore, in patients with DN, the increased cardiovascular risk associated with diabetes 
and with CKD are additive and increase as DN progresses (Adler et al., 2003; Miettinen et 
al., 1996). Thus, in a retrospective claims-based study of more than 1 million Medicare 
enrollees aged 65 years and older, the risk of cardiovascular events was significantly 
increased in those with either CKD or diabetes alone, but cardiovascular risk was greatest 
when both conditions were present (Foley et al., 2005). Interestingly, many patients with 
CKD, particularly elderly patients, may be several times more likely to die of CVD before 
progression to ESRD (Collins et al., 2003). In view of all this, one realizes that early 
preventive measures and effective therapy are crucial. For this to achieved, the mechanisms 
underlying cardiovascular organ damage in patients with DN have to be better understood. 
A better understanding may further help to identify biomarkers for early detection of 
patients at high risk. 
2. Methods 
A comprehensive systematic review focusing on diabetic nephropathy as a cardiovascular 
risk factor was performed. Pubmed and Embase were used as electronic search engines. The 
search included all published papers and was not limited to human studies or to papers 
published in English. Cross-sectional, case-control and cohort studies, systematic reviews 
and meta-analyses were analysed to assess types of cardiovascular events observed in 
patients with DN, potential pathogenetic mechanisms, cardiac consequences of disturbed 
renal function, links between DN and CVD, possible biomarkers, as well as therapeutic 
strategies to deal with DN and CVD, as discussed below. 
3. Cardiovascular disease in subjects with diabetic nephropathy  
The evaluation of DN, from research and clinical viewpoints, depends on the assessment of 
two continuous variables, albumin excretion rate (AER) and glomerular filtration rate 
(GFR). Both have been associated with the increased CVD noted in DN, as discussed below. 
3.1 Cardiovascular disease in diabetic patients with macroalbuminuria 
The role of macroalbuminuria in CVD has been outlined in the post-hoc analyses of the 
Irbesartan Diabetic Nephropathy Trial (IDNT) and the Reduction of End points in NIDDM 
with the Angiotensin II Antagonist Losartan (RENAAL) studies. The IDNT enrolled subjects 
with type 2 DM, hypertension, and macroalbuminuria (Lewis et al., 2001). Irbesartan proved 
to be superior to amlodipine or placebo with respect to renoprotection but no difference was 
detected between treatment groups on the secondary outcome of cardiovascular (CV) 
events. A post hoc analysis was performed by Anavekar et al. (2004) to assess the 
relationship between baseline AER and the CV composite (CV death, nonfatal myocardial 
infarction (MI), hospitalization for heart failure, stroke, amputation, and coronary and 
peripheral revascularization). Univariate analysis revealed that CV events progressively 
increased with increasing quartiles of baseline AER while multivariate analysis confirmed 
albuminuria as an independent risk factor for cardiovascular events with a 1.3-fold 
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increased relative risk for each natural log increase of 1 U in urine albumin-creatinine ratio 
(ACR).  
Similar results were noted in the Reduction of End points in NIDDM with the Angiotensin II 
Antagonist Losartan (RENAAL) whereby losartan was superior to placebo with regards to 
renoprotection in type 2 diabetic, hypertensive patients with macroalbuminuria. However it 
conferred no statistically significant benefit on the secondary CV outcomes (Brenner et al., 
2001), although de novo heart failure was less frequently noted in the losartan group. 
Nevertheless, in a post-hoc analysis of RENAAL, baseline albuminuria was again shown to 
be a predictor of both the prespecified composite CV end point (composite of MI, stroke, 
first hospitalization for heart failure or unstable angina, coronary or peripheral 
revascularization, or CV death) as well as of heart failure alone. With subjects stratified into 
3 groups on the basis of baseline ACR, comparison of the highest tertile with the lowest 
revealed an adjusted hazard ratio of 1.92 for the composite CV end point and 2.70 for heart 
failure. In multivariate analysis, baseline albuminuria was the strongest independent 
predictor of both outcomes. In addition, the change in AER from baseline to 6 months was 
the only dynamic correlate of adverse CV outcomes. A 50% reduction in baseline 
albuminuria translated into an 18% reduction in the composite CV end point and a 27% 
reduction in the risk of heart failure. It has thus been suggested that albuminuria serve as an 
indicator of therapeutic response. 
3.2 Cardiovascular disease in diabetic patients with microalbuminuria 
Microalbuminuria also correlates with adverse CV events. In a type 2 diabetic population, 
Mattock et al. (1998) reported that microalbuminuria was the strongest predictor of adverse 
CV outcomes with an odds ratio of 10.02. In addition, in the HOPE study, a baseline ACR 
>2.0 mg/mmol (present in 32.6% of the diabetic cohort and 14.8% of the non-diabetic cohort) 
increased the adjusted relative risk of CV events (1.83), all-cause death (2.09), and 
hospitalization for congestive heart failure (3.23). In addition, the impact of 
microalbuminuria on the primary composite outcome of CV death, MI, or stroke was 
significant in both diabetic (relative risk 1.97) and non-diabetic (relative risk 1.61) subjects 
(Mann et al., 2004).  
3.3 Cardiovascular disease in diabetic patients with renal impairment 
Declining renal function plays an important role in CVD in diabetic patients, as 
demonstrated in the Valsartan in Acute Myocardial Infarction (VALIANT) trial. This was a 
multicentre, double-blind randomized controlled trial that enrolled patients with acute 
myocardial infarction (MI) complicated by either clinical or radiologic signs of heart failure 
and/or left ventricular dysfunction. Patients were randomly assigned to receive captopril, 
valsartan, or both. GFR was estimated using the 4-component MDRD equation. It was 
shown that the likelihood of experiencing the primary end-point of all-cause mortality was 
higher in patients with than without DM for each level of renal function. In addition, a 
decrease in eGFR of 10 units was associated with hazards of 1.09 (95% confidence interval 
1.06 to 1.12, p <0.001) in patients with DM and 1.08 (95% confidence interval 1.06 to 1.10, p 
<0.001) in patients without DM for risk of fatal and nonfatal CV outcomes independent of 
treatment assignment (Anavekar et al., 2008).  
The importance of renal impairment in predicting outcome following myocardial infarction 
in diabetic patients was also investigated by Ahmed et al. (2008). It was shown that the 
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combination of renal impairment and DM was associated with a particularly high risk of MI 
and death/MI following a non-ST elevation MI, suggesting that attention to preserving 
renal function may be of particular benefit for reducing cardiovascular risk in diabetic 
patients. 
3.4 Diabetic nephropathy & peripheral arterial occlusive disease 
Peripheral arterial occlusive disease (PAOD) is a major cause of morbidity, especially 
affecting the elderly population (1-3). In addition, the main cause of mortality in patients 
with PAOD is ischaemic heart disease (IHD) as has been shown in several studies, while 
subgroup analyses suggest that PAOD carries a particularly poor prognosis in diabetes 
(Davis et al., 2006; Li J et al., 2007). 
DN has been reported to be associated with PAOD in both type 1 and type 2 diabetic 
subjects (Zander et al., 2002). Both albuminuria and declining GFR are probably associated 
with increased risk. Various studies have shown that PAOD is more prevalent in type 2 
diabetic patients with increased albumin excretion rate (Mostaza et al., 2006; Bianchi et al., 
2007). It is likely that microalbuminuria reflects widespread vascular damage.  In addition, a 
reduction in GFR has been shown to be associated with PAOD in both non-diabetic (O’Hare 
et al., 2004) and diabetic patients (Mostaza et al., 2006; Bianchi et al., 2007). Albuminuria and 
declining renal function are also independent predictors of the occurrence of PAOD in non-
Caucasian populations in both genders (Hsieh et al., 2009).  
Interestingly, in a type 2 diabetic population with advanced microvascular disease, as 
evidenced by proliferative diabetic retinopathy requiring laser treatment, we have shown 
that increasing age, total cholesterol levels, and vibration perception thresholds, together 
with declining renal function and lower BMI are independent predictors of PAOD, whilst 
microalbuminuria was not (Magri et al., In press). This implies that the association between 
impaired renal function and PAOD is not solely mediated by microvascular disease. The 
lack of association of microalbuminuria with PAOD in our study is probably best explained 
by the fact that all our patients had advanced microvascular disease, as evidenced by 
proliferative diabetic retinopathy, and had been suffering from diabetes for a long duration 
(18.6 ± 9.1 years). Therefore normoalbuminuric patients in our study probably represented a 
cohort which was genetically protected from diabetic renal disease. This suggests that the 
association of PAOD and microalbuminuria observed in other studies is mediated through 
shared environmental predisposing factors (example poor blood pressure and glycaemic 
control) in individuals who are genetically susceptible to develop renal disease. 
Yoshimura et al. (2008) have shown that in type 2 diabetic patients with normal ankle-
brachial indices (ABIs), eGFR correlated positively with flow volume (p=0.002) and 
negatively with brachial-ankle pulse wave velocity (p=0.0258) and with resistive index 
(p=0.0029) in patients with albuminuria but not in those with normoalbuminuria. This 
implies an association between nephropathy and impaired lower limb circulation secondary 
to higher arterial stiffness and increased vascular resistance in type 2 DM. Similar results 
were shown in Japanese type 2 diabetic patients with normal ABIs where the major risk 
factors for reduced flow volume were age, hypertension, and DN (r2 = 0.303, p < 0.001) 
(Suzuki et al., 2003). These results indicate that DN plays an important role in the early 
stages of PAOD in diabetes by altering vascular resistance and arterial stiffness. 
A high ABI (>1.40) has been found to be associated with an increased risk of CKD (defined 
as eGFR <60ml/min/1.73m2) in diabetic individuals at high cardiovascular risk (OR 2.4;  
1.0-6.4) but not in non-diabetic patients (Liu et al., 2010). A high ABI is a marker of 
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generalised stiffening of the lower limb arteries and is probably mediated through medial 
arterial calcification (MAC) in the majority of cases. MAC has been associated with 
increased left ventricular mass and aortic pulse-wave velocity in ESRD, leading to cardiac 
fibrosis and increased arrhythmia risk. Similar associations might be present in DM patients 
with high ABI but without severe renal disease, thus leading to increased cardiovascular 
morbidity and mortality. Nonetheless, Liu et al. conclude that further studies are needed to 
clarify the link between high ABI, CKD and CVD in diabetes. 
3.5 Diabetic nephropathy & cerebral infarction 
CKD is a known risk factor for cerebrovascular disease. In addition, stroke is more common 
in type 2 diabetic subjects with nephropathy compared to type 2 diabetic subjects without 
nephropathy (Alwakeel et al., 2009; Alebiosu et al., 2004). The independent effects of 
albuminuria and eGFR on stroke and silent cerebral infarction in type 2 DM have been 
investigated by Bouchi et al. (2009 & 2010, respectively). While a lower eGFR was associated 
with an increased risk of stroke in univariate analysis, it lost its significance in multivariate 
analysis. Clinical albuminuria remained a significant risk factor for stroke, with an adjusted 
HR of 2.40 (1.46-3.95, P=0.001) compared with normoalbuminuria (Bouchi et al., 2009). 
Miettinen et al. (1996) have previously shown an association between proteinuria and 
incident stroke in type 2 diabetic patients. Similarly, in Japanese type 2 diabetic patients, 
both a high urinary albumin creatinine ratio and a low eGFR were significantly associated 
with silent cerebral infarction (SCI) (lacunar infracts) in univariate analysis; however only 
albuminuria remained a significant risk factor for SCI in multivariate analysis (Bouchi et al., 
2010). SCI predicts incident clinically evident stroke, cardiovascular disease and dementia. 
Bouchi et al. (2010) conclude that the association between albuminuria and cerebrovascular 
disease could be explained either by common aetiological factors, including oxidative stress, 
inflammation, endothelial dysfunction, obesity, thrombotic state, hypertension and 
dyslipidaemia, or by similarities between the haemodynamic and anatomical aspects of 
renal and cerebral small vessel disease. 
In type 1 DM subjects, it has been shown that parents of patients with diabetic nephropathy 
have reduced survival which seems to be largely explained by an increase in vascular 
deaths, in particular, a four-fold increase in the number of strokes (Lindsay et al., 1999). 
Likewise, Thorn et al. (2007) have shown that type 1 diabetic patients with diabetic 
nephropathy had a higher prevalence of maternal (41 vs. 35%, p =0.046) and paternal (62 vs. 
55%, p =0.044) hypertension, maternal stroke (7.6 vs. 5.1%, P = 0.044), and paternal (4.3 vs. 
2.9%, p =0.030) type 1 diabetes, compared to type 1 diabetic subjects without nephropathy. 
Similarly, parental hypertension has been associated with nephropathy in type 2 diabetic 
Pima Indians (Nelson et al., 1996).These data suggest that there is a shared hereditary risk 
factor predisposing diabetic patients to nephropathy and their parents to an increased risk 
of vascular disease, in particular stroke. This is likely to be largely mediated through a 
genetic predisposition to higher blood pressure, but other factors may also be involved. 
4. Cardiovascular consequences of diabetic nephropathy 
Disturbed renal function in DN leads to a multitude of adverse cardiovascular effects, as 
outlined in Figure 1. Increased blood pressure together with accelerated large vessel disease 
and increased arterial stiffening and calcification lead to increased afterload whilst 
hypervolaemia and anaemia lead to increased preload with consequent adverse effects on 
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combination of renal impairment and DM was associated with a particularly high risk of MI 
and death/MI following a non-ST elevation MI, suggesting that attention to preserving 
renal function may be of particular benefit for reducing cardiovascular risk in diabetic 
patients. 
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generalised stiffening of the lower limb arteries and is probably mediated through medial 
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Diseases of Renal Parenchyma 
 
276 
the heart. These cardiac abnormalities are further augmented by the local activation of the 
renin-angiotensin system (RAS) and endothelin (ET) system, amongst others. The RAS plays 
a role in the activation of the sympathetic nervous system, the dysregulation of endothelial 
function and progression of atherosclerosis, and inhibition of the fibrinolytic system, while 
direct profibrotic actions of angiotensin II and aldosterone in the kidney and heart promote 
end-organ injury. On the other hand, serum ET-1 levels were found to be associated with 
left ventricular hypertrophy.  
Increased blood pressure is an early feature of renal disease and undoubtedly contributes 
to the excess cardiovascular risk (reviewed by Ritz et al., 2010). High blood pressure also 
predisposes to renal disease and predates the onset of diabetic nephropathy (Nelson et al., 
1993). Therefore patients with high blood pressure are at risk of developing both renal and 
cardiovascular disease. However high blood pressure is also a consequence of renal disease, 
thereby initiating a vicious cycle resulting in progression of CKD as well as in CKD being 
causally related to increased cardiovascular risk. An extensive discussion of the mechanisms 
of these inter-relationships between blood pressure and kidney disease is beyond the scope 
of this review. 
Left ventricular hypertrophy (LVH) is an important risk factor for adverse cardiovascular 
outcomes in patients with CKD. LVH has been demonstrated to be an important predictor 
of cardiovascular mortality in type 2 diabetic subjects with and without DN (Astrup et al., 
2007). In addition, there is increasing LVH with progression of nephropathy (Alebiosu et al., 
2008; Suzuki K et al., 2001). A potential pathogenic role of parathyroid hormone on LVH has 
been suggested, together with its effect on interstitial fibrosis and thickening of 
intramyocardial arterioles (Amann et al., 1994). This is consistent with several clinical 
findings showing a positive correlation between parathyroid hormone concentration and 
cardiovascular morbidity and mortality in dialysis patients (Block et al., 1998). Interestingly, 
cardiovascular autonomic neuropathy (CAN) as indicated by impaired parasympathetic 
nervous system function, has been shown to be associated with the presence of LVH in 
diabetic patients on haemodialysis. This suggests that the co-existence of CAN and LVH 
may be one of the key factors for the high incidence of cardiovascular events in diabetic 
haemodialysis patients (Nishimura et al., 2004). Likewise, Weinrauch et al. (2006) have 
demonstrated regression of LVH in DN patients occurring in parallel with improvement in 
cardiac autonomic function, as determined from heart rate variability. The authors conclude 
that there is a common mechanism linking LV mass and CAN, such that improvement in LV 
mass might be predicted through analysis of baseline heart rate variation.  
In a study in patients with CKD stages 2-4, approximately half of whom were diabetic, 
McQuarrie et al. (2010) have shown that the degree of albuminuria is independently and 
significantly associated with left ventricular mass, as assessed using volume-independent 
cardiac magnetic resonance imaging; this relationship was shown to be independent of 
blood pressure. These findings suggest that the increased left ventricular mass provides a 
potential link between elevated protein excretion, left ventricular hypertrophy (LVH) and 
the increased mortality seen in patients with CKD. 
Left ventricular diastolic dysfunction is another adverse cardiac effect (Figure 2). In a study 
of 67 patients with non-dialysis CKD, Miyazoto et al. (2005) found that DN is a significant 
predictor of LV diastolic dysfunction in CKD subjects, independent of other influencing 
factors such as age, blood pressure, renal function, anaemia and LV hypertrophy. LV 
diastolic dysfunction is characterized by elevated left ventricular end-diastolic pressure or 
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Fig. 2. Doppler evidence of left ventricular diastolic dysfunction. (A) Mitral inflow pattern 
during normal breathing (B) Mitral inflow pattern during Valsalva manoeuvre showing 
reversibility of inflow pattern (E<A), typical of restrictive pattern of diastolic dysfunction 
(C) Tissue Doppler evidence indicating diastolic dysfunction 
Mitral annular calcification (MiAC) is another important cardiac abnormality found in 
patients with CKD. This is because MiAC has been shown to predict atrial fibrillation, stroke 
and cardiovascular disease morbidity and mortality. In the Framingham Heart Study (Fox et 
al., 2006), 3047 participants (some of whom had CKD secondary to diabetes) were assessed 
for the presence of mitral annular calcification (MiAC), aortic sclerosis and aortic annular 
calcification. It was demonstrated that the combination of both CKD and MiAC was 
associated with a three-fold increased risk of death compared with those with neither CKD 
nor MiAC (p= 0.0004), following adjustment for age and gender. Interestingly, the 
association between CKD and MiAC occurred before the onset of ESRD; however, no 
significant association was found between CKD and either aortic sclerosis or aortic annular 
calcification (odds ratio 1.1 and 1.1, respectively). It is still unclear whether MiAC is a causal 
mechanism that mediates this association or a risk marker; further research is needed to 
unveil underlying pathophysiologic mechanisms. 
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Ischaemic heart disease (IHD) is strongly associated with DN. Patients with both ESRD and 
diabetes mellitus carry an increased risk of coronary atherosclerosis. The possible 
mechanisms are discussed in section 5. In addition to coronary atherosclerosis, 
abnormalities in myocardial blood flow and in coronary flow reserve could be responsible 
for cardiovascular morbidity in DN. Ragosta et al. (2004) have demonstrated that subjects 
with DN and normal coronary arteries had abnormalities in coronary velocity reserve 
(CVR). Abnormal CVR was caused by an elevation of baseline arterial peak velocity in 66% 
of these cases. The elevated baseline velocity may be caused by an increase in LV mass from 
associated long-standing hypertension, or by circulating humoral factors with vasodilator 
properties present in renal failure, for example nitric oxide. In addition, the baseline heart 
rate and the presence of diabetes mellitus with renal failure were independent predictors of 
abnormal CVR by multivariable analysis. Therefore, in the presence of end-organ damage 
caused by diabetes mellitus, abnormalities in coronary physiology may be seen in the 
absence of overt epicardial coronary artery disease. 
In addition to arterial changes, reduction in capillary density is another important factor in 
CKD which interferes with oxygen delivery. In uraemic subjects with LVH, there is a 
significant decrease in capillary density, leading to an increase in intercapillary distance, 
and potentially compromising the blood and oxygen supply of the myocardium under 
conditions of increased demand, thus rendering the myocardium more prone to ischaemic 
injury. LVH is common in diabetic subjects secondary to concomitant hypertension. These 
findings suggest that in uraemic patients with LVH, there is probably decreased expression 
of vascular endothelial growth factor or increased expression of inhibitors of capillary 
angiogenesis, such that capillary growth does not keep pace with cardiomyocyte growth 
(reviewed by Amann et al., 2006). It is possible that low capillary density or poor capillary 
recruitment puts subjects at risk of developing hypertension, kidney disease as well as 
cardiovascular disease. Further studies are needed to clarify the pathological mechanisms 
underlying the decrease in cardiac capillary supply. 
5. Potential pathogenic mechanisms 
Various mechanisms account for the cardiovascular dysfunction present in renal disease, as 
outlined below.  
5.1 Endothelial cell dysfunction 
The vascular endothelium is a versatile multifunctional tissue having many synthetic and 
metabolic properties (Figure 3). Endothelial cell dysfunction seems to be central in the 
genesis of many different aspects of cardiovascular dysfunction in subjects with DN, such as 
increased pulse wave velocity (Yokoyama et al., 2004) and decreased flow-mediated dilation 
(FMD) of the brachial artery (Yilmaz et al., 2008). Table 1 outlines the various factors leading 
to endothelial cell dysfunction. 
Yilmaz et al. (2008) have demonstrated that endothelium-dependent vascular dysfunction, as 
assessed using FMD, correlates with proteinuria in type 2 diabetic subjects with early DN. 
Interestingly, no correlation was found between proteinuria and nitroglycerine-mediated 
dilation (NMD) of the brachial artery. This suggests that there decreased bioavailability of 
nitric oxide (NO), but that the vessels remain responsive to it in DN. In addition, a positive 
association was found between proteinuria and the intracellular protein nicotinamide-
phosphoribosyltransferase (NAMPT)/visfatin, which is thought to be a marker of endothelial 
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cell damage. On the other hand, there were negative associations between proteinuria and two 
vasoprotective molecules, namely adiponectin and fetuin-A. The authors suggest that 
proteinuria might lead to endothelial dysfunction via increasing serum levels of the NO-
synthase inhibitor ADMA, probably secondary to increased protein turnover, together with 
loss of vasoprotective circulating proteins such as adiponectin and fetuin.  
 
 
Fig. 3. Endothelial Cell Properties & Functions (Reproduced from Expert Review of 
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Asymmetrical dimethylarginine (ADMA) is an endogenous competitive nitric oxide (NO) 
synthase inhibitor. It can be metabolized by dimethylarginine dimethylaminohydrolase 
(DDAH) or excreted by the kidneys (Leiper et al., 2006). It is increased in patients with 
increased cardiovascular risk (Kielstein et al., 1999; Zoccali et al., 2002; Surdacki et al., 1999) 
and predicts future cardiovascular events (Schnabel et al., 1995). Accumulation of ADMA in 
CKD could promote atherosclerosis and is related to a history of myocardial infarction 
and/or stroke in patients with type 1 DM and macroalbuminuria (Tarnow et al., 2004). In 
type 2 diabetic patients with albuminuria, increased ADMA was also shown to be linked to 
macrovascular disease, and is associated with declining GFR and subclinical inflammation, 
as assessed using high senstivity C-reactive proten (hsCRP) (Krzyzanowska et al., 2007).  
In addition to its direct inhibitory effect on endothelial NO synthase, ADMA may cause 
endothelial dysfunction via other mechanisms. These include increased superoxide 
production by activation of the NAD(P)H-oxidase, thereby interfering with NO 
bioavailability; activation the local RAS, thus contributing to the development of arteriolar 
dysfunction and increased tone; and a decrease in the number of circulating endothelial 
progenitor cells (EPCs), possibly interfering with vascular repair mechanisms (reviewed by 
Fliser, 2010). 
Insulin resistance also plays an important role in endothelial dysfunction. Insulin resistance 
has been associated with renal disease in both types 1 (Yip J et al., 1993) and 2 (Groop et al., 
1993) diabetes, thereby offering another possible explanation of the association between 
cardiovascular disease and DN. Furthermore, endothelial cell injury has recently been 
linked to increased shear stress (Boulanger et al., 2007). The latter is known to be associated 
with high blood pressure.  
Plasma levels of the soluble receptor for advanced glycation end-products (RAGE) are 
strongly associated with CVD in patients with DN (Nin et al., 2010). RAGE has been shown 
to induce the production of adhesion molecules and inflammatory cytokines, thus 
promoting endothelial and renal dysfunction, low grade inflammation and vascular 
remodeling. Through these mechanisms, RAGE may contribute to both DN and 
cardiovascular disease. 
Activation of the renin-angiotensin system in DN results in endothelial dysfunction. When 
angiotensin II acts through the AT1 receptor, it stimulates the generation of reactive oxygen 
species by NAD(P)H oxidase and other enzyme systems, leading to upregulation of 
inflammatory mediators, which include cytokines, chemokines, adhesion molecules, and 
plasminogen activator inhibitor 1, and superoxide scavenging of NO. These events promote 
endothelial dysfunction, vascular remodeling, and the progression of atherosclerosis 
(Schiffrin et al., 2004). 
There is also evidence that hyperuricaemia induces endothelial dysfunction by inhibiting 
NO production (Khosla et al., 2005), modulates inflammatory response (Kang et al., 2005), 
and stimulates vascular smooth muscle cell proliferation. In a study by Correa Leite (2011), a 
decline in GFR was associated with an increase in CVD risk factors (increased fibrinogen 
and hematocrit levels) only among subjects with higher uric acid levels. These alterations 
may promote thrombotic disorders via a hypercoagulable state and increase in blood 
viscosity. Consequently, serum uric acid measurement in patients with mild renal 
impairment may serve as a potentially useful means of identifying subjects at risk of 
developing CVD. 
Hyperhomocysteinaemia may also play a role in endothelial dysfunction. Elevated plasma 
homocysteine levels are associated with albuminuria in both type 1 (Soedamah-Muthu et al., 
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homocysteine levels are associated with albuminuria in both type 1 (Soedamah-Muthu et al., 
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2005) and type 2 diabetic patients (Aso et al., 2004). It has been suggested that elevated total 
homocysteine levels cause vascular complications secondary to oxidative stress, endothelial 
damage and decreased nitric oxide bioavailability. In addition, the increased susceptibility 
of diabetic subjects to hyperhomocysteinaemia may be secondary to an acceleration of 
glucose-induced oxidative stress on endothelial cells (Soedamah-Muthu et al., 2005). This 
hypothesis is supported by animal studies showing that homocysteine-induced endothelial 
dysfunction occurs much more readily in the presence of diabetes than in its absence 
(Schukla et al., 2002). 
5.2 Endothelial progenitor cells 
Bone marrow-derived EPCs in peripheral circulation contribute to re-endothelialization of 
injured vessels as well as to neovascularization of ischaemic lesions and therefore play a key 
role in maintaining the integrity of the vascular system. Various factors influence the 
number and function of EPCs. Mild-to-moderate renal dysfunction accompanying stable 
angina has been shown to be associated with EPC depletion, irrespective of angiographic 
CAD extent. This may exacerbate an imbalance between endothelial injury and  
EPC-mediated repair, thus contributing to high cardiovascular risk in CAD coexisting with 
renal insufficiency. In addition, the number of EPCs is decreased in both patients with type 
1 and type 2 DM, and EPCs from patients with DM have impaired function of adhesion, 
proliferation, and tubulization. All these findings indicate that EPCs play an important role 
in the pathogenesis of DN. 
Interestingly, erythropoietin (EPO) has been shown to be a potent stimulator of EPC 
proliferation and differentiation. In addition, EPO has important direct biological effects on 
mature endothelial cells, including protection against ischemia and apoptosis, modulation 
of endothelial cell-cell and cell-matrix contacts, enhancement of endothelial cell migration 
and formation of primitive vascular structures in vitro. Mature endothelial cells do not lose 
their EPO receptors, unlike erythrocytes; hence, antiapoptotic signaling persists much 
longer, making endothelial cells more resistant to ischemia-induced cell death. Fliser (2010) 
thus suggests that EPO might be a key regulator of vascular protection. The adverse effects 
noted with use of recombinant human EPO (rHuEPO) could be attributed to the abrupt 
increase in the hematocrit level in CKD patients with serious vascular problems. In addition, 
rHuEPO increases the number and activation of thrombocytes, while increasing platelet 
adherence to the injured endothelium. However, the increase in hematocrit related to 
rHuEPO treatment is not associated with an increased risk for thrombosis as long as 
endothelial NO production serves as the compensatory mechanism. Consequently, there is 
ongoing research for an optimal rHuEPO dose that is safe, or EPO analogues (example the 
carbamylated form of EPO) that maintain tissue protective effects but lack the adverse effect 
on erythropoiesis and thrombopoiesis (Fliser, 2010). 
5.3 Inflammation 
CKD results in a chronic, low-grade inflammatory process that becomes evident even in the 
early stages of the disease. Circulating levels of inflammatory markers, such as C-reactive 
protein (CRP) and interleukin-6 (IL-6), are elevated in CKD patients. Navarro et al. (2008) 
have recently shown a relationship between inflammatory activation of peripheral blood 
mononuclear cells (reflected by enhanced mRNA expression of TNF-alpha and IL-6) and 
renal involvement (reflected by increased urinary albumin excretion) in type 2 diabetic 
 
Diabetic Nephropathy: A Cardiovascular Risk Factor 
 
283 
patients. Increased inflammation could thus play a role in accelerated atherosclerosis and 
increased cardiovascular risk associated with DN. 
5.4 Advanced glycation end-products 
Advanced glycation end-products (AGEs) are products of non-enzymatic glycation and 
oxidation of proteins and lipids. They are increased in situations with hyperglycemia and 
oxidative stress such as DM. The kidney plays an important role in clearance and 
metabolism of AGEs. In CKD, AGE concentrations increase, partly by an increase in 
oxidative and carbonyl stress, leading to structural renal changes with further CKD 
progression, thus creating a vicious circle. 
AGEs and their receptors play an important role in the pathophysiology of DN (reviewed by 
Busch et al., 2010). Besides vascular damage, RAGE drives the development of 
glomerulosclerosis and promotes podocyte activation in DN. Accumulation of AGEs affects 
almost all renal structures, including basement membranes, mesangial and endothelial cells, 
podocytes and tubules. In addition, medial smooth muscle cell injury in intrarenal arteries is 
caused by interaction between glycoxidation and complement activation, leading to 
progression of DN. AGEs and RAGE also are thought to play a key role in predisposing to 
cardiovascular disease in CKD patients (Noordzij et al., 2008; Lindsey et al., 2009).  
However, even though AGEs and their receptors are involved in the pathogenesis of 
vascular and kidney disease, the role of circulating AGEs as biomarkers for cardiovascular 
risk estimation is questionable. In a post-hoc analysis of type 2 DM patients having DN from 
the IDNT cohort (Lewis et al., 2001; Berl et al., 2003), serum concentration of carboxymethyl-
lysine (an important AGE) was not found to be an independent cardiovascular or renal risk 
factor (Busch et al., 2006). This may be due to the fact that serum concentrations failed to 
correlate with AGEs deposited in target tissues. Nonetheless, further research is needed to 
elucidate the role of AGEs and their receptors in the pathophysiology of DN and associated 
co-morbidities. In addition, there is ongoing research on the possible therapeutic benefit of 
inhibitors of AGE formation and putative breakers of already formed AGEs in the 
prevention and treatment of patients with DN and diabetic cardiovascular disease. 
5.5 Lipoprotein abnormalities 
Lipoprotein abnormalities also play a role. DN is characterized by low high-density 
lipoprotein (HDL)-concentrations and elevated intermediate-density lipoprotein (IDL), both of 
which contribute to an increased cardiovascular risk. Shoji et al. (2001) have demonstrated that 
elevated serum creatinine has greater impact than albuminuria on abnormalities in IDL and 
HDL. In addition, in diabetic patients, serum lipoprotein (a) concentration is associated with 
albuminuria, further contributing to the elevated cardiovascular risk (Hernández et al., 2000). 
5.6 Adhesion molecules 
Elevated plasma concentrations of soluble adhesion molecule concentrations in patients 
with DN could play an important role in the development of atherosclerosis and increased 
cardiovascular risk. Thus, plasma concentration of soluble intercellular adhesion molecule 
(sICAM)-1 is elevated in type 1 diabetic patients with microalbuminuria and the 
concentrations of sICAM-1 as well as soluble vascular adhesion molecule (sVCAM)-1 are 
elevated in patients with macroalbuminuria and normal serum creatinine (Clausen et al., 
2000). 
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Hyperfibrinogenaemia is a cardiovascular risk factor. Tessari et al. (2006) have shown an 
upregulation of hepatic secretory proteins, albumin and fibrinogen, in albuminuric type 2 
DM subjects compared with type 2 DM normoalbuminuric patients. Such an upregulation 
seems to be responsible for the hyperfibrinogenaemia observed in the albuminuric diabetic 
patients, and could thus play a role in the adverse cardiovascular effects noted in this high 
risk population. 
5.8 Cardiac autonomic neuropathy 
Cardiac autonomic neuropathy (CAN) is another important mechanism. In type 2 DM 
patients, CAN and DN were found to be independently associated with asymptomatic CAD 
(Beck et al., 1999). In type 1 DM patients with nephropathy, CAN assessed as heart-rate 
variation during deep breathing was shown to be an independent risk factor for 
cardiovascular morbidity and mortality (Astrup et al., 2006). In addition, autonomic 
neuropathy may be associated with increased central arterial stiffness (Nemes et al., 2010). 
The mechanisms by which CAN increases cardiovascular morbidity and mortality are still 
under debate. Suggested mechanisms include impaired central control of respiration in 
patients with CAN (Sobotka et al., 1986); exercise intolerance with a reduced response in 
heart rate and blood pressure and decreased cardiac output during exercise; and possibly 
QT prolongation (Whitsel et al., 2000; Veglio et al., 2000).  
6. Other possible links between cardiovascular disease & diabetic 
nephropathy  
Several hypotheses have been proposed to explain the link between the kidney and 
cardiovascular disease. These have been reviewed by Amann et al. (2006) and are outlined 
below. 
Local factors may play a role in the cross-talk between the kidney and the cardiovascular 
system. The original Steno hypothesis (Deckert et al., 1989) suggested that enzymes 
involved in the metabolism of anionic components of the extracellular matrix (e.g. heparan 
sulphate proteoglycan) vulnerable to hyperglycaemia are probably the primary cause of 
albuminuria and the associated complications. Genetic polymorphisms of these enzymes 
could explain the variation in susceptibility to diabetic nephropathy and cardiovascular 
disease. However, there is little evidence supporting this hypothesis. An alternative 
hypothesis is a common glycocalyx defect in the glomerulus and in the systemic circulation. 
This is because the endothelial glycocalyx plays a significant role in the genesis of vascular 
pathology and controls vascular permeability (Gouverneur et al., 2006; Henry & Duling, 
1999). This might also be the case in the glomerulus; however this merits further study.  
Amann et al. also propose various pathways through which reduced renal function might 
influence endothelial function. These include the following:  
1. Accumulation of toxins that are normally excreted via the kidneys 
2. Inability of the kidney to produce active substances, example renalase. Renalase is an 
enzyme which breaks down catecholamines like adrenaline and noradrenaline in the 
circulation; its levels are markedly decreased in subjects with end-stage renal disease. In 
rodents, renalase has been shown to decrease blood pressure, heart rate, heart muscle 
contractility, and blood vessel resistance. 
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3. Reduced metabolism of substances normally metabolized by the kidney, example 
ADMA. The plasma concentration of ADMA are moderately elevated in renal failure, 
resulting in modification of gene expression patterns in endothelial cells as well as 
diminished production of nitric oxide secondary to inhibition of NO synthase. 
Systemic factors may also play a role. Atmann et al. mention enhanced sympathetic activity 
at an early stage of renal disease when whole-kidney GFR is still normal. It is thought to be 
due to increased afferent signals originating from the damaged kidney, possibly 
contributing to increased incidence of sudden death and mortality secondary to ischaemia in 
renal patients. However, the triggering intrarenal mechanisms have not yet been identified. 
In addition, Atmann et al. propose the possibility of inappropriate activation of local RAS of 
cardiovascular structures in subjects with kidney disease, as suggested by animal studies 
where local cardiovascular RAS activation was noted in uraemic or subtotally 
nephrectomised rats. 
Genetic influences probably also play a role. It has recently been shown that the P12A and 
C161T polymorphisms of the PPAR-gamma gene are important predictors of cardiovascular 
events in patients with diabetic nephropathy. The Pro/Ala genotype of the P12A 
polymorphism confers a 7.6-fold (95% CI 2.1- to 28.0-fold, p = 0.002) excess hazard of 
developing primary cardiovascular end point as compared to the Pro/Pro genotype, while 
each T allele at the 161 position confers a 83.4% (95% CI 15.2-291.9%, p = 0.011) excess 
hazard (Szeto et al., 2008). Another interesting polymorphism is the leucine 7 to proline 7 
(Leu7Pro) polymorphism, located in the signal peptide part of the human 
preproneuropeptide Y (Pettersson-Fernholm et al., 2004). In the Finnish Diabetic 
Nephropathy Study, the Pro7 substitution was more common in patients with proteinuria 
than in those with normoalbuminuria (16 vs. 11%, p < 0.05). Patients with the Pro7 allele had 
worse glycemic control (HbA(1c) 8.8 vs. 8.5%, p < 0.005), more coronary heart disease 
(CHD) (14 vs. 8%, p < 0.05), and higher serum triglycerides (1.65 vs. 1.35 mmol/l, p < 0.005) 
than patients with the wild-type genotype. In multivariate analysis, the Leu7Pro 
polymorphism was independently associated with HbA(1c) (p < 0.001), proteinuria  
(p < 0.01), and CHD (p <0.01), suggesting that the Leu7Pro polymorphism may contribute to 
the genetic susceptibility to diabetic nephropathy and CHD in type 1 diabetic patients, 
possibly by influencing glycemic control and triglycerides. 
Recently, Takenaka et al. (2010) have shown that short stature is associated with increased 
mortality in diabetic and non-diabetic subjects with ESRD. Short stature has been linked to 
nephropathy in both type 1 (Rossing et al., 1995) and type 2 diabetes (Fava et al., 2001); 
height may therefore partly explain the association between DN and cardiovascular disease. 
This may be due to common genetic and/or environmental factors predisposing to short 
stature, DN and cardiovascular disease.  
In addition to genetic influences, Brenner et al. (1988) have suggested the hypothesis of 
“nephron underdosing” whereby aberrant foetal programming secondary to genetic factors, 
malnutrition, and other insults in utero leads to the formation of fewer glomeruli. This results 
in a diminished ability to excrete sodium and thus predisposes to salt-sensitive hypertension. 
In favour of this hypothesis is the observation that both diabetic and nondiabetic renal diseases 
are seen more frequently in families with hypertension. In addition, in normoalbuminuric 
subjects, the risk for future ESRD is predicted by baseline blood pressure (Hsu et al., 2005). 
Congenital variability in filtration surface area may explain the varying susceptibility of 
patients exposed to potentially injurious renal stimuli to eventually manifest chronic 
nephropathy, as well as the different susceptibility of subsets of type 1 and type 2 diabetics to 
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develop overt glomerulopathy. Ots et al. (2004) have shown that kidney transplantation in 5/6 
nephrectomized animals protects against albuminuria and rise in blood pressure.  In humans, 
single kidney GFR declines more rapidly in uninephric individuals compared to binephric 
ones (Saxena et al., 2006). Undoubtedly, the role of foetal programming on the occurrence of 
renal and cardiovascular disease needs further study. 
7. Therapeutic strategies  
A major limitation in the interventions needed to reduce cardiovascular risk in subjects with 
DN is the fact that in the past renal patients were deliberately excluded from major 
intervention studies. Hence, current recommendations are mainly based on observational 
studies or post-hoc analyses of patients with early stages of CKD who had been enrolled in 
randomized controlled trials. However, information from controlled trials is available for 
some interventions, as outlined below.  
7.1 Blood pressure control 
The most important component of treatment is blood pressure (BP) control. Numerous 
studies have shown that the use of antihypertensive treatment in patients with DN is crucial 
in the preservation of GFR (Mogensen, 1982; Anderson et al., 1988; Parving et al., 1993) and 
to reduce mortality in this high-risk group (Parving et al., 1989; Mathiesen et al., 1989). In 
view of the fact that diabetic patients are a high risk population, the Seventh Report of the 
Joint National Committee on Prevention, Detection Evaluation and Treatment of High Blood 
Pressure (JNC 7) (2003) and American Diabetes Association (2004) have recommended a BP 
target of 130/80 mm Hg in diabetic patients and <125/75 mm Hg (Compendium of ESC 
Guidelines 2007) in the presence of renal impairment or of significant proteinuria >1 gr/24 
hours. Nonetheless, BP lowering should be gradual and monitored closely, especially in 
haemodialysis patients who often develop hypotensive episodes during fluid removal by 
ultrafiltration. This is especially important in this high-risk population, keeping in mind that 
low blood pressure predicts death, particularly in the elderly with high comorbidity and 
low diastolic blood pressure values.  
RAS blockade is the cornerstone of treatment of DN, as discussed below. In addition, 
diuretics play a crucial role in the treatment of CKD by potentiating the pressure lowering 
effect of RAS inhibitors. However, diuretics do have adverse effects on the heart and 
kidneys by triggering counterbalancing antinatriuretic mechanisms, example ACE II, 
aldosterone, decreased systemic blood pressure, and it is therefore advised that the lowest 
effective dose should be administered.  
Importantly, the combination of RAS inhibitors and low dose thiazide diuretics augments 
the reduction of albuminuria. Also, RAS inhibitors diminish the thiazide-induced reduction 
in GFR. As a result, the filtered sodium load is increased, permitting more effective 
natriuresis. However, in patients with GFR <30mL/min, thiazides cause only a minor 
increase of natriuresis and they should therefore be exchanged for, or combined with, loop 
diuretics which are effective even in advanced CKD. In addition, in DN and proteinuric 
patients, higher diuretic doses are required because in the tubule lumen diuretics are up to 
90% protein bound and natriuresis is only determined by the concentration of the free 
diuretic. 
β-blockers, example carvedilol and nebivolol, are useful second-line treatments. 
Traditionally the use of β-blockers has been discouraged in patients with diabetes because 
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they were associated with adverse effect such as weight gain, reduced peripheral blood 
flow, pronounced hypoglycemia and nightmares. However, β-blockers help decrease the 
enhanced sympathetic activity present in kidney disease. In addition, cardioselective β-
blockers have less renal circulatory side effects and are associated with less blunting of 
hypoglycemia awareness and with less elevation of lipid and glucose levels, and are thus 
preferred to the nonselective type.  
Dihydropyridine calcium antagonists should be avoided in hypertensive patients with 
albuminuria, as suggested by the results of a study conducted by Hummel et al. (2010). 
The latter have shown that dihydropyridine calcium antagonists are associated with 
increased albuminuria in patients treated with ACE inhibitors (ACEI)/ angiotensin 
receptor blockers (ARB). This is an important finding that merits further investigation 
since it is known that increases in albuminuria even in the low range are associated with 
increased cardiovascular risk. 
7.2 Renin-angiotensin system blockade 
Inappropriate activation of the RAS blockadeis a hallmark of CKD and DN. In fact, various 
studies have shown the beneficial role of ACEI and ARB in the treatment of DM in both type 
1 and 2 diabetic subjects. Thus, in the Captopril Collaborative Study Group (Lewis et al., 
1993), a significant risk reduction in nephropathy progression was shown in type 1 diabetic 
patients treated with captopril. Also, a meta-analysis of 12 trials in type 1 diabetic patients 
with microalbuminuria (The ACE Inhibitors in Diabetic Nephropathy Trialist Group, 2001) 
revealed that the treatment with ACE inhibitor for two years was associated with a 60% 
reduction in progression to macroalbuminuria and in threefold increase in regression to 
normoalbuminuria in comparison with placebo. Mathiesen et al. (1999) has shown that 
captopril has long lasting (eight years) beneficial renoprotective effect in normotensive 
patients with type 1 DM and microalbuminuria.  
Similar positive results have been demonstrated in type 2 DM. Thus, the Microalbuminuria, 
Cardiovascular and Renal Outcomes – Heart Outcomes Prevention Evaluation (MICRO–
HOPE) study (Gerstein et al., 2000) showed that overt nephropathy was reduced by 24% in 
type 2 diabetic patients treated with ramipril, resulting in significant protection against 
cardiovascular events. 
ARBs have also been shown to exhibit significant renoprotective effects. In the IRMA II 
study, Parving et al. (2001) demonstrated that irbesartan had a renoprotective effect in 
hypertensive patients with type 2 diabetes and microalbuminuria that was independent of 
its BP lowering effect. Furthermore, the restoration of normoalbuminuria was more evident 
in the group receiving irbesartan at a dose of 300 mg daily, as compared to the group 
receiving 150mg daily. Two other studies, IDNT (Lewis et al., 2001) and RENAAL (Brenner 
et al., 2001) also used ARBs, but they enrolled patients with higher grade of proteinuria and 
established renal insufficiency. In both studies, the use of ARBs led to lower levels of 
proteinuria, lower rates of decline in the GFR and later onset of ESRD than the use of control 
medications. 
By contrast, the use of RAS blockade to lower the increased cardiovascular risk in DN has 
been disappointing. Although valsartan has been reported to decrease arterial stiffness in 
patients with DN (Karalliedde et al., 2008), there are no data on hard end-points. In a recent 
meta-analysis, RAS has been shown to improve cardiovascular outcomes in proteinuric 
CKD of various types (Balamuthusamy et al., 2008). However in another meta-analysis, 
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Sarafidis et al. (2008) failed to show an effect of RAS inhibition on total mortality in DN 
patients. In conclusion, though there is strong evidence of renoprotection by both ACEIs 
and ARBs, evidence for cardiovascular protection in DN patients is still lacking. 
7.3 Statins 
Altough the effect of statin use on cardiovascular outcomes in patients with DN has not 
been extensively studied, there is strong evidence for their effectiveness in both diabetes and 
in CKD. Their effectiveness in reducing cardiovascular events in diabetic subjects was 
demonstrated in the Collaborative Atorvastatin Diabetes Study (CARDS) (2004) as well as in 
meta-analysis of all trials having a diabetes subgroup analysis (Costa et al., 2006). Subgroup 
analysis of the Cholesterol and Recurrent Events (CARE) (Tonelli et al., 2003), Management 
of Elevated cholesterol in the primary prevention Group of Adult Japanese (MEGA) 
(Nakamura et al., 2009) and the Scandinavian Simvastatin Survival Study (4S) (Chonchol et 
al., 2007) studies have all demonstrated significant cardiovascular protection in CKD 
patients. A meta-analysis by Strippoli et al. found a reduction in fatal and non-fatal 
cardiovascular events but not in total mortality. Cochrane reviews have concluded that 
statins significantly reduced the risk of all-cause and cardiovascular mortality in CKD 
patients who are not receiving renal replacement therapy (Navaneethan et al., 2009a), but 
there that was insufficient data on renal transplant patients (Navaneethan et al., 2009b). 
Statins also play an important role in renoprotection. Several meta-analyses have been 
performed to assess the effect of statins on renal function and proteinuria. Fried et al. (2001) 
performed a meta-analysis with 13 controlled prospective studies and concluded that statin 
use results in a lower rate of decline in eGFR, although the effect was small. In a second 
meta-analysis of 27 studies, Sandhu et al. (2006) have shown that statin use resulted in an 
improvement in eGFR and reduction in proteinuria. 
The renoprotective effects of statins are probably secondary to an extension of their 
modulatory effects on inflammation and oxidant stress (reviewed by Kurukulasuriya et al. 
(2007)). This is achieved through various mechanisms, mainly: 
i. Reduction of generation of reactive oxygen species (ROS) 
ii. Suppression of activity of pro-oxidant enzyme systems, mainly NADPH oxidase, 
xanthine oxidase, oxidase activity of endothelial NO-synthase 
iii. Inhibition of Rho expression, resulting in up-regulation of eNOS expression, thereby 
reducing blood pressure and  glomerular injury, together with a decrease in the surface 
protein endothelin-1 levels. The latter is a potent vasoconstrictor and mitogen, and 
might play a role in delaying glomerulosclerosis 
iv. Interference with LDL oxidation via several mechanisms 
v. Inhibition of conversion of monocytes to macrophages by inhibiting their uptake of 
oxidized LDL. 
Among their anti-inflammatory and anti-proliferative effects, statins have been shown to 
reduce levels of monocyte chemo-attractant protein-1, tumor necrosis factor-alpha (TNF-α), 
transforming growth factor-beta (TGF-β), interleukin-6, platelet-derived growth factor, 
NFκB, and mesangial proteins. These pleiotropic effects distinguish statins from other lipid-
lowering therapies (e.g. resin binders, fibrates, niacin). All the above mechanisms may  
also contribute to cardiovascular protective properties of statins, although the main 
mechanism in this case is thought to be through improving lipid profile particularly 
lowering of LDL-cholesterol. 
 




Diabetes mellitus is considered a cardiovascular disease risk equivalent. Consequently, 
subjects with DN are at higher risk than patients suffering from kidney disease secondary to 
other aetiologies. Statins decrease coronary event rates to the level equal or even greater to 
that seen in untreated subjects (Costa et al., 2006). Consequently, there is significant 
substantial residual risk. This may be partly due to the fact that statins have only limited 
effectiveness on hypertriglyceridemia and low HDL cholesterol, and they do not normalize 
the abnormal LDL size-distribution pattern seen in DM.  
Peroxisome proliferator-activated receptor (PPAR)alpha agonists, which include fibrates, 
are more effective in lowering triglycerides, in raising HDL and help to improve ratio of 
small dense: large buoyant LDL particles (Birjmohun et al., 2005; Tokuno A et al., 2007). 
Outcome trials of PPARalpha agonists have shown decreased cardiovascular morbidity  
in patients with diabetes and in those with the metabolic syndrome. In addition, plaque 
progression is diminished, and there is a decrease in both microvascular (including diabetic 
nephropathy and retinopathy) and macrovascular complications (reviewed by Staels et  
al., 2008). 
Two trials worth mentioning are the FIELD study and the DAIS study. The FIELD study 
(Keech et al., 2005) was a multinational, randomised controlled trial with about 10,000 
patients with type 2 diabetes mellitus, and not taking statin therapy at study entry. 80% of 
the participants were without previous cardiovascular disease. Participants were randomly 
assigned to micronised fenofibrate 200 mg daily or matching placebo. In the treatment 
group, the risk of the primary outcome of coronary events was not significantly reduced. 
However, fenofibrate did reduce nonfatal MI and revascularization procedures by 24%. 
Furthermore more controls were on statins, which might have attenuated any beneficial 
effect of fenofibrate. On the other hand, in the DAIS study (DAIS Group, 2001), fenofibrate 
reduced angiographic progression of CAD in type 2 diabetic patients. Since the data for 
reducing CV risk is stronger for statins, fibrates are especially useful as second-line 
treatment of dyslipidaemia in diabetic patients that cannot tolerate statins. In addition, the 
combination of fibrates with statins seems to be particularly indicated in diabetic patients 
with residual hypertriglyceridaemia and/or low HDL despite receiving statin therapy since 
fibrates help improve overall lipoprotein profile further. However, most fibrates are 
metabolized by the kidney and, in view of the risk of rhabdomyolysis, careful monitoring 
and dose adjustment is necessary when statins and fibrates are used as combination 
treatment in DN patients. 
7.5 Correction of anaemia 
Anaemia is a common complication of CKD. It is often more severe and occurs at an earlier 
stage in patients with DN than in patients with CKD secondary to other causes. This 
anaemia results from erythropoietin (EPO) deficiency. Studies have shown that recombinant 
human EPO treatment is effective in correcting erythropoietin-deficiency anaemia in 
patients with DN, besides improving quality of life and well-being in these patients.  
However, recently, there is increasing concern regarding adverse events caused by EPO 
treatment when haemoglobin (Hb) concentrations are raised above the recommended target 
of 11–12g/dL, as outlined below.  
The Normal Hematocrit Study, Cardiovascular Risk Reduction by Early Anemia Treatment 
with Epoetin-beta, Correction of Hemoglobin and Outcomes in Renal Insufficiency, and 
Trial to Reduce Cardiovascular Events with Aranesp Therapy have shown increased risk of 
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mortality and/or cardiovascular complications with targeting of a higher Hb in CKD 
patients. There is increasing debate whether it is the higher Hb level targeted in these trials 
or the erythropoiesis-stimulating agent (ESA) exposure itself that accounted for the 
observed increased risk (reviewed by Singh (2010)). This is because, in these trials, achieving 
a normal or near normal Hb was associated with improved survival and reduced 
cardiovascular risk while it seems that it was the 'targeting' of a higher Hb with ESA that 
resulted in increased morbidity. However, the results obtained, by their very nature, cannot 
prove causality. In addition, several study-inherent and methodological limitations must be 
considered before simply extrapolating the negative findings of these studies into clinical 
practice. Therefore, until new evidence becomes available from ongoing and future clinical 
studies, an upper Hb limit of 12 g/dl should not be exceeded.  
The increased morbidity with EPO treatment could be explained by its side effects arising 
from the vascular system. A frequently seen adverse effect of chronic administration of EPO 
is an increase in arterial BP; postulated mechanisms for EPO-induced hypertension include 
enhanced vascular reactivity and vasoconstrictor responses. Scalera et al. (2005) have shown 
that at concentrations corresponding to plasma levels after EPO therapy in patients with 
chronic renal failure, EPO and darbepoietin α (NESP) increase endothelial elaboration of 
ADMA and inhibition of NOS by impairing dimethylarginine dimethylaminohydrolase 
(DDAH) activity. This is probably mediated by oxidative stress. Scalera et al. thus 
demonstrate a novel mechanism for EPO-induced downregulation of NO synthesis, which 
may contribute to explain main side effects observed in patients who are treated with EPO.  
Increased blood viscosity also plays a role in EPO-induced hypertension and increases 
workload on the heart. In addition, increased whole blood viscosity is an important 
pathophysiological factor in the development of atherothrombosis and appears to be a 
strong predictor of CVD. In fact, male blood donors and women of premenopausal age with 
regular menstruation have shown reduced incidence of cardiovascular events such as 
myocardial infarction, angina, stroke, and the requirement for procedures such as 
percutaneous transluminal coronary angioplasty and coronary artery bypass graft 
compared with non-donors and postmenopausal women, respectively. This is possibly 
related to decreased whole blood viscosity. Consequently, Jeong et al. (2010) have proposed 
blood viscosity monitoring as part of cardiovascular risk assessment in the context of 
anaemia correction with ESAs. As discussed above, EPO may also increase platelet number 
and activation. 
The use of intravenous iron in the correction of anaemia in CKD is also uncertain. The vast 
majority of patients with CKD are iron-deficient secondary to multiple forms of interference 
with all phases of iron metabolism. Therefore, iron supplementation is given to CKD 
patients. Intravenous iron was demonstrated to be superior to oral iron in both hemodialysis 
and nondialysis-dependent CKD patients. Whereas correction of anemia is effective in 
reducing oxidative stress and, conceptually cardiovascular risk, intravenous iron could 
promote cytotoxicity and tissue injury, exacerbate oxidative stress and endothelial 
dysfunction, as well as inflammation and the progression of both CKD and cardiovascular 
disease (Garneata, 2008). Clinical judgment is thus necessary in each individual case to 
diagnose iron deficiency and effectively use intravenous iron.  
7.6 Antiplatelet agents 
Given the high cardiovascular morbidity and mortality associated with DN, it is reasonable 
to suggest that diabetic subjects suffering from nephropathy should be on regular aspirin 
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treatment. In fact, the American Diabetes Association (2004) suggest that diabetic patients 
>40years old with ≥1 cardiovascular risk factor should be taking prophylactic aspirin while 
the ESC guidelines (The Task Force on the Use of Antiplatelet Agents in Patients with 
Atherosclerotic Cardiovascular Disease, 2004) suggest prophylactic aspirin for diabetic 
patients with 1-year risk of CHD >1.5%. 
However, in diabetic patients, aspirin may be less effective than expected. Thus, in the 1031 
diabetic patients enrolled in the Primary Prevention Project (Sacco et al., 2003), the effects of 
aspirin 100mg daily were surprisingly poor with major vascular events being reduced by 
only 10% in diabetic individuals versus 31% in nondiabetic individuals. This was confirmed 
in two recent meta-analyses (De Berardis et al., 2009; Stavrakis et al., 2011). The role of 
aspirin in diabetic patients who are at increased risk because of renal disease remains 
inadequately investigated. The Primary Prevention Project Investigators suggest that, in 
diabetes, platelets may be activated through peculiar aspirin-insensitive mechanisms. This 
may involve hyperproduction of thromboxane from cells and tissues through aspirin-
insensitive COX-2 pathway, or alternative prostanoid producing mechanisms can be 
activated by hyperglycaemia or insulin resistance. In addition, there is increased turnover of 
platelets in DM, possibly suggesting the need for higher doses of aspirin than usual in 
diabetic patients. 
In keeping with aspirin resistance, there is increasing interest in picotamide, a dual inhibitor 
of thromboxane synthase and thromboxane receptor. In the DAVID study (Neri Serneri et 
al., 2004), >1200 patients with type 2 DM and established PAD were randomly allocated to 
picotamide 600mg or aspirin 320mg. It was demonstrated that picotamide almost halved 
general mortality compared with aspirin with a significantly lowered relative risk of death 
(0.55) and reduced, though not significantly, vascular deaths, from 4.1% to 2.1%. In addition, 
picotamide caused less bleeding and was better tolerated than aspirin. This study suggests 
that dual inhibitors of thromboxane synthase and thromboxane receptors may become 
useful therapies in cardiovascular prevention in diabetic patients. Further studies with 
picotamide and with other agents of the same class, for example ridogrel and terutroban 
sodium, are thus desirable. 
7.7 Glycosaminoglycans 
In view that microalbuminuria, the traditional hallmark of DN, is associated with alterations 
in endothelial permeability secondary to degradation of heparin-sulphate (a 
glycosaminoglycan component of the intracellular and basement membrane matrix) 
increasing attention has been focused on the role of glycosaminoglycans in the treatment of 
DN and associated cardiovascular complications.  
Special attention has been focused on sulodexide, a compound containing 80% slow-moving 
heparin and 20% dermatan sulphate, both of which have been shown to prevent 
experimental diabetic nephropathy. In the DINAS study (Gambaro et al., 2002), sulodexide 
significantly decreased albuminuria by 43% in subjects with DN and the effect persisted at 
8-month follow-up with no major adverse events. In addition, sulodexide was effective in 
both type 1 and type 2 diabetic subjects and it maintained its efficacy during concomitant 
treatment with ACE inhibitors. The reduction in albuminuria by sulodexide was confirmed 
in another study by Achour et al. (2005) where albuminuria was significantly decreased at a 
lower therapeutic dose of sulodexide, independently of diabetes type and baseline presence 
of micro- or macroalbuminuria. Interestingly, sulodexide has been shown to prevent 
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mortality and/or cardiovascular complications with targeting of a higher Hb in CKD 
patients. There is increasing debate whether it is the higher Hb level targeted in these trials 
or the erythropoiesis-stimulating agent (ESA) exposure itself that accounted for the 
observed increased risk (reviewed by Singh (2010)). This is because, in these trials, achieving 
a normal or near normal Hb was associated with improved survival and reduced 
cardiovascular risk while it seems that it was the 'targeting' of a higher Hb with ESA that 
resulted in increased morbidity. However, the results obtained, by their very nature, cannot 
prove causality. In addition, several study-inherent and methodological limitations must be 
considered before simply extrapolating the negative findings of these studies into clinical 
practice. Therefore, until new evidence becomes available from ongoing and future clinical 
studies, an upper Hb limit of 12 g/dl should not be exceeded.  
The increased morbidity with EPO treatment could be explained by its side effects arising 
from the vascular system. A frequently seen adverse effect of chronic administration of EPO 
is an increase in arterial BP; postulated mechanisms for EPO-induced hypertension include 
enhanced vascular reactivity and vasoconstrictor responses. Scalera et al. (2005) have shown 
that at concentrations corresponding to plasma levels after EPO therapy in patients with 
chronic renal failure, EPO and darbepoietin α (NESP) increase endothelial elaboration of 
ADMA and inhibition of NOS by impairing dimethylarginine dimethylaminohydrolase 
(DDAH) activity. This is probably mediated by oxidative stress. Scalera et al. thus 
demonstrate a novel mechanism for EPO-induced downregulation of NO synthesis, which 
may contribute to explain main side effects observed in patients who are treated with EPO.  
Increased blood viscosity also plays a role in EPO-induced hypertension and increases 
workload on the heart. In addition, increased whole blood viscosity is an important 
pathophysiological factor in the development of atherothrombosis and appears to be a 
strong predictor of CVD. In fact, male blood donors and women of premenopausal age with 
regular menstruation have shown reduced incidence of cardiovascular events such as 
myocardial infarction, angina, stroke, and the requirement for procedures such as 
percutaneous transluminal coronary angioplasty and coronary artery bypass graft 
compared with non-donors and postmenopausal women, respectively. This is possibly 
related to decreased whole blood viscosity. Consequently, Jeong et al. (2010) have proposed 
blood viscosity monitoring as part of cardiovascular risk assessment in the context of 
anaemia correction with ESAs. As discussed above, EPO may also increase platelet number 
and activation. 
The use of intravenous iron in the correction of anaemia in CKD is also uncertain. The vast 
majority of patients with CKD are iron-deficient secondary to multiple forms of interference 
with all phases of iron metabolism. Therefore, iron supplementation is given to CKD 
patients. Intravenous iron was demonstrated to be superior to oral iron in both hemodialysis 
and nondialysis-dependent CKD patients. Whereas correction of anemia is effective in 
reducing oxidative stress and, conceptually cardiovascular risk, intravenous iron could 
promote cytotoxicity and tissue injury, exacerbate oxidative stress and endothelial 
dysfunction, as well as inflammation and the progression of both CKD and cardiovascular 
disease (Garneata, 2008). Clinical judgment is thus necessary in each individual case to 
diagnose iron deficiency and effectively use intravenous iron.  
7.6 Antiplatelet agents 
Given the high cardiovascular morbidity and mortality associated with DN, it is reasonable 
to suggest that diabetic subjects suffering from nephropathy should be on regular aspirin 
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treatment. In fact, the American Diabetes Association (2004) suggest that diabetic patients 
>40years old with ≥1 cardiovascular risk factor should be taking prophylactic aspirin while 
the ESC guidelines (The Task Force on the Use of Antiplatelet Agents in Patients with 
Atherosclerotic Cardiovascular Disease, 2004) suggest prophylactic aspirin for diabetic 
patients with 1-year risk of CHD >1.5%. 
However, in diabetic patients, aspirin may be less effective than expected. Thus, in the 1031 
diabetic patients enrolled in the Primary Prevention Project (Sacco et al., 2003), the effects of 
aspirin 100mg daily were surprisingly poor with major vascular events being reduced by 
only 10% in diabetic individuals versus 31% in nondiabetic individuals. This was confirmed 
in two recent meta-analyses (De Berardis et al., 2009; Stavrakis et al., 2011). The role of 
aspirin in diabetic patients who are at increased risk because of renal disease remains 
inadequately investigated. The Primary Prevention Project Investigators suggest that, in 
diabetes, platelets may be activated through peculiar aspirin-insensitive mechanisms. This 
may involve hyperproduction of thromboxane from cells and tissues through aspirin-
insensitive COX-2 pathway, or alternative prostanoid producing mechanisms can be 
activated by hyperglycaemia or insulin resistance. In addition, there is increased turnover of 
platelets in DM, possibly suggesting the need for higher doses of aspirin than usual in 
diabetic patients. 
In keeping with aspirin resistance, there is increasing interest in picotamide, a dual inhibitor 
of thromboxane synthase and thromboxane receptor. In the DAVID study (Neri Serneri et 
al., 2004), >1200 patients with type 2 DM and established PAD were randomly allocated to 
picotamide 600mg or aspirin 320mg. It was demonstrated that picotamide almost halved 
general mortality compared with aspirin with a significantly lowered relative risk of death 
(0.55) and reduced, though not significantly, vascular deaths, from 4.1% to 2.1%. In addition, 
picotamide caused less bleeding and was better tolerated than aspirin. This study suggests 
that dual inhibitors of thromboxane synthase and thromboxane receptors may become 
useful therapies in cardiovascular prevention in diabetic patients. Further studies with 
picotamide and with other agents of the same class, for example ridogrel and terutroban 
sodium, are thus desirable. 
7.7 Glycosaminoglycans 
In view that microalbuminuria, the traditional hallmark of DN, is associated with alterations 
in endothelial permeability secondary to degradation of heparin-sulphate (a 
glycosaminoglycan component of the intracellular and basement membrane matrix) 
increasing attention has been focused on the role of glycosaminoglycans in the treatment of 
DN and associated cardiovascular complications.  
Special attention has been focused on sulodexide, a compound containing 80% slow-moving 
heparin and 20% dermatan sulphate, both of which have been shown to prevent 
experimental diabetic nephropathy. In the DINAS study (Gambaro et al., 2002), sulodexide 
significantly decreased albuminuria by 43% in subjects with DN and the effect persisted at 
8-month follow-up with no major adverse events. In addition, sulodexide was effective in 
both type 1 and type 2 diabetic subjects and it maintained its efficacy during concomitant 
treatment with ACE inhibitors. The reduction in albuminuria by sulodexide was confirmed 
in another study by Achour et al. (2005) where albuminuria was significantly decreased at a 
lower therapeutic dose of sulodexide, independently of diabetes type and baseline presence 
of micro- or macroalbuminuria. Interestingly, sulodexide has been shown to prevent 
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cardiovascular events in non-diabetic survivors of MI (Condorelli et al., 1994) as well as 
improving the walking performance of PAD patients, some of whom were diabetic.  
Therefore, glycosaminoglycans offer a new perspective in the treatment of diabetic 
nephropathy. However, further research is needed to investigate how and to what extent 
these agents influence the course of DN and associated cardiovascular co-morbidities. 
7.8 Lifestyle interventions 
Lifestyle interventions, mainly regular exercise and diet, play an important role in reducing 
cardiovascular risk in DN patients. Physical exercise is necessary to improve glycaemic 
control and decrease cardiovascular risk. Interestingly, in a study by Lazarevic et al. (2007) it 
was shown that six months of aerobic exercise, without any change in the medication, 
tended to decrease microalbuminuria in type 2 diabetic subjects, independently of any 
improvement in insulin resistance and oxidative stress parameters. However, further 
studies are needed to elucidate the mechanisms underlying the beneficial effects of exercise. 
In addition to restricted calorie and fat intake and adequate fibre intake, dietary 
manipulation, including protein, phosphorus, and sodium restriction, can potentially exert a 
cardiovascular protective effect in DN patients by decreasing various cardiovascular risk 
factors. Diminished sodium intake helps in achieving blood pressure control. Increasesd 
fibre intake plays an important role in lowering serum cholesterol and improving plasma 
lipid profile. A low protein may help to reduce proteinuria and in decreasing phosphorus 
intake and preventing and reversing hyperphosphatemia and secondary 
hyperparathyroidism. These, in turn, may also help ameliorate insulin sensitivity and 
metabolic control in diabetic patients, as well as increase the responsiveness to 
erythropoietin therapy, thus enabling correction of anemia. Protein-restricted diets may 
have also anti-inflammatory and anti-oxidant properties (Cupisti et al., 2007). Nonetheless, 
even though dietary restriction may be useful to decrease cardiovascular risk in the DN 
patient, further studies are needed to assess the effect of renal diets on hard outcomes, as 
cardiovascular events or mortality. 
8. Conclusion  
The present review underlines the cardiovascular risk to which patients with diabetic 
nephropathy are exposed and summarizes some of the mechanisms that lead to the 
increased risk of adverse cardiovascular events. Some of the risk factors are modifiable and 
can be improved with currently available therapy including aggressive treatment of 
dyslipidemia, antiplatelet treatment, restriction of protein intake together with adequate 
exercise. Nonetheless, further research is needed to unravel the pathophysiology underlying 
cardiovascular complications associated with diabetic nephropathy as well as to investigate 
novel therapies to enable a decrease in the morbidity and mortality associated with this 
serious diabetes-related complication. These may require new approaches including the 
management of the increased oxidative stress and low-grade inflammation.  
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cardiovascular events or mortality. 
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